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nalling pathway is a fundamental transduction cascade with key roles in development, cancer and 
neurodegeneration. Particularly, mounting evidence suggests that AD neuropathology may be under-
scored by critical dysfunction of canonical Wnt signalling. Given the close relationship between AD 
and DS, it is proposed in this thesis that Wnt abnormalities may also be present in the DS brain. This 
hypothesis is thus investigated, combining bioinformatics with RNA and protein analysis in DS mouse 
models and humans. The evidence gathered here suggests canonical Wnt signalling is dysfunctional 
in the DS brain. Most importantly, Wnt signalling activity is suppressed in the adult DS hippocampus. 
Furthermore, this thesis identifies the Hsa21-encoded kinase DYRK1A, an essential contributor to DS, 
as a novel, bimodal Wnt signalling regulator. DYRK1A may both suppress and enhance Wnt activity, 
depending on the activation state of the pathway. It is proposed that, in DS, dosage imbalance of 
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features of DS, particularly learning disability and AD-DS. Overall, these findings may provide key evi-
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Chapter 1 - General Introduction
Chapter 1 - General Introduction 
The work conducted in this thesis generally bridges two overarching research themes: 1) Down syn-
drome with its associated development of Alzheimer’s disease, and 2) the functional relationship of 
these disease mechanisms with the Wnt signalling pathway. The associated scientific literature is 
broadly introduced here, and key aspects of both themes are further discussed in detail. 
1.1 Down syndrome 
1.1.1 Overview 
Down syndrome (DS) is a genetic developmental disorder caused by the presence of an extra copy 
(trisomy) of human chromosome 21 (Hsa21) in the genome (1). First described by the UK physician 
John Langdon Down in 1866, DS is the most common human chromosomal abnormality, occurring in 
about 1/700-1000 live births in the United States (Centers for Disease Control and Prevention, 2006). 
In the vast majority of cases (95%), affected individuals possess a complete third copy of Hsa21, 
while a minority displays partial trisomy or mosaicism. The latter two result in a relatively milder variant. 
Although the severity of DS phenotypes varies widely amongst individuals affected, some specific fea-
tures are invariably present. Learning disability and developmental delay are characteristic of all cases, 
albeit in a spectrum, with some individuals requiring significant care, and some able to lead a relatively 
independent life (2). Importantly, DS has long been associated with the nearly universal development 
of Alzheimer’s disease (AD) in adult life. One of the most striking features of this condition is in fact the 
invariable presence of AD-specific neuropathology from middle age (3, 4). Not all DS individuals de-
velop clinical AD, but the risk is overall greatly increased (5). 
Fig. I.1 - Overview of characteristic features of DS.
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Several craniofacial abnormalities are pathognomonic to DS, as is its associated growth pattern, for 
which adapted charts have been developed (6). In about 40% of cases, DS children are affected by 
congenital heart disease (CHD), mostly of ventricular septal or atrioventricular nature (7, 8). While the 
risk of solid neoplasms is reduced in DS (9), affected individuals are 10-15-fold more susceptible to 
haematological malignancies, particularly childhood leukaemias (6). Transient myeloproliferative dis-
ease, a malignancy identified as unique to DS, affects roughly 1 in 10 individuals (10). Additionally, DS 
is also characterised by endocrine, gastrointestinal and sexual dysfunction. While no treatment ame-
liorating the cognitive deficits of DS exists at present, associated disorders are treated based on clini-
cal need and available therapies. Advancements in medical care and changes in societal attitudes to-
wards mental disability have resulted in a significant extension of life expectancy. With appropriate 
care, DS individuals possess a 50 to 70 years life expectancy. Comparatively, median survival in the 
US was only 9 years as recently as 1949 (11). 
1.1.2 Hsa21 in DS pathology 
The two main aetiological hypotheses for DS propose that the phenotype may arise either as a direct 
pathological effect of increased Hsa21 gene dosage, or from non-specific genetic instability caused 
by the presence of an additional chromosome (6). Starting from the 1990s, the view that a putative 
“Down syndrome critical region” (DSCR) was responsible for most features of the DS phenotype 
gained wide prominence. It originated from multiple reports indicating the distal region of the Hsa21 
long arm encoded key genes for DS pathology. Such evidence was produced in case studies on rare 
partial Hsa21 trisomies (12) and analysis of DS and non-DS relatives in selected families (13). Results 
suggested that the DSCR is necessary and sufficient for development of the signature features of DS.  
A large amount of studies have provided structural and functional characterisation of Hsa21 in the last 
2 decades. The complete sequence of the chromosome was produced for the first time in 2000 (14). 
The authors estimated Hsa21 to code for 225 functional proteins, with later studies suggesting the 
number might be as high as 364 (7). The latter have also provided a functional overview of Hsa21 
genes employing comparative genomics and bioinformatics. Known Hsa21 proteins from the Swiss-
Prot database were analysed with Gene Ontology Annotation, revealing the involvement of Hsa21 in 
87 distinct biological processes. Interestingly, signal transduction pathways are the most common. 
Furthermore, Hsa21 proteins exert as many as 81 different molecular functions, the most frequent be-
ing DNA binding, transcription and transcription factor activity. Hsa21 proteins localise to 26 different 
subcellular components, mostly to the nucleus and plasma membrane, which is consistent with their 
prominent role in signal transduction. Upon the original description of trisomy 21 in 1959, it was hy-
pothesised by LeJeune that all trisomic genes would undergo 1.5-fold overexpression relative to non-
DS levels. It has been demonstrated, however, that only 37% of Hsa21 genes are overexpressed in 
the hypothesised fashion, while 45% are increased much less significantly, 18% are subject to even 
greater overexpression, and 9% are not significantly altered (7). The authors suggest that these data 
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A large amount of studies have provided structural and functional characterisation of Hsa21 in the last 
2 decades. The complete sequence of the chromosome was produced for the first time in 2000 (14). 
The authors estimated Hsa21 to code for 225 functional proteins, with later studies suggesting the 
number might be as high as 364 (7). The latter have also provided a functional overview of Hsa21 
genes employing comparative genomics and bioinformatics. Known Hsa21 proteins from the Swiss-
Prot database were analysed with Gene Ontology Annotation, revealing the involvement of Hsa21 in 
87 distinct biological processes. Interestingly, signal transduction pathways are the most common. 
Furthermore, Hsa21 proteins exert as many as 81 different molecular functions, the most frequent be-
ing DNA binding, transcription and transcription factor activity. Hsa21 proteins localise to 26 different 
subcellular components, mostly to the nucleus and plasma membrane, which is consistent with their 
prominent role in signal transduction. Upon the original description of trisomy 21 in 1959, it was hy-
pothesised by LeJeune that all trisomic genes would undergo 1.5-fold overexpression relative to non-
DS levels. It has been demonstrated, however, that only 37% of Hsa21 genes are overexpressed in 
the hypothesised fashion, while 45% are increased much less significantly, 18% are subject to even 
greater overexpression, and 9% are not significantly altered (7). The authors suggest that these data 
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Fig. I.2 - Known structure of Hsa21 and location of the DSCR on the distal long arm, which includes DYRK1A.
17
Chapter 1 - General Introduction
1.1.3 Dementia and Alzheimer’s disease 
As introduced, virtually all DS individuals may develop early AD neuropathology. To better contextu-
alise the occurrence of this phenomenon, AD is briefly introduced here, discussing its best known fea-
tures and associated pathological processes. 
1.1.3.1 Overview 
Dementia is a blanket term identifying a wide variety of neurodegenerative conditions generally affect-
ing the ageing population. All forms of dementia share a degree of impairment in cognitive function, 
memory and behaviour. Cognitive deterioration is commonly associated with impairment in emotional 
control. It is important to differentiate dementia from the much milder, age-related cognitive decline 
observed in most of the population. Alzheimer disease (AD) is by far the most common form of de-
mentia, accounting alone for about 60-70% of all cases (World Health Organisation - WHO, 2009). 
Currently, AD affects 20% of the worldwide population over age 80. Moreover, the latest WHO projec-
tions (Dementia Report, 2013) estimate a dramatic increase in the incidence of AD throughout the 
next 4 decades, with 135 million patients potentially affected in 2050. Most cases of AD are sporadic, 
although a small minority (0.1%) of earlier onset variants appear to be inherited in an autosomal domi-
nant fashion (Familial Alzheimer disease - FAD).  
As a form of dementia, AD is essentially characterised by a linear decline in cognitive function, begin-
ning around age 65 or over. Such decline is invariably associated with progressively widespread corti-
cal atrophy. The traditional pathological hallmark of AD is deposition of neuritic plaques (NPs), com-
posed of β-amyloid peptides (Aβ), and neurofibrillary tangles (NFTs), composed of hyperphosphorylat-
ed tau protein aggregates. Clinically, the earliest and most widely recognised symptom of AD is im-
pairment and subsequent loss of short-term memory. Cognitive deterioration is accompanied, at later 
stages, by severe autonomic nervous system dysfunction. Death usually arises as a result of several 
secondary complications such as respiratory or cardiac failure. The clinical features of AD have been 
observed since the original description of the condition by Aloysius Alzheimer in 1906 (18). At present, 
no known therapeutic agent can arrest or reverse AD neurodegeneration, with acetylcholinesterase 
inhibitors such as donepezil only able to temporarily ameliorate symptoms by enhancing cholinergic 
neurotransmission (19). Although the term AD refers to the clinically overt disease, multiple lines of 
evidence suggest that the pathological process may commence years, if not decades, prior to clinical 
diagnosis (20, 21). This view established the preclinical stage of AD as an attractive target for thera-
peutic intervention. 
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favour the view of a candidate gene approach in describing DS phenotypes. Indeed, Hsa21 genes 
have been investigated in this respect. For instance, Chakrabarti and colleagues have shown that 
Olig1 and Olig2 triplication in the Ts65Dn mouse model of DS results in a developmental imbalance in 
excitatory and inhibitory neural populations of the forebrain, with an abnormal number of inhibitory 
neurons (15). Despite the available evidence, the DSCR view is being increasingly challenged. The ad-
vent of chromosome engineering techniques allowed for the development of mouse models carrying 
duplications of individual portions of Hsa21 ortholog regions (See 1.1.5). Through this method, it was 
shown by Olson and colleagues in Science that the DSCR alone is not sufﬁcient for generation of DS 
craniofacial defects (16). Additionally, non gene-speciﬁc effects of Hsa21 trisomy have been de-
scribed. Kuhn et al. have reported that Hsa21-associated microRNAs (miRNAs), small non-coding 
RNAs involved in post-transcriptional regulation, can modulate the expression of methyl CpG binding 
protein 2 (MECP2). This protein regulates the expression of target genes important for neuronal func-
tion, such as cAMP response element-binding protein (CREB) (17). The authors conclude that Hsa21 
miRNAs might contribute to some of the neurochemical features of DS.  
To date, the mechanistic role of Hsa21 in DS pathology remains elusive. While DS phenotypes cannot 
be simplistically linked to speciﬁc gene functions, a combination of gene-speciﬁc and non-speciﬁc ef-
fects is more likely than either alone. The phenotypic outcomes of Hsa21 trisomy are complex, and 
probably originate from an interplay between an overall imbalance of gene expression and speciﬁc 
effects of Hsa21 genes. Thus, the two hypotheses are not mutually exclusive and should be har-
monised instead. The evidence on Hsa21 contribution to DS introduced here is further discussed and 
expanded in section 1.4. 
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Fig. I.2 - Known structure of Hsa21 and location of the DSCR on the distal long arm, which includes DYRK1A.
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1.1.3 Dementia and Alzheimer’s disease 
As introduced, virtually all DS individuals may develop early AD neuropathology. To better contextu-
alise the occurrence of this phenomenon, AD is brieﬂy introduced here, discussing its best known fea-
tures and associated pathological processes. 
1.1.3.1 Overview 
Dementia is a blanket term identifying a wide variety of neurodegenerative conditions generally affect-
ing the ageing population. All forms of dementia share a degree of impairment in cognitive function, 
memory and behaviour. Cognitive deterioration is commonly associated with impairment in emotional 
control. It is important to differentiate dementia from the much milder, age-related cognitive decline 
observed in most of the population. Alzheimer disease (AD) is by far the most common form of de-
mentia, accounting alone for about 60-70% of all cases (World Health Organisation - WHO, 2009). 
Currently, AD affects 20% of the worldwide population over age 80. Moreover, the latest WHO projec-
tions (Dementia Report, 2013) estimate a dramatic increase in the incidence of AD throughout the 
next 4 decades, with 135 million patients potentially affected in 2050. Most cases of AD are sporadic, 
although a small minority (0.1%) of earlier onset variants appear to be inherited in an autosomal domi-
nant fashion (Familial Alzheimer disease - FAD).  
As a form of dementia, AD is mainly characterised by a continuous decline in cognitive function, begin-
ning around age 65 or over. Such decline is invariably associated with progressively widespread corti-
cal atrophy. The traditional pathological hallmark of AD is deposition of neuritic plaques (NPs), com-
posed of -amyloid peptides (A ), and neuroﬁbrillary tangles (NFTs), composed of hyperphosphorylat-
ed tau protein aggregates. Clinically, the earliest and most widely recognised symptom of AD is im-
pairment and subsequent loss of short-term memory. Cognitive deterioration is accompanied, at later 
stages, by severe autonomic nervous system dysfunction. Death usually arises as a result of several 
secondary complications such as respiratory or cardiac failure. The clinical features of AD have been 
observed since the original description of the condition by Aloysius Alzheimer in 1906 (18). At present, 
no known therapeutic agent can arrest or reverse AD neurodegeneration, with acetylcholinesterase 
inhibitors such as donepezil only able to temporarily ameliorate symptoms by enhancing cholinergic 
neurotransmission (19). Although the term AD refers to the clinically overt disease, multiple lines of 
evidence suggest that the pathological process may commence years, if not decades, prior to clinical 
diagnosis (20, 21). This view established the preclinical stage of AD as an attractive target for thera-
peutic intervention. 
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1.1.3.2 Molecular pathology of AD 
Accumulation of NPs and NFTs is an invariant feature of AD, and plays a key role in its pathogenesis. 
Aβ monomers are released from the proteolytic cleavage of amyloid precursor protein (APP), a trans-
membrane protein of elusive neuronal function. Release of Aβ is catalysed by enzymatic complexes 
known as secretases, of which 3 isoforms are known (α,β, and γ). In physiological conditions, Aβ may 
act as a positive regulator of excitatory neurotransmission in rat hippocampal slices (22). Tau, an im-
portant microtubule-associated protein (MAP), is expressed primarily in the distal axon, where it inter-
acts with tubulin, promoting its assembly into microtubules. When excessively phosphorylated, tau 
proteins form aggregates, disrupting microtubule organisation (23, 24). Although the specific mecha-
nisms leading to neuronal death remain unclear, the neurotoxic properties of Aβ peptides and NFTs 
have long been recognised (25). Several studies suggest that aberrant accumulation of oligomeric 
forms of Aβ may impair excitatory neurotransmission at hippocampal synapses and in other cortical 
regions (26-28). In the context of memory formation, Aβ oligomers have been shown to antagonise 
induction of long-term potentiation (LTP) (29), promote in vivo long term depression (LTD) and alter 
dendritic spine morphology and density in the hippocampus (30). Consistently, these effects can be 
prevented by inhibiting Aβ oligomerisation (31). Moreover, recent studies in tau knockout mice have 
revealed that this protein is necessary for hippocampal LTD, the induction of which is accompanied by 
tau phosphorylation (32). The current understanding ascribes AD pathogenesis to extensive synaptic 
loss, and oligomeric Aβ has indeed been found to be a synaptotoxic species (33-35). Despite this tox-
icity, synaptic loss is increasingly understood to be a preclinical event in AD, preceding plaque and 
NFT deposition and cognitive decline. 
Fig. I.3 - Classical model of AD neuropathology.
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1.1.4 Alzheimer disease in Down syndrome (AD-DS) 
In DS, clinical AD is diagnosed in roughly 60% of cases, starting at the fourth decade of life (5). A large 
amount of evidence supports this claim. Observations of this phenomenon even predate the 1906 
description of AD itself: in a 1876 study, Fraser and Mitchell reported the occurrence of “premature 
ageing” in a group of DS individuals (36). Later case studies in the early 20th century suggested that 
DS individuals tend to develop AD pathology as well as clinical AD (37, 38). Compelling pathological 
evidence was definitively provided by Malamud et al., who reported the invariable presence of Aβ
plaques and NFTs in all DS people aged over 35 (3). In a later study, Schweber examined extensive 
autopsy data from DS brains, concluding that AD neuropathology is a universal finding in those aged 
37 or more (39). Strikingly, DS indviduals undergo accumulation of Aβ plaques starting as early as 8 
years of age (40), with deposition rate increasing dramatically in an age-dependent manner (41).  
Neuroimaging evidence, as reviewed by Teipel and Hampel, strongly indicates that an AD-like pattern 
of cortical atrophy and Aβ deposition is observed in DS via high-resolution MRI (42). A recent histolog-
ical study also showed that while AD and AD-DS pathological specimens bear many similarities, there 
appears to be a significantly higher amount of NFTs in the latter (43). Because of the increased gene 
dosage characteristic of DS, research efforts have gone into establishing functional links between 
Hsa21 genes and AD pathology. To date, a few Hsa21-encoded proteins are interesting candidates for 
a mechanistic explanation of AD-DS, two of which are particularly worthy of mention: 
APP - The APP gene is located on the long arm of Hsa21. Because Aβ levels correlate with its ex-
pression (5, 26), APP triplication could primarily account for the increased rate of plaque deposition 
observed in DS. Consistent with this view, APP locus duplication has been reported in multiple fami-
lies with familial AD (44). 
DYRK1A - dual-specificity tyrosine-(Y)-phosphorylation–regulated kinase 1A is a highly conserved 
protein kinase with a multitude of phosphorylation functions. It was first identified in 1995 as the 
Drosophila gene minibrain (Mb) encoding a kinase necessary for post-embryonic neurogenesis (45). In 
humans, the DYRK1A gene is located on the long arm of Hsa21 and, particularly, in the DSCR. It is 
well established that DYRK1A essentially contributes to several features of DS, particularly learning 
disability and central nervous system (CNS) abnormalities throughout embryonic development (46). 
DYRK1A is a favourable candidate for a mechanistic contribution of Hsa21 to AD pathology, given its 
well described functional relationships with tau metabolism, gamma-secretase function and Aβ itself. 
These lines of evidence are explored in detail in chapter 4.3. 
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of CHD, with 63% presenting ventricular septal or atrioventricular defects. Additionally, decreased 
cerebellar neuronal density is observed in adult mice, as seen in DS (53, 54). While basal synaptic 
transmission in the Tc1 hippocampus appears normal, LTP is significantly reduced. Consistently, Tc1 
mice perform significantly worse than wild-type mice in the novel-object recognition task, a behav-
ioural measure of hippocampal-dependent spatial learning. Similarly to human DS, T-cell activation is 
defective in the Tc1 model. The Tc1 does not however present with significant DS-like craniofacial ab-
normalities, with the exception of a smaller mandible. Since its development, the Tc1 has been exten-
sively employed in DS research, revealing key aspects of DS pathology in cardiac development (55), 
haematopoiesis (56) and motor coordination (57), amongst others. 
The segmental trisomy/duplication (Ts/Dp) mice possess selected duplications of Mmu10/16/17 
regions syntenic to Hsa21, similarly to the Ts65Dn, albeit with much greater specificity (58, 59). Gen-
erally, to achieve Mmu10/16/17 duplications, loxP sequences were targeted to the relevant chromo-
somal regions in mESCs, and subsequently duplicated via transfection of a Cre-expression vector. 
Subsequently, chimeras and the resulting constitutive mutants were generated in a similar manner to 
the Tc1. Backcrossing with wild-type (C57BL/6J) mice across five generation was then performed to 
homogenise the genetic background. The nomenclature of the strains follows a system whereby the 
last three letters are taken from the name of the main developer. For instance, Ts1Tyb mice have been 
generated by Victor Tybulewicz’s laboratory. Dp1Tyb mice (59) - or the equivalent Ts1Yey (58) - are 
trisomic for Mmu16 regions of synteny to Hsa21, whilst the Dp1(10-17)Yey are trisomic for Mmu10-17 
regions, respectively. Interestingly, these mice can be crossed to generate a compound mutant con-
taining two duplications. The resulting mice can then be further crossed with the remaining strain, 
thereby resulting in a mutant trisomic for all Hsa21 syntenic regions. Yu et al. characterised these triple 
compound mutants, revealing an interesting phenotype (58, 60). Similarly to the Tc1, Dp mice dis-
played impairments in hippocampal LTP as well as altered performance in the Morris water maze test, 
a behavioural measure of hippocampal-dependent spatial learning. A consistent minority (~6.5%) pre-
sented congenital hydrocephalus. Although a rare occurrence, this has been observed in DS (61).  
Fig. I.4 - Genetic makeup overview of DS mouse models employed in this thesis, in relation to Hsa21.
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1.1.5 Mouse models of DS 
Since the advent of genetic engineering technology, several mouse models of DS have been devel-
oped. Historically, the most widely studied is the Ts65Dn, developed in 1990 by Davisson et al. (47). In 
the mouse, Hsa21 genes have their orthologs in portions of mouse chromosome 16 (Mmu16) and 
partly in Mmu10 and Mmu17. The Ts65Dn was developed via reciprocal translocation of mouse 
chromosomes 16 and 17 (Mmu16/17). As a result, the Ts65Dn is trisomic for most of Mmu16 regions 
of synteny to Hsa21. This model has been been employed in a vast amount of DS studies, and key 
lines of evidence on its usage are discussed in further detail throughout section 1.4. Despite its 
wide use, the Ts65Dn mouse is not trisomic for Hsa21 in its entirety, and a considerable number of 
triplicated genes are not Hsa21 orthologs. Furthermore, not all genes on the translocation chromo-
some are signiﬁcantly overexpressed (48). Therefore, recently developed mouse models, which more 
accurately recapitulate DS, are being increasingly used. With respect to this thesis, two classes of DS 
mouse models were employed. 
The transchromosomic (Tc1) mouse was developed by Elizabeth Fisher and Victor Tybulewicz in 
2005, and it is the ﬁrst mouse model to contain a near-complete, freely-segregating copy of Hsa21 
(49). The Tc1 mouse was generated through irradiation microcell-mediated chromosome transfer 
(MMCT). Via this approach, Hsa21 was harvested from human cells and subsequently inserted into 
mouse embryonic stem cells (mESCs). The original authors employed ﬂuorescence in situ hybridisa-
tion (FISH) to show that the resultant Hsa21-trisomic mESCs contain approximately 90% of Hsa21, 
with intact code for 92% of known Hsa21 genes. The transchromosomic mESCs were then inserted 
into a murine blastocyst, thereby giving rise to an Hsa21 trisomic mouse chimera. Chimeras were 
then mated with wild-type (C57BL/6J) mice to achieve germline transmission of Hsa21 and generate 
Tc1 offspring. Subsequent backcrosses were then performed to homogenise the Tc1 genetic back-
ground, although this results in decrease of Hsa21 transmission as the generations progress. Even 
when fully retained, however, the presence of Hsa21 in the Tc1 CNS is not ubiquitous, with an aver-
age of 66% brain nuclei and 55% spinal cord nuclei screening positive for Hsa21 via interphase FISH 
and quantitative polymerase chain reaction (qPCR), respectively (49). Nevertheless, because mo-
saicism is a frequent ﬁnding in human DS (50), this Tc1 feature might be advantageous. Because the 
Tc1 contains a freely-segregating Hsa21, it is predicted to more accurately recapitulate the DS pheno-
type. Indeed, overexpression of several DS-related genes (SOD1, SIM2, DYRK1A, and BACE2) is ob-
served in the Tc1 (49, 51). One prominent drawback of this model, however, is the known lack of 
functional overexpression of APP, which is reportedly deleted despite being originally introduced (51). 
This characteristics may hinder investigation of AD-DS phenotypes in the Tc1 mouse, which must 
therefore be crossed to APP transgenic models such as the J20 mouse (5). By contrast, DYRK1A ac-
tivity has been found to be increased in Tc1 young and aged brains (52). This study also characterised 
the Tc1 phenotype further, describing several DS-like features. Tc1 embryos display a high frequency 
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of CHD, with 63% presenting ventricular septal or atrioventricular defects. Additionally, decreased 
cerebellar neuronal density is observed in adult mice, as seen in DS (53, 54). While basal synaptic 
transmission in the Tc1 hippocampus appears normal, LTP is significantly reduced. Consistently, Tc1 
mice perform significantly worse than wild-type mice in the novel-object recognition task, a behav-
ioural measure of hippocampal-dependent spatial learning. Similarly to human DS, T-cell activation is 
defective in the Tc1 model. The Tc1 does not however present with significant DS-like craniofacial ab-
normalities, with the exception of a smaller mandible. Since its development, the Tc1 has been exten-
sively employed in DS research, revealing key aspects of DS pathology in cardiac development (55), 
haematopoiesis (56) and motor coordination (57), amongst others. 
The segmental trisomy/duplication (Ts/Dp) mice possess selected duplications of Mmu10/16/17 
regions syntenic to Hsa21, similarly to the Ts65Dn, albeit with much greater specificity (58, 59). Gen-
erally, to achieve Mmu10/16/17 duplications, loxP sequences were targeted to the relevant chromo-
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Subsequently, chimeras and the resulting constitutive mutants were generated in a similar manner to 
the Tc1. Backcrossing with wild-type (C57BL/6J) mice across five generation was then performed to 
homogenise the genetic background. The nomenclature of the strains follows a system whereby the 
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taining two duplications. The resulting mice can then be further crossed with the remaining strain, 
thereby resulting in a mutant trisomic for all Hsa21 syntenic regions. Yu et al. characterised these triple 
compound mutants, revealing an interesting phenotype (58, 60). Similarly to the Tc1, Dp mice dis-
played impairments in hippocampal LTP as well as altered performance in the Morris water maze test, 
a behavioural measure of hippocampal-dependent spatial learning. A consistent minority (~6.5%) pre-
sented congenital hydrocephalus. Although a rare occurrence, this has been observed in DS (61).  
Fig. I.4 - Genetic makeup overview of DS mouse models employed in this thesis, in relation to Hsa21.
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1.2 The Wnt signalling pathway 
The principal aim of this thesis is to investigate a potential role the Wnt signalling pathway in DS. The 
structure and function of this pathway is introduced here, and later discussed in more detail (4.1-3.1). 
1.2.1 Overview 
The Wnt signalling pathway is one of the most highly conserved transmembrane signalling cascades 
in the kingdom Animalia. The earliest identification in 1982 by Roel Nusse and Harold Varmus de-
scribed integration1 (Int1) as a murine proto-oncogene for breast cancer (62). The same research 
group was able, in 1987, to homologise Int1 to a well described Drosophila Melanogaster segmental 
polarity gene, wingless2 (Wg2), the deletion of which induced the widely known wingless fly mutation. 
The term Wnt was coined as a portmanteau of Wg2 and Int1. After three decades since its discovery, 
research has partly unraveled the complexity of this signalling pathway. At present, three diverse Wnt 
signalling branches have been described: the canonical/β-catenin pathway plays key roles in em-
bryonal development, the cell cycle, cancer and neurodegeneration; the non-canonical/planar cell 
polarity pathway (PCP) controls cytoskeletal rearrangement in development through activation of 
Rho GTPases and Jun N-terminal kinase (JNK); the Wnt Calcium pathway modulates cytosolic 
Ca2+ levels, activating calcium/calmodulin-dependent protein kinase II (CaMKII). Although distinct in 
structure and function, all three interact and share sensitivity to the Wnt family of ligands, of which 
over 19 members have been identified. Furthermore, all pathways are activated via the same trans-
membrane receptor family, named frizzled (Fz, see below). At present, the main focus of this thesis is 
canonical/β-catenin Wnt signalling. This pathway has its main effector in the transcriptionally active 
protein β-catenin. In the absence of Wnt ligands, cytoplasmic levels of β-catenin are maintained low 
via continuos proteasome-dependent degradation. This is achieved by a multi-protein complex known 
as the β-catenin destruction complex, which is composed of four proteins: 
I. Adenomatous poliposis coli (APC) was first identified as a tumour suppressor gene. Loss of 
APC is causative of familial adenomatous polyposis (63, 64). 
II. Axin forms the backbone of the complex and possesses binding sites for the other compo-
nents. In addition, its transcription is activated downstream of β-catenin, providing negative 
feedback for inactivation of the pathway. Axin was originally identified as an essential regulator 
of body axis formation during embryogenesis, hence its name (65). 
III. Glycogen synthase kinase 3β (GSK3β) and casein kinase I (CKI) act in partnership to phos-
phorylate β-catenin at S45 (66, 67), allowing its interaction with β-transducin repeat-containing 
protein (β-TrCP), part of an E3 ubiquitin ligase complex (68). Additionally, GSK3β phosphorylates 
axin (69), APC (70) and other components of the pathway. There are several described non-Wnt 
functions of GSK3β such as NFAT phosphorylation, hedgehog and insulin signalling (71). Impor-
tantly GSK3β has also been linked to tau phosphorylation (72, 73), an event mediated by a po-
tential interplay with DYRK1A (see 4.3.1). 
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In the context of Wnt function, the frizzled family of receptors deserves further mention. Fz proteins are a 
subtype of G protein-coupled transmembrane receptors, and 10 distinct members (Fz1-10) are currently 
known (62). Their established biological function is the initiation of Wnt signalling cascades, and all three 
branches of the pathway are invariably sensitive to Fz activation (62, 74). These receptors are highly 
conserved in nature both structurally and functionally, and play well described, key developmental roles 
in Drosophila, Xenopus, zebrafish, mice and humans. Fz mutations are known to exert deleterious ef-
fects on organismal development, for instance by preventing efficient wing formation in flies. All Fz mem-
bers possess a conserved, cysteine-rich extracellular domain implicated in ligand binding.  
Functionally, Fz receptors associate with and are activated by Wnt ligands. These are also of key impor-
tance. The Wnt ligand family comprises a diverse array of lipid-modified secreted glycoproteins, with 
over 30 subtypes described (62). Whilst all Wnt ligands are capable of Fz binding and activation, individ-
ual members generally target different branches of the pathway. For example Wnt3a, later employed in 
this thesis, is specific to canonical Wnt signalling activation (75). Conversely, Wnt7a and Wnt16 are more 
closely associated with the Wnt PCP pathway (76). The existence of crosstalk and shared Wnt ligand 
sensitivity between such branches is however known (77). Similarly to Fz receptors, Wnt ligands are 
highly conserved across species, and play key roles in the development of virtually all eukaryotic multi-
cellular organisms. Deletion of the Drosophila Wg gene, an ortholog of human Wnt genes, for instance, 
was shown to produce the famous wingless mutation in the original discovery of the pathway (62).  
Fig. I.5 - Visual overview of canonical Wnt signalling structure and activation mechanisms.
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1.2 The Wnt signalling pathway 
The principal aim of this thesis is to investigate a potential role the Wnt signalling pathway in DS. The 
structure and function of this pathway is introduced here, and later discussed in more detail (4.1-3.1). 
1.2.1 Overview 
The Wnt signalling pathway is one of the most highly conserved transmembrane signalling cascades 
in the kingdom Animalia. The earliest identification in 1982 by Roel Nusse and Harold Varmus de-
scribed integration1 (Int1) as a murine proto-oncogene for breast cancer (62). The same research 
group was able, in 1987, to homologise Int1 to a well described Drosophila Melanogaster segmental 
polarity gene, wingless2 (Wg2), the deletion of which induced the widely known wingless fly mutation. 
The term Wnt was coined as a portmanteau of Wg2 and Int1. After three decades since its discovery, 
research has partly unraveled the complexity of this signalling pathway. At present, three diverse Wnt 
signalling branches have been described: the canonical/β-catenin pathway plays key roles in em-
bryonal development, the cell cycle, cancer and neurodegeneration; the non-canonical/planar cell 
polarity pathway (PCP) controls cytoskeletal rearrangement in development through activation of 
Rho GTPases and Jun N-terminal kinase (JNK); the Wnt Calcium pathway modulates cytosolic 
Ca2+ levels, activating calcium/calmodulin-dependent protein kinase II (CaMKII). Although distinct in 
structure and function, all three interact and share sensitivity to the Wnt family of ligands, of which 
over 19 members have been identified. Furthermore, all pathways are activated via the same trans-
membrane receptor family, named frizzled (Fz, see below). At present, the main focus of this thesis is 
canonical/β-catenin Wnt signalling. This pathway has its main effector in the transcriptionally active 
protein β-catenin. In the absence of Wnt ligands, cytoplasmic levels of β-catenin are maintained low 
via continuos proteasome-dependent degradation. This is achieved by a multi-protein complex known 
as the β-catenin destruction complex, which is composed of four proteins: 
I. Adenomatous poliposis coli (APC) was first identified as a tumour suppressor gene. Loss of 
APC is causative of familial adenomatous polyposis (63, 64). 
II. Axin forms the backbone of the complex and possesses binding sites for the other compo-
nents. In addition, its transcription is activated downstream of β-catenin, providing negative 
feedback for inactivation of the pathway. Axin was originally identified as an essential regulator 
of body axis formation during embryogenesis, hence its name (65). 
III. Glycogen synthase kinase 3β (GSK3β) and casein kinase I (CKI) act in partnership to phos-
phorylate β-catenin at S45 (66, 67), allowing its interaction with β-transducin repeat-containing 
protein (β-TrCP), part of an E3 ubiquitin ligase complex (68). Additionally, GSK3β phosphorylates 
axin (69), APC (70) and other components of the pathway. There are several described non-Wnt 
functions of GSK3β such as NFAT phosphorylation, hedgehog and insulin signalling (71). Impor-
tantly GSK3β has also been linked to tau phosphorylation (72, 73), an event mediated by a po-
tential interplay with DYRK1A (see 4.3.1). 
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In the context of Wnt function, the frizzled family of receptors deserves further mention. Fz proteins are a 
subtype of G protein-coupled transmembrane receptors, and 10 distinct members (Fz1-10) are currently 
known (62). Their established biological function is the initiation of Wnt signalling cascades, and all three 
branches of the pathway are invariably sensitive to Fz activation (62, 74). These receptors are highly 
conserved in nature both structurally and functionally, and play well described, key developmental roles 
in Drosophila, Xenopus, zebrafish, mice and humans. Fz mutations are known to exert deleterious ef-
fects on organismal development, for instance by preventing efficient wing formation in flies. All Fz mem-
bers possess a conserved, cysteine-rich extracellular domain implicated in ligand binding.  
Functionally, Fz receptors associate with and are activated by Wnt ligands. These are also of key impor-
tance. The Wnt ligand family comprises a diverse array of lipid-modified secreted glycoproteins, with 
over 30 subtypes described (62). Whilst all Wnt ligands are capable of Fz binding and activation, individ-
ual members generally target different branches of the pathway. For example Wnt3a, later employed in 
this thesis, is specific to canonical Wnt signalling activation (75). Conversely, Wnt7a and Wnt16 are more 
closely associated with the Wnt PCP pathway (76). The existence of crosstalk and shared Wnt ligand 
sensitivity between such branches is however known (77). Similarly to Fz receptors, Wnt ligands are 
highly conserved across species, and play key roles in the development of virtually all eukaryotic multi-
cellular organisms. Deletion of the Drosophila Wg gene, an ortholog of human Wnt genes, for instance, 
was shown to produce the famous wingless mutation in the original discovery of the pathway (62).  
Fig. I.5 - Visual overview of canonical Wnt signalling structure and activation mechanisms.
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The basic functioning of canonical Wnt signalling, the main focus of this thesis, can be summarised as 
follows: transmembrane Fz receptors are coupled with LDL receptor related proteins 5 and 6 (LRP5/6). 
Fz activation by Wnt ligands induces translocation of the β-catenin destruction complex to the plasma 
membrane, primarily via recruitment of the second messenger dishevelled 1 (DVL1), which polymerises 
and interacts with Fz (78, 79). This, in turn, triggers LRP5/6 phosphorylation by GSK3β and CKI. Such 
assembly results in functional sequestration of GSK3β and CKI in a vesicular complex termed ‘signalo-
some’, effectively halting β-catenin phosphorylation and degradation. In this stabilised form, β-catenin 
undergoes nuclear translocation. Binding the T-cell and lymphoid enhancer 1 (TCF/LEF1) transcription 
factors therein activates expression of downstream target genes. This modality of action of β-catenin 
confers the Wnt pathway modulatory control over many biological processes. Wnt target genes (The 
Wnt Homepage, 2017) have roles in cell proliferation [Myelocytosis (MYC), CYCLIND1, vascular en-
dothelial growth factor (VEGF), fibroblast growth factor (FGF)], differentiation (brachyury, siamosis), and 
adhesion [(E-cadherin and neuronal cell-adhesion molecule (NRCAM)]. Furthermore, several compo-
nents of the pathway itself are also target genes, as introduced for axin. These include TCF/LEF, Fzs, 
LRPs and β-TrCP, demonstrating the existence of regulatory feedback mechanisms. Another important 
group of Wnt target genes are the dickkopfs (DKKs). They encode DKK1-4, the secreted canonical Wnt 
antagonists. DKKs exert their inhibitory action by interacting with LRP5/6 co-receptors and causing their 
internalisation (80). Recent evidence has also shown that DKK1 may induce activity of the Wnt PCP 
pathway, suggesting that the two Wnt pathways may operate in an antagonistic fashion (81). 
1.2.2 Wnt regulation of stem cell function 
In recent years, roles for Wnt signalling have been identified in a variety of biological processes. One of 
the most well-characterised is the extensive involvement of Wnt signalling in stem cell function. In 
mouse embryonic stem cells (mESCs), canonical and non-canonical Wnt signalling promote self-re-
newal (82). Furthermore, Wnt signalling blockade may also prevent mESC expansion. Wray et al. re-
ported that mESC expansion is mediated independently of β-catenin, while self-renewal is under con-
trol of the canonical pathway (83). In human embryonic stem cells (hESCs), partly conflicting reports 
indicate that canonical Wnt signalling may promote differentiation (84) and pluripotency (85). The cur-
rent view is that temporal modulation of Wnt signalling activity during development might allow the 
pathway to control both aspects of stem cell function (86). Similar effects have also been observed in 
stem cells within several adult tissue subtypes. These include the haematopoietic system (87), the 
small intestine (88), the lung (89) and the heart, where canonical Wnt signalling mediates cardiomy-
ocyte differentiation (90). Because of its ubiquitous role in controlling the rate of cell proliferation, aber-
rant Wnt signalling has been heavily implicated in the pathogenesis of several cancer types. An impor-
tant example is breast cancer. Canonical Wnt signalling controls maintenance of mammary gland 
stem cells (MaSCs) during breast development (91). Excessive activation of the pathway induces 
mammary gland tumorigenesis, as demonstrated by Shackleton et al. using mouse mammary tumour 
virus (MMTV) transgenic mice (92). Furthermore, Wnt signals may also mediate distal metastasis by 
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cancer stem cells (CSCs). When infiltrating a distal tissue, CSCs locally recruit Wnt ligands via expres-
sion of the fibroblast-derived protein periostin (93). Aberrant Wnt signalling is also associated with the 
development of haematological, pulmonary and gastrointestinal malignancies (86). Because of its key 
role in tumorigenesis, canonical Wnt signalling is widely considered an appealing therapeutic target for 
the next generation of cancer treatments. Waaler et al., for instance, showed that stabilisation of the 
β-catenin destruction complex with small molecule inhibitors may reduce tumour growth in mouse 
models of colonic carcinoma (94). 
1.2.3 Wnt signalling in neurodevelopment 
Given its cytoregulatory role in multiple tissue types, it is perhaps not surprising that Wnt signalling has 
also been linked to several cellular aspects of nervous system development. A historical finding in this 
context is the letter published in Nature by Thomas and Capecchi in 1990 (95). Employing chimeric 
mice homozygous for an Int1 (Wnt1) disrupting mutation, the authors reported that ablation of this 
gene produced a phenotype of severe cerebral defects and ataxia. Specifically, they demonstrated 
that Wnt1 is an essential requirement for normal development of the mesencephalon and meten-
cephalon. Further studies led to the identification of specific Wnt signalling roles in dorsal patterning 
and neural tube development. In a 1997 milestone study published in Nature, Ikeya et al. demonstrat-
ed the importance of localised Wnt signalling for neural crest expansion and differentiation (96). Abla-
tion of Wnt1 and Wnt3a signalling resulted in a severe reduction of gliogenic and neurogenic neural 
crest derivatives, particularly in the hindbrain and spinal cord of mutant mice. Indeed, β-catenin is an 
absolute requirement for mouse embryogenesis, and its homozygous deletion is embryonically lethal 
(97, 98). The neurodevelopmental functions of canonical Wnt signalling have been further investigated 
in the context of midbrain dopaminergic neurons (mDA). This neural population originates from a ven-
tral region of the neural tube, the floor plate (FP) (99). The FP also contributes to development of hind-
brain and spinal cord non-mDA neural populations, albeit with very low neurogenicity. Differential lev-
els of canonical Wnt signalling between these two regions appear to largely contribute to this discrep-
ancy (100). Conditional ablation of β-catenin in murine embryos results n a significant decrease in 
mDA number (100). Particularly, loss of canonical Wnt signalling was associated with decreased ex-
pression of mDA progenitor markers Lmx1a/b, Msx1 and Otx2. A severe reduction in progenitor pro-
liferation was also observed, and expression of the proneural gene Ngn2 was lost (100, 101). These 
results suggest that β-catenin is an important requirement in cell fate specification of mDA progenitors 
and consequently, neurogenesis. In gain-of-function studies employing a degradation-insensitive β-
catenin mouse mutant, however, ectopic stabilisation of β-catenin also resulted in overall reduction of 
mDA neurons. Despite an increase in progenitor cell number, reduced cell cycle exit was observed, 
ultimately resulting in decreased neurogenicity (102). Joksimovic et al. also reported that, in the same 
mouse model, net levels of Lmx1a/b were reduced by sustained canonical Wnt signalling (103). Dele-
tion of Dkk1 in knock-out mouse embryos may also affect Wnt-mediated neurogenesis (104). Het-
erozygous mutants display a significantly lower number of differentiated mDA neurons, while very few 
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The basic functioning of canonical Wnt signalling, the main focus of this thesis, can be summarised as 
follows: transmembrane Fz receptors are coupled with LDL receptor related proteins 5 and 6 (LRP5/6). 
Fz activation by Wnt ligands induces translocation of the β-catenin destruction complex to the plasma 
membrane, primarily via recruitment of the second messenger dishevelled 1 (DVL1), which polymerises 
and interacts with Fz (78, 79). This, in turn, triggers LRP5/6 phosphorylation by GSK3β and CKI. Such 
assembly results in functional sequestration of GSK3β and CKI in a vesicular complex termed ‘signalo-
some’, effectively halting β-catenin phosphorylation and degradation. In this stabilised form, β-catenin 
undergoes nuclear translocation. Binding the T-cell and lymphoid enhancer 1 (TCF/LEF1) transcription 
factors therein activates expression of downstream target genes. This modality of action of β-catenin 
confers the Wnt pathway modulatory control over many biological processes. Wnt target genes (The 
Wnt Homepage, 2017) have roles in cell proliferation [Myelocytosis (MYC), CYCLIND1, vascular en-
dothelial growth factor (VEGF), fibroblast growth factor (FGF)], differentiation (brachyury, siamosis), and 
adhesion [(E-cadherin and neuronal cell-adhesion molecule (NRCAM)]. Furthermore, several compo-
nents of the pathway itself are also target genes, as introduced for axin. These include TCF/LEF, Fzs, 
LRPs and β-TrCP, demonstrating the existence of regulatory feedback mechanisms. Another important 
group of Wnt target genes are the dickkopfs (DKKs). They encode DKK1-4, the secreted canonical Wnt 
antagonists. DKKs exert their inhibitory action by interacting with LRP5/6 co-receptors and causing their 
internalisation (80). Recent evidence has also shown that DKK1 may induce activity of the Wnt PCP 
pathway, suggesting that the two Wnt pathways may operate in an antagonistic fashion (81). 
1.2.2 Wnt regulation of stem cell function 
In recent years, roles for Wnt signalling have been identified in a variety of biological processes. One of 
the most well-characterised is the extensive involvement of Wnt signalling in stem cell function. In 
mouse embryonic stem cells (mESCs), canonical and non-canonical Wnt signalling promote self-re-
newal (82). Furthermore, Wnt signalling blockade may also prevent mESC expansion. Wray et al. re-
ported that mESC expansion is mediated independently of β-catenin, while self-renewal is under con-
trol of the canonical pathway (83). In human embryonic stem cells (hESCs), partly conflicting reports 
indicate that canonical Wnt signalling may promote differentiation (84) and pluripotency (85). The cur-
rent view is that temporal modulation of Wnt signalling activity during development might allow the 
pathway to control both aspects of stem cell function (86). Similar effects have also been observed in 
stem cells within several adult tissue subtypes. These include the haematopoietic system (87), the 
small intestine (88), the lung (89) and the heart, where canonical Wnt signalling mediates cardiomy-
ocyte differentiation (90). Because of its ubiquitous role in controlling the rate of cell proliferation, aber-
rant Wnt signalling has been heavily implicated in the pathogenesis of several cancer types. An impor-
tant example is breast cancer. Canonical Wnt signalling controls maintenance of mammary gland 
stem cells (MaSCs) during breast development (91). Excessive activation of the pathway induces 
mammary gland tumorigenesis, as demonstrated by Shackleton et al. using mouse mammary tumour 
virus (MMTV) transgenic mice (92). Furthermore, Wnt signals may also mediate distal metastasis by 
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cancer stem cells (CSCs). When infiltrating a distal tissue, CSCs locally recruit Wnt ligands via expres-
sion of the fibroblast-derived protein periostin (93). Aberrant Wnt signalling is also associated with the 
development of haematological, pulmonary and gastrointestinal malignancies (86). Because of its key 
role in tumorigenesis, canonical Wnt signalling is widely considered an appealing therapeutic target for 
the next generation of cancer treatments. Waaler et al., for instance, showed that stabilisation of the 
β-catenin destruction complex with small molecule inhibitors may reduce tumour growth in mouse 
models of colonic carcinoma (94). 
1.2.3 Wnt signalling in neurodevelopment 
Given its cytoregulatory role in multiple tissue types, it is perhaps not surprising that Wnt signalling has 
also been linked to several cellular aspects of nervous system development. A historical finding in this 
context is the letter published in Nature by Thomas and Capecchi in 1990 (95). Employing chimeric 
mice homozygous for an Int1 (Wnt1) disrupting mutation, the authors reported that ablation of this 
gene produced a phenotype of severe cerebral defects and ataxia. Specifically, they demonstrated 
that Wnt1 is an essential requirement for normal development of the mesencephalon and meten-
cephalon. Further studies led to the identification of specific Wnt signalling roles in dorsal patterning 
and neural tube development. In a 1997 milestone study published in Nature, Ikeya et al. demonstrat-
ed the importance of localised Wnt signalling for neural crest expansion and differentiation (96). Abla-
tion of Wnt1 and Wnt3a signalling resulted in a severe reduction of gliogenic and neurogenic neural 
crest derivatives, particularly in the hindbrain and spinal cord of mutant mice. Indeed, β-catenin is an 
absolute requirement for mouse embryogenesis, and its homozygous deletion is embryonically lethal 
(97, 98). The neurodevelopmental functions of canonical Wnt signalling have been further investigated 
in the context of midbrain dopaminergic neurons (mDA). This neural population originates from a ven-
tral region of the neural tube, the floor plate (FP) (99). The FP also contributes to development of hind-
brain and spinal cord non-mDA neural populations, albeit with very low neurogenicity. Differential lev-
els of canonical Wnt signalling between these two regions appear to largely contribute to this discrep-
ancy (100). Conditional ablation of β-catenin in murine embryos results n a significant decrease in 
mDA number (100). Particularly, loss of canonical Wnt signalling was associated with decreased ex-
pression of mDA progenitor markers Lmx1a/b, Msx1 and Otx2. A severe reduction in progenitor pro-
liferation was also observed, and expression of the proneural gene Ngn2 was lost (100, 101). These 
results suggest that β-catenin is an important requirement in cell fate specification of mDA progenitors 
and consequently, neurogenesis. In gain-of-function studies employing a degradation-insensitive β-
catenin mouse mutant, however, ectopic stabilisation of β-catenin also resulted in overall reduction of 
mDA neurons. Despite an increase in progenitor cell number, reduced cell cycle exit was observed, 
ultimately resulting in decreased neurogenicity (102). Joksimovic et al. also reported that, in the same 
mouse model, net levels of Lmx1a/b were reduced by sustained canonical Wnt signalling (103). Dele-
tion of Dkk1 in knock-out mouse embryos may also affect Wnt-mediated neurogenesis (104). Het-
erozygous mutants display a significantly lower number of differentiated mDA neurons, while very few 
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Dkk1 -/- embryos survive, suffering from severe abnormalities in morphogenesis and impaired fore-
brain development. These somewhat counterintuitive findings offer insight into the complexity of neu-
rodevelopmental Wnt signalling, demonstrating that tight control of β-catenin levels is required for 
mDA neurogenesis, with alterations in both directions exerting deleterious effects. 
1.2.4 Wnt signalling in synaptogenesis and memory 
Over the last decade, several studies have demonstrated that Wnt signalling is functionally indispens-
able for synaptic assembly and organisation (105). One of the earliest reports is a 2000 study by Hall 
et al. (106). The authors demonstrate that Wnt signalling is required for synapse formation at the 
presynaptic cerebellar input interface. Specifically, Wnt7a signalling modulates mossy fibre axon re-
modelling by decreasing axonal extension and stimulating growth cones in mouse cerebellar slices. 
Within the same anatomical system, deletion of Wnt7a resulted in altered distribution of presynaptic 
markers and morphological abnormalities in presynaptic axons (107). Moreover, DVL1 ablation en-
hanced this effect, with Wnt7a/DVL1 double mutant mice exhibiting impairments in neurotransmitter 
release at mossy fibre-granule cell synapses. Particularly, the frequency of miniature postsynaptic ex-
citatory currents was reduced. In mossy fibres, administration of Wnt ligands resulted in increased 
synaptic vesicle recycling (107). The importance of Fz receptors in synaptic formation has also been 
elucidated. In hippocampal cultures, Fz1-mediated Wnt3a signalling acts to increase the number of 
presynaptic terminals (108), while Wnt7a may promote synaptogenesis via Fz5 stimulation (109). 
Through concomitant action of the non-canonical and calcium pathways, Wnts also control postsy-
naptic assembly. Wnt7a is an interesting example. In the hippocampus, it stimulates the presynaptic 
terminal via the canonical pathway (110), while also activating CaMKII in the postsynaptic terminal, 
promoting dendritic spine growth and resulting in increased synaptic strength (76). The non-canonical 
and calcium pathways are able to modulate several other aspects of synaptic transmission, such as 
amplitude of inhibitory currents and GABA-A receptor number (111). Beyond synapse formation, Wnt 
signalling has important roles in maintenance of synapse function in mature neurons. Several studies 
have documented the ubiquitous expression of Wnt signalling components in the adult brain (109, 
112, 113). Purro et al. also showed that short-term exposure to DKK1 induces synaptic loss in mature 
neurons (114). Particularly, it appears to provoke changes in synaptic protein clustering, promoting 
dispersion from synaptic terminals whilst not altering overall protein levels. This effect is rescued by 
Wnt ligands, indicating that tight control of Wnt signalling is required for effective synaptic maintenance. 
Fig. I.6 - Visual summary of some known Wnt signalling target genes.
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1.2.5 Wnt signalling in AD 
As introduced previously, clinical impairment in short term memory, accompanied by progressively 
widespread synaptic loss, is an early and invariant feature of AD. Thus, given the prominent role of 
Wnt components in synaptic assembly and maintenance, a functional relationship between AD and 
aberrant Wnt signalling is not unexpected. Indeed, multiple lines of evidence have described this rela-
tionship in recent years, revealing a complex network of interactions. At the population level, a 
genome-wide association study reported the existence of an LRP6 genetic variant with significant 
links to late onset, sporadic AD (115). Such polymorphism results in reduced expression of Wnt target 
genes. Additionally, post-mortem cortical samples of AD patients demonstrate increased levels of 
DKK1 (116), while clinical findings indicate that DKK3, closely related in structure and function to 
DKK1, is elevated in plasma and cerebrospinal fluid (CSF) samples of AD patients (117). Mutations in 
presenilin-1 (PSEN1), an integral part of the γ-secretase complex, the enzymatic assembly responsi-
ble for APP cleavage into Aβ, have been linked to development of FAD. Earlier reports demonstrate 
that such mutations exert a modulatory effect on intracellular β-catenin levels, either decreasing (118), 
or increasing them (119). PSEN1 has also been shown to associate with GSK3β (120). Furthermore, 
inhibition of canonical Wnt signalling via GSK3β overexpression significantly increases the rate of tau 
phosphorylation (121, 122). Conversely Rosso et al. showed that GSK3β inhibition is a protective fac-
tor against Aβ-mediated synaptotoxicity (123). Consistently, evidence suggests that Wnt3a signalling 
activation in mice can prevent Aβ toxicity, decrease tau phosphorylation (124) and reduce the amount 
of several AD neuropathological markers (125). It is now clearly understood from in vitro evidence that 
Aβ may interact with multiple components of the Wnt pathway. For instance, it was shown to as-
sociate with the Fz receptor family (126), while the APP intracellular domain, a cytosolic counterpart of 
Fig. I.7 - Visual summary of known Wnt signalling functions.
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Dkk1 -/- embryos survive, suffering from severe abnormalities in morphogenesis and impaired fore-
brain development. These somewhat counterintuitive findings offer insight into the complexity of neu-
rodevelopmental Wnt signalling, demonstrating that tight control of β-catenin levels is required for 
mDA neurogenesis, with alterations in both directions exerting deleterious effects. 
1.2.4 Wnt signalling in synaptogenesis and memory 
Over the last decade, several studies have demonstrated that Wnt signalling is functionally indispens-
able for synaptic assembly and organisation (105). One of the earliest reports is a 2000 study by Hall 
et al. (106). The authors demonstrate that Wnt signalling is required for synapse formation at the 
presynaptic cerebellar input interface. Specifically, Wnt7a signalling modulates mossy fibre axon re-
modelling by decreasing axonal extension and stimulating growth cones in mouse cerebellar slices. 
Within the same anatomical system, deletion of Wnt7a resulted in altered distribution of presynaptic 
markers and morphological abnormalities in presynaptic axons (107). Moreover, DVL1 ablation en-
hanced this effect, with Wnt7a/DVL1 double mutant mice exhibiting impairments in neurotransmitter 
release at mossy fibre-granule cell synapses. Particularly, the frequency of miniature postsynaptic ex-
citatory currents was reduced. In mossy fibres, administration of Wnt ligands resulted in increased 
synaptic vesicle recycling (107). The importance of Fz receptors in synaptic formation has also been 
elucidated. In hippocampal cultures, Fz1-mediated Wnt3a signalling acts to increase the number of 
presynaptic terminals (108), while Wnt7a may promote synaptogenesis via Fz5 stimulation (109). 
Through concomitant action of the non-canonical and calcium pathways, Wnts also control postsy-
naptic assembly. Wnt7a is an interesting example. In the hippocampus, it stimulates the presynaptic 
terminal via the canonical pathway (110), while also activating CaMKII in the postsynaptic terminal, 
promoting dendritic spine growth and resulting in increased synaptic strength (76). The non-canonical 
and calcium pathways are able to modulate several other aspects of synaptic transmission, such as 
amplitude of inhibitory currents and GABA-A receptor number (111). Beyond synapse formation, Wnt 
signalling has important roles in maintenance of synapse function in mature neurons. Several studies 
have documented the ubiquitous expression of Wnt signalling components in the adult brain (109, 
112, 113). Purro et al. also showed that short-term exposure to DKK1 induces synaptic loss in mature 
neurons (114). Particularly, it appears to provoke changes in synaptic protein clustering, promoting 
dispersion from synaptic terminals whilst not altering overall protein levels. This effect is rescued by 
Wnt ligands, indicating that tight control of Wnt signalling is required for effective synaptic maintenance. 
Fig. I.6 - Visual summary of some known Wnt signalling target genes.
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1.2.5 Wnt signalling in AD 
As introduced previously, clinical impairment in short term memory, accompanied by progressively 
widespread synaptic loss, is an early and invariant feature of AD. Thus, given the prominent role of 
Wnt components in synaptic assembly and maintenance, a functional relationship between AD and 
aberrant Wnt signalling is not unexpected. Indeed, multiple lines of evidence have described this rela-
tionship in recent years, revealing a complex network of interactions. At the population level, a 
genome-wide association study reported the existence of an LRP6 genetic variant with significant 
links to late onset, sporadic AD (115). Such polymorphism results in reduced expression of Wnt target 
genes. Additionally, post-mortem cortical samples of AD patients demonstrate increased levels of 
DKK1 (116), while clinical findings indicate that DKK3, closely related in structure and function to 
DKK1, is elevated in plasma and cerebrospinal fluid (CSF) samples of AD patients (117). Mutations in 
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Fig. I.7 - Visual summary of known Wnt signalling functions.
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Aβ, promotes neurite outgrowth via canonical Wnt signalling inhibition (127). Particular effort has gone 
into examining the relationship between Aβ and DKK1. Following administration of exogenous Aβ, 
synaptic disassembly was induced concurrently with increased expression of DKK1 in murine brain 
slices (114). In the same study, a DKK1 neutralising antibody was able to prevent Aβ-mediated synap-
totoxicity. Consistent with this evidence, Killick et al. revealed an interesting relationship between the 
canonical and PCP pathways (81). It appears that clusterin, a canonical Wnt target gene (128), is re-
quired for the mutual interaction of Aβ and DKK1. While intracellular levels of clusterin increased fol-
lowing Aβ treatment, knockdown of clusterin reduced the Aβ-mediated increase in DKK1 expression. 
Examined against whole-genome protein expression levels in mouse primary neurons, this Aβ/clus-
terin/DKK1 pathway was then shown to drive the expression of several PCP target genes (81). Thus, 
the synaptotoxic effects of Aβ might be underlined by an altered balance between activity of the 
canonical and PCP Wnt signalling pathways.  
More recent studies increasingly support the notion of suppressed Wnt activity in AD, as well as the 
interesting possibility of therapeutic targeting of this pathway. A literature review by Cisternas and Ine-
strosa (129) discussed the importance of cerebral glucose metabolism as a crucial contributor to AD. 
This phenomenon is well known. Decreased neuronal glucose uptake and impaired metabolism is in 
fact observed in AD and other neurodegenerative diseases, and is regarded as an early mediator of 
cellular pathology. The authors argue that current evidence implicates Wnt signalling in the regulation 
of neuronal energy metabolism, with particular relevance to AD. This proposal strengthens the notion 
that therapeutic normalisation of Wnt activity in AD might constitute an effective strategy. In parallel, 
Machhi et al. recently reported on the neuroprotective effects of multi-targeted isoalloxazine deriva-
tives in rodent models of AD (130). These compounds display dual anticholinesterase and anti-Aβ ag-
gregatory and activity. The former is a known protective factor in AD, and constitutes the basis for 
currently available therapies (19). Importantly, the authors demonstrated a significant association of 
isoalloxazine treatment with Wnt signalling stimulation. AD-beneficial effects were in fact observed 
concomitantly to enhanced β-catenin and neuroD1 levels in a rat model. The latter is a well known 
Wnt target gene. These findings suggest that amelioration of AD pathology is functionally accompa-
nied by Wnt signalling activation, thus providing further support to the disease relevance of this path-
way. A similar correlation was also identified with an alternative treatment strategy for AD. In a recent 
study by Jin et al., administration of sodium selenate therapy significantly reduced AD pathology in a 
triple transgenic mouse model (131). Similarly to the Machhi et al. report, concurrent Wnt signalling 
activation was detected in selenium-treated mice, with increased levels of β-catenin and target genes 
as well as GSK3β inhibition. Data from these two studies therefore suggest that distinct AD treatment 
approaches invariably correlate with enhanced Wnt activity markers. It follows that regardless of which 
method is chosen to reduce AD pathology, canonical Wnt signalling appears to be stimulated in corre-
lation. This line of reasoning indicates a potentially critical Wnt contribution to AD. 
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Taken together, these lines of evidence indicate that alterations in Wnt signalling and AD are likely in-
terrelated. As well as interacting with APP/Aβ on multiple levels, Wnt signalling is implicated in neuro-
genesis, synaptic formation and viability, all of which are essential aspects of neuronal homeostasis. In 
parallel to recent developments in cancer biology, Wnt signalling is thus being increasingly perceived 
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1.3 Wnt signalling in DS and AD-DS? 
The essentials of AD, DS and AD-DS pathology have been considered. A vast amount of evidence 
suggests an accelerated process of AD-like pathogenesis in DS, supporting the idea that overex-
pressed Hsa21 genes exert a facilitatory effect on this phenomenon. Furthermore, an overview of the 
roles of Wnt signalling in several neuronal homeostatic processes suggests that altered Wnt activity 
influences AD pathology on multiple levels. Thus, provided that consistent AD-DS and AD-Wnt rela-
tionships exist, the possibility that altered Wnt signalling might also contribute to DS and AD-DS war-
rants investigation. This notion constitutes the primary hypothesis of this thesis. 
Fig. I.9 - The primary hypothesis. Available evidence suggests dysfunctional Wnt signalling may be associated with DS.
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In support of this idea a further line of evidence deserves mention, that is, multiple Hsa21 genes 
have been found to interact with Wnt signalling. As introduced above, the APP intracellular do-
main is a canonical Wnt signalling inhibitor which can modulate neurite morphology (127). As a 
favourable candidate for a functional AD-DS relationship, the interaction of APP with Wnt signalling 
raises the possibility that enhanced modulation of the pathway may result from enhanced APP gene 
dosage. Furthermore, the Hsa21 gene TIAM1 has been identified as a Wnt target gene promoting in-
testinal tumour development in mouse models (132). Importantly, DYRK1A was recently shown to be 
a positive regulator of the δ-catenin/Kaiso pathway, increasing δ-catenin levels in X.Laevi embryos 
and mammalian cells (133). This is a ramification of canonical Wnt signalling, with δ and β-catenin 
sharing high similarity. δ-catenin binds to the kaiso transcription factor, driving the expression of sev-
eral target genes, some of which are in common with canonical genes (siamosis, Wnt1). Studies have 
also revealed an important relationship between DYRK1A, GSK3β and tau. While DYRK1A phospho-
rylates tau at T212, this interaction has been shown to prime tau for further phosphorylation by 
GSK3β at S208 and eventual degradation (72, 73). The DYRK1A-Wnt relationship is explored in more 
detail in the introduction to chapter 4.3. 
Fig. I.10 - Preliminary evidence suggests multiple Hsa21-encoded proteins may function as Wnt signalling regulators, 
thus supporting the formulation of a candidate gene hypothesis for this thesis.
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1.4 Genes and proteins of DS: a literature overview 
The main hypothesis or this thesis was formulated in section 1.3. Before considering experimental 
results, however, it is essential to discuss the complex landscape of gene expression and protein ab-
normalities in DS. This section outlines current knowledge on these two fundamental aspects by criti-
cally assessing the available evidence. This also provides a theoretical framework to justify the exper-
imental approaches undertaken in this thesis. 
1.4.1 The DS transcriptome 
Given the genetic origin of DS pathology, it follows that the defining characteristics of this condition 
are necessarily mediated by primary alterations in gene expression. Thus it is not surprising that this 
aspect of DS has been heavily investigated over the last few decades. In light of this, the main features 
of gene expression in DS, as well as key findings in the field, are discussed in the following sections. 
1.4.1.1 The role of transcriptomics in the understanding of DS 
Massively parallel complementary DNA (cDNA) sequencing, or RNA sequencing (RNAseq), is a well-
established technique, which exploits the fundamental principle that the amount of transcript mRNA 
directly correlates with gene expression levels. This area of study is broadly known as transcriptomics. 
This relatively recent field has experienced great advances in the past decade (134), both for the fun-
damental understanding of the dynamic nature of the genome and for the investigation into a high 
number of diseases in which altered gene expression plays a key role. While the technique was origi-
nally based on microarray hybridisation technology, the advent of high-throughput next generation 
sequencing (NGS) has allowed analysis of the transcriptome to be performed on a much larger scale.  
Since the discovery of trisomy 21 as the primary cause of DS (1), investigation of the mechanisms 
mediating the phenotypic effects of this aneuploidy has proved challenging. The supernumerality of 
Hsa21 results in extremely complex, multi-layered effects on the transcriptome, the analysis of which 
can be hindered by several confounding factors. Gene expression variability, phenotypic heterogeneity 
and differential epigenetic stimuli are amongst the most important. As of today, no clear consensus 
exists still on whether features of DS are solely mediated by functional alteration of trisomic genes, or 
arise as a global effect of aneuploidy, notwithstanding the genetic repertoire of Hsa21 (135). Both 
mechanisms likely contribute to DS. However, the inherent difficulty in clarifying exactly if, and how the 
transcriptome is altered in this condition warrants the need for approaches which minimise confound-
ing factors. Experiments conducted so far have been mostly based on quantitative real-time PCR 
(qPCR), fluorescent in situ-hybridisation (FISH) microarray and NGS strategies. In the context of DS, 
these approaches have served three purposes: to confirm and characterise the aneuploid status of 
the mouse strains or human samples under examination, to investigate genome-wide alterations in 
expression signatures, and to extrapolate functional significance from such alterations. These princi-
ples were also exploited in the work described in chapter 4.1., and will serve as a conceptual basis for 
justifying the approach undertaken. 
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1.4.1.2 Gene expression profiling in DS mouse models 
Beginning in the early 2000s, a considerable amount of literature has investigated the transcriptome of 
DS mouse models (see introduction 1.1.5. for an overview of models). A seminal example is a study 
by the Antonarakis group, published in 2000 (136). In the classical Ts65Dn segmental trisomy model, 
the authors employed serial analysis of gene expression (SAGE) to probe the brain transcriptome of 
this mouse strain. Results revealed 330 differentially expressed (DEX) genes spanning several mouse 
chromosomes, 14 of which encoding ribosomal proteins. Aside from considerations regarding ribo-
somal dysfunction in DS, this study first contributed to sequencing of the mouse brain transcriptome. 
Additionally, it demonstrated the general principle that aneuploid gene dosage imbalance is not limited 
to trisomic genes, but results in genome-wide changes in expression. Similarly, subsequent work by 
Saran et al. (137) investigated the cerebellar transcriptome of the same model, in an attempt to eluci-
date mechanisms underlying the well known cerebellar dysmorphology of DS. The study found that 
overexpression of the 124 genes duplicated in the Ts65Dn cerebellum resulted in the presence of 
thousands of DEX genes, which the authors termed ‘variable trisomic transcriptome’ (VTT - this fitting 
term is henceforth adopted to refer to variability in the DS transcriptome). Concurrently, Lyle et al. em-
ployed the same mouse model to investigate expression levels of Hsa21 orthologs in six tissue types 
(138). The notion that such genes would undergo 1.5-fold overexpression in DS was mostly theoreti-
cal at the time, and this study elucidated a very important principle. The authors in fact demonstrated 
that, whilst overall the mean overexpression was close to 1.5-fold, just over a third (37%) of duplicated 
genes were expressed at this ratio. The remainder was overexpressed either below 1.5, above, or not 
overexpressed at all (for about 9% of theoretically duplicated genes). This pioneering finding implies 
the existence of complex regulatory mechanisms determining the DS phenotype, which are not nec-
essarily dependent on gene dosage only. Similarly, another study in the Ts65Dn mouse examined ex-
pression patterns of duplicated genes across nine tissue types (139). The majority demonstrated en-
hanced transcript levels, but several genes did not.  
More recent work has helped identify molecular processes potentially altered in DS, by combining 
transcriptomics with gene ontology analysis. A microarray-based study of the Ts1Cje mouse brain 
(see 1.1.5.) identified 317 DEX genes (140), mostly associated with the cerebellum and hippocampus. 
In addition to supporting the VTT theory, these results also demonstrated a unique gene expression 
profile in the Ts1Cje mouse. Functional clustering analysis predicted significant dysregulation of the 
interferon signalling pathway, establishing potential target molecular networks and highlighting the 
complex effects of aneuploidy on signalling networks. Additional molecular pathways of potential in-
terest were also identified by Guedj and colleagues (141). This study investigated gene expression in 
the adult Ts1Cje mouse hippocampus and cerebral cortex. DEX genes were significantly more con-
spicuous in the hippocampus than the cortex and, similarly to all other studies discussed, spanned 
several chromosomes. Functional analysis identified NFAT signalling and neuroinflammation as poten-
tially affected processes. The same group also investigated the foetal brain transcriptome of the Ts1C-
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je mouse (142). They identified 71 DEX genes in embryonic (E15.5) Ts1Cje brains. Interestingly, func-
tional analysis demonstrated upregulation of cell cycle markers and dysregulation of processes such 
as apoptosis and inflammation. This study provided key insight on potentially altered mechanisms at a 
critical stage of brain development, and detailed prenatal manifestations of the DS phenotype. The 
clear differences in genetic signatures between embryonic and adult Ts1Cje mouse brains (141, 142) 
also exemplify that the VTT is extremely dynamic on the temporal scale. This suggests that, in DS, the 
effects of Hsa21 trisomy on the transcriptome likely vary considerably throughout life. 
RNAseq in DS mouse models has also been very useful in characterising recently developed strains. 
The Tc1 mouse, employed in this thesis, is the first DS model expressing a near complete, freely seg-
regating Hsa21 (49). In an effort to determine the weight of each dosage-sensitive Tc1 gene, Gribble, 
Wiseman et al. combined fluorescent in situ hybridisation (FISH) with NGS technology to investigate 
the architecture of the human chromosome in this mouse (51). Results indicated that a number of 
previously unknown structural alterations of Tc1-Hsa21 are present in this mouse. The irradiation-
transferred chromosome displayed 25 de novo rearrangements, six duplications and one deletion. 
These data provided valuable knowledge to researchers employing the Tc1 mouse to investigate its 
DS phenotype. Overall, the authors identified 50 Tc1-Hsa21 genes as either disrupted or deleted, and 
thus not functionally trisomic. These included APP - already identified as disomic in the Tc1 mouse 
(49) - and the leukaemia-relevant RUNX1 gene. The key implication of these findings is that DS-like 
phenotypes described in the Tc1 mouse are unlikely to be mediated by any of the deleted genes, 
some of which are heavily implicated in DS pathology. Thus, this study provided means to reduce 
confounding factors when assessing data generated in the Tc1 mouse, including several experiments 
carried out as part of this thesis. Additionally, the authors proposed a definitive structure for Tc1-
Hsa21, and this study for the first time detailed the effects of irradiation on a human chromosome. 
Interestingly, the transcriptome-based approach has also aided investigation of strategies to amelio-
rate behavioural deficits of DS mouse models. One example is a recent study of the Ts65Dn cerebellar 
transcriptome (143). The authors investigated the effects of regular exercise on locomotor deficits of 
these mice, and probed the cerebellar transcriptome for gene expression changes. Strikingly, lifelong 
running was sufficient to alter the expression of 4,315 genes, a five-fold increase compared to euploid 
mice subjected to regular exercise. Functional annotation revealed alterations in a wide range of bio-
logical processes, most notably regulation of apoptosis and neurogenesis. In addition, several sig-
nalling pathways linked to the cell cycle were also found to be enhanced in activity. Therefore, in addi-
tion to demonstrating the beneficial effects of a behavioural intervention in the Ts65Dn mouse, the au-
thors also linked said amelioration to clear gene expression patterns. Overall, the studies discussed 
detail the advancing knowledge on the DS mouse transcriptome, and demonstrate the fundamental 
principle of the VTT, its dynamic nature and genome-wide occurrence. Additionally, they provided the 
evidential basis for combining transcriptomics with functional analysis in the exploration of target mol-
ecular pathways in DS. 
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1.4.1.3 Gene expression profiling in human DS 
Similarly to the work conducted in mice, several studies have characterised the transcriptome of hu-
man DS individuals, providing vital information on the complex genetic picture underlying this aneu-
ploidy. Performing such studies on humans has the added benefit of generating more DS-relevant 
data, with gene expression patterns originating from endogenously trisomic Hsa21 genes. However, 
confounding factors arise more commonly than in mice, owing to difficulties in generating sample 
groups with homogenous genetic background, a task easily achievable in mice through backcrossing 
and employment of littermates. Nevertheless, several studies performed on the human DS transcrip-
tome exist which partly overcome this limitation. The ideal approach, as outlined by Antonarakis (135), 
is to identify pairs of monozygotic twins discordant for DS. Due to the extreme rarity of this occur-
rence, only one report exists at present (144). 
One of the first examples of gene expression profiling in human autosomal trisomy is a microarray-
based study in cells derived from trisomies 21/13 embryos (145). Trisomic genes were found to be 
upregulated only modestly (<1.3), and high variability in expression profiles was observed amongst 
trisomic samples. However, the authors observed that the vast majority of overexpressed genes did 
not map to trisomic regions of the genome. Similarly to the work in mice discussed above, this study 
led to the novel observation of secondary, genome-wide effects of Hsa21 trisomy on the VTT. The au-
thors argue that whilst primary transcriptional alterations may be modest, secondary effects on non-
trisomic genes are likely much more pervasive. A subsequent investigation was performed in the heart 
and cerebellum of 11 DS foetuses during mid-gestation (146). Whilst the experimental design suffered 
from a mix of genders and a difference in ethnicity between DS individuals (caucasian) and euploid 
controls (African American), results clearly demonstrated enhanced transcript levels for most Hsa21 
genes. This finding highlighted the presence of primary alterations of the foetal DS transcriptome. In 
addition, the analysis also revealed the presence of 19 non-Hsa21 DEX genes, yet again in support of 
the VTT theory. An important step in characterising gene-dosage effects of trisomy on Hsa21 tran-
script levels was made by investigating adult DS-derived lymphoblastoid cells (147). Interestingly, re-
sults demonstrated that only 29% of Hsa21 transcripts (22% genes, 7% open reading frames) were 
actually overexpressed in the trisomic group. The remainder was compensated and present at similar 
expression levels to euploid controls, with a smaller proportion (15%) displaying high variability 
amongst individual cases. Perhaps surprisingly, these data imply that dosage imbalance effects only 
apply to a minority of Hsa21 genes. The authors thus conclude that this minority gene set is more 
likely to be responsible for the DS phenotype. Additionally, they speculate that the highly variable 
genes might underpin the phenotypic heterogeneity of DS individuals. These data are in line with pre-
vious findings in the Ts65Dn mouse discussed in 4.1.1.2 (138), and expanded on the key principle 
that the contribution of individual Hsa21 genes to DS is far from homogenous. This notion allows sub-
sequent work, including this thesis, to focus the aim on candidate Hsa21 genes more likely to con-
tribute significantly to DS. In the context of brain development, another study investigated the frontal 
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je mouse (142). They identified 71 DEX genes in embryonic (E15.5) Ts1Cje brains. Interestingly, func-
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regating Hsa21 (49). In an effort to determine the weight of each dosage-sensitive Tc1 gene, Gribble, 
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(49) - and the leukaemia-relevant RUNX1 gene. The key implication of these findings is that DS-like 
phenotypes described in the Tc1 mouse are unlikely to be mediated by any of the deleted genes, 
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nalling pathways linked to the cell cycle were also found to be enhanced in activity. Therefore, in addi-
tion to demonstrating the beneficial effects of a behavioural intervention in the Ts65Dn mouse, the au-
thors also linked said amelioration to clear gene expression patterns. Overall, the studies discussed 
detail the advancing knowledge on the DS mouse transcriptome, and demonstrate the fundamental 
principle of the VTT, its dynamic nature and genome-wide occurrence. Additionally, they provided the 
evidential basis for combining transcriptomics with functional analysis in the exploration of target mol-
ecular pathways in DS. 
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1.4.1.3 Gene expression profiling in human DS 
Similarly to the work conducted in mice, several studies have characterised the transcriptome of hu-
man DS individuals, providing vital information on the complex genetic picture underlying this aneu-
ploidy. Performing such studies on humans has the added benefit of generating more DS-relevant 
data, with gene expression patterns originating from endogenously trisomic Hsa21 genes. However, 
confounding factors arise more commonly than in mice, owing to difficulties in generating sample 
groups with homogenous genetic background, a task easily achievable in mice through backcrossing 
and employment of littermates. Nevertheless, several studies performed on the human DS transcrip-
tome exist which partly overcome this limitation. The ideal approach, as outlined by Antonarakis (135), 
is to identify pairs of monozygotic twins discordant for DS. Due to the extreme rarity of this occur-
rence, only one report exists at present (144). 
One of the first examples of gene expression profiling in human autosomal trisomy is a microarray-
based study in cells derived from trisomies 21/13 embryos (145). Trisomic genes were found to be 
upregulated only modestly (<1.3), and high variability in expression profiles was observed amongst 
trisomic samples. However, the authors observed that the vast majority of overexpressed genes did 
not map to trisomic regions of the genome. Similarly to the work in mice discussed above, this study 
led to the novel observation of secondary, genome-wide effects of Hsa21 trisomy on the VTT. The au-
thors argue that whilst primary transcriptional alterations may be modest, secondary effects on non-
trisomic genes are likely much more pervasive. A subsequent investigation was performed in the heart 
and cerebellum of 11 DS foetuses during mid-gestation (146). Whilst the experimental design suffered 
from a mix of genders and a difference in ethnicity between DS individuals (caucasian) and euploid 
controls (African American), results clearly demonstrated enhanced transcript levels for most Hsa21 
genes. This finding highlighted the presence of primary alterations of the foetal DS transcriptome. In 
addition, the analysis also revealed the presence of 19 non-Hsa21 DEX genes, yet again in support of 
the VTT theory. An important step in characterising gene-dosage effects of trisomy on Hsa21 tran-
script levels was made by investigating adult DS-derived lymphoblastoid cells (147). Interestingly, re-
sults demonstrated that only 29% of Hsa21 transcripts (22% genes, 7% open reading frames) were 
actually overexpressed in the trisomic group. The remainder was compensated and present at similar 
expression levels to euploid controls, with a smaller proportion (15%) displaying high variability 
amongst individual cases. Perhaps surprisingly, these data imply that dosage imbalance effects only 
apply to a minority of Hsa21 genes. The authors thus conclude that this minority gene set is more 
likely to be responsible for the DS phenotype. Additionally, they speculate that the highly variable 
genes might underpin the phenotypic heterogeneity of DS individuals. These data are in line with pre-
vious findings in the Ts65Dn mouse discussed in 4.1.1.2 (138), and expanded on the key principle 
that the contribution of individual Hsa21 genes to DS is far from homogenous. This notion allows sub-
sequent work, including this thesis, to focus the aim on candidate Hsa21 genes more likely to con-
tribute significantly to DS. In the context of brain development, another study investigated the frontal 
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cortical transcriptome of DS foetuses at mid-gestation (148). Examining neural progenitor cells, the 
authors demonstrated an average 1.5-fold transcriptional enhancement of the DSCR (see introduction 
1.1.2 for overview). Additionally, they identified a global disturbance in gene expression profiles, with 
as many as 1902 DEX genes. Ingenuity pathway analysis (IPA - see 4.1.1.4) was then employed to 
probe the dataset for functional links with cellular mechanisms and signalling pathways. Most notably, 
they detected associations with the cell cycle, cell death and oxidative stress. The latter process is 
then linked to overexpression of the Hsa21 gene S100 calcium-binding protein B (S100B). These data 
imply that, in the developing DS brain, neural progenitor cells might sustain enhanced oxidative stress. 
Perhaps more importantly, however, this study lent support to the notion that Hsa21 trisomy indeed 
results in pervasive transcriptional alterations. 
As introduced, substantial phenotypic heterogeneity is present in DS. It follows that investigation of 
gene expression patterns underlying such variability is critical to the understanding of this condition. A 
study of human DS-derived lymphoblastoid and fibroblast cell lines assessed the extent of this vari-
ability (149). qPCR was employed to measure the expression of 100 and 106 Hsa21 genes in the two 
tissue types, respectively. Similarly to Ait Yahya-Graison et al. (147), results found only a proportion of 
Hsa21 genes to be overexpressed in lymphoblastoid (39%) and fibroblast (62%) cell lines. Importantly, 
the authors compared gene expression variability between DS and euploid samples employing the 
Kolmogorov-Smirnov test. This is a standard statistical test used to determine whether a probability 
distribution significantly deviates from a reference distribution. The analysis resulted in three groups of 
gene expression distributions, ranked based on the degree of overlap with euploid distributions. The 
authors argue that the gene group with distinct non-overlapping distribution contains genes likely me-
diating the DS phenotype. By contrast, Hsa21 genes with expression variability comparable to euploid 
samples are not dosage-sensitive, and thus less involved in DS traits. This study is of fundamental 
importance. It highlighted that despite trisomy, a considerable proportion of Hsa21 genes displays 
normal expression variability. This notion is to be taken into consideration when selecting candidate 
genes for further study. Additional insight into the relative contribution of Hsa21 regions to the DS 
phenotype comes from the study of partial trisomy cases (150). These are a rarer occurrence, yet al-
lowing for more detailed dissection of DS traits. The authors employed microarray hybridisation to in-
vestigate 19 cases of partial trisomy 21. They identified distinct susceptibility regions of trisomy for 25 
DS clinical phenotypes mapping to several Hsa21 segments. Whilst these data imply that multiple 
Hsa21 portions contribute to different aspects of DS, the majority of susceptibility regions mapped to 
to a ~10 Mb portion of the chromosome. This study provided key evidence on the contribution of 
Hsa21 to the DS phenotype, further highlighting how not all chromosomal regions might be essential 
for pathology.  
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Whilst microarray studies have provided key findings elucidating gene expression in DS, they suffer 
from the limitation of only probing for a small fraction of available RNA. A more recent study employed 
large-scale RNAseq to probe the transcriptome of DS endothelial progenitor cells (151). This ap-
proach foremost demonstrated the complexity of the VTT, providing evidence for intronic transcription 
and alternative splicing of overexpressed genes. In addition to these key findings, the authors also 
identified 1787 DEX genes spanning the entire genome. Of these, 956 and 831 were up- and down-
regulated, respectively. Interestingly, only 55 of the 132 Hsa21 genes expressed in endothelial progen-
itors were elevated in DS cells. Thus, large-scale RNAseq provided evidence of previously unde-
scribed genetic mechanisms in DS, whilst also supporting the VTT theory and the heterogenous con-
tribution of Hsa21 genes. Other studies have profiled gene expression in DS at finer resolution, leading 
to interesting findings. Sullivan et al recently made a key discovery on the immune response in DS 
(152). Employing large-scale RNAseq, the authors investigated the transcriptome of DS fibroblast and 
lymphoblastoid cell lines, monocytes and T cells. Functional IPA analysis of DEX genes (see 4.1.1.5) 
revealed a consistent activation of interferon signalling across all cell types induced by Hsa21 trisomy. 
Cell-based proliferation assays were then performed to demonstrate reduced cell division following 
interferon-mediated activation of the kinases JAK1 and TYK2. This effect was rescued via treatment 
with JAK inhibitors. The authors argue that, in light of four interferon receptors being encoded on 
Hsa21, the enhanced signalling is likely due to direct gene dosage effects. Thus, the interferon path-
way may be established as a therapeutic target in future studies. Additionally, this finding is of particu-
lar relevance to this thesis, which investigates Wnt signalling in DS (see 1.2). Significant cross-talk be-
tween the two pathways has in fact been previously observed in multiple instances (153, 154).  
Contextually to brain development and pathology, RNAseq was recently performed on 11 DS brain 
regions (155), at time points spanning 14 weeks of gestation to 42 years old. This very extensive 
study was aimed at investigating spatiotemporal variations in the VTT of the DS brain throughout life. 
RNA was isolated from multiple regions of the neocortex, hippocampus and cerebellar cortex. Inter-
estingly, while global expression profiles segregated the DS group from controls, age and brain re-
gions were more significant contributors to variability than aneuploidy. This, the authors suggest, im-
plies that the brain transcriptome is extremely variable in spatiotemporal nature. Overall, 1413 DEX 
genes were identified, spanning the entire genome. Whilst Hsa21 had the highest percentage of DEX 
genes compared to all other chromosomes, these made up only a fraction (76) of the overall tran-
scriptional dysregulation. Additionally, only about 15-20% (depending on tissue) of Hsa21 genes were 
DEX. The authors also observed that whilst all Hsa21 DEX genes were upregulated, expression 
changes for all other DEX genes were roughly divided in half between up and downregulation. This 
result suggests that gene dosage imbalance in DS induces diverse alterations to the transcriptome, 
and a high number of genes actually undergoes downregulation. Amongst these, functional analysis 
of the DEX genes then identified key processes in neuronal development and maintenance as affect-
ed. It appears that gene clusters involved in oligodendrocyte maturation and myelination undergo 
38
Chapter 1 - General Introduction
cortical transcriptome of DS foetuses at mid-gestation (148). Examining neural progenitor cells, the 
authors demonstrated an average 1.5-fold transcriptional enhancement of the DSCR (see introduction 
1.1.2 for overview). Additionally, they identified a global disturbance in gene expression profiles, with 
as many as 1902 DEX genes. Ingenuity pathway analysis (IPA - see 4.1.1.4) was then employed to 
probe the dataset for functional links with cellular mechanisms and signalling pathways. Most notably, 
they detected associations with the cell cycle, cell death and oxidative stress. The latter process is 
then linked to overexpression of the Hsa21 gene S100 calcium-binding protein B (S100B). These data 
imply that, in the developing DS brain, neural progenitor cells might sustain enhanced oxidative stress. 
Perhaps more importantly, however, this study lent support to the notion that Hsa21 trisomy indeed 
results in pervasive transcriptional alterations. 
As introduced, substantial phenotypic heterogeneity is present in DS. It follows that investigation of 
gene expression patterns underlying such variability is critical to the understanding of this condition. A 
study of human DS-derived lymphoblastoid and fibroblast cell lines assessed the extent of this vari-
ability (149). qPCR was employed to measure the expression of 100 and 106 Hsa21 genes in the two 
tissue types, respectively. Similarly to Ait Yahya-Graison et al. (147), results found only a proportion of 
Hsa21 genes to be overexpressed in lymphoblastoid (39%) and fibroblast (62%) cell lines. Importantly, 
the authors compared gene expression variability between DS and euploid samples employing the 
Kolmogorov-Smirnov test. This is a standard statistical test used to determine whether a probability 
distribution significantly deviates from a reference distribution. The analysis resulted in three groups of 
gene expression distributions, ranked based on the degree of overlap with euploid distributions. The 
authors argue that the gene group with distinct non-overlapping distribution contains genes likely me-
diating the DS phenotype. By contrast, Hsa21 genes with expression variability comparable to euploid 
samples are not dosage-sensitive, and thus less involved in DS traits. This study is of fundamental 
importance. It highlighted that despite trisomy, a considerable proportion of Hsa21 genes displays 
normal expression variability. This notion is to be taken into consideration when selecting candidate 
genes for further study. Additional insight into the relative contribution of Hsa21 regions to the DS 
phenotype comes from the study of partial trisomy cases (150). These are a rarer occurrence, yet al-
lowing for more detailed dissection of DS traits. The authors employed microarray hybridisation to in-
vestigate 19 cases of partial trisomy 21. They identified distinct susceptibility regions of trisomy for 25 
DS clinical phenotypes mapping to several Hsa21 segments. Whilst these data imply that multiple 
Hsa21 portions contribute to different aspects of DS, the majority of susceptibility regions mapped to 
to a ~10 Mb portion of the chromosome. This study provided key evidence on the contribution of 
Hsa21 to the DS phenotype, further highlighting how not all chromosomal regions might be essential 
for pathology.  
37
Chapter 1 - General Introduction
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regions (155), at time points spanning 14 weeks of gestation to 42 years old. This very extensive 
study was aimed at investigating spatiotemporal variations in the VTT of the DS brain throughout life. 
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genes were identified, spanning the entire genome. Whilst Hsa21 had the highest percentage of DEX 
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age-dependent downregulation in DS samples. This finding was then validated in human and Ts65Dn 
cortical samples via digital droplet PCR and immunoblotting. Results demonstrated significant de-
creases in myelination markers MAG and MBP. Overall, this comprehensive study provided important 
knowledge on the human DS VTT and its phenotypic consequences on neuronal function. As with 
other evidence discussed, yet more support was provided to the notion that Hsa21 genes contribute 
unequally to the DS phenotype. Additionally, it confirmed that Hsa21 trisomy is sufficient to induce 
complex transcriptional alterations with spatiotemporal variability throughout the DS brain. 
In summary, the studies considered here have provided great improvements in the understanding of 
the human DS transcriptome. They demonstrated the importance of gene expression variability, the 
differential contribution of Hsa21 genes to the DS phenotypes, and the pervasiveness of genome-
wide effects of aneuploidy. 
1.4.1.4 Overall considerations 
Before discussing results, a few key conclusions can be drawn from the reviewed literature on gene 
expression in DS mouse models and humans. First and foremost, it is now clear that the prediction of 
1.5-fold overexpression need not apply to all Hsa21 genes. Second, that extensive variability in gene 
expression dysregulation exists. This implies that the differential contribution of trisomic genes to the 
DS phenotype is age and tissue-dependent, in addition to also varying amongst individuals. Third, the 
gene-dosage imbalance of a limited number of genes on Hsa21 triggers genome-wide alterations of 
extreme complexity, given the variability of results discussed above. Finally, the evidence considered 
demonstrates that combination of transcriptomics with bioinformatic analysis is a useful approach to 
investigate the intricate genetic landscape of DS. 
Fig. I.11 - Features of the variable trisomic transcriptome (VTT).
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1.4.2 The DS proteome and biochemical phenotypes 
In light of the central dogma of molecular biology, which states that gene expression (ie mRNA) linearly 
correlates with protein levels, a general prediction follows for DS: given the supernumerary Hsa21, a 
theoretical 1.5-fold increase in Hsa21-encoded proteins would be expected. However, building on 
knowledge of the DS transcriptome (1.4.1), this is likely to be the case only for a minority of genes, 
with associated substantial variation amongst individuals, genders and age. Thus, investigation of pro-
tein profiles has been crucial for the understanding of DS, and generally addresses three key necessi-
ties. First, determining the extent to which aneuploidy actually affects overall protein levels in a given 
tissue. This applies both to Hsa21-encoded and secondarily affected proteins, and allows for refined 
characterisation of the DS phenotype. Second, assessing mechanistic dysfunction of the DS cellular 
protein machinery, particularly in the context of protein folding, degradation and trafficking. Third, 
weighing the individual contribution of Hsa21-encoded proteins to DS. This last point is particularly 
important, given that identification of candidate genes is the fundamental first step in the design of 
therapeutic strategies in DS. A great deal of research effort has gone into characterising protein pro-
files in DS models and humans, mostly combining standard quantitative Western blot approaches 
with large-scale proteomics. The available literature must be taken into consideration, in order to pro-
vide a theoretical framework justifying the approach undertaken in results chapter 4.2. 
1.4.2.1 Protein profiling in DS mouse models 
As for gene expression profiling, the majority of protein studies in DS models have been conducted in 
segmental trisomy models, particularly the Ts65Dn (see introduction 1.1.5). A great proportion of  the 
available evidence has focused on proteins involved in DS neuropathology, given that intellectual dis-
ability and neurodegeneration are the two most prominent features of this condition. 
One of the seminal examples of this approach is a 1987 study by Epstein et al., which demonstrated 
an important principle (156). The authors sought to determine protein-level consequences of superox-
ide dismutase 1 (Sod1) triplication in the brain of Sod1 transgenic mice. In human DS, SOD1 is an 
Hsa21-encoded enzyme thought to be important in oxidative stress. In addition to detecting en-
hanced mouse Sod1 RNA levels, results in the same study indicated 1.6-6-fold elevations in Sod1 
enzymatic activity, detected via Western blot assessment of subunit composition of this enzyme. 
Overall, this study demonstrated that genetic triplication of an Hsa21 ortholog does indeed result in 
comparable alterations of the encoded protein. In the context of neuronal development in DS, a later 
study combined two-dimensional polyacrylamide gel electrophoresis (2-DE) and mass spectrometry 
to probe the proteome of mouse embryonic stem cells (ES) containing an additional Hsa21 (157). Two 
distinct sets of up- and downregulated proteins were identified. This finding suggests that, akin to the 
variable trisomic transcriptome (4.1.1.1), the DS proteome is also characterised by the presence of 
bidirectional changes. Several altered proteins were associated with cytoskeletal function, protein 
degradation and trafficking, mechanisms essential in neuronal homoeostasis. Only two out of 225 
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age-dependent downregulation in DS samples. This finding was then validated in human and Ts65Dn 
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and Wnt signalling-mediated telencephalic patterning in developing mice (162). This finding implies the 
possibility of altered Wnt developmental processes in the Tc1 mouse. An interesting correlation with 
this idea is found in a recent proteomic study of the embryonic Ts1Cje mouse brain (163). The authors 
demonstrated a protein profile consistent with enhanced cell proliferative processes, also corroborat-
ed in vivo. This finding suggests that dysregulated cell proliferation might constitute an early event in 
the DS embryonic brain. Similarly to findings in the Ts1Cje brain (158), protein analysis of the Tc1 
mouse brain found increased tau phosphorylation at T212 (52). This residue was hyperphosphorylat-
ed in the cerebral cortex and hippocampus of old (20 months) but not young (2 months) Tc1 mice. 
T212 is a known target of DYRK1A activity (46), and DYRK1A protein levels were elevated across all 
tissue types and ages. Additionally, GSK3β was hyperphosphorylated at the inhibitory S9 residue. 
This site is thought to mediate functional segregation of GSK3β between AKT- and Wnt signalling-as-
sociated pools (164). Whilst no differences were observed in GSK3β activity (Y216) the S9 enhance-
ment may imply an underlying shift of GSK3β activity in favour of the Wnt signalling pool. This would 
result in downregulation of Wnt signalling activity. 
Overall, the studies discussed here demonstrate the presence of complex proteomic alteration in the 
brain of DS mouse models at various developmental stages. This evidence highlights the occurrence 
of substantial heterogeneity in protein-level effects, which vary mostly according to age. Additionally, it 
is clear that the contribution of mouse proteins encoded on Hsa21 in humans is limited to a small 
number of candidates, at least in the brain. These so far include APP, SOD1 and DYRK1A, given their 
roles in Aβ deposition, oxidative stress and tau phosphorylation, respectively. 
1.4.2.2 Protein profiling in human DS 
Indeed, several lines of evidence also suggests substantial alterations in the human DS proteome. 
Similarly to transcriptomic approaches, human protein studies recapitulate features of DS more faith-
fully, but are also hindered by increased genetic variability. An early study in the brain of DS individuals 
presenting AD pathology identified an interesting phenotype (165). The authors showed alterations 
associated with glial cell proliferation, employing immunohistochemistry. A 30-fold increase in cells 
positively staining for the astrogliosis markers interleukin-1 (IL-1) and S100 was observed. A signifi-
cant increase in these proteins was also detected in brain lysates. Over the last two decades, several 
studies have investigated the proteome of fetal DS brains. The first comprehensive proteomic profile in 
this context was produced in 2000 by Opperman et al. employing 2-DE (166). Results showed that 
the vast majority of protein levels were similar to control samples, but alterations were detected in key 
cytoskeletal components, including actin and tubulin. Following, a series of five consecutive studies 
by the Lubec research group provided key findings. Proteomic analysis of fetal DS brains first demon-
strated abnormalities in multiple components of intermediate metabolism (e.g. pyruvate kinase) (167). 
The group later identified eight Hsa21-encoded proteins as significantly elevated, most importantly 
SOD1, CSTB and CBR1, which were also altered in DS mouse models (168). Interestingly, SOD1 has 
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known Hsa21-encoded proteins were upregulated (SOD1 and CCT8). The authors argue that this re-
sult is possibly caused by the limited scope of 2-DE. However, this also suggests that a minority of 
Hsa21-encoded proteins are more likely to be ZiNUiﬁJaU[ly upregulated in DS, thus contributing more 
heavily to observed phenotypes. A concomitant study investigated neuropathological protein proﬁleZ
in the brain of Ts1Cje mice (158). The Ts1Cj3 is a model possessing duplications of Mmu16 regions 
syntenic to Hsa21, but not including App or Sod1 (see introduction 1.1.5). Whilst A  metabolism was 
normal, tau phosphorylation was increased at S400, but neuroﬁbrillary tangle (NFT) aggregation was 
not present. Interestingly, a ZiNUiﬁJaU[ enhancement in levels of active glycogen synthase kinase 3  
 (GSK3 ), phosphorylated at Y216, were detected in brain lysates. Given that GSK3  is the main in-
hibitor of -catenin activation, this result is of particular relevance to this thesis, as it suggests poten-
tial downstream suppression of Wnt signalling. This study importantly showed that Hsa21 orthologs 
other than App and Sod1 may also contribute to neuropathological features of DS.  
It is worth noting that the Mmu ortholog of the Hsa21 gene DYRK1A, one of the later focuses of this 
thesis (see 4.3.2), is present in the Ts1Cje duplicated region. Several studies have indeed iKeU[iﬁeK
DYRK1A as a key contributor to tau pathology in DS models and humans. For example, Liu et al. em-
ployed the Ts65Dn mouse to demonstrate that Dyrk1a duplication produces elevated DYRK1A protein 
and activity levels in the murine brain (159). Accordingly, the authors also detected enhanced, 
DYRK1A-dependent tau phosphorylation, and hypothesised that this mechanism may contribute to 
NFT formation in vivo. In the hippocampus of the same model, another study investigated proteins 
critical for long-term synaptic plasticity (160). A ZiNUiﬁJaU[ decrease in levels of synaptophysin, a pro-
tein associated with synaptic density, was observed in the adult Ts65Dn hippocampus. This was ac-
companied by compensatory elevation of neuronal developmental proteins neurotrophin 3 (NT-3) and 
Cyclin-dependent kinase 5 (CDK5). Interestingly, CDK5 was previously shown to function antagonis-
tically to DYRK1A in the context of tau phosphorylation (159). This study elucidates another principle 
of the DS proteome: overexpression of Hsa21 genes results in pathological phenotypes compounded 
by primary alterations of key proteins as well as secondary, compensatory effects. This implies that 
complex, multi-layered protein alterations are likely to underpin neuropathological features of DS. 
More recent studies investigated the DS proteome in newly-developed models. Wang et al. employed 
isobaric tags for relative and absolute X\aU[iﬁJa[ioU (iTraq) to assess protein proﬁleZ in transchromo-
somic mouse ES cells containing a freely-segregating Hsa21 (161). These cells are also used to gen-
erate the Tc1 mouse model employed throughout this thesis (49). Interestingly, only three Hsa21- en-
coded human proteins were detected as elevated in Tc1 ES cells (cystatin B - CTSB, HMGN and 
CBR1). Overall, 37 proteins were ZiNUiﬁJaU[ly elevated, whilst 15 were decreased. These were mostly 
associated with cytoskeletal function and A  clearance. The low density lipoprotein-related proteins 
LRP2 and LRPAP1 were both found to be elevated. These belong to the same family as LRP5/6 co-
receptors important in canonical Wnt signalling (62). Consistently, LRP2 is reportedly required for Shh 
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and Wnt signalling-mediated telencephalic patterning in developing mice (162). This finding implies the 
possibility of altered Wnt developmental processes in the Tc1 mouse. An interesting correlation with 
this idea is found in a recent proteomic study of the embryonic Ts1Cje mouse brain (163). The authors 
demonstrated a protein profile consistent with enhanced cell proliferative processes, also corroborat-
ed in vivo. This finding suggests that dysregulated cell proliferation might constitute an early event in 
the DS embryonic brain. Similarly to findings in the Ts1Cje brain (158), protein analysis of the Tc1 
mouse brain found increased tau phosphorylation at T212 (52). This residue was hyperphosphorylat-
ed in the cerebral cortex and hippocampus of old (20 months) but not young (2 months) Tc1 mice. 
T212 is a known target of DYRK1A activity (46), and DYRK1A protein levels were elevated across all 
tissue types and ages. Additionally, GSK3β was hyperphosphorylated at the inhibitory S9 residue. 
This site is thought to mediate functional segregation of GSK3β between AKT- and Wnt signalling-as-
sociated pools (164). Whilst no differences were observed in GSK3β activity (Y216) the S9 enhance-
ment may imply an underlying shift of GSK3β activity in favour of the Wnt signalling pool. This would 
result in downregulation of Wnt signalling activity. 
Overall, the studies discussed here demonstrate the presence of complex proteomic alteration in the 
brain of DS mouse models at various developmental stages. This evidence highlights the occurrence 
of substantial heterogeneity in protein-level effects, which vary mostly according to age. Additionally, it 
is clear that the contribution of mouse proteins encoded on Hsa21 in humans is limited to a small 
number of candidates, at least in the brain. These so far include APP, SOD1 and DYRK1A, given their 
roles in Aβ deposition, oxidative stress and tau phosphorylation, respectively. 
1.4.2.2 Protein profiling in human DS 
Indeed, several lines of evidence also suggests substantial alterations in the human DS proteome. 
Similarly to transcriptomic approaches, human protein studies recapitulate features of DS more faith-
fully, but are also hindered by increased genetic variability.  An early study in the brain of DS individuals 
presenting AD pathology identified an interesting phenotype (165). The authors showed alterations 
associated with glial cell proliferation, employing immunohistochemistry. A 30-fold increase in cells 
positively staining for the astrogliosis markers interleukin-1 (IL-1) and S100 was observed. A signifi-
cant increase in these proteins was also detected in brain lysates. Over the last two decades, several 
studies have investigated the proteome of fetal DS brains. The first comprehensive proteomic profile in 
this context was produced in 2000 by Opperman et al. employing 2-DE (166). Results showed that 
the vast majority of protein levels were similar to control samples, but alterations were detected in key 
cytoskeletal components, including actin and tubulin. Following, a series of five consecutive studies 
by the Lubec research group provided key findings. Proteomic analysis of fetal DS brains first demon-
strated abnormalities in multiple components of intermediate metabolism (e.g. pyruvate kinase) (167). 
The group later identified eight Hsa21-encoded proteins as significantly elevated, most importantly 
SOD1, CSTB and CBR1, which were also altered in DS mouse models (168). Interestingly, SOD1 has 
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been shown to antagonise canonical Wnt signalling activation induced by reactive oxygen species in 
human cells (169). In a further study (170), DS fetal brains also displayed decreased levels of α-tubulin 
and α-internexin, proteins associated with the neuronal cytoskeleton. Tropomodulin 1 (TMOD1) and 
fatty acid binding protein (FABP) were on the other hand found to be elevated. This finding is particu-
larly relevant to this thesis, in that evidence exists linking both TMOD1 and FABP to Wnt signalling. 
TMOD1 is an actin-capping protein, and has been identified as a non-canonical Wnt target gene, be-
ing upregulated by Wnt5a (171). The activation of this pathway is known to antagonise and suppress 
canonical Wnt signalling activation (62). FABPs are considered markers of adipogenesis, and FABP4 
expression has been shown to be reduced by epigallocatechin gallate (EGCG) treatment via en-
hanced canonical Wnt signalling (172). Considering these links, increased levels of TMOD1 and FABP 
in the DS fetal brain identified by Lubec et al. could possibly reflect suppressed canonical Wnt sig-
nalling. Another recent proteomic study focused on oxidative stress pathways in the DS brain (173), 
identifying abnormal carbonylation of proteins associated with the intracellular quality control/au-
tophagy system, such as cathepsin D. The authors further characterised this phenotype functionally, 
observing decreased activity of the proteasome and autophagosome. This led to the hypothesis that 
dysfunctional protein degradation in DS may contribute to abnormal Aβ deposition in later life. The 
same authors also conducted a thorough review of proteomic evidence in the DS brain (174), arguing 
that abnormal oxidative stress is likely to contribute to neurodegeneration in this syndrome. 
In 2004, a protein study in post-mortem human DS and AD brains identified significantly elevated tau 
phosphorylation, at residues targeted by microtubule associated protein kinase (MAPK) (175). Accord-
ingly, MAPK activity was also found to be elevated. By contrast, GSK3β activity was reduced. The 
discussed Liu et al. study (4.2.1) also employed a cohort of human DS adults (159). Significantly ele-
vated DYRK1A levels were observed, in association with hyperphosphorylated tau at DYRK1A-target-
ed residues. In vitro assays also showed that such phosphorylation could induce tau aggregation. It is 
worth noting that DYRK1A protein levels are ubiquitously elevated in virtually all DS brain structures, 
spanning infancy to adulthood, and across gender and ethnicity (176). This finding places DYRK1A in 
a key position with respect to brain pathology in DS. DYRK1A function in euploidy and DS is further 
discussed in chapter 4.3.1. The Sullivan et al. study (152) demonstrated interferon (IFN) pathway dys-
regulation in the transcriptome of DS-derived cell lines. The authors also employed immunoblotting to 
probe for protein level evidence of IFN dysregulation in the same cell models, particularly looking at 
components and targets of the pathway. The analysis, conducted in DS fibroblasts, demonstrated 
significant elevation of multiple IFN receptors, and enhanced phosphorylation of the cascade compo-
nent STAT1. Moreover, the elevated IFN response was functionally assessed, suggesting that DS cells 
respond more pronouncedly to 24-hour IFN-α treatment. Overall, this study presented consistent ge-
netic and biochemical data in support of altered IFN function in DS. A similar approach has been the 
broadly overarching theme of the work presented here. 
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1.4.2.3 Overall considerations 
In summary, protein investigations in DS models and humans suggest widespread imbalances in pro-
tein homeostasis. Some of the more prominently affected processes include oxidative stress, cell pro-
liferation, proteostasis, neuronal cytoskeletal components and proteins involved in tau metabolism. In 
both DS mice and humans, several Hsa21-encoded proteins are altered, most importantly DYRK1A 
and APP, given their roles in neurodegeneration (see 4.3.1 for more info on DYRK1A). However, sub-
stantial variability and age dependence exist, arguably to a greater extent than for transcriptomic data. 
Even in the case of consecutive investigations in humans, performed by the Lubec group (167, 168, 
170, 177) and based on similar groups, results differed widely between studies. This variability applies 
to both Hsa21-encoded and secondarily affected proteins. One of the more reliably altered proteins is 
indeed DYRK1A, found to be affected in the vast majority of DS cases, and, in the context of the DS 
brain, consistently driving altered tau phosphorylation. Based upon literature evidence, DYRK1A levels 
were therefore selected as a reference marker to further confirm the aneuploid status of murine and 
human samples analysed in 4.2. 
Figure I.12 - Proteomic changes in DS are highly variable between mouse models and humans, and span 
several biological processes.
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Chapter 2 - Aims and Objectives 
Despite the likelihood of Wnt signalling involvement in DS neuropathology, no evidence directly linking 
these two phenomena exists. Thus, the studies presented here sought to clarify and characterise this 
potential relationship, combining data from DS mouse models, human brain tissue and cell lines.  
The primary hypothesis of this thesis was addressed in three logical phases, through a variety of experi-
mental techniques: 
I. Investigation of transcriptional alterations in DS: Chapter 4.1 - Analysis of the DS transcriptome: 
A. RNA sequencing of the Tc1 and Dp1Tyb mouse hippocampus and DS fibroblasts. 
B. Functional pathway analysis of RNA sequencing data via Qiagen IPA®. 
II. Investigation of protein-level Wnt signalling alterations in DS: Chapter 4.2 - Wnt signalling pro-
teins in DS mouse models and humans: 
A. Assessment of Wnt signalling activity and components in Tc1 and Dp1Tyb mouse hippocam-
pus and cerebral cortex. 
B. Assessment of Wnt signalling activity and components in the human DS hippocampus. 
III. Characterisation of a candidate Hsa21 gene for Wnt-DS phenotypes: Chapter 4.3 - DYRK1A-
mediated Wnt signalling modulation: 
A. Investigation of DYRK1A-Wnt protein interaction networks. 
B. Investigation of DYRK1A-mediated modulation of Wnt signalling activity in human cells. 
C. Investigation of DYRK1A subcellular localisation under differential Wnt activation states. 
Each experimental phase is discussed in its relative results chapter (4.1-3), whilst the overall implica-
tions and future aims are integrated and considered in the general discussion section (5.1-2). 
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Chapter 3 - Materials and Methods 
In this section, all techniques and tissues employed to generate experimental data for this thesis are out-
lined. In order to ease accessibility of this thesis to future readers from a wide variety of backgrounds, 
methods are briefly introduced conceptually before describing their application for experimental purposes. 
Therefore, in contrast to the manner in which methods are published in research articles, this section as-
sumes no prior knowledge of the techniques on the reader’s part. A generic cell biology, biochemistry and 
genetics background is however presumed. 
3.1 RNA sequencing 
Massively parallel complementary DNA (cDNA) sequencing, or RNA sequencing (RNAseq), is a well-
established technique which exploits the fundamental principle that the amount of transcript mRNA 
directly correlates with gene expression levels. Thus, RNAseq is employed to quantify genome-wide 
expression signatures with high reliability (see, 4.1.1, for a literature overview of the technique). In this 
thesis, RNA sequencing was performed on hippocampal RNA derived from Tc1 and Dp1Tyb mice 
(see 3.3 and 4.1.1 for further info on mice), in order to probe for transcriptional profiles associated 
with Wnt signalling dysregulation (4.1.2). RNA sequencing and primary data analysis were conducted 
by the Elizabeth Fisher laboratory at the UCL Institute of Neurology, as detailed in the statement of 
contributions made at the beginning of the thesis. 
3.1.1 RNA extraction and sequencing 
Total hippocampal RNA from Tc1 (n=3, 3 months old) and Dp1Tyb (n=3, 5 months old) mice was ex-
tracted using the miRNeasy mini kit (Qiagen). Tissue was disrupted mechanically using a Tissue-
Rupter, as per manufacturer's instructions and resuspended in DNase- and RNase-free water. Total 
hippocampal RNA sample quality was confirmed by Bioanalyzer (Agilent) and libraries were prepared 
with the TruSeq RNA v2 LS Kit (Ilumina). RNAseq was then performed employing the HiSeq system 
(Illumina). 
 
3.1.2 Sequencing data analysis 
Due to the presence of human genes in the Tc1 mouse, a custom reference genome was assembled 
in order to asses expression levels of Hsa21 genes. A standard mouse genome (NCBI build 37.2) was 
combined with the Hsa21 sequence (NCBI build 37.2). The RNAseq data was then aligned to this 
custom genome employing Bowtie (v2.1.0) as part of the Tophat pipeline. Overall count data were 
then generated, employing the dexseq_count.py script, before combining counts for Hsa21 genes 
and mouse orthologs. The resulting data, also including non-Hsa21 genes, was then analysed by De-
seq to generate adjusted P values. 
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3.2 Cloning 
In this thesis, cloning was employed to generate DYRK1A expression constructs. The cloned sequences, 
or inserts, were directly amplified from genomic complementary DNA (cDNA), or sub-cloned from a previ-
ous construct. The process of cloning entails a variety of standard molecular biology techniques which are 
described in 3.2.1-10. 
3.2.1 Polymerase chain reaction and DNA primer design 
The polymerase chain reaction (PCR) involves the use of thermal cycling and a recombinant DNA poly-
merase to exponentially amplify a DNA sequence of interest. PCR represents the initial stage of the cloning 
process, generating the insert to be cloned into a specific plasmid vector. For this thesis, human brain 
cDNA (Clontech) was employed as a template for amplification of DYRK1A, human isoform 1 (NCBI reference 
sequence NM_001396.3).  
Primer design - To ensure specificity of a PCR product, the sequence of interest must be primed for DNA 
polymerase binding via the action of specifically designed complementary oligonucleotides, termed primers. 
Primers are designed in pairs, forward and reverse, signalling polymerase binding at the 5’ and 3’ ends of the 
template, respectively. In the context of cloning, primers are designed to also introduce specific oligonu-
cleotide sequences compatible with the cut sites of restriction endonucleases employed at later stages (see 
3.2.3-4). All primers were designed with a standard word processor (Apple Pages) and the NCBI reference 
sequence for DYRK1A human isoform 1. The oligonucleotides were synthesised by Eurofins. Upon delivery, 
each primer was solubilised in ddH20 to a stock concentration of 100 μM and stored at -20˚C according to 
manufacturer instructions. The following table details primer sequence and cut sites introduced. 
 
Fig. M.1 - Overview of representative primer design for DYRK1A cloning.
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PCR - For PCR usage, each primer was further diluted to a working concentration of 10 μM. As well as 
primers and template, a standard PCR reaction also requires a heat-resistant DNA polymerase, deoxynu-
cleotide triphosphates (dNTPs) for template replication and a suitable buffer solution. All these were provided 
pre-mixed in the AccuPrimeTM Pfx SuperMix (22 U/ml Thermococcus species KOD thermostable, anti-KOD 
antibodies, 66 mM Tris-SO4 (pH 8.4), 30.8 mM (NH4)2SO4, 11 mM KCl, 1.1 mM MgSO4, 330 µM dNTPs, 
AccuPrime™ proteins, stabilisers - Life Technologies). All reactions were performed employing a Veriti 96-well 
thermal cycler (Applied Biosystems) with specifically programmed cycles. The table below details the steps 
and components of each standard 25 μl reaction. Following PCR, all products were subsequently analysed 
via agarose gel electrophoresis. 
3.2.2 Agarose gel electrophoresis and extraction 
Electrophoresis - For a standard 10-lane, 1% DNA gel, 500mg of UltraPureTM Agarose (Life Technologies) 
were added to 50 ml of Tris-acetate EDTA (TAE) buffer (40mM Tris-base, 20mM acetic acid, 1mM EDTA at 
pH 8.0). Reagents were mixed thoroughly in a glass flask and subsequently heated in a microwave oven 
for 30 sec. The flask was then briefly allowed to cool under running tap water. The heating-cooling cycle 
was repeated 2-3 times, as required, until complete agarose dissolution. Thereafter, 5 μl of SYBR® Safe 
DNA gel stain (Life Technologies) were added to the agarose solution to allow for DNA visualisation. The 
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Fig. M.2 - Overview of a standard PCR protocol
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Fig. M.1 - Overview of representative primer design for DYRK1A cloning.
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PCR - For PCR usage, each primer was further diluted to a working concentration of 10 μM. As well as 
primers and template, a standard PCR reaction also requires a heat-resistant DNA polymerase, deoxynu-
cleotide triphosphates (dNTPs) for template replication and a suitable buffer solution. All these were provided 
pre-mixed in the AccuPrimeTM Pfx SuperMix (22 U/ml Thermococcus species KOD thermostable, anti-KOD 
antibodies, 66 mM Tris-SO4 (pH 8.4), 30.8 mM (NH4)2SO4, 11 mM KCl, 1.1 mM MgSO4, 330 µM dNTPs, 
AccuPrime™ proteins, stabilisers - Life Technologies). All reactions were performed employing a Veriti 96-well 
thermal cycler (Applied Biosystems) with specifically programmed cycles. The table below details the steps 
and components of each standard 25 μl reaction. Following PCR, all products were subsequently analysed 
via agarose gel electrophoresis. 
3.2.2 Agarose gel electrophoresis and extraction 
Electrophoresis - For a standard 10-lane, 1% DNA gel, 500mg of UltraPureTM Agarose (Life Technologies) 
were added to 50 ml of Tris-acetate EDTA (TAE) buffer (40mM Tris-base, 20mM acetic acid, 1mM EDTA at 
pH 8.0). Reagents were mixed thoroughly in a glass flask and subsequently heated in a microwave oven 
for 30 sec. The flask was then briefly allowed to cool under running tap water. The heating-cooling cycle 
was repeated 2-3 times, as required, until complete agarose dissolution. Thereafter, 5 μl of SYBR® Safe 
DNA gel stain (Life Technologies) were added to the agarose solution to allow for DNA visualisation. The 
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Fig. M.2 - Overview of a standard PCR protocol
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lanes. After pouring, the gel was allowed to set for 30 min at room temperature. Once solidified, the gel 
was placed in a TAE-containing electrophoresis chamber connected to a Power Pac generator (Biorad). 
Prior to sample loading, 5 μl of sample loading buffer  were added to 25 μl of each PCR product solution. 
Each gel lane was subsequently loaded with 30 μl of buffered DNA sample. Additionally, two lanes were 
each loaded with 12 μl of marker solution containing 10 μl of 1Kb+ DNA ladder (NEB) and 2 μl of sample 
loading buffer to ensure correct estimation of DNA size. Once loaded, the gel was ran for 30 min at a con-
stant voltage of 100V and imaged under blue light employing a Safe ImagerTM Transilluminator (Syngene). 
In positive results, DYRK1A DNA was observed as a single band migrating to ~2.3kb. Examples are 
shown below: 
 
Gel extraction (QIAGEN protocol) - All extractions were performed employing the QIAquick® Gel Extrac-
tion Kit, which supplies all the required reagents. Bands corresponding to ~2.3 kb, the size of human 
DYRK1A isoform 1, were excised from the agarose gel using a clean surgical scalpel while being illuminat-
ed on a standalone blue light Safe ImagerTM (Life Technologies). The excised gel slice was then weighted in 
a 1.5 ml microcentrifuge tube, and 3 volumes (100 mg~100 μl) of Buffer QG (5.5 M guanidine thiocyanate, 
20 mM Tris HCl pH 6.6) were added to the tube. The mixture was subsequently incubated at 50˚C in a Ep-
pendorf ThermoMixer® F1.5 for up to 10 minutes, as required, until complete dissolution of the gel slice. 
Thereafter, 1 gel volume of isopropanol  was added. After brief vortexing on a Rotamixer (Hati) the solution 
was transferred to an 800 μl QIAquick® spin column inserted into a provided 2 ml collection tube and cen-
trifuged for 1 min at 14,680 rpm on a 5424 Tabletop Microcentrifuge (Eppendorf - “tabletop microcen-
trifuge”). The flow-through was consequently discarded, and 500 μl of Buffer QG were added to the QI-
Aquick® spin column. A further centrifugation-discarding cycle was performed. Thereafter, 750 μl of Buffer 
PE (10 mM Tris-HCl pH 7.5, 80% Ethanol) were added to wash the column. Following centrifugation and 
discarding, the column was placed in a fresh 1.5 ml microcentrifuge tube. To elute DNA out of the QI-
Aquick® spin column, 20 μl of Buffer EB (10 mM Tris HCl, ph 8.5) were added to the centre of the column, 
which was allowed to stand for 1 min and then centrifuged for a further 1 min. The flow-through collected 





Fig. M.3 - Representative DNA agarose gel results, demonstrating DYRK1A migrating to 1.5 kb.
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3.2.3 Restriction digest and phenol-chloroform isoamyl (PCI) extraction 
Restriction digest - For the PCR-amplified DYRK1A DNA, restriction sites for digestion by XbaI (cut se-
quence) and HindIII (cut sequence) were introduced by specifically designed oligonucleotide primers at the 
PCR stage (see 3.2.1). In commercially available plasmid vectors, several restriction sites are engineered 
into a “multiple cloning site” for immediate digestion. To ensure the correct introduction of compatible ends 
for ligation, both the DNA fragment and the vector backbone were digested with the same restriction en-
zymes. The restriction digest was performed on both the PCR-amplified DYRK1A DNA for ligation into the 
pRK5-FLAG vector (Addgene) and on a ready-made pCMV5-HA-DYRK1A construct (Addgene) for sub-
cloning into the pEGFP-C1 vector. All enzymes and buffers were supplied by New England Biolabs. The 
tables below detail the components of each standard 20 μl reaction. Each was incubated at 37˚C in a Ep-
pendorf ThermoMixer® F1.5 for 1 hr. 
PCI extraction -. 80 μl of distilled H20 was added to Each 20 μl reaction mixture. Thereafter, 100 μl of 
phenol-chloroform isoamyl (PCI) were added to each reaction in a fume hood. All samples were subse-
quently centrifuged for 10 min at 14,680 rpm in a tabletop microcentrifuge. During centrifugation, a solution 
containing 10 μl of 3M sodium acetate (C2H3NaO2 - pH 5.2), 250 μl of 96% (v/v) ethanol and 1 μl of glyco-
gen was prepared for each sample in clean 1.5 ml microcentrifuge tubes. Thereafter, the aqueous phase 
was removed from each centrifuged sample and added to the above mentioned sodium acetate/ethanol/
glycogen solution. Each reaction was subsequently incubated in dry ice  for up to 10 min, as required, until 
complete solidification. Once frozen, each sample was centrifuged for 15 min at 14,680 rpm in a tabletop 
microcentrifuge. Following centrifugation, the sodium acetate/ethanol solution was carefully removed from 
each reaction, leaving only the DNA-containing glycogen pellet. Each tube was then left open for 10 min to 
allow for evaporation of any residual sodium acetate/ethanol. Once dried, each DNA pellet was re-sus-
pended in Buffer EB. To account for the much higher DNA concentration of plasmid vectors, inserts were 

























Buffer 3.1 2 μl
Fig. M.4 - Restriction digest reactions employed.
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lanes. After pouring, the gel was allowed to set for 30 min at room temperature. Once solidified, the gel 
was placed in a TAE-containing electrophoresis chamber connected to a Power Pac generator (Biorad). 
Prior to sample loading, 5 μl of sample loading buffer  were added to 25 μl of each PCR product solution. 
Each gel lane was subsequently loaded with 30 μl of buffered DNA sample. Additionally, two lanes were 
each loaded with 12 μl of marker solution containing 10 μl of 1Kb+ DNA ladder (NEB) and 2 μl of sample 
loading buffer to ensure correct estimation of DNA size. Once loaded, the gel was ran for 30 min at a con-
stant voltage of 100V and imaged under blue light employing a Safe ImagerTM Transilluminator (Syngene). 
In positive results, DYRK1A DNA was observed as a single band migrating to ~2.3kb. Examples are 
shown below: 
 
Gel extraction (QIAGEN protocol) - All extractions were performed employing the QIAquick® Gel Extrac-
tion Kit, which supplies all the required reagents. Bands corresponding to ~2.3 kb, the size of human 
DYRK1A isoform 1, were excised from the agarose gel using a clean surgical scalpel while being illuminat-
ed on a standalone blue light Safe ImagerTM (Life Technologies). The excised gel slice was then weighted in 
a 1.5 ml microcentrifuge tube, and 3 volumes (100 mg~100 μl) of Buffer QG (5.5 M guanidine thiocyanate, 
20 mM Tris HCl pH 6.6) were added to the tube. The mixture was subsequently incubated at 50˚C in a Ep-
pendorf ThermoMixer® F1.5 for up to 10 minutes, as required, until complete dissolution of the gel slice. 
Thereafter, 1 gel volume of isopropanol  was added. After brief vortexing on a Rotamixer (Hati) the solution 
was transferred to an 800 μl QIAquick® spin column inserted into a provided 2 ml collection tube and cen-
trifuged for 1 min at 14,680 rpm on a 5424 Tabletop Microcentrifuge (Eppendorf - “tabletop microcen-
trifuge”). The flow-through was consequently discarded, and 500 μl of Buffer QG were added to the QI-
Aquick® spin column. A further centrifugation-discarding cycle was performed. Thereafter, 750 μl of Buffer 
PE (10 mM Tris-HCl pH 7.5, 80% Ethanol) were added to wash the column. Following centrifugation and 
discarding, the column was placed in a fresh 1.5 ml microcentrifuge tube. To elute DNA out of the QI-
Aquick® spin column, 20 μl of Buffer EB (10 mM Tris HCl, ph 8.5) were added to the centre of the column, 
which was allowed to stand for 1 min and then centrifuged for a further 1 min. The flow-through collected 





Fig. M.3 - Representative DNA agarose gel results, demonstrating DYRK1A migrating to 1.5 kb.
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3.2.3 Restriction digest and phenol-chloroform isoamyl (PCI) extraction 
Restriction digest - For the PCR-amplified DYRK1A DNA, restriction sites for digestion by XbaI (cut se-
quence) and HindIII (cut sequence) were introduced by specifically designed oligonucleotide primers at the 
PCR stage (see 3.2.1). In commercially available plasmid vectors, several restriction sites are engineered 
into a “multiple cloning site” for immediate digestion. To ensure the correct introduction of compatible ends 
for ligation, both the DNA fragment and the vector backbone were digested with the same restriction en-
zymes. The restriction digest was performed on both the PCR-amplified DYRK1A DNA for ligation into the 
pRK5-FLAG vector (Addgene) and on a ready-made pCMV5-HA-DYRK1A construct (Addgene) for sub-
cloning into the pEGFP-C1 vector. All enzymes and buffers were supplied by New England Biolabs. The 
tables below detail the components of each standard 20 μl reaction. Each was incubated at 37˚C in a Ep-
pendorf ThermoMixer® F1.5 for 1 hr. 
PCI extraction -. 80 μl of distilled H20 was added to Each 20 μl reaction mixture. Thereafter, 100 μl of 
phenol-chloroform isoamyl (PCI) were added to each reaction in a fume hood. All samples were subse-
quently centrifuged for 10 min at 14,680 rpm in a tabletop microcentrifuge. During centrifugation, a solution 
containing 10 μl of 3M sodium acetate (C2H3NaO2 - pH 5.2), 250 μl of 96% (v/v) ethanol and 1 μl of glyco-
gen was prepared for each sample in clean 1.5 ml microcentrifuge tubes. Thereafter, the aqueous phase 
was removed from each centrifuged sample and added to the above mentioned sodium acetate/ethanol/
glycogen solution. Each reaction was subsequently incubated in dry ice  for up to 10 min, as required, until 
complete solidification. Once frozen, each sample was centrifuged for 15 min at 14,680 rpm in a tabletop 
microcentrifuge. Following centrifugation, the sodium acetate/ethanol solution was carefully removed from 
each reaction, leaving only the DNA-containing glycogen pellet. Each tube was then left open for 10 min to 
allow for evaporation of any residual sodium acetate/ethanol. Once dried, each DNA pellet was re-sus-
pended in Buffer EB. To account for the much higher DNA concentration of plasmid vectors, inserts were 
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Fig. M.4 - Restriction digest reactions employed.
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3.2.4 DNA ligation 
Once purified, the digested inserts and plasmid vectors were ligated through their compatible ends to gen-
erate a desired construct. In this thesis, T4 DNA ligase (New England Biolabs® - NEB) was employed for all 
constructs. Each ligation reaction was incubated overnight at 4˚C in ligation buffer (NEB). The table below 
details the components of each 10 μl standard reaction: 
Ligation mixture
Insert - DYRK1A 7 μl
Vector - pRK5-FLAG or pEGFP-C1 1 μl
Ligation Buffer 1 μl
T4 DNA ligase 1 μl
Fig. M.5 - Ligation reaction mix.
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3.2.6 Mini-preparation of plasmid constructs (QIAGEN protocol) 
In order to confirm successful cloning, all DNA constructs amplified in bacterial cultures were extracted and 
purified on a small scale (mini-prep) prior to final preparation. This was achieved employing the QIAprep® 
Spin Miniprep Kit (QIAGEN), which supplies all required reagents. To pellet the bacterial cells, 1 ml of each 
overnight culture was transferred to a clean 1.5 ml tube and centrifuged for 3 min at 14,680 rpm in a table-
top microcentrifuge. The supernatant LB solution was then removed, the pellets were resuspended in 250 
μl of Buffer P1 (50 mM Tris-HCl, 10 mM EDTA, 100 μg/ml RNaseA, pH 8.0), and 250 μl of Buffer P2 (200 
mM NaOH, 1% SDS) were subsequently added to trigger a cell lysis reaction. The solutions were mixed 
thoroughly by inverting each tube 6 times. Thereafter, 350 μl of Buffer N3 (4.2 M Gu-HCl, 0.9 M potassium 
acetate, pH 4.8) were added to neutralise the lysis reaction and facilitate DNA binding to the spin columns 
at subsequent stages. Each tube was then centrifuged for 10 min at 14,680 rpm in a tabletop microcen-
trifuge to pellet the cell debris and large proteins released by the lysis reaction. Following, the supernatant 
was collected and transferred to a QIAprep® spin column inserted into a provided 2ml collection tube. Each 
column was then centrifuged for 1 min at 14,680 rpm to bind DNA to its membrane. The flow-through was 
discarded and the columns were washed with 750 μl Buffer PE, which was then removed by centrifuging 
each column twice for 1 min at 14,680 rpm. Thereafter, the columns were placed in clean 1.5 ml micro-
centrifuge tubes to collect the prepared DNA constructs, and 50 μl of Buffer EB were added to the mem-
brane to elute DNA. After allowing elution for 1 min, each column was centrifuged for 1 min at 14,680 rpm. 
3.2.7 Diagnostic digest 
The DNA constructs prepared were then tested to ensure the presence of desired inserts. To this end, all 
constructs were digested as in 3.2.3. Only 5 μl of DNA preparation were added to the 20 μl reaction mix-
ture, however, to account for higher concentration relative to a gel-purified PCR product. The digest prod-
ucts were subsequently analysed by agarose gel electrophoresis (See 3.2.2). In successfully ligated con-
structs, both the plasmid vector and insert were observed upon gel imaging, as two distinct bands of de-
sired size. The figure below depicts representative examples. 
Fig. M.6 - Representative diagnostic digest results, demonstrating presence of vector and insert.
DYRK1A DYRK1A
1 kb 1 kb
Uncut vector
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3.2.5 E. coli transformation and culture 
All constructs were inserted into competent bacterial cells (E. coli) in order to achieve exponential replica-
tion. This step is essential to the efficient preparation of working stocks for later experimental use. Trans-
formations were carried out for pRK5-FLAG-DYRK1A, pCMV5-HA-DYRK1A (at a prior stage following 
supply of the plasmid) and pEGFPC1-DYRK1A. For this technique, a Bunsen burner flame was employed 
throughout to maintain a sterile environment around the bacterial cells and reagents. The microcentrifuge 
tubes containing the ligation reaction were maintained at ~4˚C on ice while competent E. coli cells (stored 
at -80˚C in solution - company) were being thawed on ice. Once defrosted, 100 l of E. coli cells were 
added to the 10 l ligation reaction in the same microcentrifuge tube. The solution was then incubated on 
ice for 10 min. Thereafter, the E. coli cells were subjected to a 45 sec heat-shock at 42˚C in a JB Aqua 2s 
water bath (Grant) in order to temporarily permeabilise cell walls/plasma membranes, and allow uptake of 
the DNA construct. Following the heat-shock, the cells were incubated on ice for 2 min to recover, after 
which 250 l of lysogeny broth (LB - Sigma Aldrich) were added to provide a growth medium. The E. coli/
LB solution was then incubated at 37˚C for 1 hr while being mixed at 1,500 rpm in an Eppendorf Thermo-
Mixer® F1.5. During the incubation, bacteriological agar plates were warmed to 37˚C. After 1 hr, the E. coli/
LB solution was transferred and spread onto the plates. The agar had been previously enriched with an-
tibiotic for positive selection. For pRK5-FLAG-/pCMV5-HA-DYRK1A, ampicillin was employed, while 
kanamycin was used for DYRK1A-pEGFP-C1.All plates were incubated at 37˚C overnight. The following 
day, bacterial colonies could be observed growing on the agar surface. 5 colonies from each plate were 
gently removed from the agar plates with a 10 l pipette tip. Each tip was ejected directly into a 15 ml cen-
trifuge tube containing 10 ml of LB solution enriched with either kanamycin or ampicillin, depending on the 
construct, at a concentration of 1:1000. Each colony in solution was then allowed to further grow overnight 
at 37˚C whilst being shaken. 
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3.2.4 DNA ligation 
Once purified, the digested inserts and plasmid vectors were ligated through their compatible ends to gen-
erate a desired construct. In this thesis, T4 DNA ligase (New England Biolabs® - NEB) was employed for all 
constructs. Each ligation reaction was incubated overnight at 4˚C in ligation buffer (NEB). The table below 
details the components of each 10 μl standard reaction: 
3.2.5 E. coli transformation and culture 
All constructs were inserted into competent bacterial cells (E. coli) in order to achieve exponential replica-
tion. This step is essential to the efficient preparation of working stocks for later experimental use. Trans-
formations were carried out for pRK5-FLAG-DYRK1A, pCMV5-HA-DYRK1A (at a prior stage following 
supply of the plasmid) and pEGFPC1-DYRK1A. For this technique, a Bunsen burner flame was employed 
throughout to maintain a sterile environment around the bacterial cells and reagents. The microcentrifuge 
tubes containing the ligation reaction were maintained at ~4˚C on ice while competent E. coli cells (stored 
at -80˚C in solution - company) were being thawed on ice. Once defrosted, 100 μl of E. coli cells were 
added to the 10 μl ligation reaction in the same microcentrifuge tube. The solution was then incubated on 
ice for 10 min. Thereafter, the E. coli cells were subjected to a 45 sec heat-shock at 42˚C in a JB Aqua 2s 
water bath (Grant) in order to temporarily permeabilise cell walls/plasma membranes, and allow uptake of 
the DNA construct. Following the heat-shock, the cells were incubated on ice for 2 min to recover, after 
which 250 μl of lysogeny broth (LB - Sigma Aldrich) were added to provide a growth medium. The E. coli/
LB solution was then incubated at 37˚C for 1 hr while being mixed at 1,500 rpm in an Eppendorf Thermo-
Mixer® F1.5. During the incubation, bacteriological agar plates were warmed to 37˚C. After 1 hr, the E. coli/
LB solution was transferred and spread onto the plates. The agar had been previously enriched with an-
tibiotic for positive selection. For pRK5-FLAG-/pCMV5-HA-DYRK1A, ampicillin was employed, while 
kanamycin was used for DYRK1A-pEGFP-C1.All plates were incubated at 37˚C overnight. The following 
day, bacterial colonies could be observed growing on the agar surface. 5 colonies from each plate were 
gently removed from the agar plates with a 10 μl pipette tip . Each tip was ejected directly into a 15 ml cen-
trifuge tube containing 10 ml of LB solution enriched with either kanamycin or ampicillin, depending on the 
construct, at a concentration of 1:1000. Each colony in solution was then allowed to further grow overnight 
at 37˚C whilst being shaken. 
Ligation mixture
Insert - DYRK1A 7 μl
Vector - pRK5-FLAG or pEGFP-C1 1 μl
Ligation Buffer 1 μl
T4 DNA ligase 1 μl
Fig. M.5 - Ligation reaction mix.
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3.2.6 Mini-preparation of plasmid constructs (QIAGEN protocol) 
In order to confirm successful cloning, all DNA constructs amplified in bacterial cultures were extracted and 
purified on a small scale (mini-prep) prior to final preparation. This was achieved employing the QIAprep® 
Spin Miniprep Kit (QIAGEN), which supplies all required reagents. To pellet the bacterial cells, 1 ml of each 
overnight culture was transferred to a clean 1.5 ml tube and centrifuged for 3 min at 14,680 rpm in a table-
top microcentrifuge. The supernatant LB solution was then removed, the pellets were resuspended in 250 
μl of Buffer P1 (50 mM Tris-HCl, 10 mM EDTA, 100 μg/ml RNaseA, pH 8.0), and 250 μl of Buffer P2 (200 
mM NaOH, 1% SDS) were subsequently added to trigger a cell lysis reaction. The solutions were mixed 
thoroughly by inverting each tube 6 times. Thereafter, 350 μl of Buffer N3 (4.2 M Gu-HCl, 0.9 M potassium 
acetate, pH 4.8) were added to neutralise the lysis reaction and facilitate DNA binding to the spin columns 
at subsequent stages. Each tube was then centrifuged for 10 min at 14,680 rpm in a tabletop microcen-
trifuge to pellet the cell debris and large proteins released by the lysis reaction. Following, the supernatant 
was collected and transferred to a QIAprep® spin column inserted into a provided 2ml collection tube. Each 
column was then centrifuged for 1 min at 14,680 rpm to bind DNA to its membrane. The flow-through was 
discarded and the columns were washed with 750 μl Buffer PE, which was then removed by centrifuging 
each column twice for 1 min at 14,680 rpm. Thereafter, the columns were placed in clean 1.5 ml micro-
centrifuge tubes to collect the prepared DNA constructs, and 50 μl of Buffer EB were added to the mem-
brane to elute DNA. After allowing elution for 1 min, each column was centrifuged for 1 min at 14,680 rpm. 
3.2.7 Diagnostic digest 
The DNA constructs prepared were then tested to ensure the presence of desired inserts. To this end, all 
constructs were digested as in 3.2.3. Only 5 μl of DNA preparation were added to the 20 μl reaction mix-
ture, however, to account for higher concentration relative to a gel-purified PCR product. The digest prod-
ucts were subsequently analysed by agarose gel electrophoresis (See 3.2.2). In successfully ligated con-
structs, both the plasmid vector and insert were observed upon gel imaging, as two distinct bands of de-
sired size. The figure below depicts representative examples. 
Fig. M.6 - Representative diagnostic digest results, demonstrating presence of vector and insert.
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3.2.8 Quantification of DNA concentration  
Prior to DNA sequencing, the concentration of each construct was measured employing a NanoDrop 
2000 Spectrophotometer (Thermo Scientific), which determines micro-volume DNA concentration as a 
function of the sample’s spectral absorbance. The NanoDrop’s sample pedestal was first cleaned and sub-
sequently initialised by measuring 1 μl of distilled H20. The instrument was then blanked with 1 μl of Buffer 
EB (used to elute DNA in 3.2.6) to exclude any interference from this buffer in the final measurements. 
Thereafter, 1 μl of each DNA preparation was added to the sample pedestal to determine concentration. 
Each measurement was repeated 3 times to account for instrument error. This technique was also per-
formed on the final, large-scale DNA preparations (see 3.1.10) to determine the final stock concentration of 
each construct (see 3.5.4 for all concentrations). 
3.2.9 DNA sequencing 
All constructs employed in this thesis were validated via DNA sequencing. An external service was em-
ployed, namely the Dna Sequencing & ServicesTM, University of Dundee, Dundee, Scotland. DNA se-
quencing was performed on both small and large scale (3.2.10) preparations of each construct, in order to 
ensure consistency. For each construct Each sequencing result was analysed in comparison to the 
DYRK1A reference sequence for human isoform 1 (NM_001396.3) employing the NCBI Basic Local 
Alignment Search Tool (BLAST) and the Sequencher software suite (Gene Codes). Vector maps were also 
consulted to ascertain the insert was in frame with the tag of interest (FLAG, EGFP, HA). All constructs and 
sequencing primers required were sent in solution according to the guidelines provided by the service, or 
otherwise selected from a list of primers in-house. (see http://www.dnaseq.co.uk for further details). The 
table below details each construct analysed, its sequencing primers and the results: 




Frameshift mutation at G340 
(single nucleotide deletion)
pCMV5-HA-DYRK1A Service’s CMV Fwd Service’s CMV Rev Correct insert supplied
pEGFPC1-DYRK1A Service’s pEGFPC1 Fwd Service’s pEGFPC1 Rev Sub-cloning successful
Fig. M.7 - Sequencing primers employed.
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3.2.10 Maxi-preparation of plasmid constructs (QIAGEN protocol) 
All DNA constructs were then prepared on a large scale (maxi-prep) employing a HiSpeed® Plasmid Maxi Kit 
(QIAGEN), so as to achieve concentrations required for experimental use (See 3.5.4). To allow further expo-
nential replication of the DNA constructs, 200 μl of each bacterial culture (see 3.2.5) were allowed to grow 
overnight in a 150 ml LB solution enriched with the antibiotic to which each construct displays resistance. 
Each sterilised flask was incubated overnight at 37˚C whilst shaking. On the following day, all the 150 ml of 
overnight culture from each flask were aliquoted to 50 ml tubes and pelleted by centrifugation at top speed 
(14,000 rpm) and 4C in an 5810 R centrifuge (Eppendorf - from here on samples will be referred to as “cen-
trifuged” unless otherwise specified). The supernatant LB was then discarded and each pellet was sequen-
tially resuspended in 10 ml Buffer P1. Following, 10 ml of Buffer P2 were added to each solution to start a 
lysis reaction, which was incubated at room temperature for 5 min then neutralised by addition 10 ml of Buffer 
P3 (3.0 M potassium acetate pH 5.5). The 30 ml lysate solution was then transferred to a QIAfilter Cartridge 
(essentially a large filtered syringe) and incubated for 10 min at room temperature. Thereafter, the lysate was 
filtered into and slowly through a HiSpeed Tip, a DNA sieve previously primed with buffer QBT (750 mM NaCl, 
50 mM MOPS pH 7.0, 15% isopropanol, 0.15% triton X-100). Following the initial filtering, 60 ml of wash buf-
fer QC (1.0M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol) were allowed to slowly filter through the HiS-
peed Tip from the attached QIAfilter Cartridge. 15 ml of Buffer QF (1.25M NaCl, 50 mM Tris-HCl pH 8.5, 15% 
isopropanol) were then filtered though to elute the DNA.  
The eluate was collected in a 50 ml tube and 10.5 ml of isopropanol  were added to precipitate DNA. The 
eluate/isopropanol mix was transferred to a 30 ml syringe attached to a QIAprecipitator module, an additional 
sieve for final collection of the purified DNA construct. The solution was first filtered through the QIAprecipitator 
and the flow-through was discarded. The module was then washed twice with 2 ml of 70% ethanol and sub-
sequently dried by forcing air through the syringe twice more. To elute DNA, 1.5 ml of Buffer TE (Tris-EDTA) 
were added, filtered through the QIAprecipitaror and collected in a 1.5 ml microcentrifuge tube. This step was 
repeated twice more with the same eluate to enhance the final concentration. Following the final preparation, 
each construct was sequenced for additional confirmation and thereby employed for experimental use. 
3.2.11 Summary of expression constructs employed 
pCMV5-HA-DYRK1A and pCS2-DKK3-FLAG were obtained from MRC PPU Reagents, while pCDNA3.1-
FLAG-β-catenin was a gift from Eric Fearon (Addgene plasmid #16828). pRK5-FLAG-DVL1 was generated 
in-house as described previously (1), and pEGFP-DYRK1A was cloned as outlined above. These con-
structs were employed in luciferase assays, co-IPs and immunocytochemistry (see following sections). 
M50 Super 8X TOPflash and M51 Super 8X FOPflash were gifts from Randall Moon (Addgene plasmids 
#12456 and #12457) (2). pTK-Renilla (Renilla) was purchased from Promega. The latter three constructs 
were employed in luciferase assays to quantify Wnt signalling activity (see 3.5.5). 
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3.2.8 Quantification of DNA concentration  
Prior to DNA sequencing, the concentration of each construct was measured employing a NanoDrop 
2000 Spectrophotometer (Thermo Scientific), which determines micro-volume DNA concentration as a 
function of the sample’s spectral absorbance. The NanoDrop’s sample pedestal was first cleaned and sub-
sequently initialised by measuring 1 μl of distilled H20. The instrument was then blanked with 1 μl of Buffer 
EB (used to elute DNA in 3.2.6) to exclude any interference from this buffer in the final measurements. 
Thereafter, 1 μl of each DNA preparation was added to the sample pedestal to determine concentration. 
Each measurement was repeated 3 times to account for instrument error. This technique was also per-
formed on the final, large-scale DNA preparations (see 3.1.10) to determine the final stock concentration of 
each construct (see 3.5.4 for all concentrations). 
3.2.9 DNA sequencing 
All constructs employed in this thesis were validated via DNA sequencing. An external service was em-
ployed, namely the Dna Sequencing & ServicesTM, University of Dundee, Dundee, Scotland. DNA se-
quencing was performed on both small and large scale (3.2.10) preparations of each construct, in order to 
ensure consistency. For each construct Each sequencing result was analysed in comparison to the 
DYRK1A reference sequence for human isoform 1 (NM_001396.3) employing the NCBI Basic Local 
Alignment Search Tool (BLAST) and the Sequencher software suite (Gene Codes). Vector maps were also 
consulted to ascertain the insert was in frame with the tag of interest (FLAG, EGFP, HA). All constructs and 
sequencing primers required were sent in solution according to the guidelines provided by the service, or 
otherwise selected from a list of primers in-house. (see http://www.dnaseq.co.uk for further details). The 
table below details each construct analysed, its sequencing primers and the results: 




Frameshift mutation at G340 
(single nucleotide deletion)
pCMV5-HA-DYRK1A Service’s CMV Fwd Service’s CMV Rev Correct insert supplied
pEGFPC1-DYRK1A Service’s pEGFPC1 Fwd Service’s pEGFPC1 Rev Sub-cloning successful
Fig. M.7 - Sequencing primers employed.
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3.2.10 Maxi-preparation of plasmid constructs (QIAGEN protocol) 
All DNA constructs were then prepared on a large scale (maxi-prep) employing a HiSpeed® Plasmid Maxi Kit 
(QIAGEN), so as to achieve concentrations required for experimental use (See 3.5.4). To allow further expo-
nential replication of the DNA constructs, 200 μl of each bacterial culture (see 3.2.5) were allowed to grow 
overnight in a 150 ml LB solution enriched with the antibiotic to which each construct displays resistance. 
Each sterilised flask was incubated overnight at 37˚C whilst shaking. On the following day, all the 150 ml of 
overnight culture from each flask were aliquoted to 50 ml tubes and pelleted by centrifugation at top speed 
(14,000 rpm) and 4C in an 5810 R centrifuge (Eppendorf - from here on samples will be referred to as “cen-
trifuged” unless otherwise specified). The supernatant LB was then discarded and each pellet was sequen-
tially resuspended in 10 ml Buffer P1. Following, 10 ml of Buffer P2 were added to each solution to start a 
lysis reaction, which was incubated at room temperature for 5 min then neutralised by addition 10 ml of Buffer 
P3 (3.0 M potassium acetate pH 5.5). The 30 ml lysate solution was then transferred to a QIAfilter Cartridge 
(essentially a large filtered syringe) and incubated for 10 min at room temperature. Thereafter, the lysate was 
filtered into and slowly through a HiSpeed Tip, a DNA sieve previously primed with buffer QBT (750 mM NaCl, 
50 mM MOPS pH 7.0, 15% isopropanol, 0.15% triton X-100). Following the initial filtering, 60 ml of wash buf-
fer QC (1.0M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol) were allowed to slowly filter through the HiS-
peed Tip from the attached QIAfilter Cartridge. 15 ml of Buffer QF (1.25M NaCl, 50 mM Tris-HCl pH 8.5, 15% 
isopropanol) were then filtered though to elute the DNA.  
The eluate was collected in a 50 ml tube and 10.5 ml of isopropanol  were added to precipitate DNA. The 
eluate/isopropanol mix was transferred to a 30 ml syringe attached to a QIAprecipitator module, an additional 
sieve for final collection of the purified DNA construct. The solution was first filtered through the QIAprecipitator 
and the flow-through was discarded. The module was then washed twice with 2 ml of 70% ethanol and sub-
sequently dried by forcing air through the syringe twice more. To elute DNA, 1.5 ml of Buffer TE (Tris-EDTA) 
were added, filtered through the QIAprecipitaror and collected in a 1.5 ml microcentrifuge tube. This step was 
repeated twice more with the same eluate to enhance the final concentration. Following the final preparation, 
each construct was sequenced for additional confirmation and thereby employed for experimental use. 
3.2.11 Summary of expression constructs employed 
pCMV5-HA-DYRK1A and pCS2-DKK3-FLAG were obtained from MRC PPU Reagents, while pCDNA3.1-
FLAG-β-catenin was a gift from Eric Fearon (Addgene plasmid #16828). pRK5-FLAG-DVL1 was generated 
in-house as described previously (1), and pEGFP-DYRK1A was cloned as outlined above. These con-
structs were employed in luciferase assays, co-IPs and immunocytochemistry (see following sections). 
M50 Super 8X TOPflash and M51 Super 8X FOPflash were gifts from Randall Moon (Addgene plasmids 
#12456 and #12457) (2). pTK-Renilla (Renilla) was purchased from Promega. The latter three constructs 
were employed in luciferase assays to quantify Wnt signalling activity (see 3.5.5). 
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3.3 DS mouse models 
This section describes maintenance of Tc1, Dp1Tyb, and Dp1(10-17)Yey mice, as well surgical dissection 
procedures employed to isolate target cerebral regions. These cohorts were employed for biochemical as-
sessment of Wnt signalling and are distinct from those utilised for RNAseq and qPCR (see 3.1/4). Genetic 
material from the latter two was generated independently by the UCL Institute of Neurology. 
3.3.1 Animal husbandry and general information 
Tc(Hsa21)1TybEmcf (Tc1), Dp(16Lipi-Zbtb21)1TybEmcf (Dp1Tyb), Dp(17Abcg1-Rrp1b)1Yey (Dp(17)1Yey), 
and Dp(10Prmt2-Pdxk)1Yey (Dp(10)1Yey), mice (3-5) were bred at the Francis Crick Institute in specific 
pathogen free conditions, in a controlled environment and in accordance with the MRC Responsibility in 
the Use of Animals for Medical Research (1993) guidelines. Tc1 mice were maintained by crossing to 
(C57BL/6J x 129S8)F1 mice; all other strains were maintained by crossing with C57BL/6J mice. All ani-
mals were euthanised by cervical dislocation in accordance with the Animals (Scientific Procedures) Act 
1986 and European Directive 2010/63/EU. Brains were collected from 160 ± 28 days days old male Tc1 
mice and 131 ± 7 days old male Dp1Tyb/Dp(17)1Yey/Dp(10)1Yey mice. The tables below detail the Tc1 
and Dp1Tyb mice used to generate the experimental  groups investigated in this thesis: 
Tc1 MOUSE













05/09/13 20/03/14 196 +/-
EF6/91.3
b
05/09/13 20/03/14 196 -/-
EF6/91.3
c
05/09/13 20/03/14 196 -/-
EF6/91.8e 20/11/13 15/04/14 146
2
+/-
EF6/91.9f 24/11/13 14/04/14 141 +/-
EF6/91.8c 20/11/13 15/04/14 146 -/-







EF6/96.1g 17/11/13 11/04/14 145 +/-
EF6/89.6
a
22/09/13 20/03/14 179 -/-
EF6/96.1f 17/11/13 11/04/14 145 -/-
EF6/96.1k 17/11/13 14/04/14 148
4
+/-
EF6/97.1d 17/11/13 22/03/14 125 +/-
EF6/96.1j 17/11/13 14/04/14 148 -/-
EF6/97.1c 17/11/13 22/03/14 125 -/-
Fig. M.8 - Overview of Tc1 mice employed for biochemical Wnt signalling study in this thesis.
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Dp1Tyb MOUSE









TS1TYB/15.7c 11/01/14 04/06/2014 144 WT
TS1TYB/15.7d 11/01/14 04/06/2014 144 Ts1Tyb
TS1TYB/18.3a 26/01/14 04/06/2014 129
2
Ts1Tyb
TS1TYB/18.3b 26/01/14 04/06/2014 129 Ts1Tyb
TS1TYB/18.3c 26/01/14 04/06/2014 129 WT
TS1TYB/18.3d 26/01/14 04/06/2014 129 WT
TS1TYB/18.3e 26/01/14 04/06/2014 129 WT
TS1TYB/15.8d 01/02/14 04/06/2014 123
3
Ts1Tyb
TS1TYB/15.8e 01/02/14 04/06/2014 123 WT
TS1TYB/15.8f 01/02/14 04/06/2014 123 Ts1Tyb




TS1TYB/33.2f 05/05/15 21/09/2015 139 Ts1Tyb
TS1TYB/35.1b 05/05/15 21/09/2015 139 WT
TS1TYB/31.3d 12/05/15 21/09/2015 132
5
WT
TS1TYB/31.3e 12/05/15 21/09/2015 132 WT
TS1TYB/31.3f 12/05/15 21/09/2015 132 WT
TS1TYB/31.3g 12/05/15 21/09/2015 132 Ts1Tyb
TS1TYB/31.3h 12/05/15 21/09/2015 132 Ts1Tyb
TS1TYB/32.3h 21/05/15 21/09/2015 123 6 Ts1TybTS1TYB/32.3i 21/05/15 21/09/2015 123 WT
Fig. M.9 - Overview of Dp1Tyb mice employed for biochemical Wnt signalling study in this thesis.
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3.3 DS mouse models 
This section describes maintenance of Tc1, Dp1Tyb, and Dp1(10-17)Yey mice, as well surgical dissection 
procedures employed to isolate target cerebral regions. These cohorts were employed for biochemical as-
sessment of Wnt signalling and are distinct from those utilised for RNAseq and qPCR (see 3.1/4). Genetic 
material from the latter two was generated independently by the UCL Institute of Neurology. 
3.3.1 Animal husbandry and general information 
Tc(Hsa21)1TybEmcf (Tc1), Dp(16Lipi-Zbtb21)1TybEmcf (Dp1Tyb), Dp(17Abcg1-Rrp1b)1Yey (Dp(17)1Yey), 
and Dp(10Prmt2-Pdxk)1Yey (Dp(10)1Yey), mice (3-5) were bred at the Francis Crick Institute in specific 
pathogen free conditions, in a controlled environment and in accordance with the MRC Responsibility in 
the Use of Animals for Medical Research (1993) guidelines. Tc1 mice were maintained by crossing to 
(C57BL/6J x 129S8)F1 mice; all other strains were maintained by crossing with C57BL/6J mice. All ani-
mals were euthanised by cervical dislocation in accordance with the Animals (Scientific Procedures) Act 
1986 and European Directive 2010/63/EU. Brains were collected from 160 ± 28 days days old male Tc1 
mice and 131 ± 7 days old male Dp1Tyb/Dp(17)1Yey/Dp(10)1Yey mice. The tables below detail the Tc1 
and Dp1Tyb mice used to generate the experimental  groups investigated in this thesis: 
 
TC1 MOUSE













05/09/13 20/03/14 196 +/-
EF6/91.3
b
05/09/13 20/03/14 196 -/-
EF6/91.3
c
05/09/13 20/03/14 196 -/-
EF6/91.8e 20/11/13 15/04/14 146
2
+/-
EF6/91.9f 24/11/13 14/04/14 141 +/-
EF6/91.8c 20/11/13 15/04/14 146 -/-







EF6/96.1g 17/11/13 11/04/14 145 +/-
EF6/89.6
a
22/09/13 20/03/14 179 -/-
EF6/96.1f 17/11/13 11/04/14 145 -/-
EF6/96.1k 17/11/13 14/04/14 148
4
+/-
EF6/97.1d 17/11/13 22/03/14 125 +/-
EF6/96.1j 17/11/13 14/04/14 148 -/-
EF6/97.1c 17/11/13 22/03/14 125 -/-
Fig. M.8 - Overview of Tc1 mice employed for biochemical Wnt signalling study in this thesis.
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Dp1Tyb MOUSE









TS1TYB/15.7c 11/01/14 04/06/2014 144 WT
TS1TYB/15.7d 11/01/14 04/06/2014 144 Ts1Tyb
TS1TYB/18.3a 26/01/14 04/06/2014 129
2
Ts1Tyb
TS1TYB/18.3b 26/01/14 04/06/2014 129 Ts1Tyb
TS1TYB/18.3c 26/01/14 04/06/2014 129 WT
TS1TYB/18.3d 26/01/14 04/06/2014 129 WT
TS1TYB/18.3e 26/01/14 04/06/2014 129 WT
TS1TYB/15.8d 01/02/14 04/06/2014 123
3
Ts1Tyb
TS1TYB/15.8e 01/02/14 04/06/2014 123 WT
TS1TYB/15.8f 01/02/14 04/06/2014 123 Ts1Tyb




TS1TYB/33.2f 05/05/15 21/09/2015 139 Ts1Tyb
TS1TYB/35.1b 05/05/15 21/09/2015 139 WT
TS1TYB/31.3d 12/05/15 21/09/2015 132
5
WT
TS1TYB/31.3e 12/05/15 21/09/2015 132 WT
TS1TYB/31.3f 12/05/15 21/09/2015 132 WT
TS1TYB/31.3g 12/05/15 21/09/2015 132 Ts1Tyb
TS1TYB/31.3h 12/05/15 21/09/2015 132 Ts1Tyb
TS1TYB/32.3h 21/05/15 21/09/2015 123 6 Ts1TybTS1TYB/32.3i 21/05/15 21/09/2015 123 WT
Fig. M.9 - Overview of Dp1Tyb mice employed for biochemical Wnt signalling study in this thesis.
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3.3.2 Cortical and hippocampal dissection 
All mouse brains were dissected in a safe cabinet with laminar air flow in the Wakefield Street Biological 
Services Unit, UCL ION, London. Full-body protective equipment was worn throughout, and all tools were 
thoroughly cleaned with 70% ethanol between each dissection. The technique was carried out with stan-
dard surgical tools and naked eye (see figure below). All mice were euthanised by neck dislocation, in ac-
cordance with Home Office regulations and The Humane Killing of Animals under Schedule 1 to the Ani-
mals (Scientific Procedures) Act 1986. To minimise stress, each mouse was culled away from its cage of 
origin. Following complete neck dislocation, death was ensured by assessing for complete disruption of 
the spinal cord at vertebral levels C1-3. The head was subsequently removed. Before discarding the body, 
a small tail clipping was collected for DNA extraction and future genotyping.  
The cranial skin was then incised sagittally, beginning at the orbital midline, and separated laterally to ex-
pose the dorsal aspect of the cranium and reveal the foramen magnum. From this point, the cranial bone 
was carefully cut either side postero-anteriorly along the parietotemporal suture and then medially to the 
midline bregma. The frontal, parietal, inter parietal and occipital bones were then gently removed to reveal 
the brain, which was eased out of the cranial cavity (step 1) and transferred to a plastic dissection plate in 
10 ml of phosphate-buffered saline (PBS) on ice. The whole brain was first washed in PBS by slowly 
swirling the plate to remove any residual blood. Thereafter, it was divided sagittally in left and right hemi-
spheres (step 2) while the brain stem was removed, transferred to a 1.5 ml microcentrifuge tube, snap 
frozen at -196˚C in liquid nitrogen  and stored in dry ice at -80˚C. The hippocampi were removed from each 
sagittal cortical section by gently separating the medial aspect of the cortex from the thalamus, striatum 
and other midbrain structures and by widening the lateral ventricles, thereby exposing the hippocampus 
(step 3). Following, the hippocampus was slowly eased out of the medial cortex (step 4). The resulting cor-
tical and hippocampal samples were then snap frozen and stored in dry ice. After all dissections were car-
ried out for one cage, the samples were transferred to a New BrunswickTM -86°C Ultra-low temperature 
U725 freezer for later use. 
1 2 3 4
Fig. M.10 - Overview of cerebral dissection procedure performed on DS mouse models.
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3.4 Quantitative real-time polymerase chain reaction - qPCR 
In this thesis, qPCR was the technique of choice for quantification of DKK3 and AXIN2 expression in the 
Tc1 hippocampus. This study was undertaken to confirm preliminary RNA sequencing data (4.1.2). A total 
of 8 mice were analysed, comprising 4 Tc1 and 4 age-matched controls (n=4). The table below details the 
male mice from which the template genetic material was generated. 
3.4.1 Tc1 cDNA generation via reverse transcription  
In order to generate stable templates for qPCR use, 1 μg RNA preparations from each mouse were first 
reverse-transcribed to cDNA employing a QuantiTect® Reverse Transcription Kit (QIAGEN), which supplies 
all required reagents. All RNA preparations has been previously extracted by Elizabeth Fisher’s laboratory. 
Prior to reverse transcription, all RNA preparations were cleared of genomic DNA contamination. Samples 
were thawed on ice and made up to a 12 μl solution in RNAse-free ddH20. 2 μl of gDNA Wipeout Buffer 
(2.5-10% trometamol) were then added to each sample and incubated for 2 min at 42°C in an Eppendorf 
ThermoMixer® F1.5. Following, reverse transcription reaction mixtures were prepared as follows: 
NUMBER CODENAME AGE AT COLLECTION (d) SEX GENOTYPE - Hsa21
483288 WT A 83 m -/-
483554 WT B 95 m -/-
483565 WT C 96 m -/-
481897 WT D 95 m -/-
483289 Tc1 A 83 m -/+
509574 Tc1 B 87 m -/+
509576 Tc1 C 87 m -/+
509819 Tc1 D 77 m -/+
Fig. M.11 - Tc1 hippocampal samples used ad source of cDNA employed for qPCR.
COMPONENT VOLUME
QuantiScritpt® RT 1 μl
QuantiScritpt® RT Buffer (dNTPs) 4 μl
RT primer mix 1 μl
Template RNA 14 μl
Fig. M.12 - Reverse transcription reaction
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3.3.2 Cortical and hippocampal dissection 
All mouse brains were dissected in a safe cabinet with laminar air flow in the Wakefield Street Biological 
Services Unit, UCL ION, London. Full-body protective equipment was worn throughout, and all tools were 
thoroughly cleaned with 70% ethanol between each dissection. The technique was carried out with stan-
dard surgical tools and naked eye (see figure below). All mice were euthanised by neck dislocation, in ac-
cordance with Home Office regulations and The Humane Killing of Animals under Schedule 1 to the Ani-
mals (Scientific Procedures) Act 1986. To minimise stress, each mouse was culled away from its cage of 
origin. Following complete neck dislocation, death was ensured by assessing for complete disruption of 
the spinal cord at vertebral levels C1-3. The head was subsequently removed. Before discarding the body, 
a small tail clipping was collected for DNA extraction and future genotyping.  
The cranial skin was then incised sagittally, beginning at the orbital midline, and separated laterally to ex-
pose the dorsal aspect of the cranium and reveal the foramen magnum. From this point, the cranial bone 
was carefully cut either side postero-anteriorly along the parietotemporal suture and then medially to the 
midline bregma. The frontal, parietal, inter parietal and occipital bones were then gently removed to reveal 
the brain, which was eased out of the cranial cavity (step 1) and transferred to a plastic dissection plate in 
10 ml of phosphate-buffered saline (PBS) on ice. The whole brain was first washed in PBS by slowly 
swirling the plate to remove any residual blood. Thereafter, it was divided sagittally in left and right hemi-
spheres (step 2) while the brain stem was removed, transferred to a 1.5 ml microcentrifuge tube, snap 
frozen at -196˚C in liquid nitrogen  and stored in dry ice at -80˚C. The hippocampi were removed from each 
sagittal cortical section by gently separating the medial aspect of the cortex from the thalamus, striatum 
and other midbrain structures and by widening the lateral ventricles, thereby exposing the hippocampus 
(step 3). Following, the hippocampus was slowly eased out of the medial cortex (step 4). The resulting cor-
tical and hippocampal samples were then snap frozen and stored in dry ice. After all dissections were car-
ried out for one cage, the samples were transferred to a New BrunswickTM -86°C Ultra-low temperature 
U725 freezer for later use. 
1 2 3 4
Fig. M.10 - Overview of cerebral dissection procedure performed on DS mouse models.
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3.4 Quantitative real-time polymerase chain reaction - qPCR 
In this thesis, qPCR was the technique of choice for quantification of DKK3 and AXIN2 expression in the 
Tc1 hippocampus. This study was undertaken to confirm preliminary RNA sequencing data (4.1.2). A total 
of 8 mice were analysed, comprising 4 Tc1 and 4 age-matched controls (n=4). The table below details the 
male mice from which the template genetic material was generated. 
3.4.1 Tc1 cDNA generation via reverse transcription  
In order to generate stable templates for qPCR use, 1 μg RNA preparations from each mouse were first 
reverse-transcribed to cDNA employing a QuantiTect® Reverse Transcription Kit (QIAGEN), which supplies 
all required reagents. All RNA preparations has been previously extracted by Elizabeth Fisher’s laboratory. 
Prior to reverse transcription, all RNA preparations were cleared of genomic DNA contamination. Samples 
were thawed on ice and made up to a 12 μl solution in RNAse-free ddH20. 2 μl of gDNA Wipeout Buffer 
(2.5-10% trometamol) were then added to each sample and incubated for 2 min at 42°C in an Eppendorf 
ThermoMixer® F1.5. Following, reverse transcription reaction mixtures were prepared as follows: 
NUMBER CODENAME AGE AT COLLECTION (d) SEX GENOTYPE - Hsa21
483288 WT A 83 m -/-
483554 WT B 95 m -/-
483565 WT C 96 m -/-
481897 WT D 95 m -/-
483289 Tc1 A 83 m -/+
509574 Tc1 B 87 m -/+
509576 Tc1 C 87 m -/+
509819 Tc1 D 77 m -/+
Fig. M.11 - Tc1 hippocampal samples used ad source of cDNA employed for qPCR.
COMPONENT VOLUME
QuantiScritpt® RT 1 μl
QuantiScritpt® RT Buffer (dNTPs) 4 μl
RT primer mix 1 μl
Template RNA 14 μl
Fig. M.12 - Reverse transcription reaction
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Each reaction was incubated for 30 min at 42°C in an Eppendorf ThermoMixer® F1.5. Thereafter, the re-
verse transcriptase was inactivated by incubating at 95°C for 3 min. The ~1 μg (50 ng/μl) cDNA product 
was subsequently stored at -20°C for experimental use. For each sample, an identical reaction was per-
formed alongside, substituting the reverse transcriptase with RNAse-free ddH20 for usage as a negative 
control (-RT) to account for any non-specific amplification at the qPCR stage. 
3.4.2 DNA primer and probe design 
The qPCR technique requires the design of two primers, forward and reverse, and an additional oligonu-
cleotide probe in between the two. The probe is a slightly longer oligonucleotide tagged with a fluorophore 
at its 5’ end and a quencher at its 3’ end. The latter withholds fluorescence unless the probe binds to its 
target DNA sequence and the fluorophore is cleaved via Taq polymerase exonuclease activity. The signal 
generated is directly proportional to the amount of probe amplified and consequently, to the amount of ex-
pression of a gene of interest. Importantly, qPCR primers must be able to recognise a template sequence 
representing an expressed gene, i.e. a sequence composed solely of joined exons. For this reason, primers 
must be designed so that at least one bridges between an exon-exon boundary, while the other and the 

















Fig. M.13 - Conceptual overview of qPCR primer-probe binding and fluorescence release.
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Exon sequences for AXIN2 and DKK3 were obtained from the e!Ensembl browser (http://www.ensem-
bl.org/index.html) selecting for mouse genome. Primers and probes were designed employing Primer Ex-
press® Software (Life Technology) set on TAQman qPCR design. This program aids optimal primer design 
by providing instant information on primer G/C content, repeating patterns, secondary structures and Tm. 
Primers and probe were designed according to guidelines provided by Life Technology. Furthermore, each 
primer pair and probe was tested for specificity through the NCBI reverse ePCR web service (http://
www.ncbi.nlm.nih.gov/projects/e-pcr/forward.cgi) by running a mouse transcriptome-based virtual PCR 
reaction to confirm correct amplification of the genes of interest. All primers and probes were synthesised 
by Eurofins. Upon delivery, primers were solubilised in ddH20 while probes were dissolved in qPCR Probe 
Dilution Buffer (10 mM Tris-HCl, pH 8, 1mM EDTA) to a 100 μM stock concentration and stored at -20˚C ac-
cording to manufacturer instructions. The figures below detail primer sequence, characteristics and ePCR 
results for DKK3 and AXIN2. 
Fig. M.14 - qPCR primer sequence, characteristics and ePCR results for DKK3 and AXIN2
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Each reaction was incubated for 30 min at 42°C in an Eppendorf ThermoMixer® F1.5. Thereafter, the re-
verse transcriptase was inactivated by incubating at 95°C for 3 min. The ~1 μg (50 ng/μl) cDNA product 
was subsequently stored at -20°C for experimental use. For each sample, an identical reaction was per-
formed alongside, substituting the reverse transcriptase with RNAse-free ddH20 for usage as a negative 
control (-RT) to account for any non-specific amplification at the qPCR stage. 
3.4.2 DNA primer and probe design 
The qPCR technique requires the design of two primers, forward and reverse, and an additional oligonu-
cleotide probe in between the two. The probe is a slightly longer oligonucleotide tagged with a fluorophore 
at its 5’ end and a quencher at its 3’ end. The latter withholds fluorescence unless the probe binds to its 
target DNA sequence and the fluorophore is cleaved via Taq polymerase exonuclease activity. The signal 
generated is directly proportional to the amount of probe amplified and consequently, to the amount of ex-
pression of a gene of interest. Importantly, qPCR primers must be able to recognise a template sequence 
representing an expressed gene, i.e. a sequence composed solely of joined exons. For this reason, primers 
must be designed so that at least one bridges between an exon-exon boundary, while the other and the 

















Fig. M.13 - Conceptual overview of qPCR primer-probe binding and fluorescence release.
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Exon sequences for AXIN2 and DKK3 were obtained from the e!Ensembl browser (http://www.ensem-
bl.org/index.html) selecting for mouse genome. Primers and probes were designed employing Primer Ex-
press® Software (Life Technology) set on TAQman qPCR design. This program aids optimal primer design 
by providing instant information on primer G/C content, repeating patterns, secondary structures and Tm. 
Primers and probe were designed according to guidelines provided by Life Technology. Furthermore, each 
primer pair and probe was tested for specificity through the NCBI reverse ePCR web service (http://
www.ncbi.nlm.nih.gov/projects/e-pcr/forward.cgi) by running a mouse transcriptome-based virtual PCR 
reaction to confirm correct amplification of the genes of interest. All primers and probes were synthesised 
by Eurofins. Upon delivery, primers were solubilised in ddH20 while probes were dissolved in qPCR Probe 
Dilution Buffer (10 mM Tris-HCl, pH 8, 1mM EDTA) to a 100 μM stock concentration and stored at -20˚C ac-
cording to manufacturer instructions. The figures below detail primer sequence, characteristics and ePCR 
results for DKK3 and AXIN2. 
Fig. M.14 - qPCR primer sequence, characteristics and ePCR results for DKK3 and AXIN2
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3.4.3 qPCR 
For experimental use, primer and probe stocks were diluted to 40 μΜ (1:2.5) and 5 μM (1:20) in ddH20 re-
spectively. Furthermore, each 50 ng/μl cDNA preparation was diluted 1:10 following routine laboratory prac-
tice for moderately-to-highly expressed genes. In addition to template cDNA, primers and probe, each qPCR 
reaction requires the amplification of a stably expressed gene to provide a reference for quantification. For this 
thesis, β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were employed. Both were sup-
plied pre-mixed by Elizabeth fisher’s laboratory with primers and probe labeled with VIC® (Life Technology, 
composition not available publicly) and quenched by dihydrocyclopyrroloindole tripeptide minor groove 
binder (MGB). All reactions were incubated in TaqMan® Gene Expression Master Mix (AmpliTaq Gold® 
DNA Polymerase (Ultra Pure), Uracil-DNA glycosylase, dNTPs (with dUTP), ROX™ Passive Reference, and 
optimized buffer components), which includes DNA polymerase and substrates as well as a passive refer-
ence signal providing constitutive fluorescence to control for sample loading. The following table details the 
components of each standard 15 μl reaction: 
COMPONENT VOLUME
TaqMan® Master Mix 7.5 μl
FWD primer 0.15 μl
REV primer 0.15 μl
Probe 0.45 μl
Reference gene 0.3 μl
ddH20 5.45 μl
cDNA template or -RT 1 μl
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3.5 Cell culture, luciferase assay and immunocytochemistry 
This section details human cell lines employed, routine aspects of tissue culture, pharmacological treat-
ment and DNA transfection, novel development of a reporter human cell line and preparation of cultures for 
imaging experiments. The associated results are discussed in chapter 3 (4.3.2). 
3.5.1 General cell line maintenance 
All work with cell lines was conducted in a MSC-Advantage™ Class II Biological Safety Cabinet with lami-
nar air flow, unless otherwise specified. All cell lines were grown, stored and treated at 37˚C and 5% CO2 in 
an MCO-18AC Panasonic CO2 incubator. Four human cell lines were employed: 
Each cell line was grown and maintained in a 100 ml sterile cell culture flask, the surface of which is readily 
optimised for cell attachment. Generally, these stocks were cultured at ~106 cells/ml in order to guarantee
a high number of available cells, whilst preventing damaging over-confluent growth. This target concentra-
tion was measured regularly via fluorescence-mediated cell counting, employing a Muse® Cell Analyzer 
and Muse® Count & Viability Kit (Merck Millipore), following manufacturer’s protocols. For each cell line, 10 
ml of Dulbecco’s Modified Eagle Medium (DMEM, Gibco) were employed as a maintenance growth medi-
um. Moreover, all DMEM solutions were enriched with 100 μg/ml streptomycin and 100 U/ml penicillin to 
protect the cells against bacterial contamination. Foetal Bovine Serum (FBS) was also added to the medi-
um, in order to provide nutrients essential for cell survival.  
DMEM enriched with the above antibiotics and nutrients will henceforth be referred to solely as DMEM. 
Additionally, the growth medium for TF-stable cells was conditioned with 1:1000 G418 (Geneticin), an 
aminoglycoside antibiotic active against both prokaryotic and eukaryotic organisms. Because the 
TOPFLASH construct expressed in the TF-stable cell line (see 3.5.6) also encodes a G418 resistance 
gene, administration of this agent provides additional positive selective pressure, only allowing cells ex-
pressing the luciferase reporter to grow. 
NAME DESCRIPTION
SH-SY5Y Neuroblastoma cells. Employed in luciferase assays and DYRK1A overexpression experiments.
TF-stable Modified SH-SY5Y line, employed in all DYRK1A inhibition luciferase experiments. (see 3.5.6 for info on development of this line)
HEK293 Human embryonic kidney cells. Employed in DYRK1A overexpression and imaging experiments.
HeLa Human cervical cancer-derived, oldest cell line in existence. Employed in Airyscan imaging experiments.
Fig. M.16 - Cell lines employed.
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Fig. M.15 - Standard qPCR reaction mix.
Standards and plate setup - Each experiment was performed in a standard qPCR 96-well plate for each 
gene investigated and each reference gene considered. Prior to loading, the plate was inserted in an ice 
rack to maintain the samples at low temperature. All expression qPCR reactions require the generation of a 
standard curve quantifying gene expression in one reference sample as a function of its loaded concentra-
tion. This allows for reliable quantification of gene expression across all conditions under study. For all ex-
periments performed in this thesis, sample WT A was selected as standard. The original 50 ng/ l cDNA 
preparation obtained following 3.5.2 was diluted 1:5 (ie 2x experimental samples) and then 1:2 serially up 
to 1:80 relative to the original solution. All samples were loaded in technical triplicates to provide additional 
loading control (individual triplicates not included in final analysis). 
Amplification reaction - For each sample analysed, the corresponding -RT control was loaded along 
side, also in triplicate. Once loaded, the 96-well plate was removed from the ice rack and thereby cen-
trifuged at room temperature for 5 min at top speed. All experiments were performed employing a 7500 
Fast Real-Time PCR System (Life Technologies) controlled by homonymous software. The qPCR was set 
to run under the Quantification protocol for a standard duration of approximately 90 min.
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3.4.3 qPCR 
For experimental use, primer and probe stocks were diluted to 40 μΜ (1:2.5) and 5 μM (1:20) in ddH20 re-
spectively. Furthermore, each 50 ng/μl cDNA preparation was diluted 1:10 following routine laboratory prac-
tice for moderately-to-highly expressed genes. In addition to template cDNA, primers and probe, each qPCR 
reaction requires the amplification of a stably expressed gene to provide a reference for quantification. For this 
thesis, β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were employed. Both were sup-
plied pre-mixed by Elizabeth fisher’s laboratory with primers and probe labeled with VIC® (Life Technology, 
composition not available publicly) and quenched by dihydrocyclopyrroloindole tripeptide minor groove 
binder (MGB). All reactions were incubated in TaqMan® Gene Expression Master Mix (AmpliTaq Gold® 
DNA Polymerase (Ultra Pure), Uracil-DNA glycosylase, dNTPs (with dUTP), ROX™ Passive Reference, and 
optimized buffer components), which includes DNA polymerase and substrates as well as a passive refer-
ence signal providing constitutive fluorescence to control for sample loading. The following table details the 
components of each standard 15 μl reaction: 
Standards and plate setup - Each experiment was performed in a standard qPCR 96-well plate for each 
gene investigated and each reference gene considered. Prior to loading, the plate was inserted in an ice 
rack to maintain the samples at low temperature. All expression qPCR reactions require the generation of a 
standard curve quantifying gene expression in one reference sample as a function of its loaded concentra-
tion. This allows for reliable quantification of gene expression across all conditions under study. For all ex-
periments performed in this thesis, sample WT A was selected as standard. The original 50 ng/μl cDNA 
preparation obtained following 3.5.2 was diluted 1:5 (ie 2x experimental samples) and then 1:2 serially up 
to 1:80 relative to the original solution. All samples were loaded in technical triplicates to provide additional 
loading control (individual triplicates not included in final analysis) 
Amplification reaction - For each sample analysed, the corresponding -RT control was loaded along 
side, also in triplicate. Once loaded, the 96-well plate was removed from the ice rack and thereby cen-
trifuged at room temperature for 5 min at top speed. All experiments were performed employing a 7500 
Fast Real-Time PCR System (Life Technologies) controlled by homonymous software. The qPCR was set 
to run under the Quantification protocol for a standard duration of approximately 90 min. 
COMPONENT VOLUME
TaqMan® Master Mix 7.5 μl
FWD primer 0.15 μl
REV primer 0.15 μl
Probe 0.45 μl
Reference gene 0.3 μl
ddH20 5.45 μl
cDNA template or -RT 1 μl
Fig. M.15 - Standard qPCR reaction mix.
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3.5 Cell culture, luciferase assay and immunocytochemistry 
This section details human cell lines employed, routine aspects of tissue culture, pharmacological treat-
ment and DNA transfection, novel development of a reporter human cell line and preparation of cultures for 
imaging experiments. The associated results are discussed in chapter 3 (4.3.2). 
3.5.1 General cell line maintenance 
All work with cell lines was conducted in a MSC-Advantage™ Class II Biological Safety Cabinet with lami-
nar air flow, unless otherwise specified. All cell lines were grown, stored and treated at 37˚C and 5% CO2 in 
an MCO-18AC Panasonic CO2 incubator. Four human cell lines were employed: 
Each cell line was grown and maintained in a 100 ml sterile cell culture flask, the surface of which is readily 
optimised for cell attachment. Generally, these stocks were cultured at ~106 cells/ml in order to guarantee 
a high number of available cells, whilst preventing damaging over-confluent growth. This target concentra-
tion was measured regularly via fluorescence-mediated cell counting, employing a Muse® Cell Analyzer 
and Muse® Count & Viability Kit (Merck Millipore), following manufacturer’s protocols. For each cell line, 10 
ml of Dulbecco’s Modified Eagle Medium (DMEM, Gibco) were employed as a maintenance growth medi-
um. Moreover, all DMEM solutions were enriched with 100 μg/ml streptomycin and 100 U/ml penicillin to 
protect the cells against bacterial contamination. Foetal Bovine Serum (FBS) was also added to the medi-
um, in order to provide nutrients essential for cell survival.  
DMEM enriched with the above antibiotics and nutrients will henceforth be referred to solely as DMEM. 
Additionally, the growth medium for TF-stable cells was conditioned with 1:1000 G418 (Geneticin), an 
aminoglycoside antibiotic active against both prokaryotic and eukaryotic organisms. Because the 
TOPFLASH construct expressed in the TF-stable cell line (see 3.5.6) also encodes a G418 resistance 
gene, administration of this agent provides additional positive selective pressure, only allowing cells ex-
pressing the luciferase reporter to grow. 
NAME DESCRIPTION
SH-SY5Y Neuroblastoma cells. Employed in luciferase assays and DYRK1A overexpression experiments.
TF-stable Modified SH-SY5Y line, employed in all DYRK1A inhibition luciferase experiments. (see 3.5.6 for info on development of this line)
HEK293 Human embryonic kidney cells. Employed in DYRK1A overexpression and imaging experiments.
HeLa Human cervical cancer-derived, oldest cell line in existence. Employed in Airyscan imaging experiments.
Fig. M.16 - Cell lines employed.
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Cell passaging - The growth of each cell line was monitored daily by direct observation under a Nikon 
inverted optical microscope, to assess health status and growth confluence. All cells were passaged every 
48-72 hrs. Via this technique, a fraction of the cells is removed and transferred to a new flask, ensuring 
continuous growth while maintaining cell number and density below the flask’s surface area limit. To first 
dispose of accumulated debris and cell metabolites, all DMEM was removed from each flask. The cells 
were subsequently washed with 10 ml of Hank’s Balanced Salt Solution (HBSS, Gibco - Composition) and 
by gently swirling each flask for 10 sec. Following, the HBSS was removed and each cell line was treated 
with 1 ml of 1mg/ml trypsin. The proteolytic action of trypsin, a serine protease of pancreatic production 
normally found in the vertebrate digestive tract, disrupts cell attachment to the flasks, allowing for re-sus-
pension in solution for removal. The trypsin reaction was allowed to proceed for 1-3 min, as required, until 
cells were visibly detached. Thereafter, 9 ml of DMEM were added to each flask to re-suspend the cells 
and make the total volume up to 10 ml for ease of subsequent dilution. Each cell line was passaged as a 
fraction of the previous flask. SH-SY5Y cells were passaged 1:5 at 48 hrs, and 1:10 at 72 hrs. Differently, 
HEK293 cells were passaged 1:3 at 48 hrs, and 1:5 at 72 hrs. Each of the new flasks were prepared with 
as much DMEM as required for a total volume of 10 ml with respect to the amount of cells taken from the 
re-suspended solution. As an example, for a 1:5 passage, 2/10 ml of re-suspended SH-SY5Y cells were 
added to 8 ml of fresh DMEM in the new flask. Each cell line was passaged up to 20 times before being 
discarded and substituted with an equivalent clone.  
Cell plating for experimental use - When required for study, cells were transferred to plates specifically 
designed for experimental use. The plating technique is essentially identical to passaging, differing only in 
the re-suspended cells being transferred to a different plate at a specific dilution, rather than to a new flask. 
For this reason, cells were always plated upon passaging.

 
Experiment Plate type Cell dilution






10 ml culture plate (company)
~105 /ml
Fig. M.17 - Plates and dilutions employed for each experiment type.
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3.5.2 DYRK1A inhibition 
For all DYRK1A inhibition experiments (4.3.2.2.1), three commercially available inhibitors with diverse 
mechanisms of action were investigated: EGCG (Epigallocatechin-3-gallate), INDY ((1Z)-1-(3-Ethyl-5-hydroxy-
2(3H)-benzothiazolylidene)-2-propanone), and Harmine (7-MeO-1-Me-9H-pyrido(3,4-b)-indole). Upon delivery, 
all inhibitors were solubilised according to manufacturer instructions and stored at -20˚C in a spark-free 
freezer. Each stock solution was prepared as 1000x the concentration required experimentally. The table 
below details the properties and experimental dose of each inhibitor: 
Characterisation of the above inhibitors has shown that INDY is both the most potent and specific inhibitor. 
While EGCG shows higher potency than Harmine, the latter as been shown to inhibit DYRK1A with in-
creased specificity compared to EGCG. For all DYRK1A inhibition experiments, cells were administered 
treatment via DMEM solutions enriched with each inhibitor at a concentration of 1:1000 to achieve the re-
quired experimental dose. All treatments were performed for a duration of 6 hrs at 37˚C. 
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noncompetitive 0.33 μM 25 μM Ethanol
INDY TOCRIS bioscience
Ogawa, et al. (2010) - 
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Adayev et al., 2011 - 
Harmine is an ATP-com-









Fig. M.18 - Overview and features of DYRK1A inhibitors employed.
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and make the total volume up to 10 ml for ease of subsequent dilution. Each cell line was passaged as a 
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the re-suspended cells being transferred to a different plate at a specific dilution, rather than to a new flask. 
For this reason, cells were always plated upon passaging.
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freezer. Each stock solution was prepared as 1000x the concentration required experimentally. The table 
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quired experimental dose. All treatments were performed for a duration of 6 hrs at 37˚C. 
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3.5.3 Lithium chloride and Wnt3a administration 
For all experiments involving measurements of canonical Wnt signalling activity in human cell lines, treat-
ment was required to artificially activate the pathway. For the studies described in 4.3.2, Lithium chloride 
and Wnt3a were employed.

Lithium chloride (LiCl) -  LiCl is a potent activator of canonical Wnt signalling, an 
effect mediated by direct inhibition of the Wnt-inhibitory GSK3β (6). For this thesis 
LiCl (Sigma) was provided as a solid salt and thereby solubilised in H20 to achieve a 
5 M stock concentration. In all experiments, LiCl treatment was administered to cells 
at a dose of 40 mM in accordance with previous publications (6) by enriching 
Wnt3a - Wnt3a is a physiological ligand for canonical Wnt signalling. It exerts its 
effect by directly binding to and activating Fz receptors (7). Wnt3a was supplied by 
R&D Systems as 10 μg in lyophilised form and solubilised in 200 μl PBS to achieve 
a stock concentration of 50 μg/ml. In all experiments, Wnt3a treatment was adminis-
tered at a dose of 50 ng/ml in accordance with previous publications (6) by enriching 
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3.5.4 DNA transfection 
DNA transfection is a technique whereby a DNA construct can be temporarily integrated into a host cell for 
transient expression. This approach is widely adopted to investigate the effects of gene overexpression in a 
model system. In this thesis, DNA transfection was employed to investigate DYRK1A interaction with Wnt 
components, its effects on canonical Wnt signalling as well as its subcellular localisation under differential 
Wnt activation states. 
All transfections were executed employing the FuGENE® HD Transfection Reagent (Promega) and carried
out in SH-SY5Y, HeLa and HEK293 cells grown in 6-well or 10 cm plates (see 3.5.1). All transfection mix-
tures comprising the DNA to be inserted and the FuGENE® reagent were dissolved in 100/500 μl Opti-
MEM® (Gibco) per transfected well or plate, respectively. In all cases, FuGENE® was administered at a 3:1 
ratio relative to the μg/ml amount of DNA to be transfected. Following, the solution was incubated for 15 
min at room temperature and subsequently administered to each well or plate. The transfected cultures 
were subsequently incubated at 37˚C for 24 hrs before assaying. The table below details amounts con-
structs transfected: 
TRANSFECTED CONSTRUCTS
CONSTRUCT STOCK USE EXP
pCMV5-HA-DYRK1A 0.751 μg/μl Luciferase assay, DYRK1A expression, co-IP, ICC 0.25-5 μg/ml
pCMV5-Empty 1 μg/μl Control vector for pCMV5-HA-DYRK1A 0.25-5 μg/ml
pEGFPC1-DYRK1A 0.827 μg/μl ICC 0.25 μg/ml
pEGFPC1-Empty 1 μg/μl Control vector for pEGFPC1-DYRK1A 0.25 μg/ml
pRK5-FLAG-DVL1 1 μg/μl Luciferase assay, co-IP, ICC 0.25-5 μg/ml
pRK5-FLAG 1 μg/μl Control vector for pRK5-Myc-DVL1 0.25-5 μg/ml
pCS2-DKK3-FLAG 0.350 μg/μl Luciferase assay, co-IP 0.25-5 μg/ml
pCDNA3.1-β-cat-FLAG 1 μg/μl co-IP 5 μg/ml
pGL3-TOPFlash Luciferase 1 μg/μl Luciferase reporter. Relates TCF/β-catenin to a bioluminescent signal. 0.25 μg/ml
pGL3-FOPFlash Luciferase 1 μg/μl
Control reporter. Contains a mutated TCF/LEF binding 
site. Used to control for any non-specific effect of 
transfection.
0.25 μg/ml
pRL-Renilla Luciferase 0.1 μg/μl Constitutively active luciferase reporter. Acts as internal control to normalise experimental luciferase activity. 0.025 μg/ml
Fig. M.19 - Overview of transfected constructs, purpose and amount employed (EXP).
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DMEM with LiCl at a 1:125 concentration. Equimolar solutions of Sodium chloride (NaCl - Sigma) were 
employed as a control treatment throughout. All treatments were administered for 6 hrs at 3áC. 
DMEM with Wnt3a at a 1:1000 concentration. Equimolar amounts of PBS were employed as a control treat-
ment throughout. For DYRK1A inhibition and overexpression experiments, Wnt3a treatment was adminis-
tered for  6 hrs at 37áC. 
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3.5.3 Lithium chloride and Wnt3a administration 
For all experiments involving measurements of canonical Wnt signalling activity in human cell lines, treat-
ment was required to artificially activate the pathway. For the studies described in 4.3.2, Lithium chloride 
and Wnt3a were employed.

Lithium chloride (LiCl) -  LiCl is a potent activator of canonical Wnt signalling, an 
effect mediated by direct inhibition of the Wnt-inhibitory GSK3β (6). For this thesis 
LiCl (Sigma) was provided as a solid salt and thereby solubilised in H20 to achieve a 
5 M stock concentration. In all experiments, LiCl treatment was administered to cells 
at a dose of 40 mM in accordance with previous publications (6) by enriching 
DMEM with LiCl at a 1:125 concentration. Equimolar solutions of Sodium chloride (NaCl - Sigma) were 
employed as a control treatment throughout. All treatments were administered for a duration of 6 hrs at 
37˚C. 
Wnt3a - Wnt3a is a physiological ligand for canonical Wnt signalling. It exerts its 
effect by directly binding to and activating Fz receptors (7). Wnt3a was supplied by 
R&D Systems as 10 μg in lyophilised form and solubilised in 200 μl PBS to achieve 
a stock concentration of 50 μg/ml. In all experiments, Wnt3a treatment was adminis-
tered at a dose of 50 ng/ml in accordance with previous publications (6) by enriching 
DMEM with Wnt3a at a 1:1000 concentration. Equimolar amounts of PBS were employed as a control treat-
ment throughout. For DYRK1A inhibition and overexpression experiments, Wnt3a treatment was adminis-
tered for a duration of 6 hrs at 37˚C. 
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3.5.4 DNA transfection 
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Fig. M.19 - Overview of transfected constructs, purpose and amount employed (EXP).
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3.5.5 TCF/β-Catenin TOPFLASH luciferase assay 
The luciferase assay is a technique whereby the amount or activity of a protein of interest can be measured 
by relating it to the expression of a firefly (P. pyralis) luciferase gene (see 4.3.1 for a literature overview of the 
technique). Consequent administration of luciferase substrate generates a measurable bioluminescent signal 
directly proportional to the amount of protein of interest. In the context of this thesis, the luciferase signal was 
related to transcriptionally active, or monomeric β-catenin as a measure of canonical Wnt signalling activity. 
This was achieved via the pGL3-TOPFlash Firefly Luciferase construct, which encodes a TCF/LEF site for 
β-catenin binding upstream of a luciferase reporter.  
All luciferase assays were performed with a Dual-Luciferase® Reporter Assay System (Promega). Two gen-
eral approaches were undertaken. For DYRK1A inhibition experiments, the TF-stable cell line was em-
ployed (see 3.5.6). For DYRK1A overexpression experiments, however, to ensure all cells expressing 
DYRK1A would also concomitantly express the luciferase construct, unmodified SH-SY5Y and HEK293 
cells were co-transfected with both the DYRK1A and luciferase constructs. Additionally, this approach re-
quires an internal normalisation signal to account for differing transfection efficiencies across cell popula-
tions. This was achieved via concomitant transfection of the pRL-Renilla Luciferase construct, which pro-
vides a constitutively active renilla (R. reniformis) luciferase signal, thereby only reflecting transfection effi-
ciency. (See 3.9.3 for further details on luciferase quantification). All cells were grown and assayed in 6-well 
plates following the treatment of interest (e.g.: DYRK1A inhibition/overexpression).  


Fig. M.20 - General principle of the TCF/β-Catenin TOPFLASH luciferase assay, which relies on a reporter plasmid.
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The 6-well plates were removed from the incubator and the DMEM was subsequently discarded. Each well 
was washed twice with 10 ml of PBS. Thereafter, 250 μl of Passive Lysis Buffer (50 μl 5X Passive Lysis Buf-
fer, 200 μl dH20 - Promega) were added to each well and incubated at room temperature for 10 min and 
35 rpm rotation on a Stuart gyro-rocker SSL3 (from here on referred to as gyro-rocker). Once lysed, TF-
stable cells were assayed by adding 10 μl of lysate to 50 μl of Luciferase Assay Reagent II (Promega - i.e. 
luciferase enzyme substrate) and thereby measuring the bioluminescent signal in a GLOMAXTM 20/20 lu-
minometer (Promega), adopting the Steady-Glo® protocol with 10 sec integration. The luminescence value 
was expressed in Relative Light Units (RLU) and recorded. Each value was subsequently normalised to the 
average of each control condition (i.e.: no treatment).  
Thereafter, the average value recorded for each condition was expressed as a ratio of the normalised aver-
ages. Unmodified SH-SY5Y and HEK293 cells were assayed employing the Dual-Glo® protocol with 10 sec 
integration. Following the firefly luciferase measurement described above, each 60 μl reaction was treated 
with 50 μl of Stop & Glo® Buffer (49 μl buffer, 1 μl renilla substrate - Promega), which quenches the firefly lu-
ciferase reaction and provides a substrate for the renilla luciferase. The renilla activity was subsequently mea-
sured as an internal control. The overall luciferase signal was expressed as a ratio of firefly/renilla and the val-
ues were then normalised as above. 
For results in 4.3.2.2.1.4, luciferase activity was measured in live cells from the TF-stable line by enriching 
DMEM with 150 μg/mL D-luciferin (Systems Biosciences) and employing the IVIS system (Perkin-Elmer) to 
image plates 20 min post-treatment. 
3.5.6 Generation of SH-SY5Y cells stably expressing the the TCF/LEF-Luciferase reporter  
The SH-SY5Y cell line was engineered to stably express the pGL3-TOPFlash Firefly Luciferase construct. 
Consequently, all cells within this line produce a canonical Wnt signalling/luciferase signal, and do not re-
quire additional transfections to be assayed. This also provides the advantage of greatly increased signal-
to-noise ratio. Stable TOPflash SHSY5Y cells were made in a two-step process. Firstly, the TCF/LEF-re-
sponsive promoter and luciferase reporter from M50 Super 8x TOPflash (2) was cloned into a plasmid with 
suitable antibiotic resistance for selection in mammalian cells. To this end, the CMV promoter was removed 
from pcDNA3 by restriction digestion with BglII and NotI, and a NotI-BamHI fragment from M50 Super 8X 
TOPflash ligated into these sites. The responsiveness of the resultant plasmid to transient transfection with 
DVL1 was confirmed by luciferase assay and found to be approximately ~25% that of M50 Super 8x 
TOPflash. Secondly, this plasmid was stably transfected into SH-SY5Y cells. The plasmid was linearised by 
PvuI digestion and transfected into SH-SY5Y cells, with stably transfected cells selected for resistance to 
G418 (800 μg/ml) following standard procedures. Twelve clonal cell lines were established and compared 
for basal luciferase expression and fold-induction in response to 30mM LiCl treatment. Clone #3 was cho-
sen for experiments since the cell line displayed the greatest sensitivity to Wnt pathway activation. The cell 
line is referred to as ‘TF-stable’ throughout this thesis. 
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The 6-well plates were removed from the incubator and the DMEM was subsequently discarded. Each well 
was washed twice with 10 ml of PBS. Thereafter, 250 μl of Passive Lysis Buffer (50 μl 5X Passive Lysis Buf-
fer, 200 μl dH20 - Promega) were added to each well and incubated at room temperature for 10 min and 
35 rpm rotation on a Stuart gyro-rocker SSL3 (from here on referred to as gyro-rocker). Once lysed, TF-
stable cells were assayed by adding 10 μl of lysate to 50 μl of Luciferase Assay Reagent II (Promega - i.e. 
luciferase enzyme substrate) and thereby measuring the bioluminescent signal in a GLOMAXTM 20/20 lu-
minometer (Promega), adopting the Steady-Glo® protocol with 10 sec integration. The luminescence value 
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DVL1 was confirmed by luciferase assay and found to be approximately ~25% that of M50 Super 8x 
TOPflash. Secondly, this plasmid was stably transfected into SH-SY5Y cells. The plasmid was linearised by 
PvuI digestion and transfected into SH-SY5Y cells, with stably transfected cells selected for resistance to 
G418 (800 μg/ml) following standard procedures. Twelve clonal cell lines were established and compared 
for basal luciferase expression and fold-induction in response to 30mM LiCl treatment. Clone #3 was cho-
sen for experiments since the cell line displayed the greatest sensitivity to Wnt pathway activation. The cell 
line is referred to as ‘TF-stable’ throughout this thesis. 
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3.5.7 Slide preparation for immunocytochemistry 
For this thesis, Immunocytochemistry (ICC) was adopted to assess the subcellular localisation and translo-
cation of DYRK1A. All experiments were performed in the HeLa and HEK-293 human cell lines. 
HeLa - Cells were seeded at ~60% confluency into No. 1.5 imaging chambers (Lab-Tek) coated with 400-
600 μg/ml Matrigel (Corning) and transfected immediately using Lipofectamine 3000 (Thermo Fisher Scien-
tific) according to the manufacturer’s specifications. HA-DYRK1A was transfected at 250ng/well, or else 
co-transfected with FLAG-DVL1 at the same concentration. Wnt3a and LiCl treatment including the ap-
propriate controls were conducted as detailed above 5 hours prior to fixation. After 18 hours cells were 
fixed with 4% (w/v) paraformaldehyde (PFA) for 20 min at room temperature (RT). Samples were then per-
meabilised with 0.2% (w/v) saponin (Sigma-Aldrich) for 30 min, and blocked in 5% (v/v) donkey serum 
(Sigma-Aldrich) doped with 0.05% (w/v) saponin for 1 hour at RT. FLAG and HA primary antibodies (Sig-
ma-Aldrich) were diluted in block to 1:100, added to cells, and incubated overnight at 4°C. Secondary anti-
mouse and anti-rabbit antibodies conjugated to Alexa 488 and Alexa 594 (1:1000; Life Technologies) were 
made in block and incubated with samples for 30 min at RT. A 1:5000 Hoescht 33258 and 1:1000 Phal-
loidin 647 (both ThermoFisher Scientific) dilution in PBS was incubated for 30 mins at RT to label the nu-
cleus and F-actin respectively. Cells were thoroughly washed and Imaging was performed in fresh PBS. 
HEK293 - Cells were seeded at ~60% confluency onto glass coverslips previously coated with 0.1mg/ml 
poly-D lysine and grown into 6-well plates. Transfection was performed as above but employing 3:1 fu-
Gene HD (Promega) as transfection reagent. Treatment was also performed as above. After 18 hours cells 
were fixed with 4% (w/v) paraformaldehyde (PFA) for 20 min at RT. Samples were then permeabilised for 
30 min in 0.5% (w/v) Triton-X 100, and blocked in 5% (w/v) FBS with 0.05% (w/v) Triton-X 100. The 
DYRK1A (Abcam) rabbit polyclonal primary antibody was incubated as above at 1:500 dilution. Secondary 
anti-rabbit Alexa 488 was incubated as above. A 1:1000 DAPI (ThermoFisher Scientific) dilution in block 
buffer was incubated for 30 mins at RT to label the nucleus. 
3.5.8 Airyscan and confocal microscopy 
Airyscan microscopy is a recently developed imaging technique which offers improvements in image reso-
lution over traditional methods. Confocal microscopy is limited by the diffractive nature of light. Below a 
certain size, information is lost to light scattering, escaping detection. Confocal systems with Airyscan pos-
sess an additional detector which captures such diffracted light. Images are generated in combination by 
both detectors, thus enhancing spatial resolution. For this thesis, Airyscan imaging was performed using a 
Zeiss 880 outfitted with an Airyscan module. Data was collected using a 63x 1.4 NA objective and immer-
sion oil optimised for 30°C (Carl Zeiss). Colours were collected sequentially by frame to minimise crosstalk, 
and Airyscan processing was performed using the Airyscan module in the commercial ZEN software pack-
age (Carl Zeiss). Confocal imaging was performed using a Zeiss 710, also using a 63x 1.4 NA objective 
and immersion oil. 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3.6 Mouse, human and cell biochemistry 
The biochemical techniques described in this section were employed to measure a variety of Wnt signalling 
proteins, as well as DYRK1A, in DS mouse model and human samples, SH-SY5Y and HEK-293 cells. 
3.6.1 Generation of mouse brain lysates  
All lysates were generated from samples outlined in 3.3.1. Experimental batches A and B were extracted 
on separate attempts, as were the hippocampal and cortical samples, amounting to 8 lysates/attempt. 
The dissected samples were allowed to thaw on ice. Thereafter, each sample was suspended in 1.5 ml 
(cortex) or 500 μl (hippocampus) of brain extraction buffer (50 mM Tris, 5 mM MgCl2, 150 mM NaCl, 1% 
NP-40, protease inhibitor (tab), 1:100 phosphatase inhibitor cocktail) in a microcentrifuge tube. Following, 
each sample was lysed by mechanical disruption with a tissue homogeniser and subsequently centrifuged 
for 10 min at 14,680 rpm and 4°C in a tabletop microcentrifuge to pellet debris. Thereafter, the supernatant 
was transferred into fresh 1.5 ml tubes and aliquoted for immediate analysis or storage at -20°C. 
3.6.2 Generation of human brain lysates from post mortem DS hippocampal samples 
All post-mortem human brain samples were processed in accordance with the Human Tissue Act 
2004 and directives from the Human Tissue Authority (UK). The study was reviewed and approved by 
NHS Research Ethics committee, London-Queen Square. Samples were provided, anonymised, by 
the Newcastle brain bank, from 55 (±11) and 56 (±12) years old AD-DS individuals and age-matched 
euploid controls, respectively. All people involved had granted full research consent. 10 mg of frozen 
tissue from hippocampal and cortical samples was excised in a sterile environment and triturated with 
a plastic pestle in 130μl brain lysis buffer prior to snap-freezing in liquid nitrogen and storage at -20°C. 
3.6.3 Generation of human cell line lysates 
For DYRK1A overexpression experiments and co-IPs, proteins were extracted and purified from cells for 
subsequent biochemical analysis by SDS-PAGE and Western blotting (3.6.5-6). Following incubation in the 
desired experimental condition, DMEM was removed from each 10 ml culture plate, which was then 
washed twice with ice-cold PBS. Thereafter, each plate was treated with 1 ml of cell lysis buffer (150 mM 
NaCl, 50 mM Tris pH 7.5, 5mM EDTA and 0.25% nonyl-phenoxypolyethoxylethanol-40 (NP-40), protease 
inhibitor tab) which includes salts to preserve physiological cell acidity and osmolarity and a detergent to 
disrupt membrane structure. The lysis reaction was allowed to proceed for 2 min with gentle swirling of the 
plate on a Stuart gyro-rocker SSL3 at 10 rpm. The contents of the each plate were then detached using a cell 
scraper and the 1 ml buffer/lysate solution was subsequently transferred to a 1.5 ml centrifuge tube for a 5 min 
incubation on ice. Following, each lysate was centrifuged for 10 min at 4˚C and 14,680 rpm in a tabletop micro-
centrifuge to pellet cell debris. The supernatant was collected from each tube, transferred to a fresh 1.5 ml and 
either analysed directly, employed for co-IP or stored at -20˚C, 
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3.6.4 Co-immunoprecipitation 
Co-immunoprecipitation (co-IP) is a standard technique for the study direct protein-protein interactions. It 
relies on the fundamental principle of specific antibody-antigen binding (-immuno). Antibodies to endoge-
nous or tagged peptides can be employed to extract individual proteins from lysate solutions (-precipita-
tion) with the aid of an antibody-binding physical support, such as viscous gels or beads. The primarily 
‘pulled down’ protein is termed bait. When such protein under study is pulled down, any secondary inter-
actors (prey) physically bound to it also precipitate out of solution. The resultant fusion proteins can then be 
isolated and identified via SDS-PAGE and Western blotting (3.6.5-6). In this thesis, co-IP was employed to 
test overexpressed DYRK1A as prey for interaction with a number of key Wnt components. Baits were also 
overexpressed as FLAG-tagged constructs. FLAG peptides allow for robust precipitation of tagged pro-
teins, and greatly improve signal-to-noise ratio. In all cases, the technique was carried out in HEK-293 cells 
cultured in 10 cm plates. HEK293 cells were co-transfected with 0.5 μg/ml HA-DYRK1A and 0.5 μg/ml 
FLAG-DVL1/β-catenin-FLAG/DKK3-FLAG or relative empty controls and lysed as described above. There-
after, 40 μl of anti-FLAG M2 affinity gel (Sigma) were added to 1 ml of each lysate to bind potential fusion 
proteins. Following 1 hr of rotational incubation at 4 °C, the gel was washed five times by centrifugation 
and resuspension in cell lysis buffer. 150 ng 3xFLAG peptide (Sigma) were used to elute the fusion pro-
teins. Eluates were then denatured and analysed as described below. Each co-IP was performed inde-
pendently at least three times. 
For each co-IP performed, four transfection conditions were employed (Fig. R3.4-6). Expression of empty 
vectors acted as negative control, so as to exclude non-specific pulldown of proteins by the FLAG affinity 
gel. Expression of FLAG-tagged bait constructs alone acted as positive control, confirming detectable pull-
down at the appropriate molecular weight. Expression of the non-tagged DYRK1A prey construct alone 
was performed to exclude non-specific pulldown of overexpressed protein by the affinity gel. Expression of 
both bait and prey constructs constituted the experimental condition under investigation. Input lysates for 
the above conditions were also analysed alongside to confirm expression of the constructs under study. 
3.6.5 SDS Polyacrylamide gel electrophoresis (SDS-PAGE) 
In this thesis, SDS-PAGE was used to size-separate proteins in all samples employed for Western blot 
analysis. Prior to electrophoresis, 50 μl of NuPAGE® LDS Sample Buffer (Glycerin, LDS - Life Technologies) 
and 20 μl of NuPAGE® Sample Reducing Agent (500 mM dithiothreitol (DTT) - Life Technologies) were 
added to 130 μl of mouse/human brain and cell lysate or co-IP eluate. Each resultant 200 μl solution was 
subsequently incubated at 95°C for 5 min in an Eppendorf ThermoMixer® F1.5 to aid protein denaturing. 
Thereafter, 10 μl of each solution were loaded in a 10 or 20-lane NuPAGE® Bis-Tris Precast polyacrylamide 
gel (Life Technologies). The gel was inserted in an electrophoresis chamber (Biorad) and submerged in Nu-
PAGE® MOPS SDS Running Buffer (50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7) 
enriched with 500 μl NuPAGE® Antioxidant (Life Technologies). The gel was then ran at a voltage of 90 V 
for 1 hr 45 min. 
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3.6.6 Western blotting 
Western blotting was here employed to analyse DS mouse and human brain samples, as well as cell 
lysates from DYRK1A overexpression experiments and co-IPs. The technique is routinely performed in four 
stages: sample transfer, blocking, antibody treatment, and imaging. These are detailed below. 
Transfer - Following, SDS-PAGE, all samples were transferred to a 0.45 μm pore Immobilon-P polyvinyli-
dene fluoride (PVDF) membrane (Merck Millipore) in semi-dry conditions (i.e. minimal amounts of buffer so-
lutions required). First, appropriately sized membranes were cut out of the roll stock and briefly soaked in 
methanol and dH20 to reduce hydrophobicity. Each membrane was then submerged in sample transfer 
buffer (25 mM Tris, 192 mM glycine, 10% methanol) for 2 min, whilst 4 sheets of filter paper were briefly 
soaked in transfer buffer to provide additional solution and encapsulation during transfer. Thereafter, each 
protein gel was placed upon the membrane, with two sheets of filter paper stacked above and below. The 
transfer was then executed in a Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (Biorad) connected 
to a Power Pac 3000 (Biorad) power supply at a voltage of 20 V for 1 hr. 
Blocking - To prevent non-specific antibody binding at later stages, each transferred membrane was 
blocked via incubation in 10 ml of 5% bovine milk dissolved in Tris-buffered saline-Tween 20 (TBST - 50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for 1 hr at room temperature whilst rotating at 40 
rpm in a gyro-rocker. Following blocking, the membrane was washed 3 times in 10 ml TBST for 5 min.  
Antibody treatment - All primary and secondary antibodies employed in this thesis are detailed on the 
next page (Fig. M.20). All primary antibodies were administered at 4°C overnight in a 5% milk-TBST solu-
tion whilst rotating at 40 rpm on a gyro-rocker. All secondary antibodies were administered for 1 hr at room 
temperature also in a 5% milk-TBST solution whilst rotating. These were also pre-conjugated to horse-
radish peroxidase (HRP) for chemiluminescence detection. Following incubation, each membrane was 
washed 3 times in 10 ml TBST for 5 min and subsequently placed in 10 ml PBS for imaging and storage at 
4°C. When probing for multiple Wnt signalling proteins, the membrane was cut according to predicted 
molecular weight and each section treated separately. 
Imaging - Following antibody treatment, each membrane section was soaked in 500 μl of SuperSignal® 
West Femto Maximum Sensitivity Substrate (250 μl Proprietary luminol, 250 μl Stable Peroxide Buffer, 
Thermo Scientific) to generate a quantifiable HRP activity signal directly proportional to the amount of anti-
body bound and consequently, of the protein of interest. Immediately following application of the substrate, 
each membrane was wrapped in cling film and analysed in a GeneGnome® XRQ Chemiluminescence im-
ager (High quantum efficiency (QE) camera - Syngene) controlled by GeneSnap® software under a 10s ex-
posure with signal integration over 20 images. Thereafter, each membrane was also imaged with white 
light to ascertain protein size against the molecular weight marker (see 3.9 for details on signal quantifica-
tion and statistical analysis). 
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PRIMARY ANTIBODIES
ANTIBODY ΤΑRGET SIZE COMPANY ORIGIN DILUTION
Anti-DKK3 60 kDa Abcam® Goat 1:2000
Anti-DYRK1A 85 kDa Abnova® Mouse 1:2000
Anti-GSK3β 47 kDa Cell Signalling® Rabbit 1:2000
Anti-pGSK3α/β (S9) 47 kDa Cell Signalling® Rabbit 1:5000
Anti-β-catenin 92 kDa Cell Signalling® Rabbit 1:2000
Anti-active β-catenin 92 kDa Merck Millipore® Mouse 1:2000
Anti-β-actin 42 kDa Abcam® Mouse 1:5000
Anti-FLAG Variable Abcam® Mouse 1:2000
Anti-SC35 (nuclear speckle) 90 kDa Abcam® Mouse 1:500
SECONDARY ANTIBODIES
ANTIBODY / TARGET COMPANY ORIGIN DILUTION
Anti-Mouse IgG Santa Cruz® Rabbit 1:2000
Anti-Rabbit IgG Santa Cruz® Donkey 1:2000
Anti-Goat IgG Santa Cruz® Donkey 1:2000
Fig. M.21 - Overview of primary and secondary antibodies employed in Western blotting.
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3.7 Yeast two-hybrid screening 
Yeast two-hybrid screening (Y2H) is a long established technique for the study of direct protein inter-
actions in the artificial environment of yeast cell nuclei. In this thesis, collaboratively-generated Y2H 
data were consulted in order to search for Wnt-relevant protein interactions of the Hsa21-encoded 
kinase DYRK1A (see 4.3.2). 
3.7.1 The Jerome LeJeune Foundation interPP project 
The Jerome LeJeune Foundation (Paris, France) is a large research charity named after the homony-
mous pioneering scientist who first identified Hsa21 trisomy in DS. The foundation sponsors a wide 
variety of multi-disciplinary research aiming to further the understanding of DS and facilitate develop-
ment of effective therapeutic interventions. One of the ongoing efforts by the foundation is the protein-
protein interaction (Inter-PP) project. This decade-long endeavour aims to systematically identify and 
further characterise direct protein-protein interactions of Hsa21-encoded proteins. The InterPP data-
base is vast, and currently includes hundreds of thousands of detected interactions. Such database is 
continuously being assembled on behalf of the foundation by a partner company, Hybrigenics Ser-
vices (S.A.S., Paris, France - http://www.hybrigenics-services.com).  
Employing Y2H library screening, a high-throughput variant of the original assay, all Hsa21-encoded 
proteins are tested for any interaction possible. Such interactions are integrated in growing protein 
networks, and classified according to binding strength and reliability. Overall, the Inter-PP project aims 
to generate DS-relevant, preliminary protein interaction data for later validation, and is thus heavily col-
laborative in nature. In this thesis, partnership with the Jerome LeJeune Foundation was established, 
with the particular aim of identifying the presence of any Wnt signalling-related protein interactors of 
the kinase DYRK1A. Additionally, the DYRK1A interaction with DKK3 was further characterised by 
Hybrigenics specifically for this thesis (see, 4.3.2). The techniques, materials and analysis protocols 
associated with Y2H screening in this thesis are outlined below. 
3.7.2 ULTImate Y2H™ Analysis  
Y2H screening was performed by Hybrigenics Services. The coding sequence for full length DYRK1A 
isoform 1 (NCBI reference (NM_001396.3) was PCR-amplified and cloned into pB27 as a C-terminal 
fusion to LexA (LexA-DYR1A), and into pB29 as an N-terminal fusion to LexA (DYR1A-LexA). The 
constructs were checked by sequencing and used as a bait to screen a random-primed Adult Brain 
cDNA library constructed into pP6. pB27 and pB29 derive from the original pBTM116 vector (91), and 
pP6 is based on the pGADGH plasmid (92). For the N-LexA-DYRK1A-C and the N-DYRK1A-LexA-C 
bait constructs, 65 million (6.5-fold the complexity of the library) and 115 million (11.5-fold the com-
plexity of the library) clones were screened using a mating approach with YHGX13 (Y187 
ade2-101::loxP-kanMX-loxP, matα) and L40ΔGal4 (mat a) yeast strains as previously described (93). 
269 and 253 His+ colonies, respectively, were selected on a medium lacking tryptophan, leucine and 
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PRIMARY ANTIBODIES
ANTIBODY ΤΑRGET SIZE COMPANY ORIGIN DILUTION
Anti-DKK3 60 kDa Abcam® Goat 1:2000
Anti-DYRK1A 85 kDa Abnova® Mouse 1:2000
Anti-GSK3β 47 kDa Cell Signalling® Rabbit 1:2000
Anti-pGSK3α/β (S9) 47 kDa Cell Signalling® Rabbit 1:5000
Anti-β-catenin 92 kDa Cell Signalling® Rabbit 1:2000
Anti-active β-catenin 92 kDa Merck Millipore® Mouse 1:2000
Anti-β-actin 42 kDa Abcam® Mouse 1:5000
Anti-FLAG Variable Abcam® Mouse 1:2000
Anti-SC35 (nuclear speckle) 90 kDa Abcam® Mouse 1:500
SECONDARY ANTIBODIES
ANTIBODY / TARGET COMPANY ORIGIN DILUTION
Anti-Mouse IgG Santa Cruz® Rabbit 1:2000
Anti-Rabbit IgG Santa Cruz® Donkey 1:2000
Anti-Goat IgG Santa Cruz® Donkey 1:2000
Fig. M.21 - Overview of primary and secondary antibodies employed in Western blotting.
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histidine and 2 mM 3-AT for N-LexA-DYRK1A-C and 5 mM 3-AT for N-DYRK1A-LexA-C to maintain a 
strong selectivity and manage the slight autoactivation. The prey fragments of the positive clones were 
amplified by PCR and sequenced at their 5’ and 3’ junctions. The resulting sequences were used to 
identify the corresponding interacting proteins in the GenBank database (NCBI) using a fully automat-
ed procedure. 
3.7.3 PBS scoring 
A confidence score (PBS, for Predicted Biological Score) was attributed to each interaction. The PBS 
relies on two different levels of analysis. Firstly, a local score takes into account the redundancy and 
independency of prey fragments, as well as the distribution of reading frames and stop codons in 
overlapping fragments. Secondly, a global score takes into account the interactions found in all the 
screens performed at Hybrigenics using the same library. This global score represents the probability 
of an interaction being nonspecific. For practical use, the scores were divided into four categories, 
from A (highest confidence) to D (lowest confidence). A fifth category (E) specifically flags interactions 
involving highly connected prey domains previously found several times in screens performed on li-
braries derived from the same organism. Finally, several of these highly connected domains have been 
confirmed as false-positives of the technique and are now tagged as F. The PBS scores have been 
shown by Hybrigenics to positively correlate with the biological significance of interactions. 
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3.8 Bioinformatics 
This section details bioinformatics approaches undertaken for this thesis, namely pathway analysis of 
RNAseq, database-mediated protein interaction screening for DYRK1A, and assembly of protein in-
teraction networks. 
3.8.1 Ingenuity Pathway Analysis        
The Qiagen Ingenuity® Pathway Analysis (IPA®) tool was employed to probe mouse and human 
RNAseq datasets for association with molecular pathways, and particularly Wnt signalling. Tc1 and 
Dp1Tyb RNAseq analysis was performed on datasets of non-Hsa21/Mmu16 DEX genes at adjusted 
P<0.05 (Tc1) and P<0.01 (Dp1Tyb). In all cases, IPA analysis parameters were left at default, searching 
only for direct relationships and for human, mouse and rat orthologs. 
3.8.2 STRING and Cytoscape protein interaction network analysis 
The protein interaction database and analysis tool STRING v10.0 (58) was employed to probe for 
DYRK family-Wnt interactions in 4.3.2.1.1, and to build the networks in 4.3.2.1.5. Protein interactions 
were identified from the human interactome in both cases. For 4.3.2.1.1, each DYRK (1A/B-4) was 
individually employed as a single starting node, and networks were thereby generated by enriching 
with the 50 or 100 best-scoring direct interactors. To isolate DYRK-relevant functional associations, 
networks were limited to primary DYRK interactions, without further enriching. For 4.3.2.1.5, the inte-
grated literature/experimental basic DYRK1A network was enriched twice, with the 10 best-scoring 
primary and secondary interactors. The network was then imported into the Cytoscape analysis tool 
(http://www.cytoscape.org), and its visual properties were modified to distinguish amongst node types 
and visually aid description of the results. The network was displayed employing a spring-embedded 
layout, manually adjusted to reflect the known structure of canonical Wnt signalling. 
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3.9.4 Confocal imaging quantification 
Confocal data collected from the Zeiss 710 was used to quantify the nuclear to cytoplasmic ratio of 
HA-DYRK1A under Wnt stimulation and control conditions. Bitplane (IMARIS) was used to create 
masks to the nucleus and entire cellular volume. Alexa 488 conjugated HA-DYRK1A fluorescence in-
tensity was integrated across both masks. The nuclear signal was subsequently subtracted from the 
signal of the entire cellular volume, providing cytoplasmic HA-DYRK1A fluorescence. Data is displayed 
as a ratio of nuclear to cytoplasmic fluorescence intensity.  
3.9.5 Statistical analysis and graphs 
RNAseq data was analysed by Deseq. All P values reported were adjusted for false discovery rate 
(FDR). IPA-generated P values reported for canonical pathway analysis and disease function analysis 
were produced by Fisher’s exact test and thresholded at P<0.05. STRING protein interaction net-
works for the DYRK family were analysed by STRING, correcting for FDR. All other statistical analyses 
were performed in GraphPad Prism 07a. For mouse biochemistry, qPCR and DYRK1A expression 
experiments, reported P values were calculated by two-tailed t-test. For all Luciferase experiments, 
one-way ANOVA with post-hoc Sidak’s multiple comparisons test was employed. For dose-response 
curve experiments in 4.3.2.2.1.3, linear regression was calculated on % of maximum (LiCl + DMSO) 
values, throughout the entire dose range of 1-100 μM. All heat maps and box plots were created in 
GraphPad Prism 07. In all cases, box span represents first to third quartiles, bands represent the me-
dian of each sample group, and whiskers represent minimum/maximum values. Throughout this the-
sis, relative ‘increases’ were colour coded as red and ‘decreases’ as blue, in a combination of hues 
safe for all types of colour vision deficiency. See relevant sections of materials and methods for addi-
tional details on quantification and processing methods employed. 
For all qPCR as well as mouse and human DS immunoblotting experiments, samples were quantified 
in technical triplicate (qPCR) or duplicate (others), and the resultant values were averaged. The report-
ed n for these experiment thus represent the number of individual tissues employed. For example, 
n=8 Tc1 hippocampal samples indicates analysis of 16 total samples (including 8 WT controls) mea-
sured twice (total of 32 values quantified) in separate gels and averaged. For all cell-based experi-
ments, a minimum of three independent repeats were performed on separate days. For each experi-
mental condition under study, multiple biological replicates were employed in order to improve mea-
surement accuracy. All signal values obtained from replicates were however averaged prior to analy-
sis. In this case, therefore, all reported n represent the number of independent repeats, and the data 
were analysed accordingly. 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3.9 Data processing, quantiﬁcation, statistical analysis and representation 
This section discusses data processing, X\aU[iﬁJa[ioU and analysis in all techniques for which this as-
WeJ[^aZUo[o[Oer^iZeZWeJiﬁeKiUWrevious methods sections. 
3.9.1 Image processing 
In all western blots, only minimal image processing was performed, WoZ[X\aU[iﬁJa[ioU for illustrative 
purposes only. Raw .sgd ﬁleZ were converted to .tiff and colour-inverted to display background as 
white/grey. Average brightness was set so as to obtain a grey background and clearly visible, non-
overexposed band. Minimum and maximum levels were adjusted slightly (no more than 5-10%) to im-
prove visualisation of bands with a weaker signal, but never to values approaching, or corresponding 
to, the peak brightness levels. All processing described was performed in imageJ (Fiji version). Figures 
in 4.2.2.1-4 and 4.3.2.2.2.3 display horizontally cropped sections of representative blots, and black 
lines indicate where the image was occasionally cropped vertically. All co-IP gels in 4.3.2.1.4 are pre-
sented uncropped from 1 representative repeat. For IVIS luciferase experiments in 4.3.2.2.1.4, mini-
mum and maximum display levels were automatically set by the system according to measured sig-
UaliUKeWeUKeU[oMX\aU[iﬁJa[ioU
3.9.2 Western blot quantiﬁcation 
Protein bands were X\aU[iﬁeK from non-processed, raw image ﬁleZ only, directly at the acquisition 
stage via the GeneTools® software analyser (Syngene GeneGnome system), by manually selecting an 
identical area around each gel lane. Automatic background subtraction was applied to all X\aU[iﬁeK
bands, accounting for UoUZWeJiﬁJ luminescence to enhance accuracy of the signal. The resultant 
values for all proteins of interest were then normalised to amounts of -actin within the same gel, in 
order to provide a reliable loading control. For phospho/de-phosphoproteins analysed (active  
catenin, pS9 GSK3 ) values were ﬁrZ[ normalised to -actin and subsequently to total amounts of the 
relative protein, which were also normalised to -actin. Values were further normalised to the mean of 
the control condition (WT for mice, euploid for human samples, empty vector control for cells) for each 
individual experimental repeat. 
3.9.3 Luciferase assay quantiﬁcation 
For all luciferase experiments, TOP/FOPFLASH values X\aU[iﬁeK alone (4.3.2.2.1.1-3) or as a ratio to 
renilla luciferase activity (4.3.2.2.2.1-2) were normalised to the mean control condition signal (i.e. No 
Wnt stimulation) across all independent repeats. In 4.3.2.2.1.3, the mean normalised signal of treated 
cells with LiCl + 0.01% DMSO was assumed as maximum response and all other values expressed at 
percentages. For IVIS experiments in 4.3.2.2.1.4, preset circular regions of interest (ROIs) were ap-
plied to each well, and background was automatically corrected for by subtracting from an average 
background ROI. For all sample groups, mean, SD and SEM were calculated. 
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3.9 Data processing, quantification, statistical analysis and representation 
This section discusses data processing, quantification and analysis in all techniques for which this as-
pect was not otherwise specified in previous methods sections . 
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purposes only. Raw .sgd files were converted to .tiff and colour-inverted to display background as 
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overexposed band. Minimum and maximum levels were adjusted slightly (no more than 5-10%) to im-
prove visualisation of bands with a weaker signal, but never to values approaching, or corresponding 
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sented uncropped from 1 representative repeat. For IVIS luciferase experiments in 4.3.2.2.1.4, mini-
mum and maximum display levels were automatically set by the system according to measured sig-
nal, independent of quantification. 
3.9.2 Western blot quantification 
Protein bands were quantified from non-processed, raw image files only, directly at the acquisition 
stage via the GeneTools® software analyser (Syngene GeneGnome system), by manually selecting an 
identical area around each gel lane. Automatic background subtraction was applied to all quantified 
bands, accounting for non-specific luminescence to enhance accuracy of the signal. The resultant 
values for all proteins of interest were then normalised to amounts of β-actin within the same gel, in 
order to provide a reliable loading control. For phospho/de-phosphoproteins analysed (active β 
catenin, pS9 GSK3β) values were first normalised to β-actin and subsequently to total amounts of the 
relative protein, which were also normalised to β-actin. Values were further normalised to the mean of 
the control condition (WT for mice, euploid for human samples, empty vector control for cells) for each 
individual experimental repeat. 
3.9.3 Luciferase assay quantification 
For all luciferase experiments, TOP/FOPFLASH values quantified alone (4.3.2.2.1.1-3) or as a ratio to 
renilla luciferase activity (4.3.2.2.2.1-2) were normalised to the mean control condition signal (i.e. No 
Wnt stimulation) across all independent repeats. In 4.3.2.2.1.3, the mean normalised signal of treated 
cells with LiCl + 0.01% DMSO was assumed as maximum response and all other values expressed at 
percentages. For IVIS experiments in 4.3.2.2.1.4, preset circular regions of interest (ROIs) were ap-
plied to each well, and background was automatically corrected for by subtracting from an average 
background ROI. For all sample groups, mean, SD and SEM were calculated. 
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3.9.4 Confocal imaging quantification 
Confocal data collected from the Zeiss 710 was used to quantify the nuclear to cytoplasmic ratio of 
HA-DYRK1A under Wnt stimulation and control conditions. Bitplane (IMARIS) was used to create 
masks to the nucleus and entire cellular volume. Alexa 488 conjugated HA-DYRK1A fluorescence in-
tensity was integrated across both masks. The nuclear signal was subsequently subtracted from the 
signal of the entire cellular volume, providing cytoplasmic HA-DYRK1A fluorescence. Data is displayed 
as a ratio of nuclear to cytoplasmic fluorescence intensity.  
3.9.5 Statistical analysis and graphs 
RNAseq data was analysed by Deseq. All P values reported were adjusted for false discovery rate 
(FDR). IPA-generated P values reported for canonical pathway analysis and disease function analysis 
were produced by Fisher’s exact test and thresholded at P<0.05. STRING protein interaction net-
works for the DYRK family were analysed by STRING, correcting for FDR. All other statistical analyses 
were performed in GraphPad Prism 07a. For mouse biochemistry, qPCR and DYRK1A expression 
experiments, reported P values were calculated by two-tailed t-test. For all Luciferase experiments, 
one-way ANOVA with post-hoc Sidak’s multiple comparisons test was employed. For dose-response 
curve experiments in 4.3.2.2.1.3, linear regression was calculated on % of maximum (LiCl + DMSO) 
values, throughout the entire dose range of 1-100 μM. All heat maps and box plots were created in 
GraphPad Prism 07. In all cases, box span represents first to third quartiles, bands represent the me-
dian of each sample group, and whiskers represent minimum/maximum values. Throughout this the-
sis, relative ‘increases’ were colour coded as red and ‘decreases’ as blue, in a combination of hues 
safe for all types of colour vision deficiency. See relevant sections of materials and methods for addi-
tional details on quantification and processing methods employed. 
For all qPCR as well as mouse and human DS immunoblotting experiments, samples were quantified 
in technical triplicate (qPCR) or duplicate (others), and the resultant values were averaged. The report-
ed n for these experiment thus represent the number of individual tissues employed. For example, 
n=8 Tc1 hippocampal samples indicates analysis of 16 total samples (including 8 WT controls) mea-
sured twice (total of 32 values quantified) in separate gels and averaged. For all cell-based experi-
ments, a minimum of three independent repeats were performed on separate days. For each experi-
mental condition under study, multiple biological replicates were employed in order to improve mea-
surement accuracy. All signal values obtained from replicates were however averaged prior to analy-





automatically corrected for by subtracting from an average background ROI. For all sample groups, 
mean, SD and SEM were calculated.
3.9.4 Confocal imaging quantification 
Confocal data collected from the Zeiss 710 was used to quantify the nuclear to cytoplasmic ratio of 
HA-DYRK1A under Wnt stimulation and control conditions. Bitplane (IMARIS) was used to create 
masks to the nucleus and entire cellular volume. Alexa 488 conjugated HA-DYRK1A fluorescence in-
tensity was integrated across both masks. The nuclear signal was subsequently subtracted from the 
signal of the entire cellular volume, providing cytoplasmic HA-DYRK1A fluorescence. Data is displayed 
as a ratio of nuclear to cytoplasmic fluorescence intensity.  
3.9.5 Statistical analysis and graphs 
RNAseq data was analysed by Deseq. All P values reported were adjusted for false discovery rate 
(FDR). All IPA-generated P values reported for pathway, upstream regulator, and disease and function 
analyses were produced by Fisher’s exact test and thresholded at P<0.05. STRING protein interaction 
networks for the DYRK family were analysed by STRING, correcting for FDR. All other statistical 
analyses were performed in GraphPad Prism 07a. For mouse biochemistry, qPCR and DYRK1A ex-
pression experiments, reported P values were calculated by two-tailed t-test. For all Luciferase exper-
iments, one-way ANOVA with Tukey’s multiple comparisons correction was employed. For dose-re-
sponse curve experiments in 4.3.2.2.1.3, linear regression was calculated on % of maximum (LiCl + 
DMSO) values, throughout the entire dose range of 1-100 μM. All heat maps and box plots were cre-
ated in GraphPad Prism 07. In all cases, box span represents first to third quartiles, bands represent 
the median of each sample group, and whiskers represent minimum/maximum values. Throughout 
this thesis, relative ‘increases’ were colour coded as red and ‘decreases’ as blue, in a combination of 
hues safe for all types of colour vision deficiency. See relevant sections of materials and methods for 
additional details on quantification and processing methods employed.
3.10 Miscellaneous study design details 
Sample size - Selected based on sample/tissue availability following standard procedures for each 
technique, in order to generate statistically significant results. 
Data inclusion/exclusion criteria - All data collected for each experiment presented were included. 
Outliers - No outliers were excluded, all data in box plots includes minimum and maximum values. 
Replicates - For all mouse and human DS immunoblotting experiments, samples were quantified in 
duplicate and averaged, reported n for these experiment represent averaged duplicates. For example, 
n=8 Tc1 hippocampal samples indicates analysis of 16 total samples (including 8 WT controls) mea-
sured twice (total of 32 values quantified) in separate gels and averaged. For all cell-based experi-
ments, a minimum of three independent repeats was performed, with variable sample sizes reported 
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Chapter 4.1 - Analysis of the DS transcriptome  
4.1.1 Introduction 
The importance of transcriptomic analysis in DS, along with the key findings in the field, were dis-
cussed in the main introduction (1.4.1). In this respect, two notions are crucial: 1) Genome-wide tran-
scriptional alterations beyond Hsa21 are invariably present in DS models and humans. 2) The differen-
tial expression of both Hsa21 and secondarily affected genes is highly variable between individuals, 
and amongst individual studies. Such variability, akin to that observed in the euploid population, is 
thus a key feature of the DS transcriptome. This chapter discusses analysis of gene expression data 
generated from two murine models of DS, the Tc1 (1) and Dp1Tyb (2) (see 1.1.5), via RNA sequencing 
(RNAseq). The principal aim was to probe the hippocampal transcriptome of these models, in order to 
confirm their aneuploid status. RNA sequencing also served to investigate the presence of genome-
wide transcriptional alterations beyond Hsa21 or Mmu16 genes in the hippocampus of the two mod-
els. Additionally, gene expression data was also employed to preliminary determine the presence of 
any altered Wnt-relevant genes. A dual strategy was undertaken, combining RNA sequencing tech-
nology with bioinformatic pathway analysis tools. 
4.1.1.1 Ingenuity Pathway Analysis: a reliable and validated approach 
QIAGEN Ingenuity® Pathway Analysis (IPA®) is a powerful tool intended for the search and analysis of 
‘omics datasets. The software features a proprietary knowledge base, which employs text-mining of 
existing scientific literature to extrapolate significance from large datasets. The most common usage 
of IPA by far has been in the analysis of transcriptomics or proteomics data. The software can be 
supplied with large lists of DEX genes, along with their respective fold changes and statistical signifi-
cance values. IPA can then determine the biological meaning of such data, by 1) linking each gene to 
known biological functions and cellular compartments and 2) Identifying significantly altered signalling 
pathways by pooling the expression values of associated genes together (4.1.2.1-3.1). 3) Identifying 
which biological and diseases processes are significantly associated with observed expression pat-
terns, and predict if they are enhanced or suppressed (4.1.2.1-2.3). Taken together, these features 
allow for meaningful and unbiased investigation of ‘omics data.  
Indeed, the usage of IPA has been established and validated throughout the last decade, with hun-
dreds of studies employing this tool. Two examples in the context of DS have already been discussed 
(3, 4). Specialised literature to guide the appropriate usage of IPA also exists (5). Indeed, this strategy 
has already been adopted to investigate the Wnt signalling pathway in literature reports. A 2010 study 
(6) employed IPA to analyse the transcriptome of tumour-associated macrophages. The authors 
demonstrate that their known ability to facilitate tumour invasion is mediated by an enhancement of 
Wnt signalling activity. This was identified by IPA as a significant enrichment in Wnt-related DEX genes 
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in tumour-associated macrophages. Similarly, in the context of ischaemic heart disease, a recent 
study employed IPA to determine signalling pathways responsible for tissue factor-mediated thrombo-
sis (7). The transcriptome of tissue factor-silenced human vascular smooth muscle cells was com-
pared to wild-type tissue. The IPA analysis revealed significant dysregulation of Wnt signalling compo-
nents. These studies provide proof of concept of the reliability and sensitivity of IPA in the analysis of 
gene expression datasets. 
Overall, RNAseq and IPA were employed to answer three key experimental questions, addressed in 
the results section (4.1.2):  
I. Are DS-related Hsa21 and Mmu16 genes significantly overexpressed in the Tc1 and Dp1Tyb 
mouse hippocampus? Ie, are these true models of aneuploidy? 
II. Do any of the DEX genes in Tc and Dp1Tyb mice correlate with Wnt signalling at all? 
III. Which biological/disease functions are associated with expression patterns? 
Fig. R1.a - Conceptual overview of strategy undertaken in results section 4.1.2, harmonising existing literature 
approaches discussed in introduction 4.1.1 with modern RNA sequencing and pathway analysis tools. 
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4.1.2 Results 
4.1.2.1 Tc1 mouse 
The Tc1 mouse model incorporates a near-complete Hsa21 (1) (see 1.2.5.2) and is functionally trisom-
ic for about 75% of protein coding genes from Hsa21, spanning both arms of the chromosome. This 
mouse strain is genetically trisomic for both DYRK1A and APP, but the latter gene is not functionally 
overexpressed.

4.1.2.1.1 DEX genes and Canonical Pathway analysis 
Following RNA isolation from n=3, age-matched Tc1 and WT mouse hippocampi at 3 months of age, 
the resultant material was reverse transcribed into cDNA (see 3.1) in order to obtain a stable template 
for subsequent use. RNAseq was then performed along with statistical testing to determine which 
genes were differentially expressed (DEX) in the Tc1 hippocampus. Since Hsa21 genes in the Tc1 
mouse are human, they are not present in WT control RNA. In order to reliably assess their expression 
levels, all Hsa21 gene reads in the Tc1 group were summed to the amounts of each relevant Mmu 
ortholog, thus allowing for meaningful comparison with WT expression (see chapter 3). 
Results revealed significantly elevated expression of 148 human genes from Hsa21 (Fig. R1.1a-b), in 
accordance with previous reports on the known Tc1 genetic makeup (8). Whilst a number of Hsa21 
genes were found to be duplicated or deleted (APP), most of the key DS-related genes, including 
DYRK1A, were significantly overexpressed around 1.5-fold (Fig. R1.1b). Because the aim of this study 
was to determine genome-wide gene expression changes, these results were not included in the sub-
sequent pathway analysis, in order to restrict the scope to non-Hsa21 genes secondarily affected by 
the additional chromosome. Setting the significance cutoff at P<0.05, RNAseq then identified 62 DEX 
genes in the Tc1 hippocampus (Fig. R1.2), spanning virtually all Mmu chromosomes (Fig. R1.3).  
Taken together, these data demonstrate the presence of overexpressed Hsa21 genes in the Tc1 hip-
pocampus, confirming its aneuploid status. Thus, this mouse can be considered a reliable DS model 
for subsequent use (see 4.2.2). Additionally, RNAseq also demonstrated the presence of genome-
wide transcriptional alterations in the Tc1 hippocampus, beyond Hsa21. This is a well described phe-
nomenon known to occur in both DS models and humans, as introduced (see 1.4). 
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Fig. R1.1 - Overview of Hsa21 genes in the Tc1 mouse hippocampus (n=3, P<0.05), as detected by RNAseq. a. Expression 
levels of 148 Hsa21 genes which could reliably measured and tested for significance, presented alphabetically and colour-
coded according to log2 fold change/WT. The known status of all genes, previously determined by Gribble et al. (2013), is 
shown alongside as reference. b. Expression levels plotted as a function of significance, highlighting AD-DS-relevant genes 
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Fig. R1.2 - Mmu DEX genes in the Tc1 mouse hippocampus secondarily aﬀected by Hsa21 trisomy. Heat map repre-
sent expression levels of 62 Tc1 DEX genes (n=3, P<0.05), demonstrating the occurrence of genome-wide, bidirection-
al transcriptional alterations. Wnt-related genes detected by IPA are highlighted in bold.
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Following, the non-Hsa21 DEX gene list, along with all associated fold changes relative to WT, was 
analysed employing IPA. The software was instructed to search for expression patterns associated 
with known signalling pathways. With preliminary relevance to this thesis, IPA detected a strong asso-
ciation of the dataset with canonical Wnt signalling (P=0.00173) for seven DEX genes (FigR1.2, bold). 
These were Dkk3, Axin2, Cdh1, Cd44, Crabp2, Fos and Hapln1. 
As introduced previously, dkk3 is a secreted Wnt modulator with both antagonistic and stimulating 
properties (9, 10), part of the dickkopf family of genes and possessing known associations with hip-
pocampal development, neurogenesis and AD pathology. RNAseq revealed dkk3 to be aberrantly 
overexpressed in the Tc1 hippocampus. Axin2, which was found to be decreased, is a Wnt target 
gene related to the beta-catenin destruction complex protein axin. It is thought to function as negative 
feedback modulator, being activated by beta-catenin itself and subsequently dampening Wnt sig-
nalling activation (11, 12). Axin2, similarly to dkk3, has also been shown to participate in hippocampal 
development. Both cd44 and cdh1 are known Wnt-associated genes with roles in immune system 
function and cancer development, respectively. The former is a known Wnt target gene, meaning its 
expression may correlate with pathway activity. Both were found to be significantly decreased by 
RNAseq. Another Wnt-associated DEX gene identified was fos (c-fos). This is a well described stress-
responsive human proto-oncogene, which encodes the principal member of the fos family of tran-
scription factors. It is also a recognised Wnt target, with multiple studies linking its expression to Wnt 
signalling activation (13-15). In the Tc1 hippocampus, fos levels were found to be significantly down-
regulated. In fact, fos had the largest single decrease in the entire dataset, corresponding to approxi-
mately 7/8-fold. Additionally, the DEX gene cellular retinoic acid-binding protein II (Crabp2) is also as-
sociated with Wnt signalling, albeit the evidence is much weaker. This gene encodes a protein with 
demonstrated importance to neural axis anteroposterior patterning in Xenopus, and has been charac-
Fig. R1.3 - Mmu DEX genes in the Tc1 mouse hippocampus. The 62 Tc1 DEX genes (n=3, P<0.05) are displayed 
arranged by chromosomal number, demonstrating genome-wide, bidirectional transcriptional alterations.
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terised as an indirect target of Wnt signalling activation (16). Additionally, its human relative CRAPB1 
has been shown to participate in expansion on the neural crest in the developing CNS, a process 
tightly regulated by Wnt signalling (17). Similarly to fos, a significant decrease in crabp2 expression 
was observed in the Tc1 mouse hippocampus. Finally, hyaluronan and proteoglycan link protein 1 
(Hapln1) which was upregulated, has also been recently linked to Wnt signalling. Bioinformatics ap-
proaches have identified human HAPLN1 as a downstream target of Wnt signalling activation (18). In 
the context of human cancer, de novo HAPLN1 expression has been identified as marker of Wnt-in-
duced development of aggressive hepatocellular carcinoma (19). However, little evidence exists inves-
tigating HAPLN1 and Wnt signalling, and it is possible that the relationship between this gene and the 
pathway may be spurious. Overall, this first level of analysis preliminarily indicates that, in the Tc1 hip-
pocampus, seven non-Hsa21 DEX genes may be associated with Wnt signalling (Fig. R1.4). 
Fig. R1.4 - Contextualised overview of RNAseq-observed levels of Wnt-relevant DEX genes in the Tc1 mouse hip-
pocampus. Genes are colour-coded according to observed up-/downregulation.
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4.1.2.1.2 Diseases and functions 
Following pathway analysis, the RNAseq data was probed for associations with known diseases or 
functions by IPA, employing its proprietary annotation database which is similar in intent and scope to 
Gene Ontology (GO) annotations. Results identified a number of processes potentially altered in the 
Tc1 hippocampus (figure R1.5). A z-score was also generated to predict the direction of change of 
each annotation. Several mechanisms associated with neurodegeneration were found to be enhanced 
(eg ‘apoptosis of neurons'), whilst terms linked to cell proliferative mechanisms were suppressed (eg 
‘cell cycle progression’). Accordingly, the Tc1 hippocampus has reportedly lower synaptic density with 
dysfunctional dentate gyrus-CA3 connectivity (20) and learning deficits (1). The Tc1 mouse also dis-
plays increased spontaneous locomotion (21), and the term ‘hyperactive behaviour’ registered a posi-
tive z-score. Interestingly, several of the terms listed are also associated with canonical Wnt signalling. 
Two prominent examples include the term ‘cell proliferation of tumour cell lines’ and ‘apoptosis of neu-
rons’. The former process is a well known outcome of Wnt signalling dysregulation (22-24), with 
decades-long research efforts implicating the pathway in cell proliferation. The term was downregulat-
ed in the analysis. Neuronal apoptosis, on the other hand, was found to be enhanced. The role of Wnt 
signalling in this disease process has been substantiated in more recent years, particularly in the con-
text of Alzheimer’s disease (25, 26). Other significantly affected functions, such as ‘invasion of tumour 
cell lines’ and ‘neuronal cell death’ are also associated with Wnt signalling by the same lines of evi-
dence.  Overall, the disease and function analysis aided in demonstrating the reliability of the RNAseq 
and IPA analysis, by identifying altered neuronal mechanisms already reported in the Tc1 mouse. 
Fig. R1.5 - Diseases and functions analysis generated by IPA according to overall expression patters of 62 Tc1 DEX 
genes, plotting activation z-scores as a function of significance. In accordance with known Tc1 phenotypes, the report 
indicates upregulation (red) of neurodegenerative processes and hyperactive behaviour. By contrast, mechanisms 
associated with cell proliferation are downregulated (blue).
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4.1.2.2 Dp1Tyb mouse 
The Dp1Tyb mouse model contains a duplication of the Mmu16 region syntenic to the proximal por-
tion of the Hsa21 long arm, approximately spanning q11.2-q22.2 (2). This is by far the largest Hsa21 
syntenic region, corresponding to 48% of protein-coding genes of the human chromosome (27, 28). 
As introduced (see 1.1.5), the Dp1Tyb mouse is essentially similar to the Ts1Yey model (29, 30), pos-
sessing a duplication of the same region. This strain functionally overexpresses both DYRK1A and 
APP.  However, it must be stressed that the Dp1Tyb mouse, unlike the Tc1, should be considered as a 
partial model of DS, since only Mmu16 orthologs to Hsa21 are duplicated. This model is however 
useful to further dissect the differential contribution of Hsa21 genes to DS, given that overexpression 
is limited to a fraction of Hsa21 orthologs. These, importantly, include the DSCR (see 1.1.2). The 
RNAseq and subsequent analysis were performed in a similar manner to the Tc1 mouse. 
4.1.2.2.1 DEX genes and Canonical Pathway analysis 
Following RNA isolation from n=5, age-matched 4 months old Dp1Tyb and WT mouse hippocampi, 
the resultant material was reverse transcribed into cDNA, sequenced and analysed as in 4.1.2.1.1. 
Results demonstrated significantly elevated expression of 106 Mmu16 genes spanning the duplicated 
region (Lipi-Zbtb21) as previously described (Fig. R1.6a-b, (2)). Similarly to the Tc1 mouse, these re-
sults demonstrate the presence of overexpressed Mmu16-Hsa21 ortholog genes in the Dp1Tyb hip-
pocampus, confirming their duplicated status. Thus, this mouse can also be considered a reliable par-
tial DS model for subsequent use (see 4.2.2). Importantly, both Dyrk1a and App, essential in DS and 
AD-DS, were significantly overexpressed about 1.5-fold. These data were not included in the subse-
quent IPA analysis, as in 4.1.2.1.1. Following, RNAseq identified genome-wide transcriptional alter-
ations beyond Mmu16, as observed in the Tc1 hippocampus. At a cutoff of P<0.01, 202 non-Hsa21-
Mmu16 DEX genes were detected (Fig. R1.7), spanning all mouse chromosomes, (Fig. R1.8). This 
DEX gene list, however, did not display a significant Wnt association by IPA (P=0.057). Despite this, 
the dataset contained seven DEX genes linked to Wnt signalling (Fig. R1.7, bold). These were Fzd2 
(frizzled-2), Axin2, Podxl (Podocalyxin), Rspo1 (R-spondin1), Sox11/12 and Hapln1. 
The protein Fzd2 is a transmembrane receptor essential for canonical Wnt signalling activation (1.2.1). 
In the Dp1Tyb hippocampus, it was found to be downregulated. The expression of this receptor is 
known to be altered in several human cancers (31, 32). Podxl is a known marker of embryonic stem 
cell pluripotency (33), and its expression levels have been shown to correlate with Wnt signalling acti-
vation (34). Rspo1 is a particularly interesting DEX gene. It is a well described secreted regulator of 
Wnt signalling, and potently promotes activation of the pathway in the context of ovarian development 
(35) and angiogenesis (36). It is thought to antagonise the action of the Wnt inhibitor DKK1 (37) and to 
bind to receptors dedicated to Wnt signalling modulation, LGR4/5 (38). In the Dp1Tyb, Rspo1 expres-
sion was  found elevated. Similarly to the Tc1 mouse, hapln1 expression was also increased in the 
Dp1Tyb line. 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Fig. R1.6 - Overview of Mmu16 genes spanning the duplicated region (Lipi-Zbtb21, [2] ) in the Dp1Tyb mouse hip-
pocampus (n=5, P<0.05), as detected by RNAseq. a. Expression levels of 106 Mmu16 genes, presented as in 
R1.1a. b. Expression levels plotted as in R1.1b, highlighting AD-DS-relevant genes and demonstrating the pres-
ence of several genes not significantly duplicated (dot pattern in both panels). The theoretical 1.5-fold threshold is 
highlighted, indicating a minority of Mmu16 genes as more likely responsible for observed expression patterns and 
phenotypes.
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Fig. R1.7 - Mmu DEX genes in the Dp1Tyb mouse hippocampus secondarily aﬀected by Mmu16 duplication. Heat 
map represent expression levels of 202 Dp1Tyb DEX genes (n=5, P<0.01), demonstrating the occurrence of genome-
wide, bidirectional transcriptional alterations. Wnt-related genes detected by IPA are highlighted in bold.
98
Chapter 4.1 - Analysis of the DS transcriptome 
a
b
Fig. R1.6 - Overview of Mmu16 genes spanning the duplicated region (Lipi-Zbtb21, [2] ) in the Dp1Tyb mouse hip-
pocampus (n=5, P<0.05), as detected by RNAseq. a. Expression levels of 106 Mmu16 genes, presented as in 
R1.1a. b. Expression levels plotted as in R1.1b, highlighting AD-DS-relevant genes and demonstrating the pres-
ence of several genes not significantly duplicated (dot pattern in both panels). The theoretical 1.5-fold threshold is 
highlighted, indicating a minority of Mmu16 genes as more likely responsible for observed expression patterns and 
phenotypes.
97
Chapter 4.1 - Analysis of the DS transcriptome 
Fig. R1.7 - Mmu DEX genes in the Dp1Tyb mouse hippocampus secondarily aﬀected by Mmu16 duplication. Heat 
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wide, bidirectional transcriptional alterations. Wnt-related genes detected by IPA are highlighted in bold.
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Fig. R1.7 (contd.) - Mmu DEX genes in the Dp1Tyb mouse hippocampus.
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Overall,  
Overall, IPA analysis did not indicate an association of Dp1Tyb hippocampal gene expression with Wnt 
signalling. Thus, these data are not sufficient to infer a functional link between the pathway and ob-
served transcriptional changes. Nevertheless, it can be objectively stated that hippocampal Dp1Tyb 
RNAseq does indicate altered expression of seven genes related to Wnt signalling (Fig. R1.9). 
Fig. R1.8 - Mmu DEX genes in the Dp1Tyb mouse hippocampus. The 201 Dp1Tyb DEX genes (n=5, P<0.01) are dis-
played arranged by chromosomal number, demonstrating genome-wide, bidirectional transcriptional alterations.
Fig. R1.9 - Contextualised overview of RNAseq-observed expression levels of Wnt-relevant genes in the Dp1Tyb 
mouse hippocampus. Genes are colour-coded according to observed up-/downregulation.
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Fig. R1.7 (contd.) - Mmu DEX genes in the Dp1Tyb mouse hippocampus.
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4.1.2.2.2 Diseases and functions 
In the Dp1Tyb mouse, disease and function analysis was performed as in 4.1.2.1.3 (Fig. R1.10). The 
analysis revealed alterations in terms linked to enhanced proliferative and neuronal developmental 
processes (eg ‘sprouting’) and reduced long-term potentiation (LTP). The latter finding is in line with 
previous studies in mice with duplications in Mmu16 regions syntenic to Hsa21, which clearly demon-
strated LTP deficits (30, 39, 40). Interestingly, several of the upregulated processes are known to be 
affected by Wnt signalling activity, similarly to the Tc1 mouse. Two important examples with relevance 
to hippocampal function include ‘branching of neurites’ and LTP. The former mechanism has been 
linked to Wnt signalling, particularly in the context of neuronal development (41, 42). Wnt activation 
has been consistently associated with positive regulation of neurite branching and axonal guidance. 
Here, this process was found to be upregulated, suggesting the potential presence of overactive Wnt 
signalling. Moreover, the key process in memory formation, LTP, has also been shown to be affected 
by Wnt signalling activity. Wnt ligand secretion is known to regulate hippocampal LTP in direct correla-
tion with synaptic activity (43), and activity of the pathway is an established contributor to memory 
formation (44).   
Overall, this analysis provided additional insight into the effects of altered gene expression in the Dp1-
Tyb mouse hippocampus. Similarly to the Tc1 mouse, the presence of dysfunctional processes al-
ready described in the Dp1Tyb mouse strengthens the reliability of the RNAseq/IPA approach. 
Fig. R1.10 - Diseases and functions analysis generated by IPA according to overall expression patters of 202 Dp1Tyb 
DEX genes, plotting activation z-scores as a function of significance. In accordance with known Dp1Tyb phenotypes, 
the report indicates downregulated (blue) LTP. Mechanisms associated with cell diﬀerentiation and neuronal develop-
ment are upregulated (red).
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4.1.3 Discussion 
4.1.3.1 Key conclusions on the aneuploid status of Tc1 and Dp1Tyb mice 
The studies described in this chapter investigated the hippocampal transcriptome of 2 established DS 
mouse models via RNAseq. This primarily allowed for quantitative analysis of expression profiles in 
two gene groups: 1) Primary DS-related genes, which undergo duplication in humans affected by tri-
somy 21 (Fig. R1.1/6), and 2) Secondarily affected genes beyond Hsa21/Mmu16, with transcriptional 
alterations spanning all mouse chromosomes (Fig. R1.2-3/7-8). 
The former group is represented by detectable Hsa21 genes in the Tc1 mouse, and by Mmu16-
Hsa21 orthologs in the Dp1Tyb. For both models, the majority of theoretically duplicated genes was 
overexpressed, with the notable exception of APP in the Tc1 mouse. Importantly, all other genes rele-
vant to DS and AD-DS were detected at or around 1.5-fold overexpression (Fig. R1.1/6). Key exam-
ples include DYRK1A (see 4.3 for a detailed overview), SOD1, BACE2, and S100B. These data pro-
vided evidence on the aneuploid status of Tc1 and Dp1Tyb mice. In accordance with previous studies 
(1, 2, 8), the RNAseq performed here confirms the expected overexpression of key DS-related genes. 
Therefore, it can be stated that based on available data, these models at least partly recapitulate gene 
expression patterns observed in human DS, notwithstanding their limitations. Such conclusion is cru-
cial to this thesis, as it supports the employment of Tc1 and Dp1Tyb mice in further studies (see 
4.2.2). It is also worth noting that, with respect to the Tc1 mouse, the confirmed absence of APP 
overexpression allows for the the prediction that any potential Wnt signalling phenotypes, investigated 
later, are unlikely to be mediated by said gene in this model. 
Analysis of the latter gene group also demonstrated a key point. That is, modelled aneuploidy pro-
duced significant, genome-wide alterations in expression profiles for both mice investigated. It follows 
that overexpression of DS-related Hsa21-Mmu16 genes alone is sufficient to induce secondary tran-
scriptional changes affecting a high number of genes. As discussed in the general introduction (see 
1.4), the occurrence of this phenomenon in both DS models and humans is well described. A multi-
tude of studies in fact indicates that, in DS, altered gene expression is not limited to Hsa21 genes, 
albeit with high variability. In this respect, the literature-consistent observations made here demon-
strate the DS-like status of the mice employed, and further justify their use in later studies. 
4.1.3.2 Comparative assessment of Tc1 and Dp1Tyb mice 
To aid interpretation of the experimental data generated here, it is important to compare and contrast 
the two DS models employed. Whilst both mice essentially attempt to recapitulate trisomy 21, they 
indeed present significant differences. First and foremost, their genotypes differ extensively. The Tc1 
mouse possesses a freely-segregating, near complete Hsa21 (1, 8). Germ line transmission of the 
human chromosome is somewhat inefficient, and these mice also display mosaicism. Furthermore, 
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some Hsa21 genes are deleted, whilst others are triplicated and thus present in four copies (Fig. 
R1.1). Despite these limitations, the Tc1 mouse does overexpress the vast majority of human genes 
altered in DS, and displays several phenotypes observed in humans. Compared to other available DS 
models, the Tc1 is perhaps one of the most accurate representation of the syndrome. The Dp1Tyb, on 
the other hand, can hardly be considered a true, full model of DS per se. It must be stressed that this 
mouse only displays partial trisomy, in the form of a selectively duplicated portion of Mmu16, contain-
ing several Hsa21 orthologs. Thus Dp1Tyb models overexpress mouse genes, which represent only a 
part of the DS genotype. Indeed the duplicated region includes the DSCR, along with genes known to 
be critical for the occurrence of DS and associated pathologies (e.g.: Dyrk1a, App, Bace2, Sod1, 
Tiam1). Importantly, The Dp1-3 models were originally developed with the purpose of isolating dupli-
cations of Hsa21 orthologs on Mmu10, 16 and 17, respectively (39, 45). Each model thus retains a 
fraction of Hsa21 trisomy. Only when triple-crossed do Dp mice truly possess full trisomy. Therefore, stud-
ies performed on the Dp1Tyb mouse alone should not be taken as investigations of a true DS-like pheno-
type. Rather, they should serve as a tool to dissect the contribution of Mmu16-Hsa21 orthologs to DS.  
The marked differences between Tc1 and Dp1Tyb 
mice are clearly reflected by the RNAseq data 
presented here. Whilst both models overex-
pressed a high number of DS-related genes, only 
partial overlap was observed. Out of the 148 
(Tc1) and 106 (Dp1Tyb) Hsa21-Mmu16 genes 
detected by RNAseq, just 55 actually overlapped 
and were overexpressed in both (Fig. R1.11a). 
Amongst these, however, featured a number of 
key players in DS (DSCR3, DYRK1A, BACE2, 
SOD1, TIAM1). The remaining 93 Hsa21 (Tc1) 
and 51 Mmu16 (Dp1Tyb) DEX genes did not 
match between the two. This clearly implies po-
tentially significant differences in the phenotypic 
outcomes of Tc1 versus Dp1Tyb transcriptomes. 
It follows that direct comparison of the two mod-
els is not necessarily a reliable approach. Instead, 
the Dp1Tyb model should be seen as a means to 
isolate the effects of those Hsa-Mmu16 orthologs 
which do overlap with the Tc1 mouse. That is, 
the presence of a specific phenotype in both 
mice might be ascribed to the function of said 
genes. These differences are further highlighted 
Fig. R1.11 - Comparative expression levels of overlapping 
DEX genes in Tc1 and Dp1Tyb mice. a. Hsa21-Mmu16 
genes. b. Secondary DEX genes. In the vast majority of 
cases, expression levels correlated.
a b
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by comparative analysis of secondarily affected genes. Both models displayed genome-wide tran-
scriptional alterations, as seen in human DS. However, out of the 62 (Tc1) and 202 (Dp1Tyb) non-
Hsa21/Mmu16 DEX genes, only 9 overlapped (Fig. R1.11b). All overlapping genes excluding Cpne9 
correlated in expression level. In the context of this thesis, it is worth specifying that out of these 9 
genes, 2 were associated with Wnt signalling (AXIN2 and HAPLN1).  
Overall, whilst Tc1 and Dp1Tyb mice both partially model DS phenotypes, the genetic background of 
these organisms is markedly different. Therefore, results generated here and in later chapters of this 
thesis should be assessed in light of this notion. It need not be necessarily expected that observed 
phenotypes must present in an absolutely congruent fashion. The Tc1 and Dp1Tyb, along with addi-
tional segmental trisomy models, should be compared and contrasted to gain insight into which por-
tions of Hsa21 are most likely responsible for observed phenotypes. 
4.1.3.3 A putative Wnt contribution? 
The principal aim of this thesis is to investigate a potential link between altered canonical Wnt sig-
nalling and DS. That is, the hypothetical notion that this complex pathway may, at the very least partly, 
contribute to cellular dysfunction in the DS brain. For this reason, the RNAseq datasets were probed 
for enrichment with components of known signalling pathways, including canonical Wnt signalling.  
In the Tc1 hippocampus, a significant association was detected, suggesting that expression patterns 
might partly correlate with Wnt signalling function. This was supported by the presence of seven Tc1 
DEX genes primarily involved in Wnt activity and regulation, according to literature knowledge. It could 
be speculated that, through the transcriptional targeting of several genes, Wnt signalling might effec-
tively extend the gene dosage effects of Hsa21 trisomy to parts of the genome not primarily affected 
by the aneuploidy. However, the current analysis is not sufficient to make any further inferences. It 
cannot be stated that, simply because Wnt-associated DEX genes are present in the Tc1 mouse, the 
pathway itself is actually affected. Hippocampal RNA was derived from a cell-heterogenous sample, 
thus it is impossible to determine the cellular origin of individual gene expression patterns. This is cru-
cial to establishing whether the Wnt-associated DEX genes belong to a single, uniform signalling 
pathway. Therefore, these data only allow for the preliminary conclusion that some Wnt-related genes 
are transcriptionally altered in the Tc1 hippocampus. Such conclusion is purely based on objective 
observation, and does not imply that the DEX genes produce, or result from, Wnt signalling dysfunc-
tion. Biochemical investigation of Wnt activity in this mouse is required to reliably establish a functional 
link, if any, with the pathway (see 4.2.2).  
A similar line of reasoning applies to the Dp1Tyb mouse. Whilst a further seven Wnt-related DEX 
genes were detected, probing with IPA did not indicate a significant association with the pathway. 
Thus, no further conclusion can be drawn beyond the objective observation that a number of genes 
associated with Wnt signalling are abnormally expressed. The cell heterogeneity issue mentioned for 
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by the aneuploidy. However, the current analysis is not sufficient to make any further inferences. It 
cannot be stated that, simply because Wnt-associated DEX genes are present in the Tc1 mouse, the 
pathway itself is actually affected. Hippocampal RNA was derived from a cell-heterogenous sample, 
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the Tc1 mouse also applies to the Dp1Tyb. Thus, biochemical investigation of Wnt activity in this 
model is also required to primarily establish a functional link, if any, with the pathway (see 4.2.2). 
Granted that no inferences on the involvement of Wnt signalling in DS can be made based on the data 
discussed in this chapter, there is one finding worth of consideration. Whilst the Wnt-related DEX 
genes differed between Tc1 and Dp1Tyb datasets, two out of seven hits correlated. Specifically, Axin2 
and Hapln1 were down- and upregulated, respectively, in both mice (Fig. R1.11-12). This seeming 
consistency, albeit a weak finding, might, at least partly, suggest an underlying common alteration in 
Wnt signalling activity. It should be particularly noted that Axin2 is an established Wnt target gene, and 
its expression is known to correlate with activity of the pathway (11, 12). Overall, it may only be con-
cluded that both DS models abnormally express a number of Wnt-related genes, amongst others. 
Such abnormal expression, additionally, does not even imply that the detected genes are altered in 
relation to Wnt signalling, despite their known links with the pathway. Several other mechanisms pro-
ducing the observed transcriptional patterns may be envisioned. The seemingly Wnt-associated 
genes might be affected by the activation of unrelated pathways which function in parallel to Wnt sig-
nalling. On the other hand, non-specific aberrations in transcription factor activity, resulting from aneu-
ploidy, might also contribute to abnormal gene expression. Furthermore, structural differences be-
tween control and DS model tissues might produce alterations which are only apparently related to 
gene expression, but instead reflect shifts in cellular composition and number. Positive pathway asso-
ciations may ultimately well occur for several mechanisms other than Wnt, given the high number and 
heterogeneity of DEX genes detected in both mice. It is indeed possible that, by consulting IPA for 
enrichment in alternative pathways, multiple significant associations may be found. Given the a priori 
hypothesis of a Wnt-DS relationship made for this thesis, the IPA analysis cannot be considered to be 
unbiased. Its results, therefore, must not be taken as definitive transcriptomic evidence of said hy-
pothesis, but rather as tangential findings which warrant further investigation. Importantly, it should be 
highlighted that the only objective, reliable conclusion to be drawn from this chapter is the following: 
both Tc1 and Dp1Tyb mice overexpress their duplicated Hsa21-Mmu16 genes, which secondarily re-
sult in genome-wide transcriptional changes, as seen in human DS. 
For the purpose of this thesis it is however critical to establish whether alterations in Wnt signalling 
activity are present at the protein level in DS models and humans. This work is discussed in chapter 
4.2. In light of the DSCR view of gene contributions to DS (2, 46, 47), it is likely that a small number of 
Hsa21 genes may contribute more significantly to any putative Wnt phenotype. Therefore, mechanis-
tic investigation of potential Wnt abnormalities in DS must entail a candidate gene approach to deter-
mine which, if any, individual Hsa21 genes may be responsible. This work is described in chapter 4.3. 
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Fig. R1.12 - Visual summary of overall results obtained in this chapters. Further investigation is required to clarify the 
presence of these phenotypes, and is discussed in chapter 4.2.
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Chapter 4.2 - Wnt signalling proteins in DS mouse models and humans 
4.2.1 Introduction 
In the studies described in chapter 4.1, the Tc1 and Dp1Tyb mouse hippocampus displayed altered ex-
pression of several non-Hsa21-Mmu16 genes. This suggests the presence of genome-wide transcriptional 
changes, as seen in human DS. Amongst these genes, a small subset was identified as functionally related 
to Wnt signalling (e.g.: Axin2, Dkk3). Preliminary bioinformatic investigation via IPA demonstrated a signifi-
cant association with the Wnt pathway for the Tc1 mouse, but not the Dp1Tyb. The hippocampal tran-
scriptome of both mice nevertheless included Wnt-related DEX genes. These findings are not sufficient to 
implicate Wnt dysfunction in DS. However, for the purpose of this thesis, they constituted a preliminary 
finding, and warranted investigation. Given the detected overexpression of several DS-relevant Hsa21-
Mmu16 genes (4.1), the Tc1 and Dp1Tyb models were considered as suitable for further study.  
In order to probe for a potential Wnt-DS relationship, the next logical step is to investigate whether the ac-
tivity and components of this pathway are at all altered in this condition, at the protein level. The importance 
of proteomic studies in DS, as well as the key findings, were discussed in the main introduction (1.x). Simi-
larly to the DS transcriptome, protein changes are highly variable amongst individuals, and suggest abnor-
malities of several biological mechanisms. It is currently unknown whether such alterations include compo-
nents of Wnt signalling. This must be crucially established if a functional DS-Wnt relationship is to be pro-
posed at all. As introduced (1.2), canonical Wnt signalling heavily relies on a complex protein machinery 
controlling degradation of β-catenin and finely regulating its nuclear translocation. Therefore, whilst the 
downstream effects of Wnt signalling are transcriptional, its activation is a primarily cytosolic event. This 
implies that a number of key Wnt signalling proteins can be utilised as markers of Wnt signalling activation 
states, and thus provide validation, or falsification, of the data collected so far. In the context of Wnt sig-
nalling, the chief protein to be taken into consideration is β-catenin itself. Whilst this protein is abundant 
intracellularly, only a small fraction of its total amount is transcriptionally active. As introduced (1.2), the bio-
chemical correlate of active β-catenin is its S45 and T41-dephosphorylated form. It follows that assess-
ment of the dephosphorylated β-catenin fraction provides reliable information on activity of the pathway in 
the tissue under examination. Additionally, the assessment of levels of other Wnt components can enrich 
the analysis with further insight into the overall state of the pathway. 
This approach was undertaken for the work described here, and this chapter summarises biochemical in-
vestigation of Wnt signalling in ex vivo tissue sourced from the DS mouse model and human DS brain. 
Moreover, protein investigation is useful to confirm the aneuploid status of mouse or human tissues under 
investigation. Measurement of Hsa21-encoded proteins in fact provides a useful indicator of aneuploidy, as 
well as a practical mean of segregating samples into control and DS/model groups for analysis.  
110
109 110
Chapter 4.2 - Wnt signalling proteins in DS mouse models and humans
Chapter 4.2 - Wnt signalling proteins in DS mouse models and humans 
4.2.1 Introduction 
In the studies described in chapter 4.1, the Tc1 and Dp1Tyb mouse hippocampus displayed altered ex-
pression of several non-Hsa21-Mmu16 genes. This suggests the presence of genome-wide transcriptional 
changes, as seen in human DS. Amongst these genes, a small subset was identified as functionally related 
to Wnt signalling (e.g.: Axin2, Dkk3). Preliminary bioinformatic investigation via IPA demonstrated a signifi-
cant association with the Wnt pathway for the Tc1 mouse, but not the Dp1Tyb. The hippocampal tran-
scriptome of both mice nevertheless included Wnt-related DEX genes. These findings are not sufficient to 
implicate Wnt dysfunction in DS. However, for the purpose of this thesis, they constituted a preliminary 
finding, and warranted investigation. Given the detected overexpression of several DS-relevant Hsa21-
Mmu16 genes (4.1), the Tc1 and Dp1Tyb models were considered as suitable for further study.  
In order to probe for a potential Wnt-DS relationship, the next logical step is to investigate whether the ac-
tivity and components of this pathway are at all altered in this condition, at the protein level. The importance 
of proteomic studies in DS, as well as the key findings, were discussed in the main introduction (1.4). Simi-
larly to the DS transcriptome, protein changes are highly variable amongst individuals, and suggest abnor-
malities of several biological mechanisms. It is currently unknown whether such alterations include compo-
nents of Wnt signalling. This must be crucially established if a functional DS-Wnt relationship is to be pro-
posed at all. As introduced (1.2), canonical Wnt signalling heavily relies on a complex protein machinery 
controlling degradation of -catenin and finely regulating its nuclear translocation. Therefore, whilst the 
downstream effects of Wnt signalling are transcriptional, its activation is a primarily cytosolic event. This 
implies that a number of key Wnt signalling proteins can be utilised as markers of Wnt signalling activation 
states, and thus provide validation, or falsification, of the data collected so far. In the context of Wnt sig-
nalling, the chief protein to be taken into consideration is -catenin itself. Whilst this protein is abundant 
intracellularly, only a small fraction of its total amount is transcriptionally active. As introduced (1.2), the bio-
chemical correlate of active -catenin is its S45 and T41-dephosphorylated form. It follows that assess-
ment of the dephosphorylated -catenin fraction provides reliable information on activity of the pathway in 
the tissue under examination. Additionally, the assessment of levels of other Wnt components can enrich 
the analysis with further insight into the overall state of the pathway. 
This approach was undertaken for the work described here, and this chapter summarises biochemical in-
vestigation of Wnt signalling in ex vivo tissue sourced from the DS mouse model and human DS brain. 
Moreover, protein investigation is useful to confirm the aneuploid status of mouse or human tissues under 
investigation. Measurement of Hsa21-encoded proteins in fact provides a useful indicator of aneuploidy, as 
well as a practical mean of segregating samples into control and DS/model groups for analysis.  
Chapter 4.2 - Wnt signalling proteins in DS mouse models and humans
4.2.1.1 Characterisation of the Wnt protein machinery 
As introduced, a number of key protein-level findings in the field of Wnt signalling deserve brief con-
sideration in order to contextualise the approach undertaken in this chapter. In the basal state, the 
complex transmembrane and cytosolic machinery which composes the Wnt pathway continuously 
tags β-catenin for degradation by the proteasome. Activation of the pathway, on the other hand, halts 
this mechanism and permits nuclear translocation of β-catenin. It follows that levels of this protein 
constitute a very useful indicator of overall Wnt activity. Indeed, abundant evidence from multiple fields 
shows the reliability of quantifying active β-catenin levels to this end.  
β-catenin was first identified in the context of cell adhesion, as a cytoplasmic E-cadherin binding pro-
tein (1) required for the formation of cell-cell junctions. However, the functional diversity of β-catenin 
soon came to light when it was identified as homologue to Armadillo, a Drosophila segmental polarity 
protein (2). The same group also implicated β-catenin in Xenopus axial patterning shortly after (3). This 
apparent duality in β-catenin function was finally clarified by Funayama et al. in 1995 (4). Employing 
Xenopus embryos, the authors demonstrated that β-catenin overexpression resulted in dual body axis 
formation. Interestingly, results indicated that the cell adhesion-mediating, N-terminal of β-catenin was 
not required for the induction of the above phenotype, which remained present upon deletion of said 
sequence. The internal, adenomatous polyposis coli (APC)-binding domain of β-catenin was shown to 
be necessary for dual axis formation instead. This key result suggested a cadherin-independent role 
for β-catenin, and the authors first proposed its role as an intracellular signalling molecule. This prop-
erty of β-catenin was also linked to GSK3β, which was shown to regulate its subcellular distribution 
and axis-inducing function (5). Shortly after, the signalling importance of β-catenin was functionally 
established in a 1996 study by Morin et al., published in Science (6). The authors identified abnormal 
activation of this protein, driven by adenomatous polyposis coli (APC) inactivation, as a key event in 
the development of colorectal neoplasia. Furthermore, APC disruption is in some cases not neces-
sary, with activating β-catenin mutations identified as sufficient to induce neoplasia. This key study, 
amongst others, helped firmly establish the idea that β-catenin activation plays a fundamental role in 
Wnt-mediated tumorigenesis. Since then, a vast amount of literature has confirmed the importance of 
β-catenin in a high number of Wnt-mediated processes, and a strong consensus on its centrality to 
Wnt function exists at present (7-11).  
As introduced (see 1.2) the other essential facet of Wnt signalling is the β-catenin destruction com-
plex, which finely regulates basal activity levels. Its chief components are GSK3β, APC and axin. The 
first reports on this multi-protein complex were published independently by Behrens et al., who 
demonstrated axin binding to β-catenin, GSK3β,  and APC (12), and Yost et al., who showed the 
same interaction in the context of Xenopus axis formation (13). Reviewers now agree that the β-
catenin destruction complex is fundamentally important in Wnt function, and that alterations in any of 
its components are likely to disrupt physiological Wnt function (14, 15). One further key implication is 
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that proteins projected to significantly regulate intracellular Wnt signalling are likely to interact with all 
components of the destruction complex. One prominent example is leucine-rich repeat kinase 2 (LR-
RK2), a multi-domain protein involved in familial Parkinson’s disease and an established Wnt modula-
tor. LRRK2 has been shown in several instances to directly interact with the β-catenin destruction 
complex (16, 17).  
Finally, the dickkopf family (DKK) of secreted Wnt inhibitors is also an important protein marker of Wnt 
activity, particularly in the context of neurodegeneration. Their importance has been established in 
multiple lines of evidence. DKKs play central roles in Wnt-mediated craniofacial development (18). Ad-
ditionally, DKK1 is also a Wnt target gene itself implicated in the pathogenesis of several cancers (19) 
as well as development of midbrain dopaminergic neurons (20). Similarly, DKK3 is another important 
Wnt inhibitor, which is reportedly suppressed in cervical cancer (21) and induces apoptosis of human 
prostate cancer cells (22). Accordingly, DKK3 is also elevated in platelet progenitor cells in individuals 
affected by myeloproliferative neoplasia (23). In the context of neurodegeneration, both DKK3 and 
DKK1 are now known to be functionally important. Both are associated with hippocampal develop-
ment and AD (24-26). In the context of DS, DKK3 was identified as a potentially altered Wnt compo-
nent in the transcriptome of Tc1 mice . 
In summary, the evidence discussed here provides key information on the importance of β-catenin, 
the destruction complex and the DKKs as key protein markers for investigation of Wnt dysfunction. 
Building upon this foundation, the work described in this chapter utilised this approach to determine 
whether protein level alterations of Wnt functions were present in DS mouse models and humans. 
Fig. R2.a - Visual overview of canonical Wnt signalling structure and activation mechanisms.
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4.2.2 Results 
This section details biochemical and quantitative real-time PCR (qPCR) experiments conducted on DS 
mouse model and human tissue. Particularly, the cerebral cortex and hippocampus of Tc1 and Dp1Tyb 
mice were examined. The hippocampus of two additional segmental trisomy models, the Ts(10)Yey and 
Ts(17)Yey, was also analysed, as well as postmortem hippocampal tissue derived from AD-DS humans. 
Building upon results in chapter 4.1 (4.1.2), the main aim of this study was to investigate any potential dif-
ferences in key Wnt signalling components and assessing levels of canonical Wnt signalling activity ex vivo. 
The results were obtained combining tissue dissection, protein extraction, immunoblotting and qPCR. For 
all figures displaying box plots, box span represents first to third quartiles, bands represent the median of 
each sample group, and whiskers represent minimum/maximum values. 
4.2.2.1 Tc1 mouse  
Background details on the Tc1 model (27) are discussed in the general introduction (1.1.5) and in results 
chapter 4.1. 
4.2.2.1.1 qPCR Validation of RNAseq data 
In order to validate the Tc1 RNAseq data presented in results chapter 4.1 (4.1.2), hippocampal expression 
of Dkk3 and axin2 was investigated by qPCR. As introduced, these are two key components of canonical 
Wnt signalling, which were identified as DEX genes by RNAseq. Dkk3 is a Wnt inhibitor, whilst axin2 is a 
Wnt target gene which provides negative feedback regulation of β-catenin. 
RNAseq detected Dkk3 overexpression at approximately 1.3-fold relative to WT mice, while Axin2 was 
found be reduced to about 0.6-fold (see 4.1.2). A total of 8 (n=4, 3 months) Tc1 mice were analysed by 
qPCR. Hippocampal RNA was isolated and reverse-transcribed into cDNA (see 3.4 for primer design and 
testing). The resultant genetic material was then amplified and quantified employing standard protocols. 
For both Dkk3 and axin2, two housekeeping genes were used as loading controls, β-actin and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). Final qPCR quantification results were expressed as nor-
malised to loading control and relative to the reference sample WT A. Additionally, descriptive sta-
tistics are reported in brackets in the format (Internally normalised quantity mean ± SD, mean thresh-
old cycle- Ct ± SD). 
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Dkk3 qPCR 
β-actin control - Hippocampal Tc1 cDNA (n=4) was analysed for expression of Dkk3.  Levels of Dkk3 for 
WT A were assumed as reference and quantified to 1 (0.99±0.008, Ct=28.76±0.054). The remaining WT 
samples displayed homogenous levels of Dkk3 expression, with WT B relatively quantified to 1.004 
(0.99±0.03, Ct=29.43±0.015), WT C to 0.98 (0.97±0.12, Ct=30.3±0.008), and WT D to 0.88 (0.87±0.04, 
Ct=30.23±0.18). In the Tc1 samples, Dkk3 levels were increased, with Tc1 A relatively quantified to 1.46 
(1.45±0.02, Ct=27.93±0.03), Tc1 B to 1.37 (1.36±0.09, Ct=29.13±0.13), Tc1 C to 1.68 (1.66±0.11, 
Ct=27.65±0.01), and Tc1 D to 1.89 (1.87±0.03, Ct=21.22±0.07). Overall, and in accordance with RNAseq 
data, the Tc1 relative quantity mean indicates that hippocampal Dkk3 expression is significantly increased 
1.6-fold relative to the WT mean (1.65±0.24, P=0.0017, Fig. R2.1b). 
 
Fig. R2.1 - qPCR of Tc1 hippocam-
pal Dkk3 expression under β-actin 
loading control (n=4). a Amplification 
plot of diﬀerential fluorescence as a 
function of cycle number, demon-
strating eﬀective amplification of 
Dkk3 (red) and β-actin (light blue). b 
WT-normalised relative expression 
levels of Dkk3, indicating a signifi-
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GAPDH control - Hippocampal Tc1 cDNA (n=4) was analysed for expression of Dkk3, identically to the 
previous experiment. Levels of Dkk3 for WT A were assumed as reference and quantified to 1 (01.05±0.15, 
Ct=24.01±0.29). The remaining WT samples displayed homogenous levels of Dkk3 expression, with WT B 
relatively quantified to 1 (1.05±0.18, Ct=23.27±0.24), WT C to 0.86 (0.90±0.09, Ct=24.81±0.19), and WT 
D to 1.05 (1.12±0.43, Ct=24.71±0.63). In the Tc1 samples, Dkk3 levels were increased, although higher 
variability was observed than with β-actin normalisation. Tc1 A relatively quantified to 1.53 (1.61±0.06, 
Ct=22.74±0.09), Tc1 B to 3.25 (3.42±1.13, Ct=23.55±0.40), Tc1 C to 2.28 (2.40±0.33, Ct=22.65±0.36), 
and Tc1 D to 2.37 (2.49±0.74, Ct=20.89±0.27). Consistently to β-actin normalisation and RNAseq, the Tc1 
relative quantity mean for GAPDH indicates that DKK3 expression is significantly increased 2.4-fold relative 
to WT (2.36±0.71, P=0.008, Fig. R2.2b). 
Fig. R2.2 - qPCR of Tc1 hippocam-
pal Dkk3 expression under GAPDH 
loading control (n=4). a Amplification 
plot of diﬀerential fluorescence as a 
function of cycle number, demon-
strating eﬀective amplification of 
Dkk3 (red) and β-GAPDH (light blue). 
b WT-normalised relative expression 
levels of Dkk3, indicating a signifi-
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variability was observed than with β-actin normalisation. Tc1 A relatively quantified to 1.53 (1.61±0.06, 
Ct=22.74±0.09), Tc1 B to 3.25 (3.42±1.13, Ct=23.55±0.40), Tc1 C to 2.28 (2.40±0.33, Ct=22.65±0.36), 
and Tc1 D to 2.37 (2.49±0.74, Ct=20.89±0.27). Consistently to β-actin normalisation and RNAseq, the Tc1 
relative quantity mean for GAPDH indicates that DKK3 expression is significantly increased 2.4-fold relative 
to WT (2.36±0.71, P=0.008, Fig. R2.2b). 
Fig. R2.2 - qPCR of Tc1 hippocam-
pal Dkk3 expression under GAPDH 
loading control (n=4). a Amplification 
plot of diﬀerential fluorescence as a 
function of cycle number, demon-
strating eﬀective amplification of 
Dkk3 (red) and β-GAPDH (light blue). 
b WT-normalised relative expression 
levels of Dkk3, indicating a signifi-
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Axin2 qPCR 
β-actin control - Hippocampal Tc1 cDNA (n=4) was analysed for expression of Axin2. Levels of Axin2 for 
WT A were assumed as reference and quantified to 1 (1.54±0.15, Ct=30.92±0.08). The remaining WT 
samples displayed slightly less homogenous levels of Axin2 expression compared to Dkk3, with WT B rela-
tively quantified to 0.83 (1.28±0.26, Ct=31.77±0.010), WT C to 0.91 (1.40±0.02, Ct=30.62±0.09), and WT 
D to 1.32 (2.04±0.09, Ct=28.52±0.13). In the Tc1 samples, Axin2 levels displayed downregulation, with 
Tc1 A relatively quantified to 0.79 (1.22±0.10, Ct=32.46±0.20), Tc1 B to 0.62 (0.95±0.21, Ct=32.36±0.19), 
Tc1 C to 0.83 (1.28±0.12, Ct=30.63±0.08), and Tc1 D to 0.62 (0.96±0.07, Ct=32.73±0.13). Overall, and in 
accordance to RNAseq data, the Tc1 relative quantity mean indicates a significant 0.7-fold downregulation 
of Axin2 relative to the WT mean (0.71±0.11, P=0.048, Fig. R2.3b). 
 
Fig. R2.3 - qPCR of Tc1 hippocam-
pal Axin2 expression under β-actin 
loading control (n=4). a Amplification 
plot of diﬀerential fluorescence as a 
function of cycle number, demon-
strating eﬀective amplification of 
Axin2 (red) and β-actin (light blue). b 
WT-normalised relative expression 
levels of Axin2, indicating a signifi-
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GAPDH control - Hippocampal Tc1 cDNA (n=4) was analysed for expression of Axin2. In this experiment, 
higher variability between samples was observed, compared to previous results. Samples WT C and Tc1 B 
were excluded from the analysis due to ineffective amplification with undetectable signal. Levels of Axin2 
for WT A were assumed as reference and quantified to 1 (1.60±0.20, Ct=25.9±0.20). The remaining WT 
samples displayed variable levels of Axin2 expression, with WT B relatively quantified to 0.59 (0.95±0.13, 
Ct=25.79±0.33) and WT D to 0.62 (1.00±2.34, Ct=27.26±3.12). In the Tc1 samples, Axin2 displayed vari-
able expression, with Tc1 A relatively quantified to 0.42 (0.66±0.26, Ct=25.95±0.65), Tc1 C to 0.95 
(1.52±0.37, Ct=26.11±0.59), and Tc1 D to 0.75 (1.21±0.17, Ct=24.57±0.26). Overall, the Tc1 relative 
quantity mean indicates that Axin2 expression was not significantly altered under GAPDH control condi-
tions, but displayed a trend toward downregulation (0.78±0.32, P=0.66, Fig. R2.4b). 
Fig. R2.4 - qPCR of Tc1 hippocam-
pal Axin2 expression under GAPDH 
loading control (n=4). a Amplification 
plot of diﬀerential fluorescence as a 
function of cycle number, demon-
strating partly ineﬀective amplifica-
tion of  Axin2 (red) and β-actin (light 
blue). b WT-normalised relative ex-
pression levels of Axin2, indicating 
no significant change in the Tc1 hip-
pocampus. This experiment was 
negatively affected by highly variable 
background signal levels, which may 
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Axin2 qPCR 
β-actin control - Hippocampal Tc1 cDNA (n=4) was analysed for expression of Axin2. Levels of Axin2 for 
WT A were assumed as reference and quantified to 1 (1.54±0.15, Ct=30.92±0.08). The remaining WT 
samples displayed slightly less homogenous levels of Axin2 expression compared to Dkk3, with WT B rela-
tively quantified to 0.83 (1.28±0.26, Ct=31.77±0.010), WT C to 0.91 (1.40±0.02, Ct=30.62±0.09), and WT 
D to 1.32 (2.04±0.09, Ct=28.52±0.13). In the Tc1 samples, Axin2 levels displayed downregulation, with
Tc1 A relatively quantified to 0.79 (1.22±0.10, Ct=32.46±0.20), Tc1 B to 0.62 (0.95±0.21, Ct=32.36±0.19), 
Tc1 C to 0.83 (1.28±0.12, Ct=30.63±0.08), and Tc1 D to 0.62 (0.96±0.07, Ct=32.73±0.13). Overall, and in 
accordance to RNAseq data, the Tc1 relative quantity mean indicates a significant 0.7-fold downregulation 
of Axin2 relative to the WT mean (0.71±0.11, P=0.048, Fig. R2.3b). 
Fig. R2.3 - qPCR of Tc1 hippocam-
pal Axin2 expression under β-actin 
loading control (n=4). a Amplification 
plot of diﬀerential fluorescence as a 
function of cycle number, demon-
strating eﬀective amplification of 
Axin2 (red) and β-actin (light blue). b 
WT-normalised relative expression 
levels of Axin2, indicating a signifi-
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GAPDH control - Hippocampal Tc1 cDNA (n=4) was analysed for expression of Axin2. In this experiment, 
higher variability between samples was observed, compared to previous results. Samples WT C and Tc1 B 
were excluded from the analysis due to ineffective amplification with undetectable signal. Levels of Axin2 
for WT A were assumed as reference and quantified to 1 (1.60±0.20, Ct=25.9±0.20). The remaining WT 
samples displayed variable levels of Axin2 expression, with WT B relatively quantified to 0.59 (0.95±0.13, 
Ct=25.79±0.33) and WT D to 0.62 (1.00±2.34, Ct=27.26±3.12). In the Tc1 samples, Axin2 displayed vari-
able expression, with Tc1 A relatively quantified to 0.42 (0.66±0.26, Ct=25.95±0.65), Tc1 C to 0.95 
(1.52±0.37, Ct=26.11±0.59), and Tc1 D to 0.75 (1.21±0.17, Ct=24.57±0.26). Overall, the Tc1 relative 
quantity mean indicates that Axin2 expression was not significantly altered under GAPDH control condi-
tions, but displayed a trend toward downregulation (0.78±0.32, P=0.66, Fig. R2.4b). 
Fig. R2.4 - qPCR of Tc1 hippocam-
pal Axin2 expression under GAPDH 
loading control (n=4). a Amplification 
plot of diﬀerential fluorescence as a 
function of cycle number, demon-
strating partly ineﬀective amplifica-
tion of  Axin2 (red) and β-actin (light 
blue). b WT-normalised relative ex-
pression levels of Axin2, indicating 
no significant change in the Tc1 hip-
pocampus. This experiment was 
negatively affected by highly variable 
background signal levels, which may 
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4.2.2.1.2 Canonical Wnt signalling in the Tc1 hippocampus 
A total of 16 Tc1 mouse hippocampi (n=8, 6 months) were analysed for immunoblotting experiments. 
Quantified Western blot chemiluminescence values were normalised to loading control (β-actin) and there-
by expressed as ratio to the wild-type (WT) sample mean. Descriptive statistics are reported in brackets in 
the format (mean Tc1 relative normalised chemiluminescence ± SD, p-value). 
Ex vivo Wnt signalling activity 
To first confirm the aneuploid status of the tissue examined, hippocampal Tc1 samples were probed for 
total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
1.5-fold in Tc1 hippocampi (1.74±0.15, P<0.0001, Fig. R2.5a). To determine levels of active Wnt signalling, 
hippocampal Tc1 samples were probed for total and active β-catenin. As introduced, the biochemical cor-
relate of active β-catenin is represented by the de-phosphorylated form of the protein at the S33/37 and 
T41 residues. A specific, validated antibody was employed for immunoblotting (6). Active β-catenin levels 
were expressed as a ratio to total protein. No significant difference was observed in overall levels of β-
catenin (0.96±0.19, P=0.94, Fig. R2.5b). However, the active β-catenin fraction was significantly de-
creased 0.3-fold relative to WT samples (0.36±0.17, P=0.01, Fig. R2.5c). Overall, immunoblotting revealed 
significant downregulation of canonical Wnt signalling activity in adult Tc1 hippocampi.  
Fig. R2.5 - Immunoblotting quantification of Wnt signalling activity in the Tc1 hippocampus (n=8). a Significant 
~1.5-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c Significant 0.3-fold downregu-
lation of the active β-catenin fraction.
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Component profiling 
Hippocampal samples were probed for three additional Wnt signalling proteins: the β-catenin inhibitor 
GSK3β, its S9-phosphorylated form (p-S9) and the secreted inhibitor DKK3. As introduced, p-S9 GSK3β 
is reportedly elevated in 20 months but not 3 months old Tc1 hippocampi (28). DKK3 was found to be in-
creased by RNAseq and qPCR, and was thus tested for further validation. Levels of total GSK3β were not
significantly altered (0.76±0.20, P=0.67, Fig. R2.6a). Similarly to young Tc1 mice (28), no changes in 
amounts of p-GSK3β-S9 were detected (1.24±0.20, P=0.21, Fig. R2.6b). DKK3, however, was found to 
be significantly increased (1.59±0.52, P=0.015, Fig. R2.6c). Overall, these data suggest that whilst GSK3β 
levels are unaffected, the Tc1 mouse presents a consistent elevation of DKK3, detected across multiple 
techniques. Given its role as a Wnt inhibitor, DKK3 might contribute to the observed downregulation of ac-
tive β-catenin in the Tc1 hippocampus. 
In summary, biochemical profiling of the Tc1 hippocampus revealed a state of suppressed Wnt signalling, 
with downregulation of active β-catenin, elevated DKK3 and unaltered GSK3β. 
4.2.2.1.3 Canonical Wnt signalling in the Tc1 cortex
A total of 16 Tc1 mouse cerebral cortices (n=8, 6 months) were analysed in immunoblotting experiments. 
Data were analysed and reported as in 4.2.2.1.2. 
Ex vivo Wnt signalling activity   
To first confirm the aneuploid status of the tissue examined, cerebral cortical Tc1 samples were probed for 
total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
1.5-fold in Tc1 hippocampi (1.58±0.13, P=0.018, Fig. R2.7a). No significant difference was observed in 
Fig. R2.6 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
change in total GSK3β levels. b No change in p-S9 GSK3β levels. c Significant 1.6-fold increase in DKK3 pro-
tein levels, in accordance with RNAseq and qPCR results.
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4.2.2.1.2 Canonical Wnt signalling in the Tc1 hippocampus
A total of 16 Tc1 mouse hippocampi (n=8, 6 months) were analysed for immunoblotting experiments. 
Quantified Western blot chemiluminescence values were normalised to loading control (β-actin) and there-
by expressed as ratio to the wild-type (WT) sample mean. Descriptive statistics are reported in brackets in 
the format (mean Tc1 relative normalised chemiluminescence ± SD, p-value). 
Ex vivo Wnt signalling activity 
To first confirm the aneuploid status of the tissue examined, hippocampal Tc1 samples were probed for 
total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
1.5-fold in Tc1 hippocampi (1.74±0.15, P<0.0001, Fig. R2.5a). To determine levels of active Wnt signalling, 
hippocampal Tc1 samples were probed for total and active β-catenin. As introduced, the biochemical cor-
relate of active β-catenin is represented by the de-phosphorylated form of the protein at the S33/37 and 
T41 residues. A specific, validated antibody was employed for immunoblotting (6). Active β-catenin levels 
were expressed as a ratio to total protein. No significant difference was observed in overall levels of β-
catenin (0.96±0.19, P=0.94, Fig. R2.5b). However, the active β-catenin fraction was significantly de-
creased 0.3-fold relative to WT samples (0.36±0.17, P=0.01, Fig. R2.5c). Overall, immunoblotting revealed 
significant downregulation of canonical Wnt signalling activity in adult Tc1 hippocampi.  
Fig. R2.5 - Immunoblotting quantification of Wnt signalling activity in the Tc1 hippocampus (n=8). a Significant 
~1.5-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c Significant 0.3-fold downregu-
lation of the active β-catenin fraction.
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Component profiling 
Hippocampal samples were probed for three additional Wnt signalling proteins: the β-catenin inhibitor 
GSK3β, its S9-phosphorylated form (p-S9) and the secreted inhibitor DKK3. As introduced, p-S9 GSK3β 
is reportedly elevated in 20 months but not 3 months old Tc1 hippocampi (28). DKK3 was found to be in-
creased by RNAseq and qPCR, and was thus tested for further validation. Levels of total GSK3β were not 
significantly altered (0.76±0.20, P=0.67, Fig. R2.6a). Similarly to young Tc1 mice (28), no changes in 
amounts of p-GSK3β-S9 were detected (1.24±0.20, P=0.21, Fig. R2.6b). DKK3, however, was found to 
be significantly increased (1.59±0.52, P=0.015, Fig. R2.6c). Overall, these data suggest that whilst GSK3β 
levels are unaffected, the Tc1 mouse presents a consistent elevation of DKK3, detected across multiple 
techniques. Given its role as a Wnt inhibitor, DKK3 might contribute to the observed downregulation of ac-
tive β-catenin in the Tc1 hippocampus. 
In summary, biochemical profiling of the Tc1 hippocampus revealed a state of suppressed Wnt signalling, 
with downregulation of active β-catenin, elevated DKK3 and unaltered GSK3β. 
4.2.2.1.3 Canonical Wnt signalling in the Tc1 cortex 
A total of 16 Tc1 mouse cerebral cortices (n=8, 6 months) were analysed in immunoblotting experiments. 
Data were analysed and reported as in 4.2.2.1.2. 
Ex vivo Wnt signalling activity  
To first confirm the aneuploid status of the tissue examined, cerebral cortical Tc1 samples were probed for 
total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
1.5-fold in Tc1 hippocampi (1.58±0.13, P=0.018, Fig. R2.7a). No significant difference was observed in 
Fig. R2.6 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
change in total GSK3β levels. b No change in p-S9 GSK3β levels. c Significant 1.6-fold increase in DKK3 pro-
tein levels, in accordance with RNAseq and qPCR results.
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Fig. R2.7 - Immunoblotting quantification of Wnt signalling activity in the Tc1 cerebral cortex (n=8). a Signifi-
cant ~1.5-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c Significant 2.3-fold in-
crease of the active β-catenin fraction.
Fig. R2.8 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
change in total GSK3β levels. b No change in p-S9 GSK3β levels. c No change in DKK3 levels.
121
Chapter 4.2 - Wnt signalling proteins in DS mouse models and humans
Component profiling 
Tc1 cortical samples were also probed for the Wnt components GSK3β, p-S9-GSK3β and DKK3. Levels 
of total GSK3β were found not to be altered in the Tc1 cortex (0.91±0.26, P=0.57, Fig. R2.8a), and neither 
were levels of p-GSK3β-S9 (0.93±0.71, P=0.85, Fig. R2.8b). Similarly, no difference the amount of DKK3 
was identified (1.08±0.51, P=0.71, Fig. R2.8c). In summary, biochemical profiling of the Tc1 cortex re-
vealed a state of overactive Wnt signalling. However, protein levels of the Wnt components examined were 
normal. 
4.2.2.2 Dp1Tyb mouse 
Details on the Dp1Tyb model (29) are discussed in the introduction (1.1.5) and results chapter 4.1 (4.1.1). 
4.2.2.2.1 Canonical Wnt signalling in the Dp1Tyb hippocampus 
A total of 20 Dp1Tyb mice hippocampi (n=10, 5 months) were analysed for immunoblotting experiments. 
Data were analysed and reported as in 4.2.2.1.2-3. 
Ex vivo Wnt signalling activity 
To first confirm the aneuploid status of the tissue examined, hippocampal Dp1Tyb samples were probed 
for total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
2-fold (2.22±0.69, P=0.0001, Fig. R2.9a). No significant difference was observed in total levels of β-
catenin (0.77±0.38, P=0.45, Fig. R2.9b). However, and similarly to the Tc1 cortex, the active β-catenin 
fraction was substantially increased over 3-fold relative to WT samples (3.36±1.54, P=0.0001, Fig. R2.9c). 
Component profiling 
Dp1Tyb hippocampal samples were also probed for the Wnt components GSK3β and DKK3. Levels of 
total GSK3β did not appear to be altered (0.90±0.32, P=0.62, Fig. R2.10a). However, amounts of DKK3 
were significantly elevated nearly 3-fold (2.78±1.5, P=0.004, Fig. R2.10b). 
In summary, biochemical profiling of the Dp1Tyb hippocampus revealed a state of upregulated Wnt sig-
nalling, with unaltered GSK3β levels. The prominent elevation in DKK3 is also of particular interest, as it ap-
parently contrasts with its known Wnt inhibitory role.  
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total cortical levels of -catenin (1.05±0.25, P=0.52, Fig. R2.7b). However, the active -catenin fraction 
was significantly increased 2.3-fold relative to WT samples (2.28±1.21, P=0.012, Fig. R2.7c). In contrast 
to hippocampal results, these data suggest significant activation of the pathway in the Tc1 cortex, a trend 
which warrants careful interpretation and further validation.
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total cortical levels of β-catenin (1.05±0.25, P=0.52, Fig. R2.7b). However, the active β-catenin fraction 
was significantly increased 2.3-fold relative to WT samples (2.28±1.21, P=0.012, Fig. R2.7c). In contrast 
to hippocampal results, these data suggest significant activation of the pathway in the Tc1 cortex, a trend 
which warrants careful interpretation and further validation, as no cortical RNAseq data was available to 
formulate predictions.
Fig. R2.7 - Immunoblotting quantification of Wnt signalling activity in the Tc1 cerebral cortex (n=8). a Signifi-
cant ~1.5-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c Significant 2.3-fold in-
crease of the active β-catenin fraction.
Fig. R2.8 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
change in total GSK3β levels. b No change in p-S9 GSK3β levels. c No change in DKK3 levels.
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Component profiling   
Tc1 cortical samples were also probed for the Wnt components GSK3 , p-S9-GSK3  and DKK3. Levels 
of total GSK3  were found not to be altered in the Tc1 cortex (0.91±0.26, P=0.57, Fig. R2.8a), and neither 
were levels of p-GSK3 -S9 (0.93±0.71, P=0.85, Fig. R2.8b). Similarly, no difference the amount of DKK3 
was identified (1.08±0.51, P=0.71, Fig. R2.8c). In summary, biochemical profiling of the Tc1 cortex re-
vealed a state of overactive Wnt signalling. However, protein levels of the Wnt components examined were 
normal. 
4.2.2.2 Dp1Tyb mouse 
Details on the Dp1Tyb model (29) are discussed in the introduction (1.1.5) and results chapter 4.1 (4.1.1). 
4.2.2.2.1 Canonical Wnt signalling in the Dp1Tyb hippocampus 
A total of 20 Dp1Tyb mice hippocampi (n=10, 5 months) were analysed for immunoblotting experiments. 
Data were analysed and reported as in 4.2.2.1.2-3. 
Ex vivo Wnt signalling activity 
To first confirm the aneuploid status of the tissue examined, hippocampal Dp1Tyb samples were probed 
for total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
2-fold (2.22±0.69, P=0.0001, Fig. R2.9a). No significant difference was observed in total levels of -
catenin (0.77±0.38, P=0.45, Fig. R2.9b). However, and similarly to the Tc1 cortex, the active -catenin 
fraction was substantially increased over 3-fold relative to WT samples (3.36±1.54, P=0.0001, Fig. R2.9c). 
Component profiling 
Dp1Tyb hippocampal samples were also probed for the Wnt components GSK3  and DKK3. Levels of 
total GSK3  did not appear to be altered (0.90±0.32, P=0.62, Fig. R2.10a). However, amounts of DKK3 
were significantly elevated nearly 3-fold (2.78±1.5, P=0.004, Fig. R2.10b). 
In summary, biochemical profiling of the Dp1Tyb hippocampus revealed a state of upregulated Wnt sig-
nalling, with unaltered GSK3  levels. The prominent elevation in DKK3 is also of particular interest, as it ap-
parently contrasts with its known Wnt inhibitory role.  
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Fig. R2.9 - Immunoblotting quantification of Wnt signalling activity in the Dp1Tyb hippocampus (n=10). a Sig-
nificant ~2-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c Significant increase of 
the active β-catenin fraction to a substantial ~3.4-fold.
Fig. R2.10 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
change in total GSK3β levels. b Significant 2.8-fold increase in DKK3 protein levels.
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4.2.2.2.2 Canonical Wnt signalling in the Dp1Tyb cortex 
A total of 20 Dp1Tyb mouse cerebral cortices (n=10, 5 months) were analysed for immunoblotting experi-
ments. Data were analysed and reported as in 4.2.2.1.2. 
Ex vivo Wnt signalling activity  
To first confirm the aneuploid status of the tissue examined, cerebral cortical Dp1Tyb samples were probed 
for total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
2-fold (2.18±0.66, P=0.0005, Fig. R2.11a). However, Wnt signalling activity was normal in the Dp1Tyb 
cerebral cortex, with unaltered levels of total (1.04±0.88, P=0.78, Fig. R2.11b) and active (1.44±0.64, 
P=0.11, Fig. R2.11c) β-catenin.
Overall, whilst the Dp1Tyb cortex displays enhanced DYRK1A levels, no differences in Wnt signalling activi-
ty are present at this time point. Therefore, no additional investigation of Wnt components was performed 
in this tissue type. 
4.2.2.3 Additional segmental trisomy models 
The presence of Wnt signalling activity alterations in the Tc1 and Dp1Tyb models provides support for 
the main hypothesis of this thesis, but also warrants the question of which Hsa21 genes are more 
likely to mediate the Wnt phenotype. Since Hsa21 genes are numerous, formulation of a candidate 
gene hypothesis for later study can be aided by further dissecting Hsa21 trisomy in smaller segments. 
For this purpose, canonical Wnt signalling activity was investigated in two additional segmental tri-
somy models, the Ts1(10)Yey and Ts1(17)Yey (30). As introduced, these mice possess duplications of 
Hsa21 syntenic regions on Mmu10 and 17, respectively, and do not include the DSCR. 
Fig. R2.11 - Immunoblotting quantification of Wnt signalling activity in the Dp1Tyb cerebral cortex (n=10). 

a Significant ~2-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c No change in the 
active β-catenin fraction.
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Fig. R2.9 - Immunoblotting quantification of Wnt signalling activity in the Dp1Tyb hippocampus (n=10). a Sig-
nificant ~2-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c Significant increase of 
the active β-catenin fraction to a substantial ~3.4-fold.
Fig. R2.10 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
change in total GSK3β levels. b Significant 2.8-fold increase in DKK3 protein levels.
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4.2.2.2.2 Canonical Wnt signalling in the Dp1Tyb cortex 
A total of 20 Dp1Tyb mouse cerebral cortices (n=10, 5 months) were analysed for immunoblotting experi-
ments. Data were analysed and reported as in 4.2.2.1.2. 
Ex vivo Wnt signalling activity 
To first confirm the aneuploid status of the tissue examined, cerebral cortical Dp1Tyb samples were probed 
for total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
2-fold (2.18±0.66, P=0.0005, Fig. R2.11a). However, Wnt signalling activity was normal in the Dp1Tyb 
cerebral cortex, with unaltered levels of total (1.04±0.88, P=0.78, Fig. R2.11b) and active (1.44±0.64, 
P=0.11, Fig. R2.11c) β-catenin. 
Overall, whilst the Dp1Tyb cortex displays enhanced DYRK1A levels, no differences in Wnt signalling activi-
ty are present at this time point. Therefore, no additional investigation of Wnt components was performed 
in this tissue type. 
4.2.2.3 Additional segmental trisomy models 
The presence of Wnt signalling activity alterations in the Tc1 and Dp1Tyb models provides support for 
the main hypothesis of this thesis, but also warrants the question of which Hsa21 genes are more 
likely to mediate the Wnt phenotype. Since Hsa21 genes are numerous, formulation of a candidate 
gene hypothesis for later study can be aided by further dissecting Hsa21 trisomy in smaller segments. 
For this purpose, canonical Wnt signalling activity was investigated in two additional segmental tri-
somy models, the Ts1(10)Yey and Ts1(17)Yey (30). As introduced, these mice possess duplications of 
Hsa21 syntenic regions on Mmu10 and 17, respectively, and do not include the DSCR. 
Fig. R2.11 - Immunoblotting quantification of Wnt signalling activity in the Dp1Tyb cerebral cortex (n=10). 

a Significant ~2-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c No change in the 
active β-catenin fraction.
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4.2.2.3.1 Canonical Wnt signalling in the Ts1(10)Yey and Ts1(17)Yey hippocampus 
A total of 10 Ts1(10-17)Yey mice hippocampi (n=5, 6 months) were analysed for immunoblotting experi-
ments. Data were analysed and reported as in 4.2.2.1.2-3. 
Ex vivo Wnt signalling activity 
Overall, Wnt signalling activity was normal in the hippocampus of both models. Total β-catenin was unaf-
fected (Ts1(10)Yey - 1.73±1.31, P=0.30; Ts1(17)Yey - 1.80±1.23, P=0.75, Fig. R2.12a/c). Similarly, no 
differences in active β-catenin were detected  (Ts1(10)Yey - 0.85±1.31, P=0.76; Ts1(17)Yey - 1.55±0.96, 
P=0.28, Fig. R2.12b/d). 
In summary, these results indicate unaffected Wnt signalling in the Ts1(10)Yey and Ts1(17)Yey models, sug-
gesting that Hsa21 syntenic regions on Mmu10 and 17 are unlikely to mediate the phenotype observed in 
the Tc1 mouse. These data are particularly important, because they indicate that Hsa21 orthologs on 
Mmu16, overexpressed in the Dp1Tyb mouse, are more likely to underlie the observed Wnt alterations. 
Fig. R2.12 - Immunoblotting quantification of Wnt signalling activity in the Ts1(10)Yey and Ts1(17)Yey hip-
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4.2.2.4 Human DS 
Having established the presence of substantial Wnt alterations in the hippocampus of two key DS 
mouse models, the next logical step was to investigate whether this signalling pathway is affected in 
human DS individuals. The work conducted in mice provided validation of previous experiments, but it 
is by itself not sufficient to reliably conclude that abnormal Wnt signalling correlates with DS. There-
fore, human DS brain tissue was employed to characterise potential Wnt signalling changes in Hsa21 
trisomy. A total of n=8 postmortem human DS hippocampal samples were sourced from the Newcas-
tle Brain Bank, along with 8 euploid controls. Both sample groups included a mix of males and fe-
males. Samples were age-matched, with no significant difference in age of death observed (Euploid - 
55±5.5 yrs; DS - 53±7 yrs, P=0.62, Fig. R2.13a). Samples were also matched for postmortem delay 
of tissue collection, in order to minimise differences due to differential protein degradation. No signifi-
cant difference in postmortem delay was observed (Euploid - 36.5±29.5 hrs; DS - 58.8±33 hrs, 
P=0.18, Fig. R2.13b). Clinical information for each group (Fig. R2.13c) indicated that all DS individu-
als suffered from AD at the time of death (AD-DS), with most displaying extensive brain pathology as 
classified by Braak staging. Conversely, all euploid controls were not affected by AD. 	
Fig. R2.13 - Overview of human 
DS samples employed. a No 
significant diﬀerence in age of 
death. b No significant diﬀerence 
in postmortem delay of sample 
collection. c Clinical overview of 
all individuals whose brain tissue 
was analysed, indicating diag-
nosed AD in virtually all DS cas-
es, and extensive neuropatholo-
gy in most (Braak staging).AD-DS AD-DSEuploidEuploid
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4.2.2.4.1 Canonical Wnt signalling in the adult human DS hippocampus 
Ex vivo Wnt signalling activity 
To first confirm the aneuploid status of the human tissue examined, hippocampal samples were probed for 
total levels of DYRK1A. As expected, DYRK1A was found to be significantly increased at approximately 
1.5-fold (1.82±0.69, P=0.0061, Fig. R2.14a). Consistently with all mice examined, no significant difference 
was observed in total levels of β-catenin (1.34±0.97, P=0.42, Fig. R2.14b). However, similarly to the Tc1 
hippocampus, the active β-catenin fraction was substantially downregulated nearly 3-fold (0.43±0.22, 
P=0.0021, Fig. R2.14c). These data indicate that, in human AD-DS hippocampi, canonical Wnt signalling 
is potently suppressed. 
Fig. R2.14 - Immunoblotting quantification of Wnt signalling activity in the human DS hippocampus (n=8).

a Significant ~1.5-fold elevation in DYRK1A protein levels. b No change in total β-catenin. c Significant 3-fold 
downregulation of the active β-catenin fraction to a similar extent to the Tc1 hippocampus.
AD-DS AD-DS AD-DSEuploidEuploidEuploid
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Component profiling 
Human DS hippocampal samples were also probed for the Wnt components GSK3β and DKK3. Levels of 
total GSK3β did not appear to be altered (0.90±0.32, P=0.62, Fig. R2.15a). However, amounts of DKK3 
were significantly reduced 3-fold (0.33±0.21, P=0.0147, Fig. R2.15b). These data suggest that DKK3 al-
terations are associated with the DS hippocampus, since they were also present in both the Tc1 and Dp1-
Tyb models, albeit in the opposite direction. 
In summary, the investigation conducted in humans DS individuals provided, for the first time, evidence of 
substantially suppressed canonical Wnt signalling activity, with an associated decrease in levels of DKK3. 
4.2.3 Discussion 
The work described in this chapter provided initial support to the main hypothesis of this thesis, by 
investigating potential protein level alterations of Wnt signalling activity and components in DS models 
and humans. The diverse array of proteomic alterations in DS was discussed in the main introduction 
(1.x), elucidating the associated high variability and relative contribution of a small number of Hsa21-
encoded proteins. Overall, the data presented here clearly demonstrate that, at the protein level, Wnt 
signalling is dysfunctional in DS. Given that abnormalities were found in both models as well as human 
hippocampi, the combined interpretation of chapter 4.2 data lends support to the main hypothesis of 
this thesis. However, a non-trivial degree of variability was observed between tissue types and models 
examined. This further elucidates the idea put forth previously i.e. that, if present, Wnt alterations in 
DS are likely multi-directional, given the complexity and fine regulation of the pathway. Thus, possible 
interpretations and implications for later work are explored in this section. 
Fig. R2.15 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
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Fig. R2.15 - Immunoblotting quantification of Wnt signalling components in the Tc1 hippocampus (n=8). a No 
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Component profiling   
Human DS hippocampal samples were also probed for the Wnt components GSK3  and DKK3. Levels of 
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Tyb models, albeit in the opposite direction. 
In summary, the investigation conducted in humans DS individuals provided, for the first time, evidence of 
substantially suppressed canonical Wnt signalling activity, with an associated decrease in levels of DKK3. 
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investigating potential protein level alterations of Wnt signalling activity and components in DS models 
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(1.4), elucidating the associated high variability and relative contribution of a small number of Hsa21-
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signalling is dysfunctional in DS. Given that abnormalities were found in both models as well as human 
hippocampi, the combined interpretation of chapter 4.2 data lends support to the main hypothesis of 
this thesis. However, a non-trivial degree of variability was observed between tissue types and models 
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DS are likely multi-directional, given the complexity and ﬁne regulation of the pathway. Thus, possible 
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4.2.3.1 Functional significance  
Overall, qPCR and protein studies in this chapter provided one key finding in the understanding of DS: 
Wnt abnormalities are present at the protein level. It has to be noted, however, that given the available 
data, this notion is presently only applicable to the DS brain, and particularly the hippocampus. It re-
mains to be determined whether such abnormalities are present in other cell types critical to DS 
pathology, such as heart tissue or the haematopoietic system. Given the statistical significance of dif-
ferences in observed active β-catenin levels, however, it can be generally concluded that cerebral Wnt 
signalling is indeed affected by Hsa21 trisomy.  
Out of all the data presented, studies conducted in the Tc1 and human DS hippocampi are perhaps 
the most compelling, for a number of reasons. In both conditions, a substantial downregulation of ac-
tive β-catenin was observed. Given current knowledge on the importance of Wnt signalling in nervous 
system development and homoeostatic function (11, 31, 32), it can be inferred that the observed de-
greed of suppression, 3-fold on average, is likely to result in significant downstream effects. Particular-
ly, inhibition of Wnt signalling in the DS hippocampus may primarily affect adult neurogenesis, a critical 
process in memory formation. Lie et al. reported on the essential regulatory role of canonical Wnt sig-
nalling on hippocampal neurogenesis (33), a mechanism through which the Wnt pathway is well 
known to affect memory formation processes such as LTP and neuronal network signal processing 
(34). Therefore, although no functional circuit data is available in this study, literature knowledge sup-
ports the inference that the observed extent of Wnt signalling dysregulation in DS may deleteriously 
affect hippocampal function. This is particularly relevant to AD. Given that all human samples exam-
ined originated from DS individuals affected by clinical AD, the data are consistent with previous re-
ports of Wnt signalling downregulation in AD (26, 35).  
Additionally, alterations in DKK3, an AD-related Wnt inhibitor regulating hippocampal development and 
neurogenesis (24, 25), are present in both mouse models and human DS. It remains unclear, however, 
why DKK3 alterations go in opposite directions in the Tc1 and human DS hippocampus. Given that 
DKK3 functions as a Wnt antagonist, an enhancement in protein levels would be expected in the hu-
man DS hippocampus, which was not the case for the data reported here. Similarly, enhanced active 
β-catenin levels in the Dp1Tyb hippocampus would be expected to correlate with decreases in DKK3 
protein levels. A significant enhancement in DKK3 was observed instead. These data are difficult to 
reconcile, but may in part be due to possibly dual DKK3 functions in Wnt regulation. Reports exist 
suggesting that, in particular tissue types, DKK3 may function as a promoter of canonical Wnt sig-
nalling. For example, Nakamura et al reported potent Wnt-stimulating effects of DKK3 in a retinal glial 
cell line, a tissue type relevant to nervous system function (36). It is possible, therefore, that DKK3 al-
terations might positively drive Wnt signalling in specific contexts, which however remain to be deter-
mined.  
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In parallel, AXIN2 expression was decreased in the Tc1 hippocampus. This gene has a distinct pattern 
of expression, specific to both the developing and adult hippocampal dentate gyrus (37), and its pro-
tein levels are proportionally related to canonical Wnt signalling activity (38). The downregulation of 
AXIN2 observed in the Tc1 hippocampus could further account for the concomitant decrease in Wnt 
signalling activity. The observed absence of alterations in GSK3β levels in all tissues examined sug-
gests, on the other hand, that the described Wnt phenotypes are possibly independent of GSK3β ac-
tivity. However, since abnormal S9 phosphorylation of GSK3β is indeed observed in the brain of aged 
Tc1 mice (28), it is possible that GSK3β changes are age-dependent, and only become detectable at 
later stages of life.  
Another unclear finding is the observed enhancement of active Wnt signalling in the Tc1 cortex. Whilst 
all Wnt components were normal, significantly increased active β-catenin was observed. There are 
two possible interpretations for this finding. Overactive Wnt signalling in the cerebral cortex may repre-
sent an early feedback compensation, given the high degree of connectivity between hippocampal 
and cortical areas in the brain. Alternatively, this result might suggest that Hsa21-encoded proteins 
potentially responsible for Wnt alterations may be capable of bidirectional regulation of signalling activ-
ity, depending on basal activation levels and/or developmental stage. Some studies have reported 
that aberrant Wnt signalling activation in mature mouse neurons may result in transient neuronal prog-
enitor proliferation, also followed by apoptosis (39). Interesting, Cyclin D1 levels were found to be ele-
vated in FAD post mortem brain samples (40, 41). Upregulation of this key mitotic regulation may in-
duce forced cell cycle entry and subsequent apoptosis. Thus, it is possible that negative effects of 
Wnt signalling upregulation might also be present in DS. This implies that physiological, basal Wnt ac-
tivity requirements might influence the direction of change induced by aberrant expression of Hsa21 
genes. This idea warrants further mechanistic studies aimed at clarifying the underlying mechanisms. 
In summary, if the Tc1 and human DS hippocampal data are considered independently of other re-
sults, a consistent pattern of Wnt suppression emerges, whereby Hsa21 trisomy may facilitate neu-
rodegeneration with a some contribution from suppressed Wnt signalling. Overall, considering all data 
available, it can be concluded that, albeit somewhat inconsistent in direction of change, Wnt signalling 
is indeed functioning abnormally in DS (Fig. R2.16). This novel finding suggests that, provided mech-
anisms are clarified in future work, Wnt signalling function may be established as a critical contributor 
to DS brain pathology, with the consequential hypothesis that pharmacological targeting of this path-
way might constitute a viable strategy for therapeutic development (see 5.2.2). 
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4.2.3.2 Implications 
The presence of substantial Wnt dysregulation in the DS brain at the protein level (Fig. R2.16) war-
rants the subsequent need of determining which Hsa21 genes are more likely to underlie the ob-
served phenotypes. This experimental question is critical to convincingly establish whether or not 
Hsa21 trisomy truly affects Wnt signalling in DS. While data discussed so far reliably demonstrate the 
presence of abnormalities of the pathway, they provide no insight into the underling causal relationship 
between Hsa21 and Wnt signalling. It is indeed possible that, in DS, Wnt dysfunction might not result 
from aberrant activity of primarily overexpressed genes, especially given the genome-wide effects of 
Hsa21 trisomy on gene expression (4.1.3).  
To answer this question, candidate Hsa21 genes must be functionally investigated in relation to Wnt 
signalling. In this respect, observations made in the Ts1(10/17)Yey hippocampus are particularly im-
portant. Specifically, given that no Wnt signalling alterations were detected in the hippocampus of ei-
ther model, Hsa21 genes synthenic to Mmu10/17 regions are most likely not responsible for the phe-
notypes observed in other DS models and humans. Conversely, since β-catenin activity was abnormal 
in the Dp1Tyb model, the scope of investigation can be restricted to Hsa21 syntenic genes on 
Mmu16. There are indeed multiple interesting candidates in this region, most importantly APP and 
DYRK1A, both reportedly crucial for DS and AD pathology. Given that APP is not functionally overex-
pressed in the Tc1 mouse, however (4.1.2., (27, 42)), DYRK1A was selected for further investigation in 
this thesis. The DYRK1A protein is already known to functionally interact with two key Wnt compo-
nents, namely GSK3β (43-45) and p120/δ-catenin (46). Moreover, its known role as a regulator of sig-
nalling pathways (47, 48) makes it an ideal candidate for Wnt modulation in DS (see 4.3.1 for a de-
tailed overview of DYRK1A function). 
It cannot be excluded however, that APP may also contribute to the Wnt phenotype in DS, given its 
key importance in AD pathogenesis and its overexpression in the DS brain. The studies investigating a 
potential DYRK1A-Wnt functional interaction are discussed in chapter 4.3. 
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4.2.3.2 Implications 
The presence of substantial Wnt dysregulation in the DS brain at the protein level (Fig. R2.16) war-
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presence of abnormalities of the pathway, they provide no insight into the underling causal relationship 
between Hsa21 and Wnt signalling. It is indeed possible that, in DS, Wnt dysfunction might not result 
from aberrant activity of primarily overexpressed genes, especially given the genome-wide effects of 
Hsa21 trisomy on gene expression (4.1.3).  
To answer this question, candidate Hsa21 genes must be functionally investigated in relation to Wnt 
signalling. In this respect, observations made in the Ts1(10/17)Yey hippocampus are particularly im-
portant. Specifically, given that no Wnt signalling alterations were detected in the hippocampus of ei-
ther model, Hsa21 genes synthenic to Mmu10/17 regions are most likely not responsible for the phe-
notypes observed in other DS models and humans. Conversely, since β-catenin activity was abnormal 
in the Dp1Tyb model, the scope of investigation can be restricted to Hsa21 syntenic genes on 
Mmu16. There are indeed multiple interesting candidates in this region, most importantly APP and 
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It cannot be excluded however, that APP may also contribute to the Wnt phenotype in DS, given its 
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Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
4.3. Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation 
4.3.1 Introduction 
The work described so far elucidated two key points: first, canonical Wnt signalling abnormalities in 
DS are suggested by transcriptional profiles in two mouse models. Second, Wnt alterations are also 
present at the protein level, with observed abnormalities in β-catenin activity and amounts of the in-
hibitor DKK3. This phenotype is observed in multiple tissue types of DS mouse models, as well as the 
postmortem hippocampus of DS individuals also diagnosed with AD. This phenotype is, however, di-
rectionally inconsistent, and may vary depending on tissue type. Particularly, the Tc1 mouse and hu-
man DS hippocampi both display substantially reduced Wnt signalling activity, whilst the Tc1 cerebral 
cortex and Dp1Tyb hippocampus possess enhanced activity of the pathway. Additionally, no alteration 
is observed in mice with duplications of Mmu10 and 17 regions syntenic to Hsa21, suggesting 
Mmu16 orthologs are more desirable candidates. Overall, these findings demonstrate that Wnt sig-
nalling alterations are present in DS, but do no provide any evidence as to which DS-relevant Hsa21 
genes might be responsible. Several potential mechanisms may be envisioned: some Hsa21 genes 
may directly modulate Wnt signalling or influence certain cellular processes which then affect Wnt sig-
nalling. Alternatively, the Wnt alterations observed may be completely independent of the specific 
function of Hsa21 genes, and rather result from non-specific alterations in gene expression induced 
by aneuploidy.  
To investigate which of these hypotheses best accounts for the observations made so far, a candidate 
gene approach was undertaken. As introduced, the most appealing candidate given the data current-
ly available is DYRK1A, which is unequivocally overexpressed in the all DS tissues examined. This is in 
contrast to APP, another likely candidate for Wnt modulation, which is not functionally overexpressed 
in the Tc1 model, which nevertheless presents Wnt abnormalities. For these reasons, mechanistic 
studies into a potential Wnt modulatory role for DYRK1A were performed, and the results are de-
scribed in this chapter.  
Before discussing them, however, it is necessary to introduce scientific evidence on the known func-
tions of DYRK1A and its role in DS and neurodegeneration. The available literature will serve as a con-
ceptual basis to justify the experimental work presented thereafter. Given the CNS-oriented scope of 
this thesis, current knowledge on DYRK1A function is preferentially discussed in this context. Overall, 
four main themes deserve consideration: First, that DYRK1A is a multifaceted kinase with multiple 
roles in health and disease. Second, that abnormal DYRK1A function is a key feature of DS neurode-
generation. Third, that it is capable of finely regulating several signalling pathways. Fourth, that existing 
evidence preliminarily implicates DYRK1A in Wnt function, making it an ideal candidate for the studies 
carried out in this chapter. 
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4.3.1.1 DYRK1A: a multifaceted, dual-specificity kinase 
DYRK1A is a member of the dual-specificity tyrosine-(Y)-phosphorylation–regulated kinase (DYRK) 
family of highly conserved protein kinases. From a phylogenetic perspective, the DYRK family is itself 
integral to the CMGC group of eukaryotic kinases. This group includes Cyclin-dependent kinase 
(CDK), Mitogen-activated protein kinase (MAPK), Glycogen synthase kinase (GSK - important in Wnt 
signalling) and CDK-like kinase (CLK) (1). Members of the DYRK family all possess a conserved kinase 
domain in close proximity to a DYRK homology domain, also known as DH-box [amino acid - (aa se-
quence: DDDNXDY). They however differ in the composition of amino/acid terminal regions (2). The 
DYRK family is additionally divided into three subclasses, one of which includes the vertebrate 
DYRK1A/B and DYRK2-4 genes. 
DYRK1A itself is a highly conserved protein kinase with a multitude of phosphorylation functions. It 
was first identified in 1995 as the Drosophila gene minibrain (Mbn), encoding a protein essentially re-
quired for post-embryonic neurogenesis (3). The DYRK1A protein consists of 763 amino acids and 
multiple domains. Specifically, it possesses a kinase domain, two nuclear localisation signals (NLS), a 
PEST domain (riche in proline (P), glutamate (E), serine (S), and threonine (T), a highly conserved 13-
histidine repeat (poly-H tail) and a C-terminal S/T rich region. The enzyme is able to self-activate or 
undergo priming by other kinases. The two NLSs, both functional, are located at the N-terminal and 
within the kinase domain (4). No known DYRK1A function is currently ascribed to the PEST domain or 
S/T rich region (5). 
DYRK1A is a dual-specificity kinase, meaning it displays both tyrosine (Y) and serine/threonine kinase 
activities. However, the dual-specificity nature refers to its known autophosphorylation capabilities (5). 
DYRK1A in fact displays self-activation via phosphorylation of the Y321 residue. Particularly, the pro-
tein possesses a conserved Y-X-Y motif within the activation loop of the kinase domain, similarly to all 
other DYRK family members (2). Autophosphorylation of the second Y residue has been shown to be 
essential for DYRK1A kinase activation (6), hence the ‘Y-regulated’ nomenclature. This notion also re-
portedly applies to other DYRK members of the mammalian subclass (7). Whilst this activation modali-
ty is also present in MAPKs, it does not require a priming kinase and is instead an autophosphoryla-
tion event, as introduced (6). A key 2005 study by Lochhead et al. mechanistically characterised 
DYRK1A activation in Drosophila (8). This study demonstrated an important feature of DYRK1A func-
tion. The self-activating autophosphorylation was shown to occur during mid-translation, when the 
protein is not fully mature. A transient, intermediate form of DYRK1A catalyses this activating phos-
phorylation at the Y-X-Y motif, after which the Y-kinase activity is lost permanently. These findings also 
imply that once synthesised, the mature DYRK1A protein is constitutively active. Importantly, it follows 
that total protein levels of DYRK1A directly correlate with kinase activity. This notion is relevant to DS, 
as it suggests that in this condition, DYRK1A overexpression may result in a chronic 1.5-fold en-
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4.3. Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation 
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ly available is DYRK1A, which is unequivocally overexpressed in the all DS tissues examined. This is in 
contrast to APP, another likely candidate for Wnt modulation, which is not functionally overexpressed 
in the Tc1 model, which nevertheless presents Wnt abnormalities. For these reasons, mechanistic 
studies into a potential Wnt modulatory role for DYRK1A were performed, and the results are de-
scribed in this chapter.  
Before discussing them, however, it is necessary to introduce scientific evidence on the known func-
tions of DYRK1A and its role in DS and neurodegeneration. The available literature will serve as a con-
ceptual basis to justify the experimental work presented thereafter. Given the CNS-oriented scope of 
this thesis, current knowledge on DYRK1A function is preferentially discussed in this context. Overall, 
four main themes deserve consideration: First, that DYRK1A is a multifaceted kinase with multiple 
roles in health and disease. Second, that abnormal DYRK1A function is a key feature of DS neurode-
generation. Third, that it is capable of finely regulating several signalling pathways. Fourth, that existing 
evidence preliminarily implicates DYRK1A in Wnt function, making it an ideal candidate for the studies 
carried out in this chapter. 
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other DYRK family members (2). Autophosphorylation of the second Y residue has been shown to be 
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hancement of kinase activity. Another study later demonstrated that, while common to al DYRK family 
members, this mechanism varies slightly between DYRKs (9).All known DYRK1A substrates undergo 
phosphorylation at S/T residues only. Overall, DYRK1A is thought to function as a proline-directed ki-
nase, since its consensus phosphorylation sequence has been identified as RPX(S/T)P (10). More re-
cent reviews however suggest that this might not be the only phosphorylation sequence, given that 
not all described DYRK1A substrates are compatible with the consensus motif (11, 12). Literature on 
DYRK1A and the DYRK family is extensive, and has been excellently reviewed in multiple instances, 
available for further consultation (5, 11-13). 
4.3.1.1.1 DYRK1A in health and disease 
According to multiple reports, DYRK1A is virtually expressed ubiquitously under physiological condi-
tions (13-15). These data underscore the critical importance of homoeostatic DYRK1A function in 
health and disease. DYRK1A is known to functionally localise prominently to the nucleus, but also the 
cytosol, phosphorylating over 12 different substrates involved in several cellular functions (5, 12, 16). 
Well described DYRK1A substrates have been linked to mRNA splicing, protein translation and regu-
lation of endocytic, catabolic and apoptotic mechanisms. For this reason, DYRK1A is understood to 
exert a pleiotropic role in multiple molecular aspects of development and adult life (5). Evidence has 
implicated DYRK1A function in multiple pathological processes, including tumour proliferation, regula-
tion of bone stability and cardiac hypertrophy (17-20). DYRK1A has also been linked to neurodegen-
erative disease through identification of its substrates. Examples include α-synuclein and septin 4 (21, 
22), two key proteins in Parkinson’s disease (PD), and huntingtin interacting protein-1 (Hip-1) an im-
portant contributor to Huntington’s disease (HD - (23)).  Despite this knowledge, the precise role(s) of 
DYRK1A in CNS function remains elusive. Nonetheless, this question has been heavily investigated. 
As introduced, the seminal Tejedor et al. study (3), which first identified Mbn (DYRK1A) in Drosophila, 
Fig. R3.a - Domains of the DYRK1A protein, 763 amino acids long. The kinase loop undergoes autophospho-
rylation at Y321 during DYRK1A synthesis, after which the enzyme remains constitutively active.
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emphasised its importance in CNS development. Loss-of-function Mbn mutations in fly larvae im-
paired neurogenesis, but also substantially reduced cerebral hemispheric volume. This Mbn pheno-
type was particularly shown to result from abnormal spatial arrangement of proliferating neuroblasts, 
implying direct Mbn-mediated modulation of developmental patterning in the Drosophila larval brain. 
Indeed, Dyrk1a knock-out (KO) studies in mice have long demonstrated the key importance of this 
kinase in CNS development and function. Fotaki et al. were among the first to investigate DYRK1A in 
this context (24). They showed that heterozygous Dyrk1a KO mice display overall smaller body size, 
with substantial reductions in brain and liver volume. Homozygous Dyrk1a KO, however, is embryoni-
cally lethal at mid-gestation, a phenotype accompanied by severe developmental delay. Additionally, 
the authors reported that homozygous Dyrk1a KO results in significantly decreased neuronal number 
in the developing superior colliculus. These data not only suggests that DYRK1A is a necessary re-
quirement for embryonic survival and CNS development, but also that it directly affects neuronal or-
ganisation at the cellular level.  
Another study later expanded on this notion, demonstrating alterations in cortical neuronal dendritic 
architecture in heterozygous Dyrk1a KO mouse embryos (25). At the whole brain level, Dyrk1a copy 
number significantly affects cerebral weight, volume, viability and growth in mice (26). Guedj et al. em-
ployed three DS models to characterise complex developmental effects of Dyrk1a dosage on cerebral 
morphology. These were highly dependent on brain region. For instance, DYRK1A gain-of-function 
increased ventricular and superior collicular volume, consistently with KO data by Fotaki et al., which 
demonstrated a reduction (24). By contrast, cortical neuronal density was found to be reduced in 
mice overexpressing Dyrk1a, whilst, thalamic nuclear neuronal density positively correlated with 
Dyrk1a dosage (26). These highly complex phenotypes underscore the fundamental importance of 
fine DYRK1A regulation throughout CNS development. It follows that the impact of DYRK1A triplica-
tion in human DS neurodevelopment is likely heterogeneous. Similar observations have also been 
made in human cases of DYRK1A mutations. Two studies in fact demonstrated that DYRK1A-deleting 
or truncating mutations are sufficient to produce microcephaly (27, 28).  
Importantly, DYRK1A is also a known regulator of the cell cycle. Najas et al. recently characterised 
interesting DYRK1A effects on the cell cycle in the context of cortical neuronal differentiation (29). This 
is particularly relevant to DS, since prenatal deficits in neuronal development are associated with intel-
lectual disability in this condition. The authors reported that nuclear levels of Cyclin D1, a key mediator 
of cell cycle progression, are finely regulated by DYRK1A in Ts65Dn mouse embryonic neuronal prog-
enitors. Enhanced DYRK1A levels in transgenic embryos reduced nuclear Cyclin D1, and prolonged 
G1 phase duration. This resulted in abnormal proliferation of progenitor cells, further leading to de-
creased neurogenic mitosis. An overall reduction in cortical neuronal number was observed, both em-
bryonically and postnatally. Furthermore, reports indicate that DYRK1A may directly promote Cyclin 
138
Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
hancement of kinase activity. Another study later demonstrated that, while common to al DYRK family 
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health and disease. DYRK1A is known to functionally localise prominently to the nucleus, but also the 
cytosol, phosphorylating over 12 different substrates involved in several cellular functions (5, 12, 16). 
Well described DYRK1A substrates have been linked to mRNA splicing, protein translation and regu-
lation of endocytic, catabolic and apoptotic mechanisms. For this reason, DYRK1A is understood to 
exert a pleiotropic role in multiple molecular aspects of development and adult life (5). Evidence has 
implicated DYRK1A function in multiple pathological processes, including tumour proliferation, regula-
tion of bone stability and cardiac hypertrophy (17-20). DYRK1A has also been linked to neurodegen-
erative disease through identification of its substrates. Examples include α-synuclein and septin 4 (21, 
22), two key proteins in Parkinson’s disease (PD), and huntingtin interacting protein-1 (Hip-1) an im-
portant contributor to Huntington’s disease (HD - (23)).  Despite this knowledge, the precise role(s) of 
DYRK1A in CNS function remains elusive. Nonetheless, this question has been heavily investigated. 
As introduced, the seminal Tejedor et al. study (3), which first identified Mbn (DYRK1A) in Drosophila, 
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rylation at Y321 during DYRK1A synthesis, after which the enzyme remains constitutively active.
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made in human cases of DYRK1A mutations. Two studies in fact demonstrated that DYRK1A-deleting 
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D1 degradation (30). Single-cell analysis revealed that, in DS-derived human fibroblasts, DYRK1A 
overexpression prolongs G1 duration, similarly to mouse results by Najas et al. (29). This effect ap-
pears dependent on Cyclin D1 phosphorylation by DYRK1A, which leads to its degradation. Accord-
ingly, pharmacological DYRK1A inhibition was sufficient to rescue this phenotype (30). These data 
overall suggest that downregulation of Cyclin D1 by aberrant DYRK1A activity may directly affect neu-
ronal development in DS. Interestingly, Cyclin D1 is a well known canonical Wnt target gene (31). β-
catenin activity indeed regulates its expression and mediates abnormal cell proliferation in several 
cancer types (32, 33). This established relationship implies that DYRK1A might modulate Cyclin D1 
through Wnt signalling activity. Despite its inhibitory effect on Cyclin D1, DYRK1A may also promote 
neuronal differentiation. Hammerle et al. showed that DYRK1A is transiently expressed in the verte-
brate CNS neuroepithelium prior to neuronal differentiation (34, 35). Interestingly, DYRK1A kinase ac-
tivity positively correlated with arrested cell proliferation. In mouse and chick CNS tissue, DYRK1A ap-
pears to upregulate transcription of Cyclin-dependent kinase inhibitor p27 (KIP1), an important regula-
tor of cell cycle exit. Another cell cycle regulator, Cyclin-dependent kinase-like 5 (CDKL5) is also a 
substrate of DYRK1A. The subcellular localisation of CDKL5 is reportedly controlled by DYRK1A via 
phosphorylation (36). With relevance to Wnt signalling, it has been shown that concomitant DYRK1A 
and GSK3β inhibition positively regulates proliferation of human pancreatic β-cells (37). The authors 
interestingly argue that this effect might be mediated by enhancement of β-catenin signalling. 
Fig. R3.b - Visual summary of DYRK1A substrates and function, demonstrating the importance of this kinase 
in a wide variety of biological processes.
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In summary, extensive evidence implicates DYRK1A function in several cellular processes and particu-
larly CNS development. The indispensable DYRK1A requirement for embryonic survival and homoeo-
static neurodevelopment support the role of this kinase as a key player in DS and as a candidate 
modulator for the Wnt phenotypes observed so far in this thesis. 
4.3.1.1.2 The role of DYRK1A in DS and AD-DS 
The DYRK1A gene is located on a portion of Hsa21 termed the Down syndrome critical region (DSCR 
- (38)). As introduced, the DSCR is currently thought to be a critical mediator of DS pathology (39), 
and particularly influences the development of intellectual disability in DS (40) (see 1.1.2 for an over-
view of the DSCR). Indeed, a DS-like phenotype is invariably associated with DYRK1A overexpression 
is mouse models (11, 14, 41, 42), and several studies have shown the contribution of this kinase to 
DS pathology. In the context of DS-related leukaemias, for instance, DYRK1A has been shown to be a 
potent megakaryoblastic oncogene due to its inhibitory effects on NFAT signalling, an important path-
way in leukemogenesis (43). Abundant evidence now suggests that DYRK1A significantly contributes 
to several neuropathological features of DS (11, 38, 44). First, as introduced, DYRK1A overexpression 
correlates with enhanced DYRK1A transcript and protein levels in DS fetal and adult brains (41, 45). In 
mice, multiple Dyrk1a overexpression and deletion studies in the adult CNS (15, 46, 47) and embryon-
ic brain (26, 29, 34, 35, 48) elucidated its key importance in homeostatic control of neuronal function 
and development. 
With respect to AD-DS, DYRK1A is a favourable candidate to explain a potential mechanistic contri-
bution of Hsa21 to the development of AD pathology. There are several lines of evidence supporting 
this view. As an initial consideration, both APP and tau, two proteins crucial to AD pathogenesis, have 
been identified as in vitro phosphorylation targets of DYRK1A in multiple independent studies (49-53), 
which are discussed in further detail below. From a biochemical viewpoint, the consistency of these 
data suggests a potential functional relationship between DYRK1A, APP and tau. In 2007, Kimura et 
al. (50) investigated potential Hsa21 markers in a Japanese population of AD patients. The analysis 
revealed a significant association between DYRK1A levels and the presence of AD. A more recent 
study corroborated this finding, by identifying levels of plasma DYRK1A as a previously unknown risk 
factor for sporadic AD (54). This further strengthens the functional DYRK1A-AD relationship by 
demonstrating that DYRK1A abnormalities extend, beyond the CNS, to the highly dynamic haemato-
logical system. Additionally, Kimura et al (50) demonstrated that tau is a substrate of DYRK1A, phos-
phorylated at T212 (p-T212). Such interaction was observed both in vivo mouse brains and in vitro. In 
the same study, the authors additionally reported that acute administration of Aβ, in neuroblastoma 
cells and in mice, results in overexpression of DYRK1A. A concurrent, similar study also observed the 
same tau phosphorylation mechanism in the brain of transgenic DYRK1A mice (51). These findings 
suggest that DYRK1A may be a key player in both AD-DS and sporadic AD pathogenesis. According-
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D1 degradation (30). Single-cell analysis revealed that, in DS-derived human fibroblasts, DYRK1A 
overexpression prolongs G1 duration, similarly to mouse results by Najas et al. (29). This effect ap-
pears dependent on Cyclin D1 phosphorylation by DYRK1A, which leads to its degradation. Accord-
ingly, pharmacological DYRK1A inhibition was sufficient to rescue this phenotype (30). These data 
overall suggest that downregulation of Cyclin D1 by aberrant DYRK1A activity may directly affect neu-
ronal development in DS. Interestingly, Cyclin D1 is a well known canonical Wnt target gene (31). β-
catenin activity indeed regulates its expression and mediates abnormal cell proliferation in several 
cancer types (32, 33). This established relationship implies that DYRK1A might modulate Cyclin D1 
through Wnt signalling activity. Despite its inhibitory effect on Cyclin D1, DYRK1A may also promote 
neuronal differentiation. Hammerle et al. showed that DYRK1A is transiently expressed in the verte-
brate CNS neuroepithelium prior to neuronal differentiation (34, 35). Interestingly, DYRK1A kinase ac-
tivity positively correlated with arrested cell proliferation. In mouse and chick CNS tissue, DYRK1A ap-
pears to upregulate transcription of Cyclin-dependent kinase inhibitor p27 (KIP1), an important regula-
tor of cell cycle exit. Another cell cycle regulator, Cyclin-dependent kinase-like 5 (CDKL5) is also a 
substrate of DYRK1A. The subcellular localisation of CDKL5 is reportedly controlled by DYRK1A via 
phosphorylation (36). With relevance to Wnt signalling, it has been shown that concomitant DYRK1A 
and GSK3β inhibition positively regulates proliferation of human pancreatic β-cells (37). The authors 
interestingly argue that this effect might be mediated by enhancement of β-catenin signalling. 
Fig. R3.b - Visual summary of DYRK1A substrates and function, demonstrating the importance of this kinase 
in a wide variety of biological processes.
p
139
Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
In summary, extensive evidence implicates DYRK1A function in several cellular processes and particu-
larly CNS development. The indispensable DYRK1A requirement for embryonic survival and homoeo-
static neurodevelopment support the role of this kinase as a key player in DS and as a candidate 
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al. (50) investigated potential Hsa21 markers in a Japanese population of AD patients. The analysis 
revealed a significant association between DYRK1A levels and the presence of AD. A more recent 
study corroborated this finding, by identifying levels of plasma DYRK1A as a previously unknown risk 
factor for sporadic AD (54). This further strengthens the functional DYRK1A-AD relationship by 
demonstrating that DYRK1A abnormalities extend, beyond the CNS, to the highly dynamic haemato-
logical system. Additionally, Kimura et al (50) demonstrated that tau is a substrate of DYRK1A, phos-
phorylated at T212 (p-T212). Such interaction was observed both in vivo mouse brains and in vitro. In 
the same study, the authors additionally reported that acute administration of Aβ, in neuroblastoma 
cells and in mice, results in overexpression of DYRK1A. A concurrent, similar study also observed the 
same tau phosphorylation mechanism in the brain of transgenic DYRK1A mice (51). These findings 
suggest that DYRK1A may be a key player in both AD-DS and sporadic AD pathogenesis. According-
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ly, elevated total DYRK1A and p-T212-tau levels have been observed in adult brains of both AD-DS 
and sporadic AD patients (52, 55). Liu et al. demonstrated that gain-of-function Dyrk1a mutations are 
sufficient to increase protein levels of APP, Aβ and p-p-T212-tau, resulting in tau inhibition and neu-
rofibrillary aggregation (52). These findings were concurrently replicated in an independent study by 
Ryoo et al. (53). In DS, DYRK1A is also reportedly capable of indirectly regulating tau splicing, and its 
overexpression results in abnormal ratios of different tau isoforms (56). The authors showed that this 
mechanism relies on DYRK1A-mediated phosphorylation of alternative splicing factor (ASF), a regula-
tor of tau-splicing. Furthermore, the protein presenilin 1 (PSEN1), an integral part of the γ-secretase 
complex regulating Aβ production, is reportedly phosphorylated by DYRK1A (57). In the phosphory-
lated state, PSEN1 appears to stabilise the enzymatic complex and enhance its amyloidogenic activi-
ty, with obvious implications for AD. Several studies also demonstrated deleterious functional effects 
of Dyrk1a overexpression in the hippocampus of DS mouse models. Overall, data indicate that aber-
rant DYRK1A activity produces deficits in hippocampal-dependent episodic and spatial memory 
(58-62). 
Taken together, these studies support the view that excessive amounts of DYRK1A might directly 
contribute to the AD-facilitatory effect of Hsa21 trisomy, and also provide a functional link between Aβ 
production and tau phosphorylation. Given the high spatiotemporal variability of DYRK1A overexpres-
sion in human DS discussed previously (4.1-2.1), however, the exact contribution of DYRK1A to AD-
DS pathology might prove difficult to establish definitively. One overarching possibility may be found in 
the known regulatory role of DYRK1A over multiple signalling pathways important for brain develop-
ment and function, which is discussed in the next section. 
Fig. R3.c - Known contribution of DYRK1A to features of sporadic AD and AD-DS.
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4.3.1.1.3 Signalling pathway regulation by DYRK1A 
The evidence discussed so far elucidated the wide array of DYRK1A functions in several biological 
mechanisms, and essentially, its indispensable necessity for embryonic survival and CNS develop-
ment. Indeed, intracellular signalling pathways are highly conserved key mechanism regulating devel-
opment. It follows that the effects of abnormal DYRK1A expression in DS may be mediated by modu-
lation of one or more signalling pathways. Combination of literature knowledge on DYRK1A with the 
Wnt phenotypes so far observed (see 4.1-2) led to the formulation of one of the main hypotheses of 
this thesis. That is, Wnt signalling dysfunction in the DS brain might occur through potential modula-
tion by DYRK1A. Whilst not being the only feasible candidate gene, DYRK1A may contribute signifi-
cantly to the Wnt-DS relationship (see next section). This hypothesis partly builds on the known regu-
latory functions of DYRK1A in several pathways with structural and functional similarity to Wnt sig-
nalling. Accumulating evidence, in fact, suggest that multiple DYRK1A substrates are involved in intra-
cellular signalling pathways. These include NFAT, receptor tyrosine kinase (RTK), Notch and hedgehog 
(Hh) signalling, and are briefly considered here. 
NFAT signalling is a conserved pathway regulating several aspects of immune, vascular and nervous 
system development (63). When dephosphorylated in the cytosol, NFAT transcription factors translo-
cate to the nucleus and drive gene expression, similarly to β-catenin (64). Conversely, NFAT phospho-
rylation by multiple kinases, including GSK3β, leads to inactivation of the pathway (65, 66). Interest-
ingly, NFAT is reportedly phosphorylated by multiple DYRKs(1A) (44, 67). The data show this to be a 
priming phosphorylation event, a known property of DYRK1A, which stimulates further phosphoryla-
tion by GSK3β and casein kinase 1 (CK1), ultimately leading to NFAT inactivation and cytoplasmic ac-
cumulation. The functional importance of GSK3β and CK1 in Wnt signalling (68), as well its known 
overlap with NFAT, is strongly suggestive of a potential DYRK1A effect on Wnt activity. DYRK-mediat-
ed NFAT inhibition has observable functional consequences on NFAT-regulated processes such as 
differentiation of erythrocytes and osteoclasts (19, 69) as well as pathological cardiomyocyte hyper-
trophy (18).  
DYRK1A also reportedly affects RTK signalling, a pathway important in cell metabolism, migration 
and differentiation. Particularly, RTK regulates synaptic plasticity, angiogenesis and tumour growth 
(70). This pathway possesses several well described positive and negative modulators, which fine 
tune RTK activity (71). Interestingly, DYRK1A was shown to upregulate RTK signalling activity through 
direct interaction with components of this pathway, in the neuronal cytosolic and membrane com-
partments (72, 73). A further study suggest that this effect is also dependent on DYRK1A kinase activ-
ity, which positively correlates with RTK output in rat and human cell lines (74). 
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opment. It follows that the effects of abnormal DYRK1A expression in DS may be mediated by modu-
lation of one or more signalling pathways. Combination of literature knowledge on DYRK1A with the 
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rylation by multiple kinases, including GSK3β, leads to inactivation of the pathway (65, 66). Interest-
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overlap with NFAT, is strongly suggestive of a potential DYRK1A effect on Wnt activity. DYRK-mediat-
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DYRK1A also reportedly affects RTK signalling, a pathway important in cell metabolism, migration 
and differentiation. Particularly, RTK regulates synaptic plasticity, angiogenesis and tumour growth 
(70). This pathway possesses several well described positive and negative modulators, which fine 
tune RTK activity (71). Interestingly, DYRK1A was shown to upregulate RTK signalling activity through 
direct interaction with components of this pathway, in the neuronal cytosolic and membrane com-
partments (72, 73). A further study suggest that this effect is also dependent on DYRK1A kinase activ-
ity, which positively correlates with RTK output in rat and human cell lines (74). 
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The Notch signalling pathway is also highly conserved, and regulates developmental tissue pattern-
ing, cell fate specification, proliferation and apoptosis (75). The main mediators of this pathway are 
Notch receptors. These transmembrane receptors are enzymatically cleaved upon Notch activation, 
leading to nuclear translocation of their intracellular domain (NICD), which drive gene expression as 
transcriptional activators (75, 76). Evidence suggests that, in neurons, DYRK1A may physically inter-
act with and phosphorylate NICD, thereby inhibiting Notch signalling activity (77). In the same study, 
this effect is accompanied by reduction of Notch-mediated suppression of neuronal differentiation. 
Hh signalling is crucial for organ development and neural tube patterning (78), while also promoting 
mitosis in several neuronal precursor cell types throughout the CNS (79). The main mediators of Hh 
signalling belong to the Gli family (Gli1–3) of transcription factors (80), which translocate nuclearly 
upon Hh activation. Reports indicate that DYRK1A prolongs nuclear localisation of Gli1 in a kinase-
dependent manner, thereby enhancing Hh activity (81, 82). Despite Gli1 being a DYRK1A substrate, 
however, Hh pathway activation does not in itself affect DYRK1A kinase activity (81).
In summary, these studies strongly suggest the presence of a functional relationship between 
DYRK1A and several signalling pathways structurally similar to Wnt signalling. Importantly, some of the 
pathways discussed here do indeed functionally overlap with Wnt, such as NFAT and hh (68). The ev-
idence discussed thus provides a logical basis to the main hypothesis of this chapter.  
4.3.1.1.4 DYRK1A: a potential Wnt signalling regulator? 
In addition to the pathways discussed above, formulation of the Wnt-DYRK1A hypothesis in this thesis is 
also supported by a number of studies indicating a possible effect of DYRK1A on Wnt signalling activity. 
(see 1.2 for an overview of the pathway).  
Importantly, DYRK1A has been shown to be a positive regulator of p120/δ-catenin signalling (83). This 
pathway is a ramification of canonical Wnt signalling, with δ and β-catenin sharing high structural similari-
ty. δ-catenin binds the Kaiso transcription factor, driving expression of several target genes, some of 
which are in common with canonical Wnt genes (e.g SIAMOSIS, WNT1). In X. laevi embryos and mam-
malian cells, DYRK1A reportedly enhances δ-catenin levels and signalling activity (83). Co-expression of 
DYRK1A and δ-catenin in X. laevi resulted in dual head formation and severe developmental abnormali-
ties. This suggests that a potential DYRK1A-mediated imbalance in developmental Wnt signalling activity 
might also be deleterious in human DS, given the enhanced gene dosage of this kinase. 
Some studies have also revealed a relationship between DYRK1A and GSK3β. DYRK1A appears to func-
tion as a GSK3β priming kinase, tagging NFAT for further phosphorylation by GSK3β, as discussed 
above, (44). This ultimately results in NFAT inactivation and degradation. Interestingly, this DYRK1A prim-
ing mechanism appears to also regulate other GSK3β substrates. Degradation of the circadian protein 
CRY2, for instance, is reportedly promoted by an analogous priming phosphorylation by DYRK1A (84). 
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With relevance to DS neuropathology, DYRK1A-GSK3β priming also applies to tau metabolism. DYRK1A 
phosphorylates tau at T212 , and this interaction has been shown to stimulate further phosphorylation by 
GSK3β at S208 and eventual tau degradation (49, 85). Liu et al showed enhanced tau aggregation by 
DYRK1A overexpression, as discussed above (52). Interestingly, this phenotype was also dependent on 
secondary phosphorylation by GSK3β. The occurrence of this phenomenon in three distinct and mostly 
unrelated processes suggest the presence of a general mechanism. Given the importance of GSK3β in 
Wnt signalling activation, DYRK1A priming might also apply to GSK3β-regulated Wnt substrates. Even if 
not the case, such a consistent functional link warrants the question of whether DYRK1A priming might 
secondarily affect multiple GSK3β functions by modulating its substrate preference. As introduced previ-
ously, it has been shown that GSK3β is abnormally phosphorylated at the S9 residue in aged but not 
young/adult Tc1 mouse brains ((86) - 4.2.2). Given that this phosphoresidue is inhibitory (87, 88), Shep-
pard et al. argue that Hsa21 trisomy might lead to an age-dependent decrease in GSK3β activity. It is 
thus possible to hypothesise that, because of the Wnt inhibitory role of GSK3β, prolonged GSK3β inhibi-
tion in DS might lead to an altered state of canonical Wnt signalling. As introduced above, Shen et al. (37) 
reported enhanced β-cell proliferation following concomitant kinase inhibition of DYRK1A and GSK3β. 
The authors speculated that this effect might be mediated by modulation of β-catenin signalling. 
A putative DYRK1A effect on Wnt signalling, however, need not solely be dependent on its relationship 
with GSK3β. The complexity of both Wnt function and DYRK1A modulation of other pathways implies 
that other mechanisms may be at play, possibly synergistically. First, GSK3β interacts with several cy-
tosolic Wnt components. It may thus be argued that the primary DYRK1A effect on Wnt, if present, might 
occur through secondary DYRK1A interactions with other components of the pathway, for instance di-
sheveled-1 (DVL1), CK1 or β-catenin itself. Second, it should be kept into consideration that DYRK1A is 
most prominently a nuclear kinase, as introduced. In parallel, Wnt signalling activation indeed ultimately 
relies on transcriptional activity of nuclear β-catenin. It is therefore possible that enhanced DYRK1A activi-
ty in the nucleus might also affect Wnt signalling within this compartment, independent of cytoplasmic 
effects. This overall implies the intriguing possibility that distinct Wnt-regulatory mechanisms by DYRK1A 
might exist in relation to its subcellular localisation. The functional importance of DYRK1A intracellular dis-
tribution is therefore introduced briefly here. 
Fig. R3.d - Summary of DYRK1A-mediated modulation of signalling pathways, including the Wnt/δ-catenin branch.
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The Notch signalling pathway is also highly conserved, and regulates developmental tissue pattern-
ing, cell fate specification, proliferation and apoptosis (75). The main mediators of this pathway are 
Notch receptors. These transmembrane receptors are enzymatically cleaved upon Notch activation, 
leading to nuclear translocation of their intracellular domain (NICD), which drive gene expression as 
transcriptional activators (75, 76). Evidence suggests that, in neurons, DYRK1A may physically inter-
act with and phosphorylate NICD, thereby inhibiting Notch signalling activity (77). In the same study, 
this effect is accompanied by reduction of Notch-mediated suppression of neuronal differentiation. 
Hh signalling is crucial for organ development and neural tube patterning (78), while also promoting 
mitosis in several neuronal precursor cell types throughout the CNS (79). The main mediators of Hh 
signalling belong to the Gli family (Gli1–3) of transcription factors (80), which translocate nuclearly 
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however, Hh pathway activation does not in itself affect DYRK1A kinase activity (81).
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pathways discussed here do indeed functionally overlap with Wnt, such as NFAT and hh (68). The ev-
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4.3.1.1.4 DYRK1A: a potential Wnt signalling regulator? 
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(see 1.2 for an overview of the pathway).  
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ty. δ-catenin binds the Kaiso transcription factor, driving expression of several target genes, some of 
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might also be deleterious in human DS, given the enhanced gene dosage of this kinase. 
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thus possible to hypothesise that, because of the Wnt inhibitory role of GSK3β, prolonged GSK3β inhibi-
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A putative DYRK1A effect on Wnt signalling, however, need not solely be dependent on its relationship 
with GSK3β. The complexity of both Wnt function and DYRK1A modulation of other pathways implies 
that other mechanisms may be at play, possibly synergistically. First, GSK3β interacts with several cy-
tosolic Wnt components. It may thus be argued that the primary DYRK1A effect on Wnt, if present, might 
occur through secondary DYRK1A interactions with other components of the pathway, for instance di-
sheveled-1 (DVL1), CK1 or β-catenin itself. Second, it should be kept into consideration that DYRK1A is 
most prominently a nuclear kinase, as introduced. In parallel, Wnt signalling activation indeed ultimately 
relies on transcriptional activity of nuclear β-catenin. It is therefore possible that enhanced DYRK1A activi-
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effects. This overall implies the intriguing possibility that distinct Wnt-regulatory mechanisms by DYRK1A 
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Fig. R3.d - Summary of DYRK1A-mediated modulation of signalling pathways, including the Wnt/δ-catenin branch.
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4.3.1.1.5 Subcellular localisation: the master key to DYRK1A function? 
As introduced, DYRK1A functionally localises to both nuclear and cytosolic subcellular compartments. 
This has been clearly demonstrated endogenously, in a variety of neuronal cellular model systems in-
cluding human, mouse and chick (15, 47, 89). This localisation pattern is variable, however. For ex-
ample, DYRK1A expression is prominently cytosolic in glial cell lines (47). In the mouse brain, two 
studies identified an additional subdistribution of the DYRK1A cytosolic fraction (74, 90). DYRK1A re-
portedly segregates into three distinct functional pools: soluble, ‘free’ cytoplasmic DYRK1A, a pool 
associated with trafficking vesicles and a third in association with the neuronal plasma membrane. A 
number of studies have also shown that, under conditions of ectopic overexpression, DYRK1A prefer-
entially localises to the nucleus of mouse hippocampal neurons, neural cells of the embryonic neocor-
tex and several human cell lines (4, 13, 77, 81, 91-94). As introduced, DYRK1A sub-localises to the 
nucleus further by associating with nuclear speckles, when overexpressed and endogenously (4, 77).  
Importantly, the nuclear-to-cytosolic ratio of DYRK1A is finely regulated. A 2002 study by Hammerle et 
al. (34) employed chicken cerebellar neuronal precursor cells to investigate DYRK1A localisation dur-
ing neuronal differentiation. The authors detected a substantial rearrangement of subcellular DYRK1A 
distribution, in favour of the cytosolic compartment, at critical stages of Purkinje cell differentiation. 
This study also observed dynamic, persistent nuclear/cytosolic trafficking of DYRK1A. The presence 
of DYRK1A in both subcellular compartments, as well as fine regulation of its distribution, has been 
suggested to primarily serve as a means to segregate DYRK1A from its substrates (5). DYRK1A func-
tion may thus be modulated by influencing its availability to substrates. Interestingly, it appears that 
subcellular distribution of DYRK1A might be regulated through its differential phosphorylation. Kacz-
marski et al. employed fractionation and 2DE to isolate three distinct DYRK1A pools in mouse and 
human brain lysates (95). DYRK1A was found in cytosolic, cytoskeletal and nuclear fractions with dis-
tinct isoelectric points, indicative of differential phosphorylation. This finding was further investigated 
via phosphate-affinity gel electrophoresis, which showed significant shifts in migration of DYRK1A 
bands depending on subcellular compartment. The authors then employed mass spectrometry to pin-
point this phosphorylation-dependent localisation to specific DYRK1A residues. The study however 
failed to identify any candidate kinases for this mechanism, which remain undetermined.  
Overall, it is clear from the evidence discussed that DYRK1A localisation to subcellular compartments 
is highly dynamic, finely regulated and thus likely to significantly affect its function. It follows that its 
investigation, in the context of a potential DYRK1A-Wnt interaction, might provide important informa-
tion on the nature of this putative relationship. If present, a functional overlap between DYRK1A and 
Wnt signalling is indeed likely to be reflected by specific localisation patterns of this kinase. 
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4.3.1.2 Luciferase-based quantification of Wnt signalling activity, an established approach 
In this chapter, acute changes in Wnt signalling activity were measured in live cells. This was accom-
plished by measuring levels of active β-catenin via luciferase assay, a well established technique (see 
methods 3.5.5). This assay is widely employed in the investigation of a high number of biological pro-
cesses, and is a validated tool for the study of Wnt signalling activity in live cells. Key evidence illus-
trating the advantages of this technique is briefly discussed below. 
Luciferase (from the latin Lucifer, ‘light carrier’) collectively describes a family of oxidative enzymes ca-
pable of chemically producing light, a phenomenon termed bioluminescence. An array of different Lu-
ciferase enzymes exists in nature, and they are found in several organisms, most prominently in the 
firefly (P. pyralis), sea pansy (R. reniformis) and the Photobacterium prokaryotic genus. The former two 
are employed in the experiments described in this chapter. At a general level, luciferase produces light 
via ATP-dependent oxidation of a substrate termed luciferin to oxyluciferin. The energy produced by 
this reaction is released in the form of light. Upon oxidation, oxyluciferin electrons switch to a transient 
excited quantum state which is then followed by release of photons and return to the ground state. 
Thus, in contrast with fluorescent and photoproteins, bioluminescence is an active, energy-dependent 
and easily measurable process. This notion makes luciferase activity particularly useful for biological 
assays, which have now been employed for over half a century. The firefly luciferase system was 
characterised in the mid 20th century, by the pioneering work of William McElroy and colleagues. Lu-
ciferin was first purified in 1949 (96), and the same group later developed the first luciferase assay 
protocol. By the late 60s, studies employing this technique began to appear (97). Since then, the lu-
ciferase assay has been employed in several fields of molecular biology, the method has been per-
fected over time and is now standardised. Regardless of the specific application, this technique relies 
on quantifying luciferase bioluminescence under substrate-saturating conditions, whereby enzyme 
concentration is the only rate-limiting step. It follows that light output can be utilised as a direct, ap-
proximately linear correlate of whichever biological process is under study. 
The luciferase assay is ideal for measuring activity of signalling pathways, and is widely employed in 
this sense. Luciferase genes have been cloned and their expression can thus be manipulated in sev-
eral experimentally useful ways. With respect to intracellular signalling, the activity of transcription fac-
tors under study can be made to promote luciferase expression. Administration of luciferin conse-
quently results in a measurable signal representative of pathway activity. This approach is employed in 
the study of several signalling pathways, indeed including canonical Wnt signalling. In the latter case, 
transcriptional activity of TCF/LEF factors stimulated by β-catenin is the preferred luciferase quantifica-
tion method. The advent of molecular cloning allowed for the engineering of expression systems 
specifically driving luciferase output via TCF/LEF-β-catenin activation. Such systems can be employed 
as expression vectors in eukaryotic and prokaryotic cell lines, or genomically integrated into any mod-
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4.3.1.1.5 Subcellular localisation: the master key to DYRK1A function? 
As introduced, DYRK1A functionally localises to both nuclear and cytosolic subcellular compartments. 
This has been clearly demonstrated endogenously, in a variety of neuronal cellular model systems in-
cluding human, mouse and chick (15, 47, 89). This localisation pattern is variable, however. For ex-
ample, DYRK1A expression is prominently cytosolic in glial cell lines (47). In the mouse brain, two 
studies identified an additional subdistribution of the DYRK1A cytosolic fraction (74, 90). DYRK1A re-
portedly segregates into three distinct functional pools: soluble, ‘free’ cytoplasmic DYRK1A, a pool 
associated with trafficking vesicles and a third in association with the neuronal plasma membrane. A 
number of studies have also shown that, under conditions of ectopic overexpression, DYRK1A prefer-
entially localises to the nucleus of mouse hippocampal neurons, neural cells of the embryonic neocor-
tex and several human cell lines (4, 13, 77, 81, 91-94). As introduced, DYRK1A sub-localises to the 
nucleus further by associating with nuclear speckles, when overexpressed and endogenously (4, 77).  
Importantly, the nuclear-to-cytosolic ratio of DYRK1A is finely regulated. A 2002 study by Hammerle et 
al. (34) employed chicken cerebellar neuronal precursor cells to investigate DYRK1A localisation dur-
ing neuronal differentiation. The authors detected a substantial rearrangement of subcellular DYRK1A 
distribution, in favour of the cytosolic compartment, at critical stages of Purkinje cell differentiation. 
This study also observed dynamic, persistent nuclear/cytosolic trafficking of DYRK1A. The presence 
of DYRK1A in both subcellular compartments, as well as fine regulation of its distribution, has been 
suggested to primarily serve as a means to segregate DYRK1A from its substrates (5). DYRK1A func-
tion may thus be modulated by influencing its availability to substrates. Interestingly, it appears that 
subcellular distribution of DYRK1A might be regulated through its differential phosphorylation. Kacz-
marski et al. employed fractionation and 2DE to isolate three distinct DYRK1A pools in mouse and 
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4.3.1.2 Luciferase-based quantification of Wnt signalling activity, an established approach 
In this chapter, acute changes in Wnt signalling activity were measured in live cells. This was accom-
plished by measuring levels of active β-catenin via luciferase assay, a well established technique (see 
methods 3.5.5). This assay is widely employed in the investigation of a high number of biological pro-
cesses, and is a validated tool for the study of Wnt signalling activity in live cells. Key evidence illus-
trating the advantages of this technique is briefly discussed below. 
Luciferase (from the latin Lucifer, ‘light carrier’) collectively describes a family of oxidative enzymes ca-
pable of chemically producing light, a phenomenon termed bioluminescence. An array of different Lu-
ciferase enzymes exists in nature, and they are found in several organisms, most prominently in the 
firefly (P. pyralis), sea pansy (R. reniformis) and the Photobacterium prokaryotic genus. The former two 
are employed in the experiments described in this chapter. At a general level, luciferase produces light 
via ATP-dependent oxidation of a substrate termed luciferin to oxyluciferin. The energy produced by 
this reaction is released in the form of light. Upon oxidation, oxyluciferin electrons switch to a transient 
excited quantum state which is then followed by release of photons and return to the ground state. 
Thus, in contrast with fluorescent and photoproteins, bioluminescence is an active, energy-dependent 
and easily measurable process. This notion makes luciferase activity particularly useful for biological 
assays, which have now been employed for over half a century. The firefly luciferase system was 
characterised in the mid 20th century, by the pioneering work of William McElroy and colleagues. Lu-
ciferin was first purified in 1949 (96), and the same group later developed the first luciferase assay 
protocol. By the late 60s, studies employing this technique began to appear (97). Since then, the lu-
ciferase assay has been employed in several fields of molecular biology, the method has been per-
fected over time and is now standardised. Regardless of the specific application, this technique relies 
on quantifying luciferase bioluminescence under substrate-saturating conditions, whereby enzyme 
concentration is the only rate-limiting step. It follows that light output can be utilised as a direct, ap-
proximately linear correlate of whichever biological process is under study. 
The luciferase assay is ideal for measuring activity of signalling pathways, and is widely employed in 
this sense. Luciferase genes have been cloned and their expression can thus be manipulated in sev-
eral experimentally useful ways. With respect to intracellular signalling, the activity of transcription fac-
tors under study can be made to promote luciferase expression. Administration of luciferin conse-
quently results in a measurable signal representative of pathway activity. This approach is employed in 
the study of several signalling pathways, indeed including canonical Wnt signalling. In the latter case, 
transcriptional activity of TCF/LEF factors stimulated by β-catenin is the preferred luciferase quantifica-
tion method. The advent of molecular cloning allowed for the engineering of expression systems 
specifically driving luciferase output via TCF/LEF-β-catenin activation. Such systems can be employed 
as expression vectors in eukaryotic and prokaryotic cell lines, or genomically integrated into any mod-
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el organism. The first luciferase construct for Wnt quantification is a plasmid incorporating eight TCF/
LEF sites upstream of a luciferase reporter gene. It was developed in 1997 by Van de Wetering et al., 
in a study examining the role of TCF genes in Drosophila (98). The construct is usually referred to as 
(M50 Super 8x) TOPFlash. It was later improved and made publicly available by Veeman et al. (99), 
who employed the construct in a zebrafish study of developmental Wnt function. Since then, lu-
ciferase quantification has become an established and reliable approach in the field of Wnt signalling. 
TOPflash vectors are now widely available, and continue to be used in recent high quality publications, 
for instance in the context of breast and colorectal cancer (100, 101). 
Indeed, the Kirsten Harvey research group, which funded and directed the project of this thesis, has 
accumulated great expertise in luciferase-based Wnt signalling investigation. Several studies have 
been published by the group, in which the technique was employed and optimised. In 2012, Berwick 
& Harvey first demonstrated that leucine-rich repeat kinase 2 (LRRK2), an important contributor to 
familial Parkinson’s disease (PD), plays a key structural role in Wnt signalling function (102). The pro-
tein was shown to act as a scaffold for multiple Wnt components through direct interaction. Luciferase 
assays in neuroblastoma cells importantly demonstrated that LRRK2 expression is sufficient to en-
hance active Wnt signalling levels. Additionally, PD-associated pathogenic LRRK2 mutations reduce 
this effect in the same system. The group also showed in a later study that a PD-protective LRRK2 
mutant exerts the opposite effect, enhancing LRRK2-mediated elevation of active Wnt signalling (103). 
Luciferase assays were also recently employed by the same group to assess LRRK2 effects on basal 
Wnt signalling activity in modified embryonic fibroblasts (MEFs) of LRRK2 KO mice (104). Strinkingly, 
KO cells displayed enhanced basal β-catenin and Axin2 transcriptional activity. Conversely LRRK2 
expression significantly suppressed basal TOPFlash activity, a phenotype enhanced by pathogenic 
LRRK2 variants. Overall, combined evidence from the luciferase technique led to the discovery of a 
fine Wnt regulatory role of LRRK2, which is capable of both enhancement and repression of pathway 
activity dependent on previous activation state. 
In summary, the luciferase assay is a validated and well-established technique in the Wnt signalling 
field. Building on its strength and reproducibility, and the expertise of the Kirsten Harvey Group, it was 
thus employed to address the primary experimental question of this chapter i.e. to determine whether 
DYRK1A is capable of modulating Wnt signalling activity. 
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4.3.2 Results 
The link between DS and AD has long been documented (see 1.1.4), and several studies now suggest 
alterations in canonical Wnt signalling may play a significant role in the pathogenesis of AD (see 1.2.5). The 
existence of these relationships along with evidence implicating some Hsa21 genes in Wnt signalling (see 
1.3), as well as the data gathered so far (4.1-2) led to a candidate gene hypothesis for the observed Wnt 
abnormalities in DS. Given the evidence discussed above, DYRK1A was selected as the initial Hsa21 can-
didate for effects on the Wnt pathway. However, this choice does not exclude the participation of other 
Hsa21 genes, such as APP.  The aim of the studies presented here was threefold:  
I. To characterise, explore and summarise Wnt-related protein-protein interaction networks for 
DYRK1A, combining public database knowledge (STRING), Yeast two hybrid screening (Y2H) 
and co-immunoprecipitation (co-IP) with Western blotting. 
II. To investigate whether acute manipulation of DYRK1A activity might exert modulatory effects 
on canonical Wnt signalling via luciferase assays and overexpression. 
III. To investigate the effects of Wnt signalling activation on the subcellular localisation of DYRK1A 
via quantitative immunocytochemistry.  
In the vast majority of experiments performed, human cell line systems were employed, to more closely 
represent human physiology. 
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4.3.2.1 DYRK1A-Wnt protein interaction networks 
In order to preliminarily investigate DYRK1A as a candidate Wnt signalling modulator, the interactome 
of this kinase was interrogated for Wnt-relevant protein interactions, employing multiple techniques. 
4.3.2.1.1 STRING-based DYRK family interaction with Wnt components 
The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) is a large database combin-
ing known and predicted protein interaction networks (http://string-db.org; (105)). Its content is de-
rived from “genomic context predictions, high-throughput lab experiments, conserved co-expression, 
automated text-mining and previous knowledge in databases”. STRING v10 was first employed to 
assess Wnt-related protein interactions for the entire vertebrate DYRK kinase family (DYRK1A/B, 
DYRK2-4). Each DYRK member was placed as the single starting node of a network comprising the 
first 50 or 100 best-scoring direct interactors. Overrepresentation/functional analysis was then per-
formed on the resultant list of proteins by STRING, for enrichment with the Gene ontology (GO) or 
KEGG term “Wnt signalling pathway” (Fig. R3.1). In all conditions, and for all DYRK members, a signif-
icant association with Wnt signalling was detected whilst accounting for false-discovery rate 
(FDR<0.05). Overall, DYRK family members were shown to possess from 3 up to 16 Wnt-related in-
teraction partners. These data thus suggest that existing database and experimental knowledge al-
ready implicates the DYRK family in Wnt signalling. 
Fig. R3.1 - STRING-generated 
overview Wnt-relevant protein in-
teractions for the entire DYRK fami-
ly of kinases, plotting gene count 
as a function -log false discovery 
rate (FDR) of enrichment with the 
GO and KEGG terms ‘Wnt sig-
nalling pathway’.
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4.3.2.1.2 Yeast two-hybrid screening reveals several DYRK1A-WNT interactions 
Preliminary screening of the DYRK family indicated the presence of Wnt-related protein interactions. 
This finding was then further investigated by consulting a large protein interaction database part of the 
InterPP project, funded and conducted by Hybrigenics ltd. on behalf of the Jerome LeJeune Founda-
tion (Paris, Fr - fondationlejeune.org). This ongoing project represents an effort to identify and charac-
terise protein-protein interactions in the DS brain. Interactions are detected via yeast two-hybrid 
screen (Y2HS) technology, employing all known Hsa21-encoded proteins as bait and/or prey against 
an adult brain cDNA library. For DYRK1A, a lex-A-based construct was employed. The database fea-
tures a confidence scoring system termed PBS (PIM biological score) to assess the reliability of an 
observed interaction, ranging from A (extremely likely) to E (false positive/autoactivation ; see methods 
3.7 for an overview of this database, techniques employed and scoring systems).  
Setting the cut off at score C (moderate), the database was thus searched for DYRK1A partners with 
known functional relevance to Wnt signalling. The search identified an interesting array of potential 
DYRK1A interactions with Wnt-related proteins (Fig. R3.2). In yeast, DYRK1A reportedly interacts with 
DKK3, which was found to be altered in DS mice and humans, and LRP1B, a member of the LRP 
canonical Wnt signalling co-receptor family. Weaker protein protein interactions reported include Wnt 
inhibitory factor 1 (WIF1), LRP1 and 4. Additionally, the murine proteins Lrp1 and Lrp1b also interact-
ed with mouse Dyrk1a in Y2H assays. The ligand Wnt3 and α-catenin were also reported to weakly 
interact with mouse and human DYRK1A, respectively. These data overall demonstrate multiple 
DYRK1A interactions with key Wnt components, and thus provide initial support to the main hypothe-
sis of this chapter. 
Fig. R3.2 - Visual summary of DYRK1A interactions with Wnt signalling components, as detected by Y2H screening. 
Lines are colour-coded to represent PIM Biological Score (PBS), a surrogate P value indicating the reliability of each 
interaction. Here, the highest scoring  DYRK1A interactors were DKK3 and Lrp1b.
150
Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
4.3.2.1 DYRK1A-Wnt protein interaction networks 
In order to preliminarily investigate DYRK1A as a candidate Wnt signalling modulator, the interactome 
of this kinase was interrogated for Wnt-relevant protein interactions, employing multiple techniques. 
4.3.2.1.1 STRING-based DYRK family interaction with Wnt components 
The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) is a large database combin-
ing known and predicted protein interaction networks (http://string-db.org; (105)). Its content is de-
rived from “genomic context predictions, high-throughput lab experiments, conserved co-expression, 
automated text-mining and previous knowledge in databases”. STRING v10 was first employed to 
assess Wnt-related protein interactions for the entire vertebrate DYRK kinase family (DYRK1A/B, 
DYRK2-4). Each DYRK member was placed as the single starting node of a network comprising the 
first 50 or 100 best-scoring direct interactors. Overrepresentation/functional analysis was then per-
formed on the resultant list of proteins by STRING, for enrichment with the Gene ontology (GO) or 
KEGG term “Wnt signalling pathway” (Fig. R3.1). In all conditions, and for all DYRK members, a signif-
icant association with Wnt signalling was detected whilst accounting for false-discovery rate 
(FDR<0.05). Overall, DYRK family members were shown to possess from 3 up to 16 Wnt-related in-
teraction partners. These data thus suggest that existing database and experimental knowledge al-
ready implicates the DYRK family in Wnt signalling. 
Fig. R3.1 - STRING-generated 
overview Wnt-relevant protein in-
teractions for the entire DYRK fami-
ly of kinases, plotting gene count 
as a function -log false discovery 
rate (FDR) of enrichment with the 
GO and KEGG terms ‘Wnt sig-
nalling pathway’.
149
Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
4.3.2.1.2 Yeast two-hybrid screening reveals several DYRK1A-WNT interactions 
Preliminary screening of the DYRK family indicated the presence of Wnt-related protein interactions. 
This finding was then further investigated by consulting a large protein interaction database part of the 
InterPP project, funded and conducted by Hybrigenics ltd. on behalf of the Jerome LeJeune Founda-
tion (Paris, Fr - fondationlejeune.org). This ongoing project represents an effort to identify and charac-
terise protein-protein interactions in the DS brain. Interactions are detected via yeast two-hybrid 
screen (Y2HS) technology, employing all known Hsa21-encoded proteins as bait and/or prey against 
an adult brain cDNA library. For DYRK1A, a lex-A-based construct was employed. The database fea-
tures a confidence scoring system termed PBS (PIM biological score) to assess the reliability of an 
observed interaction, ranging from A (extremely likely) to E (false positive/autoactivation ; see methods 
3.7 for an overview of this database, techniques employed and scoring systems).  
Setting the cut off at score C (moderate), the database was thus searched for DYRK1A partners with 
known functional relevance to Wnt signalling. The search identified an interesting array of potential 
DYRK1A interactions with Wnt-related proteins (Fig. R3.2). In yeast, DYRK1A reportedly interacts with 
DKK3, which was found to be altered in DS mice and humans, and LRP1B, a member of the LRP 
canonical Wnt signalling co-receptor family. Weaker protein protein interactions reported include Wnt 
inhibitory factor 1 (WIF1), LRP1 and 4. Additionally, the murine proteins Lrp1 and Lrp1b also interact-
ed with mouse Dyrk1a in Y2H assays. The ligand Wnt3 and α-catenin were also reported to weakly 
interact with mouse and human DYRK1A, respectively. These data overall demonstrate multiple 
DYRK1A interactions with key Wnt components, and thus provide initial support to the main hypothe-
sis of this chapter. 
Fig. R3.2 - Visual summary of DYRK1A interactions with Wnt signalling components, as detected by Y2H screening. 
Lines are colour-coded to represent PIM Biological Score (PBS), a surrogate P value indicating the reliability of each 
interaction. Here, the highest scoring  DYRK1A interactors were DKK3 and Lrp1b.
150
Thereafter, serial culture dilutions up to a factor of 10-3 were assessed via drop Y2H assay (Fig. R3.3). 
Cultures were grown on either non-selective and selective media (see 3.7). Under the former condi-
tions all cultures grew successfully, throughout all dilution factors (Fig. R3.3a, top square, lanes 1-5). 
This result indicates successful yeast transformation and expression of the exogenous constructs. 
Fig. R3.3 - he DKK3 binds the poly-H tail of 
DYRK1A. (a) Drop Y2H assay demonstrating a 
strong DKK3-DYRK1A interaction, which is 
abolished by mutation of the poly-histidine 
stretch of DYRK1A (lanes 7-8): 1 Positive Con-
trol (Smad/Smurf), 2 Negative Control (lexA-ø/
AD-ø), 3 Negative Control (LexA-Dyrk1A /AD-
ø), 4 Interaction DYRK1A/DKK3 aa131-aa245, 
5 Interaction DYRK1A/Fam53C aa339-452, 6 
Negative Control (LexA-DYRK1A-poly-A/AD-
ø), 7 Interaction LexA-DYRK1A-poly-A/DKK3 
aa131-aa245 8 Interaction LexA-DYRK1A-
poly-H/Fam53C. (b) Graphical summary de-
picting mutation sequence in a (lanes 7-8).
a b
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However when cultured in selective growth medium, which requires a positive interaction for yeast 
survival, only positive control- and DYRK1A+DKK3/Fam53C-positive cells grew successfully (Fig. 
R3.3a, bottom square, lanes 1/4-5). Overall, these data confirm the previously observed DYRK1A-
DKK3 interaction against reliable controls. 
Concomitantly, the sequence of the lex-A-DYRK1A construct was engineered in order to mutate its C-
terminal poly-H tail (aa 589-763) into a poly-alanine (poly-A) sequence (Fig. R3.3b, middle). As dis-
cussed, the poly-H tail is important for DYRK1A interactions and nuclear speckle localisation (4, 11). 
Mutagenesis was thus performed to determine where the poly-H tail is necessary for the DKK3 inter-
action. The DYRK1A-poly-A construct was expressed in yeast cells under the same conditions as 
above. Whilst all cultures grew in non-selective medium (Fig. R3.3a, top square, lanes 6-8), no inter-
action was detected for DKK3 (bottom square, lane 7). The Fam53C interaction, being mediated by 
the kinase domain of DYRK1A, was unaffected by the poly-A mutation (Fig. R3.3a, bottom square, 
lane 8). Overall, these data demonstrate that the DYRK1A-DKK3 interaction is likely mediated by the 
poly-H tail of DYRK1A. Nevertheless, its mutation to poly-A does not appear to alter kinase domain 
binding of other DYRK1A substrates. 
4.3.2.1.4 DYRK1A precipitates with DKK3 and DVL1, but not β-catenin 
Following Y2H results, co-immunoprecipitation (co-IP) was employed to confirm the DKK3-DYRK1A 
interaction in human cells, and investigate other potential, Wnt-relevant DYRK1A protein partners. 
Three further Wnt signalling components were selected for this study, namely DVL1, GSK3β and β-
catenin. All are essential mediators of Wnt signalling activation and inhibition (68). 
Co-iP was performed in HEK-293 cells (~105 cells/ml, n=3 cultures/condition), via 24hr co-expres-
sion of 0.5μg/ml FLAG-tagged candidate interactors and HA-tagged DYRK1A, or relative empty con-
trol vector. Following FLAG bead-mediated precipitation and purification of tagged proteins, results 
were analysed via SDS-PAGE/IB alongside cell lysate control samples. For all interactors tested, im-
munoblotting with an endogenous antibody revealed expression of HA-DYRK1A in lysates, as a band 
migrating to ~90 kDa in accordance with its known molecular weight (11) (Fig. R3.4-6, lanes 2/4, 
clear triangle). DKK3 was also observed in control lysates, as a band migrating to approximately 60 
kDa when probed for with an anti-FLAG antibody (Fig. R3.4, lanes 3-4, clear arrow). In contrast, the 
predicted molecular weight of DKK3 is theoretically ~30 kDa (106). It is however known that most of 
the DKK3 pool undergoes both N- and O-glycosylation in order to facilitate secretion (107, 108). This 
post-translational modification is likely to affect the observed molecular weight of DKK3. When ex-
pressed alone, DKK3 was precipitated by FLAG beads, also migrating to 60 kDa as a high-density 
band (Fig. R3.4, lanes 7/8, dark arrow).  
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4.3.2.1.3 The poly-Histidine tail of DYRK1A interacts with DKK3 
Given the presence of transcriptional and protein-level DKK3 alterations in DS (4.1-2), and the high PIM 
score of the hereby reported DYRK1A-DKK3 interaction, this relationship was further characterised by 
Hybrigenics via Y2H assay (see 3.7 for specifics of the Y2H protocol). Yeast cells were transformed with 
the lex-A-DYRK1A expression construct employed as prey for screening in 4.3.2.1.2, and grown for 
72 hours as liquid cultures. They were also co-transformed with either an empty lex-A bait vector 
(lexA-ø), a construct comprising the dickkopf domain of DKK3 in isolation (aa131-aa245) or a portion 
of Family With Sequence Similarity 53 Member C (Fam53C; aa339-452). The latter is known interac-
tor of DYRK1A at the kinase domain, here acting as positive control. To verify functionality of the as-
say, yeast cells were additionally co-transformed with positively (Smad/Smurf) and negatively (lexA-ø/
AD-ø)-interacting control bait/prey constructs in separate, but parallel reactions. 
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Fig. R3.5 - Expressed DYRK1A and DVL1 interact via FLAG pulldown in HEK293-cells. Left: input lanes demonstrat-
ing appropriate expression of both proteins (clear arrow/triangle). Right: co-IP lanes demonstrating precipitation of 
DVL1 when expressed alone and with DYRK1A (dark arrow), as well as co-precipitation of DYRK1A when expressed 
with DVL1, but not when alone (dark triangle). IB: immunoblotting antibody.
Fig. R3.4 - Expressed DYRK1A and DKK3 interact via FLAG pulldown in HEK293-cells. Left: input lanes demonstrat-
ing appropriate expression of both proteins (clear arrow/triangle). Right: co-IP lanes demonstrating precipitation of 
DKK3 when expressed alone and with DYRK1A (dark arrow), as well as precipitation of DYRK1A when co-expressed 
with DKK3, but not when alone (dark triangle). IB: immunoblotting antibody.
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This finding helps guarantee the functionality and specificity of the FLAG bead co-IP reaction. Under 
these conditions, no DYRK1A signal was detected. Consistently with previous results, DYRK1A pre-
cipitated when co-expressed with DKK3-FLAG, and was detected in co-IP samples (Fig. R3.4, lane 
8, dark triangle). DYRK1A was also co-expressed with FLAG-DVL1, a key second messenger for 
Wnt signalling (see 1.2). Expression of DVL1 was observed in cell lysates via FLAG staining (Fig. R3.5, 
lanes 3-4, clear arrow), and the protein was precipitated by FLAG beads when expressed alone (lane 
7, dark arrow). Under these conditions, no DYRK1A signal was detected. Interestingly, however, DVL1 
and DYRK1A co-precipitated when expressed together (Fig. R3.5, lane 8, dark triangle). Lastly, 
DYRK1A was also tested for interaction with β-catenin-FLAG. This protein was successfully detected 
in cell lysates as migrating to >100 kDa, in accordance with its known molecular weight (Fig. R3.6, 
lanes 3-4, clear triangle). β-catenin was also precipitated by FLAG beads, with or without DYRK1A 
co-expression (Fig. R3.6, lanes 7-8, dark triangle). In both conditions, however, DYRK1A did not 
precipitate, and was undetectable in co-IP samples despite substantial expression in cell lysates (Fig. 
R3.6, lanes 2/4, clear arrow). 
Overall, these data provide further evidence on the participation of DYRK1A in Wnt protein networks. 
The previously detected DKK3 interaction was confirmed, and an additional interaction with DVL1, but 
not β-catenin, was also observed. This suggests that DYRK1A might be capable of modulating Wnt 
signalling activity on multiple levels, possibly affecting β-catenin indirectly. 
Fig. R3.6 - Expressed DYRK1A and β-catenin do not interact via FLAG pulldown in HEK293-cells. Left: input lanes 
demonstrating appropriate expression of both proteins (clear arrow/triangle). Right: co-IP lanes demonstrating precip-
itation of β-catenin when expressed alone and with DYRK1A (top dark triangle). No DYRK1A signal was detected in 
co-IP samples were both constructs were expressed. IB: immunoblotting antibody.
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Fig. R3.7 - Visual summary of 
DYRK1A-Wnt interactions considered 
so far, combining Y2H screening (dou-
ble lines), co-IPs (dotted lines) and 
previously published interactions (solid 
lines). Network nodes highlighted in 
red were employed as seed network 
for enrichment via STRING (See next 
page).
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The network was then enriched employing the STRING database. Components of the basic network 
in R3.7 were used as starting nodes, selecting human as default organism (Fig. R3.7, red circles). 
This initial network, or first shell, was enriched with the 10 best-scoring interactors for any node, in-
cluding DYRK1A. A further shell was then added, comprising the 10 best-scoring secondary interac-
Fig. R3.8 - STRING-enriched DYRK1A-Wnt interaction network, displayed by Cytoscape. Following enrichment (See 
main text), the network was manually adjusted to reflect the known structure of canonical Wnt signalling, and contex-
tualise the results for easier consultation.
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4.3.2.1.5 STRING/Cytoscape interaction network analysis 
The studies presented so far iKeU[iﬁeK an array of DYRK1A protein interactions with components of 
Wnt signalling. Database knowledge and enrichment analysis preliminary suggested a functional Wnt 
relationship within the DYRK family interactome. Y2H screening JoUﬁrTeK the presence of multiple 
Wnt-relevant DYRK1A interactors, most notably DKK3 which binds the poly-H tail of DYRK1A. Addi-
tionally, co-IP evidence JoUﬁrTeK this interaction and iKeU[iﬁeK a further association with DVL1. The 
presence of multiple interactions implies that DYRK1A might participate in a larger protein network 
iUﬂ\eUJiUN the Wnt pathway on several levels. To investigate this idea, the Cyt scape analysis soft-
ware was employed along with STRING in order to build a network of potentially DS-relevant 
DYRK1A-Wnt interactions. This also served to summarise and contextualise all known and newly 
iKeU[iﬁeK+@92(>U[iU[eraJ[ioUZaiKiUNo]eralliU[erWretation of the results available. 
To achieve this goal, DYRK1A was ﬁrZ[ placed as the hub of a basic network (Fig. R3.7) comprising: 
 A) The Hybrigenics-reported DKK3 interaction B) Previously published interactions between  DYRK1A,
p120/  catenin (CTNND1- 83), and GSK3  (109) C) The co-iP detected interactions with DVL1  and
DKK3 (Fig. R3.4-5).
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The network was then enriched employing the STRING database. Components of the basic network 
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This initial network, or first shell, was enriched with the 10 best-scoring interactors for any node, in-
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tors of any node in the enriched first shell. The network diameter, or distance between each node, 
was limited to 3, meaning that each node is no more than one degree of interaction away from 
DYRK1A, and from any other. This choice was made to better highlight interconnectedness. The re-
sultant network (Fig. R3.8) has 140 edges and 25 nodes. The network was then displayed via the Cy-
toscape network analysis tool (see 3.8.2) in a spring-embedded layout, manually adjusted to reflect 
the known structure of canonical Wnt signalling (Fig. R3.8). Interestingly, some of the proteins auto-
matically added to the network by STRING, such as, DKK3, Axin2, β-catenin and CDH1 were also 
found to be altered in DS models and humans (Fig. R3.8, blue/grey circles - see 4.1-2.2). 
In summary, based on combined literature, database and experimental knowledge, these data sug-
gest DYRK1A might be involved in a wide variety of Wnt signalling mechanisms, either directly or via 
modulation of other pathway components. 
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4.3.2.2 DYRK1A is a bimodal Wnt signalling regulator 
The presence of a complex DYRK1A-Wnt interaction network suggests the possibility that DYRK1A may 
functionally affect signalling activity of this pathway, therefore potentially contributing to the Wnt phenotypes 
previously observed in DS models in humans (see 4.1-2). This possibility must therefore be studied further. 
In this section, potential effects of DYRK1A on Wnt signalling activity were investigated via luciferase assay 
and overexpression. Acute, transient manipulation of DYRK1A activity was achieved either via pharmaco-
logical kinase inhibition or DYRK1A overexpression. The latter approach relies on the notion that DYRK1A 
is constitutively active, and total protein levels thus linearly correlate with kinase activity. 
4.3.2.2.1 DYRK1A inhibition and canonical Wnt signalling activity in SH-SY5Y cells 
Descriptive statistics are reported in parentheses in the format (mean,±SD mean, P). All luciferase values 
are reported as normalised to control in the text, but are expressed as log2-transformed in figures to aid 
visualisation, due to large fold changes (see 3.9). 
4.3.2.2.1.1 LiCl-mediated Wnt activation 
SH-SY5Y cells (n=3, ~2独104 cells/ml, 3 replicates/condition) stably expressing the TCF/LEF TOPFlash 
luciferase reporter (TF-stable, see 3.5.6), were administered a 5 hr 40 mM LiCl dose to activate canonical 
Wnt signalling. Concomitant DYRK1A inhibitor treatment was employed to investigate potential modulation 
of active β-catenin levels (Fig. R3.9a-b). All results are expressed as a ratio to the basal control condition 
mean (40mM NaCl treatment with ethanol or DMSO). LiCl+Ethanol treatment alone induced an approxi-
Fig. R3.9 - DYRK1A inhibition reduces levels of LiCl-induced canonical Wnt signalling activity quantified via TOPflash lu-
ciferase assay. a SH-SY5Y cells stably expressing the TCF-LEF luciferase reporter (n=3) were treated with 40 mM LiCl or 
NaCl control for 5 hours with or without 25 μM EGCG, 25 μM INDY or 10 μM Harmine. 0.1% ethanol and 0.01% DMSO 
were employed as negative control treatments for EGCG and INDY/Harmine, respectively. All inhibitors significantly reduced 
activation (blue bars). b Heat map representing log2fold changes/NaCl alone for individual luciferase-expressing cultures. 
Data analysed by one-way ANOVA with post-hoc Sidak’s multiple comparisons test.
a b
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mately 10-fold increase in luciferase signal relative to NaCl+Ethanol (9.7±0.4, P=0.012), and LiCl+DMSO 
treatment resulted in a 14-fold increase (14.5±3.1, P<0.0001) relative to NaCl+DMSO. The effect of LiCl is 
well reported in the literature and confirms successful Wnt signalling activation. Following, administration of 
LiCl+25 μM EGCG led to a 4-fold increase in luciferase activity relative to NaCl+Ethanol (4.4±1.2, 
P=0.013). While the pathway was indeed stimulated, EGCG treatment resulted in a significantly reduced 
extent of activation, approximately 2-fold relative to LiCl+Ethanol (Fig. R3.9a, left blue - 2.2, P=0.038). A 
similar trend was observed for INDY and Harmine treatments. Administration of LiCl+25 μM INDY induced a 
4-fold increase in luciferase activity relative to NaCl+DMSO (3.9±0.8, P=0.038), corresponding to ~3-fold re-
duced extent of activation relative to LiCl+DMSO (Fig. R3.9a, right blue - 3.7, P=0.009). Similarly, LiCl+10 
μM Harmine treatment resulted in a 4-fold increase in signal relative to NaCl+DMSO (3.9±0.7, P=0.017). 
Compared to LiCl+DMSO activation, Harmine treatment also weakened the signal approximately 4-fold 
(Fig. R3.9a, far right blue - 3.7, P=0.021). In all conditions, none of the inhibitors exerted any detectable 
effect on basal luciferase activity. These data overall suggest that DYRK1A kinase inhibition may downregu-
late LiCl-activated, but not basal Wnt signalling. 
  
4.3.2.2.1.2 Wnt3a-mediated Wnt activation 
TF-stable cells (n=3, ~2独104 cells/ml, 3 replicates/condition), were treated with 50 ng/ml Wnt3a for 5 hrs 
to activate canonical Wnt signalling in a physiological fashion (Fig. R3.10a-b). The same dose of DYRK1A 
inhibitor treatment from 4.3.2.2.1.1 was employed to investigate potential modulation of the pathway. Wn-
t3a+Ethanol treatment alone produced an approximately 7-fold increase in luciferase signal relative to 
PBS+Ethanol (6.9±0.4, P=0.01) while Wnt3a+DMSO treatment resulted in a 6-fold increase (6.3±0.3, 
P=0.004) relative to PBS+DMSO. Administration of Wnt3a+EGCG led to a 5-fold increase in luciferase ac-
Fig. R3.10 - Same as Fig. R3.9 but employing 50ng/ml Wnt3a stimulation. All inhibitors but EGCG significantly reduced 
activation (blue bars). Data analysed by one-way ANOVA with post-hoc Sidak’s multiple comparisons test.
a b
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tivity relative to PBS+Ethanol (5.3±0.9, P=0.021). Under Wnt3a+EGCG stimulation, no significant differ-
ence in extent of activation was observed relative to Wnt3a+Ethanol (Fig. R3.10a, left blue - 1.3, P=0.97). 
Administration of Wnt3a+INDY induced a 2-fold increase in luciferase activity relative to PBS+DMSO (2.3±1.1, 
P=0.043), corresponding to a ~3-fold reduced extent of activation compared to Wnt3a+DMSO (Fig. 
R3.9a, right blue - 2.7, P=0.027). Similarly, Wnt3a+Harmine treatment resulted in a 2-fold increase in sig-
nal relative to PBS+DMSO (1.9±0.6, P=0.032). Harmine treatment also weakened the signal approximately 
3-fold (Fig. R3.9a, far right blue - 3.2, P=0.015) compared to Wnt3a+DMSO activation. In all conditions, 
none of the inhibitors exerted any detectable effect on basal luciferase activity. These data suggest that un-
der Wnt3a stimulation, the extent of pathway activation may be significantly reduced by DYRK1A inhibition 
with INDY and Harmine, but not with EGCG. 
Taken together, the DYRK1A inhibition data suggest that interference with DYRK1A activity may reduce the 
ability of LiCl or Wnt3a to stimulate the canonical Wnt signalling pathway. According to the INDY results, 
DYRK1A might also act as a Wnt modulator in the absence of pathway stimulation. These preliminary find-
ings suggest a potential interaction between DYRK1A and Wnt signalling activity. 
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4.3.2.2.1.3 Investigation of a dose-dependent relationship for INDY 
Because of its reportedly superior specificity, INDY was selected for further investigation, in order to deter-
mine whether the observed downregulation of active Wnt signalling induced by INDY could fall under a 
dose-response function. A potential linear relationship between INDY treatment and Wnt signalling activity 
would suggest that DYRK1A modulates activity of the pathway in a dose-dependent fashion. 
For this experiment, TF-stable cells (n=3, ~2独104 cells/ml, 3 replicates/condition) were co-treated for 6 
hrs with 40 mM LiCl or NaCl and a log-equidistant range of INDY doses (0, 1, 3, 10, 30, 100 μM - Fig. 
R3.11). Luciferase signal values were expressed as ratio to the basal control condition mean (NaCl treat-
ment). LiCl treatment alone induced a 21-fold increase in luciferase signal (21.0±2.9, P<0.0001). This was 
assumed as maximum response and tested against increasing INDY doses in the presence of LiCl. No 
significant effect was observed for LiCl+1 or 3 μM INDY, albeit the sample means displayed a trend to-
wards decrease (1 μM - 19.3±5.9, P=0.96, 91%; 3 μM - 15.6±1.0 P=0.072, 75%). A dose-dependent 
significant decrease in pathway activation was observed throughout the remaining range of INDY treat-
ments. A dose of 10 μM resulted in signal reduction to 62% (13.1±2.7, P=0.004), 30 μM to 54% 
(11.3±4.7, P=0.0004) and 100 μM to 16% (3.3±0.9, P<0.0001). Regression analysis of the LiCl data 
showed linearity (R2=0.8), fitting a function of significantly non-zero slope (f(x)=-0.7x+84, P=0.009; Fig. 
R3.11a, red). This finding suggests the presence of a dose-response relationship between INDY treatment 
and Wnt activation. Linearity was most evident between 3-30 μM INDY. Interestingly, the same dose range 
was identified by Ogawa et al., the original developers (110), as linearly inhibiting tau phosphorylation and 
NFAT signalling activity. These are two common DYRK1A substrates, indicating the response observed 
here is possibly DYRK1A-specific. No significant effect of INDY treatment was observed with NaCl except 
at 100 μM, when basal response was decreased to 83% (0.8±0.1, P=0.002, not shown). Overall, these 
data suggest that DYRK1A inhibition may linearly modulate canonical Wnt signalling in the activated state. 
Fig. R3.11 - The inhibitory eﬀect of INDY on LiCl-induced activation is dose-dependent. a Doses 
of 1-100 μM INDY (n=3) were administered for 5 hours and luciferase activity was plotted as 
percentage of control treatment. Linear regression analysis indicated a dose-response relation-
ship (P=0.009, R2=0.8, f(x)=-0.7x+84). b Heat map showing values normalised to LiCl + 0.01% 
DMSO for individual cultures. Data analysed by one-way ANOVA with post-hoc Sidak’s multiple 
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4.3.2.2.1.4 DYRK1A inhibition in live cells 
The effects of INDY-mediated DYRK1A inhibition on canonical Wnt signalling activity were also tested in 
live, non-lysed cells from the TF-stable line (Fig. R3.12). Cells (n=3, ~104 cells/ml, 3 replicates/condition) 
were treated with either 40 mM LiCl or 50 ng/ml Wnt3a and relative controls for 5 hours, with or without 
administration of 25 μM INDY. Following 20 min treatment with 150 μg/mL D-luciferin, imaging through the 
IVIS system (see 3.5.5) detected significant Wnt stimulation with both LiCl (3.4±1.5, P=0.026) and Wnt3a 
(4.7±1.0, P=0.0004, Fig. R3.12, left, rows 2/4). In line with previous results, INDY treatment significantly 
reduced activation levels ~3-fold with LiCl (1.3±0.6, P=0.047) and ~2-fold with Wnt3a (2.5±0.7, P=0.012 - 
Fig. R3.12, right, rows 2/4). No effect was detected on basal activity levels (0.6±0.2, P=0.94; 0.7±0.3, 
P=0.90 - right, rows 1/3). These data further indicate that DYRK1A kinase inhibition reduces active, but 
not basal Wnt signalling activity. 
Fig. R3.12 - Eﬀect of INDY in live, non-lysed stable SH-SY5Y cells (n=3). Samples were treated as in R3.9-10, with or 
without 25 μM INDY and imaged live, employing the IVIS system. Signal intensity represents photon counts/s. In both 
stimulating conditions, DYRK1A inhibition significantly reduced active but not basal Wnt signalling activity (right side). 
Data analysed by student t-test.
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here is possibly DYRK1A-specific. No significant effect of INDY treatment was observed with NaCl except 
at 100 μM, when basal response was decreased to 83% (0.8±0.1, P=0.002, not shown). Overall, these 
data suggest that DYRK1A inhibition may linearly modulate canonical Wnt signalling in the activated state. 
Fig. R3.11 - The inhibitory eﬀect of INDY on LiCl-induced activation is dose-dependent. a Doses 
of 1-100 μM INDY (n=3) were administered for 5 hours and luciferase activity was plotted as 
percentage of control treatment. Linear regression analysis indicated a dose-response relation-
ship (P=0.009, R2=0.8, f(x)=-0.7x+84). b Heat map showing values normalised to LiCl + 0.01% 
DMSO for individual cultures. Data analysed by one-way ANOVA with post-hoc Sidak’s multiple 




Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
4.3.2.2.1.4 DYRK1A inhibition in live cells 
The effects of INDY-mediated DYRK1A inhibition on canonical Wnt signalling activity were also tested in 
live, non-lysed cells from the TF-stable line (Fig. R3.12). Cells (n=3, ~104 cells/ml, 3 replicates/condition) 
were treated with either 40 mM LiCl or 50 ng/ml Wnt3a and relative controls for 5 hours, with or without 
administration of 25 μM INDY. Following 20 min treatment with 150 μg/mL D-luciferin, imaging through the 
IVIS system (see 3.5.5) detected significant Wnt stimulation with both LiCl (3.4±1.5, P=0.026) and Wnt3a 
(4.7±1.0, P=0.0004, Fig. R3.12, left, rows 2/4). In line with previous results, INDY treatment significantly 
reduced activation levels ~3-fold with LiCl (1.3±0.6, P=0.047) and ~2-fold with Wnt3a (2.5±0.7, P=0.012 - 
Fig. R3.12, right, rows 2/4). No effect was detected on basal activity levels (0.6±0.2, P=0.94; 0.7±0.3, 
P=0.90 - right, rows 1/3). These data further indicate that DYRK1A kinase inhibition reduces active, but 
not basal Wnt signalling activity. 
Fig. R3.12 - Eﬀect of INDY in live, non-lysed stable SH-SY5Y cells (n=3). Samples were treated as in R3.9-10, with or 
without 25 μM INDY and imaged live, employing the IVIS system. Signal intensity represents photon counts/s. In both 
stimulating conditions, DYRK1A inhibition significantly reduced active but not basal Wnt signalling activity (right side). 
Data analysed by student t-test.
162
Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
4.3.2.2.2 DYRK1A overexpression and canonical Wnt signalling activity  
4.3.2.2.2.1 DVL1-mediated Wnt activation 
TOPFlash transfection 
In this experiment, the effect of DYRK1A overexpression with or without Wnt signalling activation was in-
vestigated by co-transfection of the TOPFlash luciferase construct (Fig. R3.13 - see 3.5.5)  SH-SY5Y cells 
(n=9, ~2独104 cells/ml, 3 replicates/condition) were co-transfected with 0.25 μg/ml DYRK1A, DVL1, both 
or relative control vector. Similarly to experiments 1-3, luciferase signal values were expressed as a ratio to 
the basal control condition mean (pCMV5-empty+pRK5-myc-empty). Surprisingly, DYRK1A overexpres-
sion alone induced a significant 4-fold decrease in luciferase signal (Fig. R3.13a, blue - 0.2±0.2, P=0.007) 
relative to basal control. Activation of the pathway was confirmed by DVL1 overexpression, which resulted 
in a 8-fold increase in signal (8.5±7.8, P<0.0001). Concomitant overexpression of DVL1 and DYRK1A pro-
duced a remarkable 40-fold increase in signal relative to basal control (Fig. R3.13a, red - 35.5±35.7, 
P<0.0001), corresponding to a 4-fold enhancement of Wnt activation relative to DVL1 transfection alone 
(4.2, P=0.002). These data suggest that, in the active state, canonical Wnt signalling activity may be posi-
tively modulated by DYRK1A overexpression. 
Fig. R3.13 - Bimodal Wnt eﬀects of DYRK1A expression in the SH-SY5Y line. a Cells (n=9) were co-transfected with 0.25 
μg/ml HA-DYRK1A, FLAG-DVL1, both, or empty vector controls for 24 hrs. 0.25 μg/ml TOPflash and 0.025 μg/ml constitu-
tively active renilla luciferase constructs were employed as reporters, with signal quantified as TOPflash/Renilla ratio. All 
values displayed as log2fold transform relative to empty vector transfection. Adjacent graph demonstrates same experiment 
employing mutant reporter construct FOPflash-luciferase. b Heat map represent values for individual luciferase-expressing 
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FOPFlash transfection 
In order to control for any non-specific signal effect of DNA transfection, the same experiment was carried 
out by transfection of the mutated FOPflash construct which does not relate canonical Wnt signalling activ-
ity to a luciferase signal (Fig. R3.13a, right panel). DYRK1A overexpression alone had no effect on lu-
ciferase signal (0.8±0.2, P=0.91) relative to basal control. DVL1 overexpression alone produced no signifi-
cant change in signal intensity (0.9±0.4, P=0.68). Similarly, concomitant overexpression of DVL1 and 
DYRK1A did not exert a significant effect on luciferase signal (0.8±0.2, P=0.58). 
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FOPFlash transfection 
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4.3.2.2.2.2 Combined effects of DYRK1A and DKK3 expression on Wnt signalling activity 
Given the consistently observed DYRK1A-DKK3 interaction, the individual and combined effects of 
these two proteins on canonical Wnt signalling activity were also investigated via luciferase assay (Fig. 
R3.14). For this experiment, 0.25 μg/ml HA-DYRK1A, DKK3-FLAG and FLAG-DVL1 were expressed 
for 24 hrs in SH-SY5Y cells (n=3, ~2独104 cells/ml, 3 replicates/condition), either alone on in all pos-
sible combinations. Similarly to results discussed above, DYRK1A induced a significant decrease in 
Wnt signalling activity when expressed alone (Fig. R3.14a, blue - 0.4±0.1, P=0.01). DKK3, however, 
had no detectable effect when expressed alone (0.9±0.2, P=0.99). Also similarly, DVL1 expression 
induced a significant increase in Wnt activation (32.4±25.4, P<0.005), further enhanced by the pres-
ence of DYRK1A (Fig. R3.14a, red - 62.7±18.4, P=0.02). When co-expressed with DVL1, DKK3 did 
not affect Wnt activation (33.5±22.7, P=0.006, comparative P=0.97). However, in the presence of all 
three proteins, DKK3 expression prevented the DYRK1A-enhancing effect, with luciferase levels com-
parable to DVL1 alone (Fig. R3.14a, light red - 28.9±16.5, P=0.008, comparative P=0.99). Overall, 
luciferase signals in this study were overall more variable than previous experiments, and it is more 
difficult to reliably interpret the data. DKK3 does not exert a detectable effect on basal or active Wnt 
signalling in this system. However, it might be able to reduce or prevent DYRK1A-mediated enhance-
ment of DVL1 Wnt signalling.  
Fig. R3.14 - Combined Wnt eﬀects of DYRK1A and DKK3 expression in the SH-SY5Y line. a Cells (n=3) were co-transfected 
with 0.5 μg HA-DYRK1A, DKK3, DVL1, or empty vector controls in all combinations for 24 hrs. Luciferase assay conducted 
as above. Same eﬀects of DYRK1A±DVL1 (blue, red). No eﬀect of DKK3±DVL1. When all three present, the DYRK1A en-
hancing eﬀect on DVL1 was removed (light red). b Heat map represent values for individual luciferase-expressing cultures. 
Data analysed by one-way ANOVA with post-hoc Sidak’s multiple comparisons test.
a b
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4.3.2.2.2.3 Effects of DYRK1A expression on GS3Kβ 
The luciferase data above demonstrated that DYRK1A is capable of bimodal Wnt regulation in neuroblas-
toma cells. Active Wnt signalling is enhanced by DYRK1A overexpression, whilst basal activity levels are 
potently downregulated. The latter effect was further examined, by investigating whether the observed Wnt 
inhibition correlates with changes in GSK3β protein levels. GSK3β is a long established Wnt component 
and chief intracellular inhibitor of β-catenin (68). Additionally, it possesses a functional relationship with 
DYRK1A (84, 85, 109) (see 4.3.1). It is therefore possible that the substantial Wnt downregulation observed 
in the presence of DYRK1A (Fig. R3.13, blue) might be accompanied by changes in GSK3β levels. 
In order to investigate this hypothesis, 0.5μg/ml HA-DYRK1A or relative empty control vector were ex-
pressed in HEK-293 cells  (n=6, ~105 cells/ml, 4 replicates/condition) for 24 hrs and analysed via SDS-
PAGE/IB (Fig. R3.15). DYRK1A protein levels were found to be significantly elevated over 2-fold (2.4±1.4, 
P=0.0006) compared to control samples, as expected (Fig. R3.15a). Interestingly, DYRK1A overexpres-
sion also induced a significant ~1.5-fold increase in total GSK3β (1.5±0.2, P=0.03 - Fig. R3.15b). This re-
sult supports the hypothesis formulated above, and preliminarily indicates that protein amounts of GSK3β 
may be directly affected by DYRK1A activity. Additionally, the p-S9 fraction of GSK3β was also examined 
under DYRK1A overexpression. Phosphorylation of this residue is reportedly elevated in the cerebral cortex 
and hippocampus of aged Tc1 mice (86), but is unaltered in 2 months and 6 months old animals ((86), 
4.2.2). The p-S9 phosphoresidue is also known to inhibit GSK3β activity, and is regulated by AKT (111). 
Surprisingly, DYRK1A overexpression resulted in a significant 3-fold decrease of the p-S9-GSKβ fraction, 
quantified as a ratio to total GSK3β (0.3±0.2, P=0.02 - Fig. R3.15c). Overall, these data suggest that en-
hanced DYRK1A activity may be sufficient to elevate GSK3β levels, and reduce its inhibitory phosphoryla-
tion at S9. This is consistent with the previously observed basal Wnt inhibition by DYRK1A, and imply that 
such an effect may be accompanied by enhanced GSK3β activity. 
Fig. R3.15 - DYRK1A expression is suﬃcient to enhance total protein amounts of GSK3β and alter its phosphorylation sta-
tus at Ser9. SH-SY5Y cells (n=4) were transfected with 0.5 μg/ml HA-DYRK1A for 24 hrs. a As expected, DYRK1A levels 
were elevated. b Total levels of GSK3β were enhanced. c Phosphorylation at Ser9, as expressed by ratio to total protein, 
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Fig. R3.14 - Combined Wnt eﬀects of DYRK1A and DKK3 expression in the SH-SY5Y line. a Cells (n=3) were co-transfected 
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Data analysed by one-way ANOVA with post-hoc Sidak’s multiple comparisons test.
a b
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4.3.2.3 Wnt signalling control over DYRK1A subcellular localisation 
The experiments so far outlined in this chapter demonstrated that DYRK1A participates in complex 
Wnt protein interaction networks (4.3.2.1), and is also capable of bimodal Wnt regulation (4.3.2.2). 
These findings support the initial candidate gene hypothesis of DYRK1A-meditated Wnt signalling 
modulation, and must be investigated further. A wide variety of DYRK1A substrates and functions is 
currently known (11). If this kinase is indeed capable of regulating Wnt signalling intracellularly, such 
property should be reflected by detectable changes in DYRK1A homoeostasis. Thus, the presence of 
this novel DYRK1A-Wnt relationship warrants the question of whether DYRK1A may itself be function-
ally regulated by Wnt activation states. As introduced, subcellular localisation is a key regulator of 
DYRK1A function (4.3.1.1.5). Whilst prominently a nuclear protein, DYRK1A does also localise to the 
cytoplasm, and the highly dynamic balance between these two subcellular compartments is finely 
regulated. Nuclear/cytoplasmic shuttling primarily serves the purpose of functionally directing DYRK1A 
to differential substrate pools. Indeed, the Wnt signalling pathway possesses both nuclear and cyto-
plasmic components important for activation. Given the hereby observed bimodal Wnt regulation by 
DYRK1A, which is activation dependent, it was thus hypothesised that such modulation might occur 
in distinct subcellular compartments. 
In order to address this hypothesis, an imaging approach was undertaken. Employing quantitative 
immunocytochemistry and overexpression, the subcellular localisation of DYRK1A was investigated in 
relation to multiple Wnt activation states. Particularly, quantitation was used to objectively assess the 
subcellular distribution of DYRK1A. To ensure consistency, the same Wnt activation methods de-
scribed above where employed (4.3.2.2), i.e. LiCl or Wnt3a stimulation, and DVL1 overexpression. All 
experiments were performed in the HeLa and HEK-293 human cell lines, combining high-resolution 
Airy-scan and confocal fluorescence microscopy (see 3.5.7-8 and 3.9 for info on sample preparation, 
primary and secondary (Alexa Fluor®) antibodies employed, fluorescence quantification protocols and 
statistical analysis). 
4.3.2.3.1 Nuclear DYRK1A localises to the speckle compartment 
Prior to addressing a potential Wnt-dependent effect on DYRK1A localisation, a qualitative pilot study was 
conducted with a dual purpose. First, to verify the consensus DYRK1A localisation as mostly nuclear in cell 
homoestatic conditions. Second, to replicate previous reports of DYRK1A sub-localisation to nuclear 
speckles (4). A GFP-tagged DYRK1A construct was expressed in HEK-293 cells (~2独104 cells/ml, n=3) 
for 24 hrs (Fig. R3.16). Cells were then collected, fixed and immunostained as described (see 3.5.7). DAPI 
staining was employed as nuclear marker, whilst a primary antibody to Serine/arginine-rich splicing factor 2 
(SC35) was selected as nuclear speckle marker. Confocal microscopy demonstrated a detectable GFP-
DYRK1A signal, which localised diffusely to the nucleus (Fig. R3.16, green) with discrete punctae of en-
hanced fluorescence (green triangles). DYRK1A also appeared to localise to the nuclear interchromatin 
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space, visible as a sharp reduction in DAPI signal (Fig. R3.16, blue triangle). SC-35 staining successfully 
identified nuclear speckles as distinct intranuclear punctae (Fig. R3.17, red triangle) also localising to the 
interchromatin space (Fig. R3.17, blue triangle). As previously reported, GFP-DYRK1A co-localised with 
SC-35 (Fig. R3.17, yellow triangle), thus confirming its association with nuclear speckles and the reliability 
of experimental setup employed thereafter. 
 
Fig. R3.16 - Pilot study of DYRK1A localisation. 24 hr expression of GFP-DYRK1A (green) resulted in nuclear lo-
calisation of the protein overlapping DAPI staining, and displaying fluorescent punctae (green arrow, centre) pos-
sibly within the interchromatin space (blue arrow, left).
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4.3.2.3 Wnt signalling control over DYRK1A subcellular localisation 
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These findings support the initial candidate gene hypothesis of DYRK1A-meditated Wnt signalling 
modulation, and must be investigated further. A wide variety of DYRK1A substrates and functions is 
currently known (11). If this kinase is indeed capable of regulating Wnt signalling intracellularly, such 
property should be reflected by detectable changes in DYRK1A homoeostasis. Thus, the presence of 
this novel DYRK1A-Wnt relationship warrants the question of whether DYRK1A may itself be function-
ally regulated by Wnt activation states. As introduced, subcellular localisation is a key regulator of 
DYRK1A function (4.3.1.1.5). Whilst prominently a nuclear protein, DYRK1A does also localise to the 
cytoplasm, and the highly dynamic balance between these two subcellular compartments is finely 
regulated. Nuclear/cytoplasmic shuttling primarily serves the purpose of functionally directing DYRK1A 
to differential substrate pools. Indeed, the Wnt signalling pathway possesses both nuclear and cyto-
plasmic components important for activation. Given the hereby observed bimodal Wnt regulation by 
DYRK1A, which is activation dependent, it was thus hypothesised that such modulation might occur 
in distinct subcellular compartments. 
In order to address this hypothesis, an imaging approach was undertaken. Employing quantitative 
immunocytochemistry and overexpression, the subcellular localisation of DYRK1A was investigated in 
relation to multiple Wnt activation states. Particularly, quantitation was used to objectively assess the 
subcellular distribution of DYRK1A. To ensure consistency, the same Wnt activation methods de-
scribed above where employed (4.3.2.2), i.e. LiCl or Wnt3a stimulation, and DVL1 overexpression. All 
experiments were performed in the HeLa and HEK-293 human cell lines, combining high-resolution 
Airy-scan and confocal fluorescence microscopy (see 3.5.7-8 and 3.9 for info on sample preparation, 
primary and secondary (Alexa Fluor®) antibodies employed, fluorescence quantification protocols and 
statistical analysis). 
4.3.2.3.1 Nuclear DYRK1A localises to the speckle compartment 
Prior to addressing a potential Wnt-dependent effect on DYRK1A localisation, a qualitative pilot study was 
conducted with a dual purpose. First, to verify the consensus DYRK1A localisation as mostly nuclear in cell 
homoestatic conditions. Second, to replicate previous reports of DYRK1A sub-localisation to nuclear 
speckles (4). A GFP-tagged DYRK1A construct was expressed in HEK-293 cells (~2独104 cells/ml, n=3) 
for 24 hrs (Fig. R3.16). Cells were then collected, fixed and immunostained as described (see 3.5.7). DAPI 
staining was employed as nuclear marker, whilst a primary antibody to Serine/arginine-rich splicing factor 2 
(SC35) was selected as nuclear speckle marker. Confocal microscopy demonstrated a detectable GFP-
DYRK1A signal, which localised diffusely to the nucleus (Fig. R3.16, green) with discrete punctae of en-
hanced fluorescence (green triangles). DYRK1A also appeared to localise to the nuclear interchromatin 
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space, visible as a sharp reduction in DAPI signal (Fig. R3.16, blue triangle). SC-35 staining successfully 
identified nuclear speckles as distinct intranuclear punctae (Fig. R3.17, red triangle) also localising to the 
interchromatin space (Fig. R3.17, blue triangle). As previously reported, GFP-DYRK1A co-localised with 
SC-35 (Fig. R3.17, yellow triangle), thus confirming its association with nuclear speckles and the reliability 
of experimental setup employed thereafter. 
 
Fig. R3.16 - Pilot study of DYRK1A localisation. 24 hr expression of GFP-DYRK1A (green) resulted in nuclear lo-
calisation of the protein overlapping DAPI staining, and displaying fluorescent punctae (green arrow, centre) pos-
sibly within the interchromatin space (blue arrow, left).
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4.3.2.3.2 LiCl-mediated Wnt activation 
HeLA or HEK-293 cells were cultured (~2独104 cells/ml, n=3 cell clusters), expressing 0.5 μg/ml HA-
DYRK1A for 24 hrs. (Fig. R3.18-20). Concomitantly, 40 mM LiCl or equimolar NaCl were administered for 
5 hrs. Cells were then collected, fixed and immunostained. For all experiments hereafter, an anti-HA anti-
body was employed for DYRK1A detection. Hoechst and DAPI stains were employed to visualise the nu-
cleus in HeLA and HEK-293 cells, respectively. F-actin staining was also performed in HeLA cells to visu-
alise cell boundaries. The latter cell line served to produce representative, high-resolution images. HEK-293 
cells were imaged at lower resolution, in order to generate ‘population’ samples for quantification and sta-
tistical testing.  
Under basal Wnt signalling conditions, overexpressed DYRK1A mostly localised to the nucleus. Represen-
tative Airy-scan images demonstrated a prominent nuclear DYRK1A signal in HeLa cells, with little cyto-
plasmic fluorescence observable (Fig. R3.18a, green). This is consistent with previous reports on DYRK1A 
localisation (4, 11), confirming its role as a nuclear kinase. In the presence of LiCl stimulation, however, 
DYRK1A appeared to nearly completely redistribute out of the nucleus, with extremely low signal in this 
compartment. (Fig. R3.18b, green). This finding was accompanied by enhanced DYRK1A cytoplasmic 
fluorescence, which appeared diffuse. 3D z-stacking further illustrated this phenotype (Fig. R3.19). The 
same experiment was conducted in HEK-293 cells to quantify the ratio of nuclear to cytoplasmic (N/C) 
DYRK1A fluorescence (Fig. R3.20a-b). Under basal conditions, DYRK1A was predominantly nuclear (n=3 
cell clusters, 2.0±0.4). However, LiCl significantly decreased the DYRK1A N/C ratio in favour cytoplasmic 
localisation (0.4±0.2, P=0.003). Overall, this experiment demonstrates that LiCl treatment is sufficient to 
significantly redistribute DYRK1A out of the nucleus and into the cytoplasmic compartment.  
Fig. R3.17 - Pilot study of DYRK1A localisation with nuclear speckles. 24 hr expression of GFP-DYRK1A (green) 
resulted in nuclear localisation of the protein displaying intranuclear fluorescent punctae (green arrow). SC-35 
staining demonstrated speckle morphology (red arrow) and co-localisation with DYRK1A punctae (yellow arrow).
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Fig. R3.18 - Wnt activation shuttles DYRK1A out of the nucleus. Airyscan microscopy of 5-hour 
40mM NaCl (a) or LiCl (b) treatment in HeLa cells. DYRK1A (green) localised to the nucleus (blue) 




Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
 
4.3.2.3.2 LiCl-mediated Wnt activation 
HeLA or HEK-293 cells were cultured (~2独104 cells/ml, n=3 cell clusters), expressing 0.5 μg/ml HA-
DYRK1A for 24 hrs. (Fig. R3.18-20). Concomitantly, 40 mM LiCl or equimolar NaCl were administered for 
5 hrs. Cells were then collected, fixed and immunostained. For all experiments hereafter, an anti-HA anti-
body was employed for DYRK1A detection. Hoechst and DAPI stains were employed to visualise the nu-
cleus in HeLA and HEK-293 cells, respectively. F-actin staining was also performed in HeLA cells to visu-
alise cell boundaries. The latter cell line served to produce representative, high-resolution images. HEK-293 
cells were imaged at lower resolution, in order to generate ‘population’ samples for quantification and sta-
tistical testing.  
Under basal Wnt signalling conditions, overexpressed DYRK1A mostly localised to the nucleus. Represen-
tative Airy-scan images demonstrated a prominent nuclear DYRK1A signal in HeLa cells, with little cyto-
plasmic fluorescence observable (Fig. R3.18a, green). This is consistent with previous reports on DYRK1A 
localisation (4, 11), confirming its role as a nuclear kinase. In the presence of LiCl stimulation, however, 
DYRK1A appeared to nearly completely redistribute out of the nucleus, with extremely low signal in this 
compartment. (Fig. R3.18b, green). This finding was accompanied by enhanced DYRK1A cytoplasmic 
fluorescence, which appeared diffuse. 3D z-stacking further illustrated this phenotype (Fig. R3.19). The 
same experiment was conducted in HEK-293 cells to quantify the ratio of nuclear to cytoplasmic (N/C) 
DYRK1A fluorescence (Fig. R3.20a-b). Under basal conditions, DYRK1A was predominantly nuclear (n=3 
cell clusters, 2.0±0.4). However, LiCl significantly decreased the DYRK1A N/C ratio in favour cytoplasmic 
localisation (0.4±0.2, P=0.003). Overall, this experiment demonstrates that LiCl treatment is sufficient to 
significantly redistribute DYRK1A out of the nucleus and into the cytoplasmic compartment.  
Fig. R3.17 - Pilot study of DYRK1A localisation with nuclear speckles. 24 hr expression of GFP-DYRK1A (green) 
resulted in nuclear localisation of the protein displaying intranuclear fluorescent punctae (green arrow). SC-35 
staining demonstrated speckle morphology (red arrow) and co-localisation with DYRK1A punctae (yellow arrow).
169
Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation
 
Fig. R3.18 - Wnt activation shuttles DYRK1A out of the nucleus. Airyscan microscopy of 5-hour 
40mM NaCl (a) or LiCl (b) treatment in HeLa cells. DYRK1A (green) localised to the nucleus (blue) 
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Fig. R3.19 - 3D reconstruction of z-stacks generated from images in R3.18, further demonstrating 
the observed phenotype.
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Fig. R3.20 - Nuclear/cytoplasmic DYRK1A ratio. (a) Same conditions as in R3.18, but in 
HEK-293 cells and imaged via confocal microscopy. (b) Significant reduction in DYRK1A nu-
clear localisation upon 5hr 40 mM LiCl treatment. For each condition, n=3 cell clusters were 
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Fig. R3.19 - 3D reconstruction of z-stacks generated from images in R3.18, further demonstrating 
the observed phenotype.
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Fig. R3.20 - Nuclear/cytoplasmic DYRK1A ratio. (a) Same conditions as in R3.18, but in 
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4.3.2.3.3 Wnt3a-mediated Wnt activation 
For this experiment HeLA or HEK-293 were cultured, transfected, stained and imaged as in 4.3.2.3.2. 
In this case, however, Wnt signalling activation was obtained via administration of 50 ng/ml Wnt3a or 
PBS, for 5 hours prior to sample collection (Fig. R3.21-23). Similarly to results above, overexpressed 
DYRK1A mostly localised to the nucleus under basal Wnt signalling conditions (Fig. R3.21a, green). 
Representative Airy-scan images demonstrated a prominent nuclear DYRK1A signal in HeLa cells, 
with little cytoplasmic fluorescence observable. In the presence of Wnt3a stimulation, however, 
DYRK1A redistributed out the nucleus similarly to LiCl treatment (Fig. R3.21b, green). Consistently, 
this finding was accompanied by diffuse DYRK1A cytoplasmic fluorescence. 3D z-stacking further 
illustrated this phenotype (Fig. R3.22).  
The same experiment was conducted in HEK-293 cells to quantify the DYRK1A fluorescence N/C ra-
tio (Fig. R3.23a-b). Under basal conditions, DYRK1A was predominantly nuclear (n=3 cell clusters, 
2.2±0.5). However, similarly to LiCl treatment, Wnt3a significantly decreased the DYRK1A N/C ratio in 
favour cytoplasmic localisation (0.8±0.03, P=0.016). Overall, this experiment demonstrates that, in 
addition to LiCl, the endogenous Wnt3a ligand may also significantly redistribute DYRK1A out of the 
nucleus and into the cytoplasmic compartment. Imaging data so far suggests that pharmacological 
Wnt activation may redirect DYRK1A activity to the cytoplasm, thus restricting its nuclear access. 
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Fig. R3.21 - Same experiment as R3.18, but employing 5hr 50ng/ml Wnt3a stimulation. Under these 
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Fig. R3.21 - Same experiment as R3.18, but employing 5hr 50ng/ml Wnt3a stimulation. Under these 
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Fig. R3.22 - 3D reconstruction of z-stacks generated from images in R3.21, further demonstrating 
the observed phenotype.
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Fig. R3.23 - Nuclear/cytoplasmic DYRK1A ratio. (a) Same conditions as in R3.21, but in 
HEK-293 cells and imaged via confocal microscopy. (b) Significant reduction in DYRK1A nu-
clear localisation upon 5hr 50 ng/ml Wnt3a treatment. For each condition, n=3 cell clusters 
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Fig. R3.22 - 3D reconstruction of z-stacks generated from images in R3.21, further demonstrating 
the observed phenotype.
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Fig. R3.23 - Nuclear/cytoplasmic DYRK1A ratio. (a) Same conditions as in R3.21, but in 
HEK-293 cells and imaged via confocal microscopy. (b) Significant reduction in DYRK1A nu-
clear localisation upon 5hr 50 ng/ml Wnt3a treatment. For each condition, n=3 cell clusters 
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4.3.2.3.4 DVL1 treatment: DYRK1A co-localises with DVL1 in cytoplasmic phase transitions 
Given the observed DYRK1A interaction with DVL1 (Fig. R3.5), and their combined enhancement of 
active Wnt signalling (Fig. R3.13), the subcellular localisation of these two proteins was also investi-
gated (Fig. R3.24-26). Its characterisation might provide important mechanistic information on the 
DYRK1A-DVL1 mediated enhancement of active Wnt signalling observed previously. 
HeLA and HEK-293 cells were cultured, stained and imaged as in 4.3.2.3.2-3. HA-DYRK1A and FLAG-
DVL1 along with relative control vectors were expressed at 0.5 μg/ml for 24 hrs. (Fig. R3.24). Cells were 
then collected, fixed and immunostained as described, with additional FLAG staining for DVL1 visualisa-
tion. As shown above, DYRK1A mostly localised to the nucleus when overexpressed alone (Fig. R3.24a, 
green). Representative Airy-scan images demonstrated a prominent nuclear DYRK1A signal in HeLa cells, 
with little cytoplasmic fluorescence observable. When DVL1 was overexpressed, imaging revealed its dis-
tinctive, vesicle-like cytoplasmic staining pattern (Fig. R3.24b, red). This is a known property of DVL1, 
which is prone to form ‘aggregates’ such as the ones observed here. This tendency is currently ascribed to 
membraneless compartmentalisation via liquid-liquid phase transitions (112) (see 4.3.3 for further discus-
sion). When co-expressed with DVL1, DYRK1A appeared to redistribute out of the nucleus, as observed 
previously (Fig. R3.24b, green). Strikingly, however, DYRK1A prominently relocalised to the DVL1 signal, 
assuming its vesicle-like staining pattern, with co-localisation of the the two proteins observed (Fig. 
R3.24b, yellow). 3D z-stacking further illustrated this phenotype (Fig. R3.25).  
As before, the same experiment was conducted in HEK-293 cells to quantify the DYRK1A fluorescence N/
C ratio (Fig. R3.26a-b). Under basal conditions, DYRK1A was predominantly nuclear (n=3 cell clusters, 
1.6±0.2). Consistently with pharmacological Wnt stimulation, DVL1 overexpression also resulted in a signif-
icant reduction of the DYRK1A N/C ratio, in favour cytoplasmic localisation (0.4±0.2, P=0.002). This finding 
represents a previously unreported intracellular configuration of DYRK1A, which appears to associate di-
rectly with DVL1 phase transitions. Additionally, the imaging data further validate the DYRK1A-DVL1 inter-
action, which was detected via co-IP under similar transfection conditions. 
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Fig. R3.24 - Same experiment as R3.18/21, but employing 0.5 μg/ml FLAG-DVL1 expression to stim-
ulate Wnt activity. Under these conditions, nuclear DYRK1A (a, green) also redistributed into the cy-
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Fig. R3.24 - Same experiment as R3.18/21, but employing 0.5 μg/ml FLAG-DVL1 expression to stim-
ulate Wnt activity. Under these conditions, nuclear DYRK1A (a, green) also redistributed into the cy-
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Fig. R3.25 - 3D reconstruction of z-stacks generated from images in R3.24, further demonstrating 
the observed phenotype and vesicle-like appearance of DYRK1A-DVL1 aggregates.
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In summary, the imaging studies presented here elucidated a key aspect of the DYRK1A-Wnt relationship. 
Not only is DYRK1A capable of modulating Wnt signalling bidirectionally, but the pathway itself appears to 
regulate DYRK1A localisation. Wnt activation in facts may promote nuclear export of DYRK1A and its as-
sociation with cytoplasmic DVL1 proteins. 
Fig. R3.26 - Nuclear/cytoplasmic DYRK1A fluorescence ratio. (a) Same condi-
tions as in R3.24, but in HEK-293 cells and imaged via confocal microscopy. 

(b) Significant reduction in DYRK1A nuclear localisation with 24 hr DVL1 overex-
pression. For each condition, n=3 cell clusters were analysed, comprising n=28 
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Fig. R3.25 - 3D reconstruction of z-stacks generated from images in R3.24, further demonstrating 
the observed phenotype and vesicle-like appearance of DYRK1A-DVL1 aggregates.
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4.3.3 Discussion 
The key evidence concerning DYRK1A structure, function and localisation was discussed. The impor-
tance of DYRK1A in several biological mechanisms, most prominently CNS development and neu-
ronal function, was also highlighted. DYRK1A is an essential contributor to DS neuropathology, and its 
aberrant activity is required for several features of the complex DS phenotype. Moreover, DYRK1A ex-
erts significant control over multiple signalling pathways, and preliminary evidence also implicates the 
activity of this kinase in Wnt signalling regulation. Based on these lines of evidence, the experiments 
outlined in this chapter aimed to investigate DYRK1A as a candidate Wnt signalling modulator poten-
tially contributing to the Wnt-DS phenotypes described previously (4.1-2).  
The studies conducted here initially characterised a complex, multi-layered functional relationship be-
tween DYRK1A and canonical Wnt signalling. An unbiased STRING database screen first showed that 
the DYRK family interactome is significantly enriched with Wnt components, for all members. Follow-
ing, Y2H screen and co-IP demonstrated that DYRK1A physically interacts with several Wnt compo-
nents, most notably DKK3 and DVL1, but not β-catenin.  
At this point, it is important to clarify that the significance of a DYRK1A-DKK3 interaction is con-
tentious. Despite being detected by two distinct techniques, this interaction is unlikely to occur in in-
tact cells. Multiple studies have in fact shown that, functionally, DKK3 is a secreted protein (106-108). 
Given that DYRK1A localisation is exclusively intracellular (11), the two proteins are extremely unlikely 
to functionally bind in vivo. It cannot thus be excluded that the DYRK1A-DKK3 interaction may instead 
result from the two proteins being artificially placed in proximity by cell lysis. This calls into question 
any functional relationship between DYRK1A and DKK3. For a counterpoint, however, it should be 
mentioned that DKK3 function and localisation are not as well established as for other Dickkopf family 
members, such as DKK1. As stated, DKK3 secretion has indeed been observed experimentally (106-
108). Nevertheless, recent evidence suggests that an alternative, cytosolic function of DKK3 may ex-
ist. Leonard et al. (113) have in fact reported on a novel intracellular gene product encoded on the 
Dkk3 locus in mice. The protein, termed Dkk3b, was shown to suppress β-catenin activity intracellu-
larly, by preventing its nuclear translocation. This is purportedly achieved by Dkk3-mediated seques-
tration of β-catenin in cytosolic complexes with β-TrCP. Furthermore, the authors showed Dkk3b to be 
a key requirement for early mouse development. This study thus suggests that DKK3 might possess 
additional, non-secretory Wnt functions. It follows that the DYRK1A interaction reported here may ap-
ply to a potential cytosolic counterpart of DKK3, rather than to the secreted protein. Literature knowl-
edge in this regard is limited, however, and the data generated here are not sufficient to exclude the 
potentially artefactual nature of the DYRK1A-DKK3 interaction. This remains a strong possibility, and 
no definitive conclusions can be drawn until further studies are performed. 
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Despite this issue, current evidence suggests DYRK1A may indeed participate in Wnt-related protein 
networks. To explore this idea, all detected interactions were combined with the known DYRK1A-Wnt 
partners GSK3β and p120/δ-catenin (83, 109) into a larger, computationally enriched network. This 
approach exploited experimental and literature knowledge to highlight the tight functional proximity 
between DYRK1A and Wnt signalling components, either primarily or secondarily interacting. Follow-
ing, potential effects of DYRK1A on β-catenin transcriptional activity were tested directly via luciferase 
assay. This revealed a novel, bimodal Wnt regulatory role of DYRK1A. Particularly, the data suggest 
that DYRK1A is capable of both suppressing and enhancing Wnt signalling activity. DYRK1A overex-
pression was shown to potently downregulate basal β-catenin activity. When the pathway was stimu-
lated, however, DYRK1A exerted the opposite effect, further increasing activation several fold. This 
enhancement may also be prevented by co-expression of the DYRK1A interactor and Wnt antagonist 
DKK3. Accordingly, pharmacological inhibition of DYRK1A reduced active Wnt signalling in a dose-
dependent manner. Basal Wnt activity levels were not detectably affected by kinase inhibition treat-
ment, however. In support of DYRK1A-mediated downregulation of basal Wnt signalling, overexpres-
sion of this kinase also resulted in elevation of total GSK3β levels. Such increase was accompanied by 
reduced GSK3β phosphorylation at its inhibitory Ser9 residue, suggesting potential functional modula-
tion by DYRK1A.  
Bimodal Wnt signalling regulation by DYRK1A thus appears to be activation-dependent. Ultimately, 
the subcellular localisation of DYRK1A was investigated in relation to previously investigated Wnt acti-
vation states. Quantitative immunocytochemistry revealed that DYRK1A distribution may be affected 
by Wnt signalling stimulation. Whilst overexpressed DYRK1A was mostly nuclear under basal condi-
tions, activation of Wnt signalling led to significant redistribution in favour of the cytoplasmic com-
partment. 
In summary, the data overall indicate that DYRK1A interacts with Wnt components, regulates activity 
of the pathway and is itself controlled by Wnt signalling (Fig. R3.27). This set of findings generally es-
tablishes DYRK1A as a novel Wnt signalling modulator, with several ramifications for the understand-
ing of DS pathology. However, the data presented here also convey a highly complex picture, with 
findings not always logically consistent, which requires careful interpretation before any conclusion 
can be drawn. The aim of this discussion is thus twofold:  
I. To contextualise and predict the possible functional consequences of DYRK1A-mediated Wnt 
signalling modulation in cellular homoeostasis and more generally, DS pathology. 
II. To outline the technical limitations of the present findings, and identify possible strategies to 
further explore the newly characterised DYRK1A-Wnt relationship. 
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4.3.3 Discussion 
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I. To contextualise and predict the possible functional consequences of DYRK1A-mediated Wnt 
signalling modulation in cellular homoeostasis and more generally, DS pathology.
II. To outline the technical limitations of the present findings, and identify possible strategies to 
further explore the newly characterised DYRK1A-Wnt relationship.
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Despite this issue, current evidence suggests DYRK1A may indeed participate in Wnt-related protein 
networks. To explore this idea, all detected interactions were combined with the known DYRK1A-Wnt 
partners GSK3  and p120/ -catenin (83, 109) into a larger, computationally enriched network. This 
approach exploited experimental and literature knowledge to highlight the tight functional proximity 
between DYRK1A and Wnt signalling components, either primarily or secondarily interacting. Follow-
ing, potential effects of DYRK1A on -catenin transcriptional activity were tested directly via luciferase 
assay. This revealed a novel, bimodal Wnt regulatory role of DYRK1A. Particularly, the data suggest 
that DYRK1A is capable of both suppressing and enhancing Wnt signalling activity. DYRK1A overex-
pression was shown to potently downregulate basal -catenin activity. When the pathway was stimu-
lated, however, DYRK1A exerted the opposite effect, further increasing activation several fold. This 
enhancement may also be prevented by co-expression of the DYRK1A interactor and Wnt antagonist 
DKK3. Accordingly, pharmacological inhibition of DYRK1A reduced active Wnt signalling in a dose-
dependent manner. Basal Wnt activity levels were not detectably affected by kinase inhibition treat-
ment, however. In support of DYRK1A-mediated downregulation of basal Wnt signalling, overexpres-
sion of this kinase also resulted in elevation of total GSK3  levels. Such increase was accompanied by 
reduced GSK3  phosphorylation at its inhibitory S9 residue, suggesting potential functional modula-
tion by DYRK1A.  
Bimodal Wnt signalling regulation by DYRK1A thus appears to be activation-dependent. Ultimately, 
the subcellular localisation of DYRK1A was investigated in relation to previously investigated Wnt acti-
vation states. Quantitative immunocytochemistry revealed that DYRK1A distribution may be affected 
by Wnt signalling stimulation. Whilst overexpressed DYRK1A was mostly nuclear under basal condi-
tions, activation of Wnt signalling led to ZiNUiﬁJaU[ redistribution in favour of the cytoplasmic com-
partment. 
In summary, the data overall indicate that DYRK1A interacts with Wnt components, regulates activity 
of the pathway and is itself controlled by Wnt signalling (Fig. R3.27). This set of ﬁUKiUNZ generally es-
tablishes DYRK1A as a novel Wnt signalling modulator, with several raTiﬁJa[ioUZ for the understand-
ing of DS pathology. However, the data presented here also convey a highly complex picture, with 
ﬁUKiUNZ not always logically consistent, which requires careful interpretation before any conclusion 
can be drawn. The aim of this discussion is thus twofold:  
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Generally speaking, the obvious implication of the data presented here is that DYRK1A might contribute to 
the abnormal Wnt phenotypes observed in DS mouse models and humans at the protein level (4.2). It fol-
lows that Wnt signalling, as regulated by DYRK1A, might in the future be established as a target pathway 
for therapeutic intervention in DS. This proposal, associated potential strategies, as well as current evi-
dence on DS-DYRK1A therapies, are considered in detail in the general discussion of this thesis (5.2). 
4.3.3.1 Bimodal DYRK1A regulation of Wnt signalling: potential mechanisms 
It should first be stressed that the likelihood of functional Wnt regulation by DYRK1A is underscored 
by its participation in protein interaction networks relevant to this pathway. The power of the analysis 
conducted in this context relies on the combination of literature and experimental evidence. This 
demonstrated an important point: DYRK1A need not be placed more than two interactors away for 
the entire Wnt signalling pathway to be automatically included in a network. This suggests multiple 
potential access routes of DYRK1A to modulation of the Wnt pathway. However, an important consid-
eration must be made at this point. The enriched network generated here should not necessarily be 
taken as factual in a definitive sense. It could be argued that seeding any network with a small number 
of Wnt components will yield a comprehensive Wnt signalling network, and this might indeed be the 
case. Rather, the purpose of generating a larger network was simply to place the observed and previ-
ously reported DYRK1A-Wnt interactions into the wider context of this pathway. For this reason, this 
network was not analysed for enrichment in functional terms, because doing so would incur signifi-
cant bias, given that the network was originally constructed with several Wnt components. However, 
because the initial nodes were combined based on experimental evidence, it can be reliably conclud-
ed that the enriched network as least theoretically represents predicted but not definitively proven in-
teractions. In support of this point, it is perhaps not surprising that some network nodes added by 
string (e.g. CDH1, FOS) were also identified as differentially expressed genes in DS models (4.1). 
The notion that DYRK1A might participate in a highly-interconnected Wnt interaction network implies 
that its kinase activity might affect Wnt signalling. This was indeed the case when the pathway was 
investigated via luciferase assay. It should be conceded that the observed bimodal Wnt regulation by 
DYRK1A is somewhat counterintuitive. It may be generally argued that a kinase-regulated mechanism 
should exert consistent, homogeneous effects on its targets. For instance, DYRK1A effects on tau 
phosphorylation inevitably lead to its inhibition and accumulation (11), and no report currently sug-
gests and opposite effect. Literature evidence however suggests that DYRK1A might indeed regulate 
target processes bidirectionally. For instance, it is well known that NFAT transcriptional activity is inhib-
ited by DYRK1A (110). Another study however suggests that in specific contexts, DYRK1A might also 
enhance NFAT signalling (114). Additionally, as introduced, DYRK1A exerts bimodal effects on cell 
proliferation, both promoting and countering neuronal differentiation depending on tissue type (24, 26, 
29). This suggests that DYRK1A may be expected to bimodally regulate Wnt signalling. And indeed, 
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other known Wnt regulators are capable of such modulation. A prominent example mentioned here is 
LRRK2, which was shown to both promote and suppress Wnt signalling based on activation state, 
similarly to DYRK1A (102-104). It is interesting that the Wnt abnormalities here observed, in DS mod-
els and humans, were also bidirectional and varied based on tissue type and/or organism. It may be 
speculated that the bimodal Wnt effects of DYRK1A might be reflected in this phenotype, although 
this remains to be determined.  
The imaging data presented here may shed light on why DYRK1A appears to drive Wnt signalling in 
both directions. When overexpressed under basal conditions, DYRK1A localised to the nucleus, and 
also suppressed Wnt signalling activity. It follows that, within the nucleus, DYRK1A might directly par-
ticipate in transcriptional mechanisms suppressing β-catenin activation. Conversely, since DYRK1A 
was prominently cytoplasmic upon Wnt signalling activation, its enhancing effects might be mediated 
in this compartment, possibly via interaction with DVL1. An additional potential contributor to DYRK1A 
modulation of Wnt signalling is GSK3β. Here, it was shown that DYRK1A overexpression is sufficient 
to increase protein levels of GSK3β, with a small reduction in Ser9 phosphorylation. Importantly, a re-
cent key finding by Song et al demonstrated that DYRK1A interacts with and phosphorylates GSK3β 
at T356 (109). This interaction resulted in GSK3β inactivation and amelioration of an obesity pheno-
type in TgGSK3β mice. Reviewed evidence has clearly showed a prominent regulatory role of Wnt 
signalling in adipogenesis (115). Therefore, DYRK1A may contribute to Wnt signalling activation via 
GSK3β inhibition. Whilst in the nucleus, DYRK1A has little access to cytosolic GSK3β. Upon Wnt sig-
nalling activation, however, recruitment to DVL1 phase partitions may bring DYRK1A in close proximity 
to GSK3β, resulting in inhibition of the latter and further enhancement of active Wnt signalling. GSK3β 
might also be involved in nuclear effects of DYRK1A, given that it can itself localise to the nucleus and 
suppress Wnt signalling activity (116, 117). As introduced, DYRK1A employs priming phosphorylation 
to target substrates for further modification by GSK3β and subsequent degradation (44, 49, 84, 85). A 
similar interaction might alternatively allow DYRK1A to direct GSK3β phosphorylation to additional 
Wnt signalling components. These may include AXIN, APC, LRP5/6 and β-catenin itself, all substrates 
of GSK3β. On the other hand, It is also possible that Wnt regulation by DYRK1A is achieved via multi-
ple pathways including p120/δ-catenin, NFAT, and non-Wnt GSK3β substrates. At present, however, 
the nature of these mechanisms remains speculative, and they must be further investigated to clarify 
exactly how DYRK1A may control Wnt signalling activity. In summary, however, it can be concluded 
that the studies outlined here provide novel, preliminary insight into a complex, bimodal DYRK1A-Wnt 
relationship. 
Assuming the reliability of these findings at least on a preliminary level, they can be further interpreted. 
The wider implication of this dualistic DYRK1A effect in DS is that a complex, multi-directional tempo-
ral and spatial alteration in Wnt target gene expression may occur throughout life. In addition to being 
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dosage-sensitive, DYRK1A is also a constitutively active kinase. It follows that in DS, where the default 
level of DYRK1A expression is chronically elevated, Wnt signalling might be linearly affected as a con-
sequence, in a direction determined by local activation states. This implies that tissue types with low 
basal Wnt signalling levels, such as adult neurons, may suffer from further downregulation. Conversely, 
developmental switches in Wnt signalling activity, or physiological activation in adult tissue may be ab-
normally enhanced by chronic DYRK1A overexpression. Both over- and under-activation of Wnt sig-
nalling in the hippocampus are expected to be deleterious during brain development (106), neurogen-
esis (118) and LTP (119), as fine regulation is crucial. Indeed, human DS hippocampi displayed de-
creased Wnt signalling activity (4.2.2), which is also known to contribute to idiopathic AD neu-
ropathology [(120-123) see 5.1-2 for integrated discussion of all data generated in this thesis]. Overall, 
the original hypothesis formulated in this chapter was corroborated by experimental data and contex-
tualised within the relevant literature. It appears that DYRK1A is capable of Wnt signalling regulation, 
with complex effects which may contribute to critical dysfunction of this pathway in DS. However, 
much remains to be determined on the mechanistic nature of the Wnt-DYRK1A relationship. 
4.3.3.2 Limitations and future approaches 
Despite the interesting nature of these novel findings, there are a number of technical limitations inher-
ent to the methods employed which deserve consideration. They are briefly discussed here, along 
with potential countermeasures for subsequent work (see 5.2 and 6 for more general considerations 
on future directions). First, the majority of data presented were generated in overexpression systems. 
Whilst DYRK1A is indeed overexpressed in DS, the high protein abundance resulting from artificial ex-
pression might not faithfully recapitulate physiological conditions. It is possible that endogenous 
DYRK1A overexpression in DS might be much milder, and therefore unlikely to affect Wnt signalling to 
the extent observed in luciferase assays. This idea also applies to some of the interaction studies per-
formed, which employed co-IP of FLAG-tagged proteins. Such approach greatly enhances through-
put, but at the cost of specificity. It may be speculated that, under endogenous conditions, DYRK1A 
might be much less likely to interact with DVL1 or DKK3.  
It is also important to mention that the employment of LiCl as a Wnt stimulation method (4.3.2.2) is 
not an entirely reliable approach if performed alone. Lithium is in fact well known to inhibit a wide 
range of kinases other than GSK3β. Although Wnt activation was indeed detected with LiCl treatment, 
it cannot be excluded that other non-specific effects might be present, thus constituting a potential 
confounding factor. For this reason, Wnt3a treatment and DVL1 overexpression were here employed 
alongside so as to improve the reliability of results. Future studies should therefore aim to replicate 
these results employing additional Wnt stimulation methods, such as alternative ligands and overex-
pression of other activating components (e.g. β-catenin, FZD).  
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With respect to the co-IP data, another key limitation is present. These experiments were performed 
employing beads pre-conjugated with a FLAG antibody. Whilst this approach enhances pull-down 
efficiency and reduces time required, it does not allow for the inclusion of important experimental con-
trols. In traditional co-IP experiments, beads are generally conjugated to a specific antibody in-house, 
prior to pull-down. This ensures that the presence of non-specific binding products is controlled for, 
specifically by conjugating the beads to an unrelated antibody and by employing no antibody at all 
(mock IP). Since FLAG beads are not supplied with such controls, alternative non-conjugated beads 
should have been employed in the experiments here. This strategy introduces variability, since non-
equivalent beads and additional conjugation steps would be performed specifically for the controls. 
They were thus not included here for these reasons. Instead, non-specific binding was controlled for 
by incubating the FLAG beads in empty vector-transfected cell lysates. This helped exclude spurious 
protein binding by the FLAG antibody. It is however essential to state that all co-IP interactions report-
ed here must be validated by alternative approaches including the above mentioned controls. In 
summary, verification of these results must crucially be performed both via overexpression and en-
dogenously before any definitive conclusion can be made. 
Interpretation of imaging data might be limited by the fact that overexpression induces abnormally 
high intracellular accumulation of proteins under study, possibly resulting in non-physiological pheno-
types. Without detracting from the validity of these results, future studies should aim to validate and 
characterise the Wnt-DYRK1A relationship from a more endogenous viewpoint. For instance, KO cell 
systems could be employed to determine the presence of any DYRK1A-mediated effects on basal 
and active Wnt signalling. Endogenous co-precipitation of proposed DYRK1A interactors should also 
be proven under physiological conditions, and in multiple tissue types. Likewise, imaging approaches 
should aim to reliably detect endogenous DYRK1A levels and investigate how they might, if at all, be 
altered by Wnt activation. Subsequent studies should also validate DYRK1A-mediated Wnt modula-
tion in less artificial cell systems. The neuroblastoma cell lines employed here is highly proliferative, 
and might respond to Wnt signalling in non-physiological ways. Thus, the effects of DYRK1A could 
more appropriately be investigated in primary neuronal cultures derived from both mice and humans.  
These proposed approaches might help further establish the novel findings presented here, and ex-
pand knowledge on the complex role of DYRK1A in DS and Wnt signalling. 
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Chapter 5 - General Discussion 
The existence of a profound interplay between DS and early development of AD has long been document-
ed (1). Moreover, alterations in canonical Wnt signalling are currently thought to contribute to AD pathogen-
esis (2-4). The well known importance of this signalling pathway in several neuronal developmental and 
homoeostatic processes implies that Wnt dysfunction in AD or DS could reasonably lead to cell pathology. 
Despite preliminary evidence of multiple Hsa21 genes interacting with Wnt signalling, no direct Wnt-DS re-
lationship has yet been described. For these reasons, this thesis sought to investigate a potential correla-
tion between Hsa21 trisomy and Wnt signalling alterations (4.1-2) and to characterise the effects of a se-
lected Hsa21 candidate, DYRK1A, on Wnt signalling function (4.3). The studies conducted thus generated 
multiple lines of evidence overall establishing, for the first time, Wnt signalling as a significant contributor to 
DS. These are briefly summarised here, and specifically discussed in each results chapter. The purpose of 
this concluding section is to consider all results in the general context of DS, and offer insight into how they 
might be expanded upon by future work, particularly in the context of therapeutic development. 
5.1 Summary of all results 
Results are first briefly summarised and discussed critically, in order to conceptually recap the conclusions 
of each set of studies and lay the basis for an integrative discussion (see 4.1-3.3 for chapter-specific dis-
cussion points). 
Fig. D.1 - Diagrammatic integrated summary of all results in this thesis.
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Fig. D.1 - Diagrammatic integrated summary of all results in this thesis.
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5.1.1 Wnt signalling is potentially abnormal in DS  
As discussed in the general introduction, genetic (1.4.1) and protein (1.4.2) work conducted in DS high-
lights complex alterations linked to several biological processes. Such abnormalities feature a degree of 
variability between tissue types and organisms examined. This phenomenon was similarly observed here, 
when DS-related and secondary transcriptional changes were examined (4.1) along with Wnt pathway 
components and activity (4.2). Nevertheless, this does not subtract from the preliminary conclusions that 
can be drawn from the data. First, modelled trisomy recapitulates phenotypes seen in human DS, as ob-
served via hippocampal RNAseq (4.1). This confirms the reliability of Tc1 and Dp1Tyb mice. Second, 
Hsa21 trisomy is sufficient to affect Wnt signalling in the DS brain (4.2), at least for the parameters as-
sessed here and most importantly the active β-catenin fraction. Given the presently limited understanding 
of molecular mechanisms in DS, this notion has important implications for the global understanding of this 
syndrome. The main findings in this regard can overall be summarised through the following key points: 
I. The hippocampal transcriptome of DS mouse models recapitulates features of the human syn-
drome, and preliminarily suggests an association with altered Wnt signalling (4.1): 
A. DS-relevant Hsa21-Mmu16 genes are overexpressed, as seen in human DS. 
B. Genome-wide, secondary transcriptional alterations are observed, similarly to humans. 
C. In both mouse models, a number of secondarily affected genes are Wnt-related: 
1. The Tc1 hippocampal transcriptome displays reduced expression of the Wnt target gene 
Axin2, and enhanced expression of Dkk3, amongst others.  
2. The Dp1Tyb hippocampus displays reduced expression of the Wnt target gene Axin2 and 
the Wnt receptor gene Fzd2, amongst others.  
II. Wnt signalling activity dysfunction is observed at the protein level in the DS brain (4.2): 
A. β-catenin activity is significantly altered in the CNS tissue of DS mouse models and humans. 
B. The abnormalities detected correlate with enhancements in DYRK1A levels. 
C. Protein changes are complex, tissue-specific and multidirectional: 
1. The Tc1 and human DS hippocampus both display suppression of Wnt signalling activity. 
2. The Dp1Tyb hippocampus and Tc1 cerebral cortex, however, possess enhanced Wnt sig-
nalling activity, whilst the Dp1Tyb cortex is unaffected. 
3. The Wnt antagonist DKK3 is reduced in the human DS hippocampus, but enhanced in Tc1 
and Dp1Tyb hippocampi, whilst GSK3β remains unaffected throughout. 
III. Candidate genes for the observed Wnt phenotype likely map to Mmu16 orthologs (4.2): 
A. Both Tc1 and Dp1Tyb mice overexpress Mmu16 orthologs, and displayed altered Wnt signalling. 
B. No alterations in hippocampal Wnt signalling activity were observed in Dp1(10-17)Yey mice. 
C. Therefore, Mmu10-17 orthologs are much less likely to mediate the Wnt phenotypes observed 
in DS mouse models and human hippocampi. 
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5.1.2 DYRK1A regulates canonical Wnt signalling activity 
Conceptually, the second overarching finding of this thesis is the identification of the candidate Hsa21 gene 
DYRK1A as a novel Wnt signalling modulator. As discussed (4.3.1/3), DYRK1A is well placed to account 
for the Wnt phenotypes observed in mice and humans, given its location on Mmu16 and known impor-
tance for learning disability in DS. The evidence hereby generated linking DYRK1A to Wnt function can 
overall be summarised through the following key points: 
IV. DYRK1A participates in complex Wnt signalling protein interaction networks: 
A. Unbiased STRING database screening identified significant Wnt-associated interaction part-
ners for all members of the DYRK family of kinases. 
B. Yeast two-hybrid demonstrated multiple DYRK1A interactions with Wnt signalling compo-
nents, most notably DKK3, which binds DYRK1A at a nuclear speckle-localising sequence. 
C. Co-immunoprecipitation showed DYRK1A interacts with DKK3 and DVL1, but not β-catenin. 
D. Integration of these results (B-C) with literature evidence for DYRK1A binding of p-120/δ-
catenin and GSK3β via STRING generated a highly interconnected network, demonstrating 
the functional proximity of DYRK1A to all major Wnt signalling components. 
V. DYRK1A is a novel, bimodal canonical Wnt signalling regulator: 
A. DYRK1A kinase inhibition reduces active but not basal Wnt signalling activity.  
B. The Wnt inhibitory effects of INDY are dose-dependent. 
C. DYRK1A overexpression greatly reduces basal Wnt activity whilst enhancing active signalling 
D. DYRK1A overexpression enhances total GSK3β protein levels, whilst reducing p-S9.  
E. Whilst DKK3 exerts no effect on active or basal Wnt signalling, it may be able to prevent 
DYRK1A-mediated enhancement of DVL1/Wnt activation. 
VI. Wnt signalling activation affects subcellular DYRK1A localisation: 
A. DYRK1A is prominently nuclear at basal Wnt activity levels. 
B. Wnt signalling activation induces significant cytoplasmic redistribution of DYRK1A. 
C. The effect applies to LiCl, Wnt3a and DVL1-induced activation. 
D. DYRK1A co-localises with cytoplasmic DVL1 phase transitions. 
Overall, these results suggest a novel Wnt regulatory role for DYRK1A, which might influence Wnt sig-
nalling bimodally whilst being itself regulated by activity of the pathway. A further general principle may 
be preliminarily extrapolated from 5.1.1-2. Chronic dysregulation of Wnt and other transcriptional sig-
nalling pathways, due to triplication of modulators such as DYRK1A, may effectively extend gene 
dosage imbalance to a high number of secondary targets, possibly accounting for the known 
genome-wide transcriptional alterations typical of DS. 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5.1.3 Critical evaluation of experimental results 
Having summarised the main experimental conclusions of this thesis, it is important at this point to take a 
step back and critically evaluate results in light of some existing technical limitations. These might in fact 
hinder interpretative discussion of the data and, particularly in some cases, constitute non-trivial confound-
ing factors. Alternative interpretations of key results, along with potential strategies to validate or confute 
them, must therefore be considered. They are discussed in this section, chapter by chapter and overall, so as 
to emphasise the preliminary nature of this thesis’ findings and ensure neutrality is maintained. 
5.1.3.1 Chapter 4.1 - Analysis of the DS transcriptome 
In this chapter, hippocampal gene expression profiles of Tc1 and Dp1Tyb mice were investigated via 
RNAseq. The main purpose here was to preliminarily assess the aneuploid status of these two models. 
Results were quite clear in this respect, especially in light of the relevant literature discussed (1.4.1). It is not 
surprising that Tc1 and Dp1Tyb mice display the expected DS-like pattern of Hsa21/Mmu16 gene overex-
pression. In both cases, primary transcriptional alterations were consistent with previous reports (5-7). This 
reproducibility also applied to one of the main limitations inherent to the RNAseq data, i.e. the loss of func-
tional trisomy for the APP gene in Tc1 mice. This finding implies the artificial silencing of any phenotypic 
contribution of APP to the Tc1 hippocampus, whereas this gene is of fundamental importance in human 
DS and AD-DS. It follows that transcriptional and biochemical abnormalities identified in this mouse, prima-
ry or secondary, cannot possibly be mediated by APP overexpression. Thus if present, they should occur 
independently of said gene, and must be considered as such. No conclusion regarding APP may then be 
made for the Tc1 mouse, and this is a significant limiting factor in the context of AD-DS. On the other hand, 
however, the absence of APP in this model might also be advantageous, in the sense that it allows for iso-
lation of phenotypic contributions by other key DS genes, such as DYRK1A. Importantly, the functional loss 
of APP in the Tc1 mouse is not a novel finding, and has been previously reported (6). A sensible strategy to 
address this issue, as suggested by reviewers, is to crossbreed Tc1 mice with the established J20 line, an 
AD model which overexpresses two FAD-associated APP mutants (8). This would indeed provide a more 
faithful recapitulation of DS, by accounting for the full effects of APP trisomy. In the context of this thesis, it 
can be proposed that Tc1-J20 hybrids should be employed in further RNAseq and biochemical studies. 
Such and approach would aim to compare and contrast the phenotypes here observed and assess their 
validity. This consideration also applies to the primary hypothesis of this thesis, i.e. a potential contribution of 
Wnt signalling to DS. 
In this regard, there is another key obstacle to the interpretation of results reported in 4.1. As already dis-
cussed (4.1.3.3), the RNAseq and IPA analyses, alone, are not sufficient to infer a significant contribution of 
abnormal Wnt signalling to the transcriptional profiles generated from either DS model. Granted, the objec-
tive presence of multiple DEX genes functionally associated to Wnt signalling was indeed observed. Prom-
inent examples include the canonical Wnt target and negative regulator Axin2, reduced in both mice, the 
inhibitor Dkk3, increased in the Tc1, and the transmembrane receptor Fzd2, reduced in the Dp1Tyb. Addi-
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tionally, canonical pathway analysis via IPA demonstrated a statistical association of canonical Wnt sig-
nalling with the Tc1 dataset, which was also the most significant enrichment for this mouse. By contrast, 
however, the Dp1Tyb data did not register a positive enrichment with the Wnt pathway, which only trended 
in association. Taken together, these findings only allow for the objective conclusion that, in the hippocam-
pal transcriptome of two DS models, a number of secondary DEX genes are Wnt-related. This inference is 
supported by established literature knowledge of said genes (9, 10). Crucially, however, based on these 
data no further claim can be made without incurring considerable bias. There are simply too many con-
founding factors to deduce an overall involvement of Wnt in DS. As discussed (4.1.3.3), for instance, based 
on these findings it is impossible to dissect which individual hippocampal cell types contributed differential 
amounts of mRNA to the sequenced samples. This is indeed a critical issue. Determining the cellular origin 
of specific gene expression patterns is in fact paramount to even proposing the involvement of a coherent 
biological pathway. The transcriptional profiles detected here might distribute to distinct cell types, and not 
manifest concomitantly in any one population. Importantly, the hippocampus is notoriously composed of a 
wide spectrum of cell types beyond neurons, including microglia and oligodendrocytes. Even within these 
three types there are several known subclasses. For all these data show, the observed phenotypes might 
not even be neuronal at all. This calls into question the idea that such Wnt-related DEX genes may directly 
contribute to neurodegeneration. Moreover, there is little overlap in secondary expression patterns between 
the two mouse models, with Axin2 being the sole primary Wnt component common to both. This may be 
at least partly accounted for by the significant genetic differences which set the two models apart, as dis-
cussed previously (4.1.3.2). However, this in itself may be seen as an additional confounding factor, pre-
venting any further interpretation. 
As a result it may only be stated that, for the scope of this thesis, some Wnt-related DEX genes are simply 
present in the hippocampus of two DS models. This constitutes a strictly preliminary indication, which 
might nevertheless deserve further inquiry. In order to clarify or equally refute this claim, additional studies 
are mandatory. For instance, it may be advisable to replicate the approach in 4.1.2 employing an extended 
range of DS models as well as human samples. Such a strategy should entail the use of genetic material 
obtained from dissected tissue, as in 4.1.2, as well as primary cultures derived from multiple, distinct cell 
types across all mouse models and/or humans. The latter effort should employ single-cell RNAseq in order 
to determine whether biologically-coherent signalling pathway defects are at all present and consistently 
replicable. In light of these reasons, therefore, great care must be exercised when considering results ob-
tained in chapter 4.1. Overall, the only sensible conclusion to be drawn here is that these models recapitu-
late DS to a reasonable extent, and are thus reliable for employment in later studies. 
196
Chapter 5 - General Discussion 
5.1.3 Critical evaluation of experimental results 
Having summarised the main experimental conclusions of this thesis, it is important at this point to take a 
step back and critically evaluate results in light of some existing technical limitations. These might in fact 
hinder interpretative discussion of the data and, particularly in some cases, constitute non-trivial confound-
ing factors. Alternative interpretations of key results, along with potential strategies to validate or confute 
them, must therefore be considered. They are discussed in this section, chapter by chapter and overall, so as 
to emphasise the preliminary nature of this thesis’ findings and ensure neutrality is maintained. 
5.1.3.1 Chapter 4.1 - Analysis of the DS transcriptome 
In this chapter, hippocampal gene expression profiles of Tc1 and Dp1Tyb mice were investigated via 
RNAseq. The main purpose here was to preliminarily assess the aneuploid status of these two models. 
Results were quite clear in this respect, especially in light of the relevant literature discussed (1.4.1). It is not 
surprising that Tc1 and Dp1Tyb mice display the expected DS-like pattern of Hsa21/Mmu16 gene overex-
pression. In both cases, primary transcriptional alterations were consistent with previous reports (5-7). This 
reproducibility also applied to one of the main limitations inherent to the RNAseq data, i.e. the loss of func-
tional trisomy for the APP gene in Tc1 mice. This finding implies the artificial silencing of any phenotypic 
contribution of APP to the Tc1 hippocampus, whereas this gene is of fundamental importance in human 
DS and AD-DS. It follows that transcriptional and biochemical abnormalities identified in this mouse, prima-
ry or secondary, cannot possibly be mediated by APP overexpression. Thus if present, they should occur 
independently of said gene, and must be considered as such. No conclusion regarding APP may then be 
made for the Tc1 mouse, and this is a significant limiting factor in the context of AD-DS. On the other hand, 
however, the absence of APP in this model might also be advantageous, in the sense that it allows for iso-
lation of phenotypic contributions by other key DS genes, such as DYRK1A. Importantly, the functional loss 
of APP in the Tc1 mouse is not a novel finding, and has been previously reported (6). A sensible strategy to 
address this issue, as suggested by reviewers, is to crossbreed Tc1 mice with the established J20 line, an 
AD model which overexpresses two FAD-associated APP mutants (8). This would indeed provide a more 
faithful recapitulation of DS, by accounting for the full effects of APP trisomy. In the context of this thesis, it 
can be proposed that Tc1-J20 hybrids should be employed in further RNAseq and biochemical studies. 
Such and approach would aim to compare and contrast the phenotypes here observed and assess their 
validity. This consideration also applies to the primary hypothesis of this thesis, i.e. a potential contribution of 
Wnt signalling to DS. 
In this regard, there is another key obstacle to the interpretation of results reported in 4.1. As already dis-
cussed (4.1.3.3), the RNAseq and IPA analyses, alone, are not sufficient to infer a significant contribution of 
abnormal Wnt signalling to the transcriptional profiles generated from either DS model. Granted, the objec-
tive presence of multiple DEX genes functionally associated to Wnt signalling was indeed observed. Prom-
inent examples include the canonical Wnt target and negative regulator Axin2, reduced in both mice, the 
inhibitor Dkk3, increased in the Tc1, and the transmembrane receptor Fzd2, reduced in the Dp1Tyb. Addi-
195
Chapter 5 - General Discussion 
tionally, canonical pathway analysis via IPA demonstrated a statistical association of canonical Wnt sig-
nalling with the Tc1 dataset, which was also the most significant enrichment for this mouse. By contrast, 
however, the Dp1Tyb data did not register a positive enrichment with the Wnt pathway, which only trended 
in association. Taken together, these findings only allow for the objective conclusion that, in the hippocam-
pal transcriptome of two DS models, a number of secondary DEX genes are Wnt-related. This inference is 
supported by established literature knowledge of said genes (9, 10). Crucially, however, based on these 
data no further claim can be made without incurring considerable bias. There are simply too many con-
founding factors to deduce an overall involvement of Wnt in DS. As discussed (4.1.3.3), for instance, based 
on these findings it is impossible to dissect which individual hippocampal cell types contributed differential 
amounts of mRNA to the sequenced samples. This is indeed a critical issue. Determining the cellular origin 
of specific gene expression patterns is in fact paramount to even proposing the involvement of a coherent 
biological pathway. The transcriptional profiles detected here might distribute to distinct cell types, and not 
manifest concomitantly in any one population. Importantly, the hippocampus is notoriously composed of a 
wide spectrum of cell types beyond neurons, including microglia and oligodendrocytes. Even within these 
three types there are several known subclasses. For all these data show, the observed phenotypes might 
not even be neuronal at all. This calls into question the idea that such Wnt-related DEX genes may directly 
contribute to neurodegeneration. Moreover, there is little overlap in secondary expression patterns between 
the two mouse models, with Axin2 being the sole primary Wnt component common to both. This may be 
at least partly accounted for by the significant genetic differences which set the two models apart, as dis-
cussed previously (4.1.3.2). However, this in itself may be seen as an additional confounding factor, pre-
venting any further interpretation. 
As a result it may only be stated that, for the scope of this thesis, some Wnt-related DEX genes are simply 
present in the hippocampus of two DS models. This constitutes a strictly preliminary indication, which 
might nevertheless deserve further inquiry. In order to clarify or equally refute this claim, additional studies 
are mandatory. For instance, it may be advisable to replicate the approach in 4.1.2 employing an extended 
range of DS models as well as human samples. Such a strategy should entail the use of genetic material 
obtained from dissected tissue, as in 4.1.2, as well as primary cultures derived from multiple, distinct cell 
types across all mouse models and/or humans. The latter effort should employ single-cell RNAseq in order 
to determine whether biologically-coherent signalling pathway defects are at all present and consistently 
replicable. In light of these reasons, therefore, great care must be exercised when considering results ob-
tained in chapter 4.1. Overall, the only sensible conclusion to be drawn here is that these models recapitu-
late DS to a reasonable extent, and are thus reliable for employment in later studies. 
196
Chapter 5 - General Discussion 
5.1.3.2 Chapter 4.2 - Wnt signalling proteins in DS mouse models and humans  
In this chapter, protein level analysis of DS model and human brain tissue was undertaken, in order to pri-
marily investigate a hypothesis of Wnt signalling contribution to DS. It may overall be conceded that results, 
in this case, are more robust than those in 4.1. QPCR analysis of Dkk3 and Axin2 in the Tc1 mouse first 
demonstrated significantly enhanced and reduced expression, respectively, of the two genes. Importantly, 
this result was consistent with RNAseq data, providing support to the idea that the two Wnt components 
might indeed be abnormal in this model. Immunoblotting investigation of canonical Wnt activity and com-
ponents then revealed what is perhaps the key finding of this thesis. That is, Wnt signalling alterations are 
present in the hippocampus of both mice as well as human DS individuals (4.2.2.1-4). The most significant 
observation here is that both Tc1 and human hippocampi display consistent suppression of canonical Wnt 
signalling activity, a notion which agrees with current evidence implicating suppression of this pathway in 
AD. However, some inconsistencies are present in these data which are difficult to reconcile. For instance, 
protein changes are, in some cases, directionally divergent across tissues. DKK3 levels are decreased in 
the human DS hippocampus, as opposed to Tc1 and Dp1Tyb mice. The latter two also display diametrical-
ly opposite Wnt signalling changes, with enhanced activity observed in the Dp1Tyb hippocampus. Even 
within the Tc1 brain there is variability, ad cortical samples display an increase in Wnt activity, opposite to 
hippocampal tissue. Overall, the observed differences compared to control samples are however statisti-
cally significant and replicable. It is therefore difficult to absolutely question their presence, which might pro-
visionally be assumed. However, the inconsistencies outlined above suggest considerable complexity of Wnt 
dysregulation in DS, with a potentially heterogeneous, variable picture. As such, based on these data, it is nei-
ther recommended nor possible to extrapolate a uniform conclusion as to the direction of Wnt abnormalities 
in the DS brain. It should also be stressed that the cell type origin issue raised in the previous section also ap-
plies here. It is not possible, at present, to clearly dissect the source of altered β-catenin activity levels. 
The evidence gathered in 4.2 overall suggest novel, significant Wnt signalling abnormalities in the DS brain, 
which are more likely to manifest in vivo as suppression in the hippocampus. These findings are however 
somewhat contradictory, and further exploratory studies must be performed for full validation or eventual 
refutation. A sensible strategy in this regard may be to replicate all analyses in 4.2 employing an extended 
range of DS tissues. Additional mouse models must be incorporated, as well as a greater number of tissue 
types, within the brain and beyond. Furthermore, it is crucial to determine whether Wnt changes vary, or 
are present at all, over a comprehensive age range. Here, mice were assessed at a single time point of 4-6 
months of age, whilst human tissue was examined post-mortem. It follows that the available evidence only 
allows to preliminary conclude the presence of Wnt abnormalities at a specific age. No further inferences 
can be made without speculation. In summary, chapter 4.2 results indicate a possible contribution of al-
tered, and likely suppressed, canonical Wnt signalling to the DS brain. These findings must however be 
clarified and validated before being considered scientifically sound. 
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5.1.3.3 Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation 
This chapter investigated a candidate gene hypothesis for DYRK1A, a crucial contributor to DS, as a po-
tential Wnt signalling modulator. This hypothesis was formulated to at least partly account for the Wnt phe-
notypes observed in 4.2. Such proposal is based on current knowledge on the key roles of DYRK1A in DS 
(11), as well as the observation that segmental trisomy models for Mmu10/17, which lack DYRK1A over-
expression, do not display abnormal Wnt signalling biochemically (4.2.2.3). To address this hypothesis, 
yeast and human cell lines were employed to investigate DYRK1A-Wnt effects, combining studies on pro-
tein interactions, luciferase-mediated Wnt activity and, lastly, subcellular localisation. Data in this chapter 
overall suggest DYRK1A might participate in Wnt protein interaction networks and regulate Wnt signalling 
bimodally, whilst being itself influenced by the pathway via subcellular localisation. These key results, along 
with the associated limitations and proposed clarifying strategies, are assessed and detailed in sections 
4.3.3.1-2 and 5.2.2.2. The most critical example in this regard, requiring validation, is the surprising finding of 
a DYRK1A interaction with DKK3, the reportedly secreted inhibitor also altered in DS models and humans. 
In summary, it should be reiterated that whilst the data collected in 4.3 do suggests DYRK1A has the ability 
to modulate Wnt signalling across multiple model systems, the existence of these effects in vivo cannot be 
postulated, due to lack of evidence. Therefore, extensive further studies are an absolute requirement to 
clarify if, and how, DYRK1A overexpression might impact Wnt signalling in DS. The importance of this ne-
cessity is unquestionable. Nevertheless, it does not detract from the novel findings of chapter 4.3, which 
for the first time demonstrated Wnt modulation by DYRK1A, a fundamental kinase in DS and DS-AD. 
5.1.3.4 Overall considerations 
The evidence gathered here, due to its novel nature, is limited by several factors. These were discussed 
along with some alternative interpretations. It is obvious that, at present, the preliminary implication of Wnt 
signalling in DS is far from clear. This thesis only aims to provide an initial direction for further scientific in-
quiry. An in depth mechanistic account of how Wnt signalling may induce pathology in DS remains to be 
provided. The process by which bimodal Wnt regulation by DYRK1A alters finely tuned developmental and 
adult Wnt signalling remains elusive. Ultimately, the complex tapestry of Wnt dysregulation in a multi-
faceted condition such ad DS has only been scratched at the surface. Its directionality, extent and exact 
contribution to DS phenotypes are yet to be fully determined. 
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5.1.3.3 Chapter 4.3 - DYRK1A-mediated Wnt signalling modulation 
This chapter investigated a candidate gene hypothesis for DYRK1A, a crucial contributor to DS, as a po-
tential Wnt signalling modulator. This hypothesis was formulated to at least partly account for the Wnt phe-
notypes observed in 4.2. Such proposal is based on current knowledge on the key roles of DYRK1A in DS 
(11), as well as the observation that segmental trisomy models for Mmu10/17, which lack DYRK1A over-
expression, do not display abnormal Wnt signalling biochemically (4.2.2.3). To address this hypothesis, 
yeast and human cell lines were employed to investigate DYRK1A-Wnt effects, combining studies on pro-
tein interactions, luciferase-mediated Wnt activity and, lastly, subcellular localisation. Data in this chapter 
overall suggest DYRK1A might participate in Wnt protein interaction networks and regulate Wnt signalling 
bimodally, whilst being itself influenced by the pathway via subcellular localisation. These key results, along 
with the associated limitations and proposed clarifying strategies, are assessed and detailed in sections 
4.3.3.1-2 and 5.2.2.2. The most critical example in this regard, requiring validation, is the surprising finding of 
a DYRK1A interaction with DKK3, the reportedly secreted inhibitor also altered in DS models and humans. 
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to modulate Wnt signalling across multiple model systems, the existence of these effects in vivo cannot be 
postulated, due to lack of evidence. Therefore, extensive further studies are an absolute requirement to 
clarify if, and how, DYRK1A overexpression might impact Wnt signalling in DS. The importance of this ne-
cessity is unquestionable. Nevertheless, it does not detract from the novel findings of chapter 4.3, which 
for the first time demonstrated Wnt modulation by DYRK1A, a fundamental kinase in DS and DS-AD. 
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The evidence gathered here, due to its novel nature, is limited by several factors. These were discussed 
along with some alternative interpretations. It is obvious that, at present, the preliminary implication of Wnt 
signalling in DS is far from clear. This thesis only aims to provide an initial direction for further scientific in-
quiry. An in depth mechanistic account of how Wnt signalling may induce pathology in DS remains to be 
provided. The process by which bimodal Wnt regulation by DYRK1A alters finely tuned developmental and 
adult Wnt signalling remains elusive. Ultimately, the complex tapestry of Wnt dysregulation in a multi-
faceted condition such ad DS has only been scratched at the surface. Its directionality, extent and exact 
contribution to DS phenotypes are yet to be fully determined. 
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5.2 Wider implications of a DS-Wnt relationship 
Despite the limitations outlined in 5.1.3, a Wnt signalling contribution to DS is likely, at the very least partial-
ly. For the purpose of this extended discussion, this principle can thus be initially assumed as valid, and 
utilised as a framework to argue in favour of two wider implications. First, that several aspects of DS, be-
yond neurodegeneration, may be accounted for by underlying alterations in Wnt signalling function. Sec-
ond, that a Wnt-DYRK1A pathway may, in the future, be targeted therapeutically in DS.  
It should be stressed that this discussion does not presume the absolute validity of results discussed. 
Rather, it builds on the key preliminary findings of this thesis, in order to explore more far-reaching implica-
tions. These nevertheless essentially rely on further validation of the data generated here. This necessity, 
without doubt, takes experimental priority. It is in fact logically required before knowledge on a Wnt-DS rela-
tionship, if any, may at all be translated therapeutically. 
5.2.1 Links between Wnt signalling and known DS phenotypes 
The evidence generated in this thesis demonstrates the involvement of Wnt signalling in a least three dis-
tinct tissue types in DS: the hippocampus, cerebral cortex and fibroblasts. Despite no presently available 
data on other physiological systems or tissues, the known pervasiveness of Wnt signalling function in many 
biological mechanisms warrants the question of whether this pathway is globally affected in DS, beyond 
the CNS. The main logical premise of this idea is based on the fact that Hsa21 trisomy extends to all cell 
types in DS, regardless of individual variability or mosaicism. Consequently, the Wnt modulatory properties 
of Hsa21 genes such as DYRK1A most likely apply to any tissue in which such genes are overexpressed. 
Without speculating on exactly how Wnt modulation may occur, it is nevertheless possible to superimpose 
the general notion of dysfunctional Wnt signalling on several DS phenotypes other than CNS pathology. 
Interestingly, multiple characteristics of DS might be conceptually accounted for by underlining alterations in 
Wnt signalling activity, by integrating evidence generated here with literature knowledge on Wnt function. 
This approach may help establish a conceptual basis for future investigation. 
Characteristic craniofacial morphology - Individuals affected by DS possess distinctive physical traits 
which are especially manifest in the face and head, and through altered growth patterns (12). A key study 
outlining such features was produced in 1993 by Allanson et al. (13). The authors recruited 199 DS individ-
uals spanning a wide age range (0.5-61 years) and performed a measured set of 21 ‘anthropometric’ cran-
iofacial traits. Amongst these, three were identified as 98-99% likely to uniquely distinguish DS individuals 
from controls: reduced ear length and maxillary arc growth, as well as brachycephaly. Such findings reflect 
the core developmental component of DS. It follows that these physical characteristics must arise as a di-
rect result of finely altered developmental body/head patterning. Indeed, Wnt signalling is known to regulate 
key aspects of facial development. Brugmann et al., for instance, demonstrated the profound effects of 
Wnt signalling disruption in mouse and chicken facial morphogenesis (14). Tcf/Lef null mice reportedly pre-
sented substantially altered facial features and brachycephaly. In utero administration of DKK1 accordingly 
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produced similar defects. Analogous mechanisms were also observed in chick embryos. In mice, facial 
morphogenesis is also associated with expression of canonical Wnt ligand genes (15). These data suggest 
highly conserved regulation of facial development by Wnt signalling in vertebrate organisms. In humans, 
altered Wnt activity or responsiveness at critical stages of development might indeed contribute to the 
characteristic craniofacial morphology of DS. The largely homogeneous features of this DS trait amongst 
individuals point to a consistent mechanism, to which Wnt signalling is well placed to participate in accor-
dance with current evidence. 
Congenital heart disease - Another well described feature of DS is the wide occurrence of congenital 
heart disease (CHD), which poses considerable risk to neonatal and adult survival, and usually requires 
surgical intervention. As introduced (1.1.1), CHD in DS mostly affects ventricular and atrioventricular septal 
development (16, 17), significantly impairing physiological cardiac function. CHD encompasses a variety of 
conditions, but it generally arises as a result of abnormal cardiogenesis. At the cellular level, this implies dis-
rupted developmental control over renewal, migration and differentiation of cardiovascular progenitor cells. 
Interestingly, all three mechanism are well known to be finely regulated by the Wnt signalling pathway, 
which plays fundamental roles in all aspects of cardiogenesis. Wnt gradients of activity control fate specifi-
cation of precursor cells, cardiac morphogenesis, valve and conduction system development (18). The Wnt 
pathway also controls tissue remodelling and growth responses of the mature heart, in physiological and 
pathological conditions (19). In the context of CHD, one critical component affected is the outflow tract 
(OFT). This is a transient structure connecting the developing ventricles with the aortic sac, and is remod-
elled throughout cardiogenesis. The OFT ultimately gives rise to the aortic and pulmonary trunks and asso-
ciated valves, whilst also contributing endocardial cell layers to the developing septa. Defects in OFT mor-
phogenesis are a major contributor to CHD. Qyang et al. demonstrated that canonical Wnt signalling is 
necessary for normal OFT development (20). Deletion of β-catenin in cardiovascular precursors prevents 
differentiation and results in their accumulation, ultimately leading to substantial OFT morphogenic defects. 
The authors conclude that the canonical Wnt pathway is a fundamental mediator of cardiac progenitor de-
velopment, and a key player in CHD development. These data overall imply that the wide occurrence of 
CHD in DS may be underscored by dysfunctional Wnt signalling, given the critical importance of this path-
way in cardiogenesis.  
Differential susceptibility to cancer - DS produces complex alterations in cancer risk relative to the eu-
ploid population. A 2007 report on the Australian DS population (21) identified no overall difference in total 
cancer incidence. Risk ratios for individual cancer types were however significantly altered. Interestingly, DS 
people suffer from higher rates of leukaemia, whilst solid tumours occur less frequently. This compound 
differential risk is intriguing, as it suggests a potential multi-faceted mechanism. It is well established that 
enhanced Wnt activity is a primary event in the development of several cancer types (10, 22-28). In euploid 
individuals, Wnt-initiated tumorigenesis is generally thought to arise from activation of degradation-resistant 
β-catenin or APC mutations. In DS, chronic Wnt signalling modulation by Hsa21 genes such as DYRK1A 
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might produce similar, or opposite outcomes. Thus, Wnt dysfunction might potentially contribute to the 
differential cancer susceptibility in DS (21). High basal Wnt levels in proliferative haematopoietic cells may, 
for example, be exacerbated by DYRK1A overexpression, which does indeed play a role in DS-related 
leukemias (29). Conversely, the decreased incidence of certain types of solid tumour may arise from sup-
pression of Wnt signalling. A prominent example is colonic carcinoma, which is less common in DS (30). 
Reports indicate that Wnt signalling inhibition may reduce tumour growth in mouse models of colon cancer 
(31). Therefore, it may be hypothesised that chronic Wnt dysfunction in DS might contribute to secondary 
alterations in cancer susceptibility. 
Immune system dysfunction - A striking characteristic of DS pathology is the known global dysfunction 
of the immune system. Accumulating evidence in the past four decades suggests a substantial deficiency 
in overall immune function inherent to DS and manifest throughout life, worsening in an age-dependent 
manner (32, 33). An early report by Cossarizza et al. demonstrated complex alterations in numbers of cir-
culating lymphocytes (34). The authors assessed all subtypes of peripheral blood cells in adult DS, and 
identified reductions in the number B lymphocytes and CD4+ (helper) T cells. Conversely, CD8+ (cytotoxic) 
T lymphocytes were significantly increased along with natural killer (NK) cells. Interestingly, these changes 
are somewhat analogous to those observed in euploid individuals of advanced age. However, immune 
system defects in DS are reportedly present in infancy as well. A flow cytometry study conducted in DS 
children aged 0-12 years identified overall reductions in lymphocyte, monocyte and granulocyte numbers, 
suggestive of immune suppression (35). One subclass of pro-inflammatory monocytes (CD16+), however, 
was significantly elevated, potentially underlying chronic inflammatory disease in DS. Together, these data 
suggest that a key component of the innate immune system might be overactive in DS infancy, whilst 
adaptive immunity may be suppressed or deficient altogether in both infancy and adulthood. The 
haematopoietic stem cell system plays a crucial role in determining the immunological makeup of circulat-
ing leukocytes, by regulating precursor fate and rate of differentiation. As introduced (1.2.2), the Wnt sig-
nalling pathway is an essential modulator of haematopoietic stem cell function (36). Several lines of evi-
dence now heavily implicate this pathway in regulation of lymphocyte development (37). Reviewers sug-
gest that homoestatic Wnt signalling activity is important for regulation of undifferentiated lymphocyte pre-
cursor pools and rate of terminal differentiation (38). Aside from the resulting impact on development of 
haematological malignancies, which are indeed more common in DS, these data imply that Wnt dysfunc-
tion may also result in abnormal immunological profiles akin to those observed in DS individuals. Thus, im-
mune dysfunction in DS may partly result from chronic dysregulation of Wnt-mediated haematopoiesis. 
Overall, these evidence-based considerations demonstrate that multidirectional alterations in Wnt signalling 
are likely to affect biological processes regulated by the pathway, inevitably leading to highly complex phe-
notypes. Given the tight regulation and differential tissue requirements of Wnt signalling function, a number 
of key manifestations of DS may thus be considered in this light. It should be stressed, however, that these 
associations remain inferential at present, and require experimental validation of each potential hypothesis. 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Fig. D.2 - Several features of DS are potentially accounted for, at least partly, by underlying Wnt signalling abnormalities. 
These considerations are derived from literature knowledge and experimental evidence generated here.
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5.2.2 Potential therapeutic strategies: establishing Wnt signalling as a target pathway in DS 
The key implication of the findings presented throughout this thesis is that Wnt signalling regulation by 
DYRK1A may be established as a novel target for therapeutic development in DS neuropathology and 
beyond. Such a strategy might entail a three-sided approach: 1) Targeting aberrant DYRK1A activity in 
particularly Wnt-susceptible tissue types such as the adult hippocampus 2) Directly targeting under/
over-activation of Wnt signalling and target genes, depending on tissue-specific directional changes. 
3) Differentially tackling Wnt signalling dysfunction in both development and adulthood. These ap-
proaches are particularly attractive, chiefly because Wnt signalling and DYRK1A have been heavily 
investigated therapeutically. Therefore, future translation of the present findings into a viable therapeu-
tic approach, aimed at normalising Wnt function in DS, would build upon solid foundations. 
5.2.2.1 Wnt-based therapies in AD and neurodegeneration 
As introduced (1.2.5), canonical Wnt signalling activity appears suppressed in the AD brain, leading to 
synaptic degeneration particularly in the hippocampus. Several lines of evidence clearly suggest that 
Aβ-induced Wnt signalling defects contribute heavily to AD pathogenesis and progression (2-4, 39, 
40). Stimulation of neuronal Wnt signalling is thus currently viewed as a promising strategy in AD and 
other neurodegenerative diseases (41-43). Given the strong link between AD-DS, and the involvement 
of Wnt signalling newly identified here, therapeutic targeting of this pathway may prove beneficial in 
DS neuropathology as well. Due to its complexity, the Wnt pathway may be effectively targeted at 
multiple levels.  
One prominent example is the employment of Wnt ligands as candidate agents. This family of small 
glycoproteins is well suited for therapeutic development, mainly because of small molecular size as 
well as the ability to activate Wnt signalling physiologically. It is now well established that Wnt sig-
nalling stimulation is neuroprotective in AD (39, 44). In hippocampal neurons, Aβ accumulation leads 
to suppression of excitatory post synaptic currents (EPSCs), a hallmark of early synaptic degenera-
tion. Cerpa et al. demonstrated that, in cultured hippocampal slices, co-administration of Wnt5a and 
Aβ prevents EPSC suppression relative to Aβ alone (40), whilst Wnt7a stabilises the synaptic vesicle 
cycle (45). Wnt3a treatment, employed in this thesis to activate Wnt signalling, similarly prevents Aβ 
neurotoxicity and improves neuronal viability in rat hippocampal neurons (39). In the same study, Aβ 
administration reduced expression of the Wnt target gene engrailed-1 whilst enhancing GSK-3β and 
tau phosphorylation. Both effects were prevented by Wnt3a. Consistently, Kawamoto et al. demon-
strated that Wnt3a also rescues Aβ neurotoxicity in PC-12 cells, an effect accompanied by enhanced 
β-catenin protein levels (46). 
In addition to Wnt ligand administration, GSK3β activity may also be modulated pharmacologically to 
achieve significant Wnt stimulation. In this thesis, the GSK3β inhibitor LiCl was employed successfully 
with this purpose. This compound is currently prescribed as a mood stabiliser for the treatment of 
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bipolar disorder. In hippocampal progenitor cells, LiCl promotes proliferation and neuronal differentia-
tion via Wnt signalling activation (47, 48). GSK3β inhibition is reportedly sufficient to achieve neuropro-
tection in primary hippocampal neurons and transgenic murine models of AD (3). Particularly, Fiorentini 
et al. showed that long-term LiCl administration in APP transgenic mice reduces neuropathology, 
promotes hippocampal neurogenesis and improves cognitive defects (48). Another candidate method 
targeting GSK3β activity is administration of curcumin, a derivative of turmeric currently employed in a 
variety of industries as a cosmetic product or food colouring agent. In neuroblastoma cells expressing 
the APPswe mutant, curcumin treatment was shown to activate Wnt signalling in a dose-dependent 
manner (49). The authors also observed that Wnt stimulation was accompanied by enhanced β-
catenin expression and nuclear translocation, increased Cyclin D1 levels as well as reduced GSK3β 
activity. GSK3β is also inhibited by AF267B, a small molecule previously known as an M1 muscarinic 
Acetylcholine (ACh) receptor agonist. AF267B is thus capable of Wnt signalling activation via GSK3β 
(50). In APP transgenic mice, this property was shown to result in reduced hippocampal Aβ/tau 
pathological burden and improved cognitive performance in spatial tasks (51). These findings also 
raise the possibility of cross-talk between Wnt function and cholinergic transmission. Consistently, 
nicotinic receptor activation also appears to stimulate canonical Wnt signalling activity, as shown by 
Inestrosa et al. (52). Nicotine administration in cultured hippocampal neurons prevented suppression 
of the pathway induced by Aβ and enhanced expression of the α7 nicotinic ACh receptor gene, which 
the authors identified at as a novel Wnt target. Another study also reported that enhancement of ACh 
activity, through acetylcholinesterase inhibition, results in Wnt signalling activation and reduced amy-
loidogenic activity in an APP transgenic mouse model (53). 
Fig. D.3 - Overview of Wnt-based therapeutic approaches in AD. Current evidence indicate Wnt stimulation as a 
promising strategy in the treatment of AD and other neurodegenerative diseases.
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variety of industries as a cosmetic product or food colouring agent. In neuroblastoma cells expressing 
the APPswe mutant, curcumin treatment was shown to activate Wnt signalling in a dose-dependent 
manner (49). The authors also observed that Wnt stimulation was accompanied by enhanced β-
catenin expression and nuclear translocation, increased Cyclin D1 levels as well as reduced GSK3β 
activity. GSK3β is also inhibited by AF267B, a small molecule previously known as an M1 muscarinic 
Acetylcholine (ACh) receptor agonist. AF267B is thus capable of Wnt signalling activation via GSK3β 
(50). In APP transgenic mice, this property was shown to result in reduced hippocampal Aβ/tau 
pathological burden and improved cognitive performance in spatial tasks (51). These findings also 
raise the possibility of cross-talk between Wnt function and cholinergic transmission. Consistently, 
nicotinic receptor activation also appears to stimulate canonical Wnt signalling activity, as shown by 
Inestrosa et al. (52). Nicotine administration in cultured hippocampal neurons prevented suppression 
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Fig. D.3 - Overview of Wnt-based therapeutic approaches in AD. Current evidence indicate Wnt stimulation as a 
promising strategy in the treatment of AD and other neurodegenerative diseases.
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Another appealing target is the DKK family of Wnt inhibitors. As introduced, DKKs are secreted glyco-
proteins which bind to LRP5/6 and Kremen receptors, preventing Wnt ligand binding (54). Multiple 
DKK members have been linked to AD. DKK3 is important in hippocampal development and neuro-
genesis, and is elevated in plasma and CSF of AD patients (9, 55). Similarly, DKK1 expression is en-
hanced by Aβ treatment in primary rat hippocampal neurons, and is increased in AD brains as report-
ed by Caricasole et al. (56). The authors also showed that DKK1 knockdown in cultured neurons 
treated with Aβ enhances GSK3β inhibition and reduces apoptosis, thus suggesting Wnt-mediated 
neuroprotective effects. DKKs may be targeted pharmacologically with antagonist to LRP5/6 binding. 
Given that DKKs and Wnt ligands interact with two distinct binding sequences on LRP5/6, such an 
approach would likely not affect Wnt ligand binding, which is desirable (57). To this end, Iozzi et al. 
developed NCI8642, a small molecule DKK1 inhibitor (58). The compound was shown to compete 
with DKK1 for LRP6 binding, thus reducing its Wnt antagonistic effects. Alternatively, neutralising anti-
bodies targeted against DKK1 have also shown promise. Purro et al. employed anti-DKK1 in mouse 
brain slices treated with Aβ, demonstrating a substantial reduction in synaptic loss (59). These data 
overall illustrate that Wnt-based therapeutic development for AD is already well underway, and offers 
promising results, potentially translatable to DS. 
5.2.2.2 Targeting DYRK1A in DS 
According to the data generated here, the flip side of a Wnt-based therapeutic approach in DS is tar-
geting of aberrant DYRK1A activity. And indeed, employment of DYRK1A inhibitors to target cognitive 
deficits in DS is a rapidly developing field with promising results (11, 60-64). As outlined in methods 
(3.5.2) and results (4.3.2), three DYRK1A inhibitors were employed in this thesis, EGCG, INDY and 
Harmine (60, 65, 66). All three are reasonably well described, and preliminary evidence on their poten-
tial therapeutic application has been generated.  
The green tea polyphenol EGCG is an appealing candidate, primarily due to its ability to cross the pla-
centa and blood-brain barrier (BBB), both very useful in the context of DS (67). A variety of approach-
es has explored the potential therapeutic effects of EGCG-mediated DYRK1A inhibition. In Dyrk1a 
transgenic (Tg) mouse models, several lines of evidence suggest long-term EGCG treatment might be 
beneficial. Young and adult TgDyrk1a mice fed green tea extracts or EGCG display improvements in 
hippocampal neurogenesis, prefrontal cortical LTP, neurotransmission and cognitive deficits (68-70). 
Additionally, developmental brain defects in TgDyrk1a mice may be corrected by chronic EGCG ad-
ministration via a green tea polyphenol diet starting at gestation (65). Similar effects have been report-
ed in the Ts65Dn mouse model of DS. Long-term EGCG treatment in this model reportedly rescues 
defects in hippocampal LTP and learning/memory behavioural tasks (71, 72). However, contradicting 
reports also showed no improvement in cognitive performance, including memory tasks, of Ts65Dn 
mice treated with purified EGCG up to a dose of 100mg/kg/day (73). On the other hand, Valenti et al. 
showed a beneficial effect of EGCG treatment on mitochondrial function in Ts65Dn hippocampal 
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neural progenitor cells (74). A recent study by Stagni et al. investigated acute and long-term effects of 
EGCG treatment (75). Postnatal Ts65Dn mice (day 3-15) were administered daily intravenous EGCG 
treatment at 25 mg/kg. Beneficial effects were observed at treatment cessation, with improved hip-
pocampal/cortical cell number, connectivity, and neurogenesis. However, such improvements were 
lost in adulthood, with persistent cognitive impairment and cellular defects observed in EGCG-treated 
Ts65Dn mice at 42 days. Interestingly, the authors also reported enhanced total GSK3β levels in the 
Ts65Dn hippocampus, an effect rescued by EGCG treatment. This result is consistent with the en-
hancement of total GSK3β levels induced by DYRK1A overexpression observed in this thesis (4.3.2), 
and supports the finding of EGCG-mediated effects on canonical Wnt signalling activity.  
A number of preliminary investigations has also considered EGCG-based therapies in human DS. Two 
consecutive studies by De la Torre et al. showed that long term (3-12 months) EGCG treatment in 
young DS adults improves cognitive performance and visual memory, whilst also enhancing the effica-
cy of cognitive training (72, 76). However, these effect were lost 3 months post treatment cessation, 
suggesting the potential requirement of life-long DYRK1A inhibition therapy in DS. EGCG treatment 
also rescued mitochondrial function and stimulated mitochondrial biogenesis in human DS-derived 
fibroblast and lymphoblast cell cultures (77). These trials, whilst promising, still suffer from design limi-
tations due to the low number of participants and heterogeneous composition of the treatment ad-
ministered, which included several green tea compounds other than EGCG. 
In a similar fashion, the plant-derived DYRK1A inhibitor harmine has reportedly produced biologically 
relevant effects. In cellular models, harmine is able to reduce phosphorylation of multiple DYRK1A 
substrates including tau (78, 79) and rescue premature neuronal progenitor differentiation (80). INDY is 
relatively less characterised, despite its high DYRK1A specificity. However, Ogawa et al. showed that 
INDY treatment may correct abnormal morphogenesis in DYRK1A transgenic Xenopus embryos (66). 
It should be stressed that a potential DYRK1A inhibition therapy in DS is not without significant risk of 
unwanted side effects. Excessive suppression of DYRK1A activity is known to result in severe devel-
opmental abnormalities, given that heterozygous loss-of-function mutations are deleterious in mice 
and humans (81-83). Future effort should thus be aimed at devising target-specific approaches focus-
ing DYRK1A inhibition to relevant tissues and developmental stages. These data nevertheless demon-
strate that DYRK1A inhibition is a promising approach for treatment of cognitive deficits and brain de-
velopmental abnormalities in DS, although this remains to be heavily investigated. Taken together, 
these lines of evidence suggest that modulation of DYRK1A activity in DS preliminarily appears bene-
ficial, though continuing treatment might be necessary for sustained effects.  
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neural progenitor cells (74). A recent study by Stagni et al. investigated acute and long-term effects of 
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ficial, though continuing treatment might be necessary for sustained effects.  
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5.2.2.3 A Wnt-DYRK1A therapy for DS neurodevelopment and AD-DS? 
Mounting evidence convincingly suggests that multiple types of Wnt stimulation therapy might provide 
substantial benefit to AD patients. Concomitantly, standalone DYRK1A inhibition therapy also shows 
encouraging results in DS. It is important to appreciate that Wnt stimulation in AD should be directly 
translatable to DS, since AD neuropathology in this condition is essentially similar to sporadic disease, 
save for the much earlier age of onset and accelerated pathogenesis. This notion implies a further 
point for discussion, in light of the results of this thesis. That is, the more aggressive nature of AD-DS 
compared to sporadic AD might be, at least partly, underpinned by enhanced Wnt modulation due to 
Hsa21 trisomy. Surely APP triplication is in itself sufficient to enhance Aβ deposition (8), and this idea 
is not disputed here. However, if genes such as APP (84) and DYRK1A (4.3.2) are indeed capable of 
reducing basal Wnt signalling, Hsa21 trisomy in DS might significantly enhance AD development 
through Wnt modulation. Specifically, Aβ/tau pathology and overexpressed DYRK1A would synergisti-
cally suppress basal Wnt signalling in a vicious cycle, to a greater extent than in sporadic AD. The op-
posite of this phenomenon could however be exploited therapeutically in AD-DS, and may actually be 
Fig. D.4 - Summary of therapeutically beneficial eﬀects of DYRK1A inhibition reported so far in the literature. EGCG 
is the sole inhibitor to have been employed in pilot clinical trials by De la Torre et al., with promising results.
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advantageous. As discussed, basal Wnt signalling activity is predicted to be downregulated further by 
DYRK1A overexpression. If, however, Wnt signalling were to be activated by means of any of the 
methods outlined above, the evidence presented in this thesis would suggest a potential further en-
hancement of their Wnt stimulatory effects in DS, due to DYRK1A overexpression (4.3.2-3). This pos-
es the fundamental question of how DYRK1A should be targeted. Intuitively, it would seem obvious 
that DYRK1A inhibition is the necessary approach, given its excessive activity in DS. However, taking 
into account the bimodal Wnt regulatory effects of DYRK1A, one could argue that its overexpression 
in the adult DS hippocampus, in the presence of pharmacological Wnt stimulation, might be benefi-
cial. Chronic administration of Wnt ligands or GSK3β inhibitors might induce cytoplasmic redistribution 
of DYRK1A (4.3.2) and further enhance β-catenin activity. This nevertheless remains to be determined, 
as a precondition to further exploring the feasibility of a DYRK1A-Wnt therapy in DS.  
Prospective study design - An initial approach to answer this question would be to design a study 
investigating the effects of ± Wnt stimulation ± DYRK1A inhibition on validated markers of AD and DS 
pathology, employing primary hippocampal cultures, human cell lines and animal models. The four 
treatment combinations should be tested with or without the presence of AD and/or DS pathology, 
induced either via pharmacological treatment or via an animal model. Markers should include Aβ/tau 
aggregation and species ratio, synaptic degeneration (Neurogranin, YKL-40), neurogenesis (BrdU), 
apoptosis (Annexin V, DNA fragmentation), neuronal number (NeuN), LTP (EPSCs), inflammation, be-
haviour (Learning and memory, spatial tasks) or any other identified in the literature as reliable. In par-
allel, Wnt signalling activity and expression of target genes should be monitored for each condition via 
a combination of genetic/bioinformatic, biochemical and imaging studies. This approach would pro-
vide basic evidence on 1) Whether Wnt modulation at all has any beneficial effect in AD-DS and 2) If 
DYRK1A inhibition provides any additional improvement on AD-DS pathology. Current evidence is 
strongly predictive of observing positive effects of Wnt signalling stimulation alone in the proposed 
model systems. Regarding 2), the luciferase data generated here (4.3.2) suggests that DYRK1A inhibi-
tion would reduce the extent of activation produced by Wnt treatments, whilst overexpression should 
produce the opposite effects. According to the evidence available in AD, which associates Wnt activi-
ty with neuroprotection, such a result would be predictive of improved beneficial effects without 
DYRK1A inhibition. This seems counterintuitive, given that DYRK1A is overactive in DS. Its default 
overexpression may however be advantageous to improve the potency of Wnt stimulating treatments 
in AD-DS. This is an intriguing possibility, but it must be determined experimentally. It is equally feasi-
ble that DYRK1A inhibition might, at least initially, be more beneficial, or that either condition has no 
measurable effect on Wnt-mediated amelioration of AD markers. If proven beneficial, DYRK1A modu-
lation therapy as an adjuvant to Wnt stimulation might also be advantageous in sporadic AD, given the 
involvement of DYRK1A in this condition (85, 86). It may be further speculated that whilst DYRK1A 
enhancement is unlikely to be beneficial in DS, given its default high activity, exploiting DYRK1A to fur-
ther stimulate active Wnt signalling might prove useful in AD. This possibility also merits further inquiry. 
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Ultimately, it should be kept into consideration that brain pathology in DS is complex and multifaceted, 
and likely to require combinatorial drug therapy. Multiple approaches aside from DYRK1A inhibition are 
being investigated at present, and have been excellently reviewed by Dierssen (87). Additional thera-
peutic strategies include normalisation of gene dosage, neurotransmitter replacement to stimulate 
both excitatory and inhibitory networks as well as targeting of cellular pathways controlling neurogen-
esis and plasticity. The latter approach may well include Wnt signalling modulation, given the involve-
ment of this pathway in both mechanisms. 
Fig. D.5 - Visual summary of a proposed study design for immediate follow up of the data generated here. Diﬀerent 
combinations of Wnt stimulation and DYRK1A inhibition methods should be tested for eﬃcacy against multiple AD 
and DS markers whilst monitoring Wnt signalling activity in parallel.
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5.2.2.4 Beyond neurodegeneration and the DS brain 
The other important CNS aspect of DS which could be tackled therapeutically is neurodevelopment. 
This is a crucial time point for the onset of learning disability and cognitive deficits, and restoration of 
homoestatic DYRK1A-Wnt function could prove beneficial. The observed enhancement of active Wnt 
signalling by DYRK1A implies that, during brain development, the high basal levels of Wnt activity 
might be deleteriously enhanced by DYRK1A overexpression. Aberrant over activation of Wnt sig-
nalling has indeed been shown to negatively impact neurogenesis and forebrain development in multi-
ple instances (88-90). Thus, provided that the exact direction of Wnt dysfunction in DS neurodevel-
opment is established by future studies, a potential therapy might seek to suppress Wnt signalling ac-
tivity, with or without concomitant normalisation of DYRK1A. To this end, the field of cancer therapy 
provides several attractive possibilities. As discussed, excessive β-catenin activity is now recognised 
as a key pathogenic event in several cancers (91, 92). For this reason, a high number of pharmaceuti-
cal agents which inhibit Wnt signalling on multiple levels already exists (93-95). These include synthet-
ic small molecule β-catenin blockers, neutralising antibodies targeted against several Wnt compo-
nents, and modulatory peptides mimicking the binding properties of Wnt ligands. Reviewers have ar-
gued, however, that Wnt inhibition therapy alone might not be sufficient to arrest cancer progression, 
but may nevertheless be beneficial in combination with other therapeutic approaches (93). These 
compounds might thus be prospectively employed in DS tissues displaying excessive Wnt signalling.  
The complex landscape of Wnt function in AD, DS and AD-DS, and knowledge on potential therapeu-
tic strategies imply that other features of DS might respond to a Wnt-DYRK1A normalising treatment. 
The most prominent examples are CHD and leukaemia, both highly prevalent in DS. As discussed, 
these secondary pathologies possess known links with Wnt signalling function, and might thus be 
ameliorated through Wnt modulation. Prenatal and perinatal Wnt stimulation in the developing DS 
heart may prevent development of CHD. Likewise, administration of Wnt antagonists in infancy may 
reduce the progression of haematological malignancies. These possibilities, however, cannot be inves-
tigated before the tissue specificity and directionality of Wnt changes in DS is established in vivo.  
5.2.2.5 Overall considerations 
In summary, there is a long way ahead in the development of effective strategies for the treatment of 
DS and associated pathologies. Whilst available evidence is promising, a number of essential condi-
tions must be satisfied for such strategies to prove successful. Perhaps the most important is devising 
a way to effectively target abnormal Wnt signalling in a tissue and direction-specific manner. Attempts 
at therapy design might otherwise prove ineffective or harmful. In the long term, therapeutic develop-
ment will have to address more complex challenges inherent to drug design such as effective delivery 
to the brain, tissue selectivity, side effects and feasibility of prenatal treatment. These notions lie beyond 
the scope of this thesis, however, and are best addressed once more evidence has been generated. 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to the brain, tissue selectivity, side effects and feasibility of prenatal treatment. These notions lie beyond 
the scope of this thesis, however, and are best addressed once more evidence has been generated. 
210
6 Conclusions and future work: an avenue for the treatment of DS 
DS remains the most common human aneuploidy and genetic cause of AD. For nearly 60 years since the 
discovery of trisomy of chromosome 21 as its primary cause, the cellular and molecular mechanisms un-
derlying this condition have remained largely unclear. Despite improvements in life expectancy and quality 
of life for individuals affected, no pharmacological therapy is available to ameliorate the many features of 
DS. Additionally, the nearly universal occurrence of AD-DS poses an ever greater challenge to the ageing 
DS population. The studies discussed in this thesis have provided initial evidence of a functional Wnt-DS-
AD relationship. There is preliminary indication that aberrant Wnt signalling may contribute to DS, primarily 
to abnormal neurodevelopment and AD-DS. Furthermore, such contribution is, at least partly, mediated by 
DYRK1A modulation of Wnt signalling. Both notions may be employed to develop therapies at a later date, 
though much evidence is yet to be gathered prior to achieving this. A set of pressing experimental ques-
tions should include: 
I. Does DYRK1A directly phosphorylate any Wnt signalling components? If so, how does this af-
fect the Wnt substrate(s)? 
II. What is the molecular mechanism of DYRK1A-mediated Wnt modulation? How might it be in-
terfered with pharmacologically? What are effects of DYRK1A overexpression on Wnt targets? 
III. Does DYRK1A phase transition with DVL1? If so, does this result in functional segregation of 
DYRK1A from cytoplasmic substrates? Does DYRK1A stimulate DVL1 activation, as observed, 
through this mechanism? 
IV. How do other Hsa21-encoded Wnt regulators mechanistically contribute to dysfunction of the 
pathway in DS? (E.g.: APP, TIAM1). Does Aβ suppress cerebral Wnt signalling similarly to AD? 
V. Is Wnt signalling affected in other brain areas? Do Wnt signalling alterations change with age? 
VI. Are there any Wnt abnormalities in other DS tissue types? E.g.: myocardium and heart conduc-
tion system, haematopoietic stem cells, pancreatic β-cells. 
VII. Which tissue types would benefit most from Wnt stimulation or suppression? E.g: hippocam-
pus-stimulate, stem cells-suppress. 
VIII. What are the combined effects off Wnt ± DYRK1A modulation on markers of AD in DS? E.g.: 
prospective study. 
In the long term, the continuing study and potential clinical translation of this thesis’ findings might open 
avenues for treatment strategies in DS, aimed at normalising Wnt signalling function throughout life. It is 
hoped that future research efforts will expand on this model, in order to control this condition therapeutical-
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